DDrare: Database of Drug Development for Rare Diseases

Home Back

96. Crohn disease
[ 890 clinical trials, 832 drugs（DrugBank: 211 drugs), 161 target genes / 201 target pathways ]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = -aminosalicylic acid; 0.25 mg rpc1063; 0114-0006b; 10% metronidazole ointment; 1000 iu d3; 13-valent pneumococcal conjugated vaccine (pcv13); 1mg rpc1063; 2'-fucosyllactose; 23-valent polysaccharide pneumococcal vaccine; 23-valent polysaccharide pneumococcal vaccine (pneumovax tm); 4-aminosalicylic acid; 4-aminosalicylic acid extended release granules; 40 mg msb11022; 42942019; 5-aminosalicylate; 5-aminosalicylate (pentasa, ferring); 5-aminosalicylic acid; 5-asa; 5-asa, prednisone, azathioprine or remicade; 5-htp; 5000 iu d3; 549-0261/f02-01; 6 mercaptopurine; 6-[(methyl-4-nitro-1h-imidazol-5-yl)thio]-1h-purine; 6-mp; 683699; 6mp; 80 mg dr-6mp; 99mtc-s-hynic certolizumab pegol; ?-3 polyunsaturated fatty acid; Ab1010; Abatacept; Abbv-066; Abr-215062 sodium salt; Abt-494; Abt-874; Abx464; Accelerated 1 hour-infusion; Accelerated 30 minutes-infusion; Acetate; Adalimumab; Adalimumab (40 mg); Adalimumab (d2e7); Adalimumab 40 mg eow or ew; Adalimumab and infliximab; Adalimumab injection; Adalimumab prn; Adult human mesenchymal stem cells; Agri-king synbiotic (aksb); Ain457; Albendazole; Albendazole (eskazole); Alemtuzumab; Alequel; Alfacalcidol; Alicaforsen; Alicalm (polymeric liquid formula); Allo-asc; Allo-asc-cd; Allogeneic bone marrow derived human mesenchymal stem cells (hmscs); Allogeneic stem cell therapy; Allogenic eascs 5 million cells/ml suspension for injection cx601; Allogenic eascs 5 million cells/ml suspension for injection. cx601; Allopurinol; Allopurinol sandoz 100 mg, tabletten; Allopurinol sodium; Alx-0600; Amg 139; Amg 181; Amg 827; Amg 827 210 mg; Amg 827 350 mg; Amg 827 700 mg; Amgevita 40mg solution for injection; Aminosalicylic acid; Ammonium chloride; Amoxicillin; An100226; Andecaliximab; Andosan; Anti tnf alfa.; Anti tnf humanized antibody fab fragment-peg conjugate; Anti tnf therapy including infliximab; Anti-cd3; Anti-cd3 monoclonal antibody; Anti-il-12; Anti-interferon-gamma monoclonal antibody; Anti-madcam antibody; Anti-tnf; Anti-tnf discontinuation: physiological saline solution; Anti-tnf drug; Anti-tnf therapy; Anti-tnf: infliximab (infusion); Anti-tnf:adalimumab (subcutaneus); Apd334; Apd371; Apixaban; Apixaban 2.5 milligram; Application of adalimumab; Ast-120; Atorvastatin; Autologous cd34-selected peripheral blood stem cells transplant; Autologous mesenchymal stromal cell; Autologous ovalbumin-specific type 1 regulatory t lymphocytes expanded population; Autologous stem cell transplantation; Azathioprin-ratiopharm 25mg filmtabletten; Azathioprin-ratiopharm 50 mg filmtabletten; Azathioprine; Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Azatioprina; Azd9056; Azithromycin; Azithromycin + metronidazole; B. theta; Bacteriophage preparation; Bacteriotherapy; Bean; Beta carotene; Beta carotene from dunaliella algae; Betamethasone; Bfahf-2; Bi 655066; Bi 655066 10 mg/ml; Bi 655066 90 mg/ml; Bi 655130; Bi 695501; Bibr 796 bs, 20 mg; Bibr 796 bs, 5 mg; Bifidobacterium infantis; Bifidobacterium infantis 35624; Biological samplings; Biosimilar; Biosimilar infliximab; Bli-1300 high dose; Bli-1300 low dose; Blood and stools samples; Blood sampling; Bms-188667; Bms-936557 (anti-ip-10 antibody); Bms-945429; Bms-986165; Bms986165; Bone marrow derived mesenchymal stem cells (mscs); Boulardii; Brazikumab; Brazikumab high dose; Brazikumab low dose; Bt-11 1,000 mg; Bt-11 active; Budenofalk; Budenofalk 3mg gastro-resistant capsules; Budenofalk 9mg gastro-resistant granules; Budesonide; Budesonide ( zentacort capsules 3mg ); Bupivacaine; Bupivacaine/epinephrine/dexamethasone; Bupropion; C326, il-6 inhibitory avimer protein; Caffeine; Caffeine 100 mg; Calcitonin nasal spray (salmon); Calcitriol; Calcium; Calcium carbonate; Cannabidiol; Cannabis; Cannabis, medical; Carbon; Carbonate; Carnitine; Cc-5013; Ccx282-b; Cdp6038; Cdp870; Celebrex; Certican; Certolizumab; Certolizumab pegol; Certolizumab pegol (cdp870); Certolizumab pegol (czp); Certolizumab pegol (rinn); Certolizumab pegol 400 mg; Chadox2 hav; Chenodeoxycholic acid; Chenodiol; Chenofalk; Chloride; Cholecalciferol; Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol concentrate; Chondroitin sulfate; Cimzia; Cimzia 200 mg solution for injection; Ciprofloxacin; Ciprofloxacin hydrochloride; Clarithromycin; Clofarabine; Clofazimine; Cnto 1275; Cnto1275; Cnto1959; Colecalciferol; Colesevelam; Colony-purified bacteroides thetaiotaomicron (b.theta); Cortecosteroid; Corticosteroid; Cosmofer; Cosmofer 50mg/ml solution for infusion or injection; Cp-461; Cp-690,550; Cp-690,550-10; Cpsi-2364; Crohn's disease; Crohns disease exclusion diet + pen; Crown; Ct-p13; Ct-p13 sc (infliximab); Ctla4ig; Curcumin; Cx601; Cyclophosphamide; D9421-c; D9421-c capsule 3 mg; D9421-c, 15mg; D9421-c, 9mg; Darvadstrocel; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Decortin; Decortin 20 mg; Decortin 5 mg; Dehydroepiandrosterone; Dehydroepiandrosterone [dhea]; Dekristol 20.000 ie; Delayed release 6 mercaptopurine; Delayed release 6mp or calcitriol vs. purinethol; Denosumab; Dexamethasone; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dextran; Dextromethorphan; Dextromethorphan 30 mg; Dhea; Diet 1; Diet 2; Dietary therapy; Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon; Diflucan; Dlx105; Doxycycline; Doxycycline hyclate; E-device; E6011; E6011 10 mg/kg; E6011 15 mg/kg; E6011 2 mg/kg; E6011 5 mg/kg; Early immunosuppressants (azathioprine, methotrexate); Eb8018 (first-in-class fimh blocker); Efalizumab; Eicosapentaenoic acid; Entecavir; Enteral nutrition; Enteral nutrition.; Entocort; Entocort cr; Entocort® kapseln; Entyvio; Epanova; Epanova™ (omega-3 free fatty acids); Epaxal berna (virosomal hepatitis a vaccine); Epinephrine; Erb-041; Ergocalciferol; Ery-dex; Erythropoietin; Eskazole; Etiprednol dicloacetate; Etrolizumab; Eu/1/99/116/003; Evaluation of biological predictive factors of clinical response to ustekinumab; Everolimus; Exclusive enteral nutrition; Exclusive enteral nutrition therapy; Expanded allogenic adipose-derived adult stem cells; Expanded autologous adipose-derived adult stem cells (eascs); Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eascs); Faecal microbiota transplantation; Fe 999301; Fecal microbial transplant; Fecal microbial transplantation; Fecal microbiota transplant; Fecal microbiota transplant (fmt); Fecal microbiota transplantation; Fecal microbiota transplantation (fmt); Ferric carboxy maltose; Ferric carboxymaltose; Ferric maltol; Ferrous sulphate; Ffp104; Filgotinib; Filgrastim; Fish oil; Fitc-adalimumab; Flagyl; Fluconazole; Fludarabine; Fludarabine phosphate; Fluorine f 18; Folatescan (technetium tc 99mec20); Fosfomycin; G-csf; G321605; Ged-0301; Glatiramer; Glatiramer acetate; Glpg0634; Glpg1205; Glutamine; Golimumab; Green tea; Growth hormone; Gs-6034; Gsk1070806; Gsk1605786; Gsk1605786 500 mg; Gsk1605786 capsule; Gsk1605786 chemocentryx: formulation a; Gsk1605786 gsk direct-fill: formulation c; Gsk1605786 gsk modified-process: formulation d; Gsk1605786 gsk tablet: formulation e; Gsk1605786 gsk: formulation b; Gsk1605786a; Gsk2330811; Guselkumab; Hematopoietic stem cell transplantation; Hepatitis a vaccine; Herpes zoster vaccine; Hextend; High oligosaccharide group; High-dose cyclophosphamide; Hmpl004; Hmpl004-6599; Hum291; Human anti-il-12 antibody; Human insulin; Human monoclonal antibody (cnto 1275) to interleukin 12p-40; Human placenta-derived cells pda001 intravenous infusion; Human plasma for fractionation; Humira; Humira (adalimumab); Humira 40 mg solution for injection in pre-filled syringe; Humira 40mg solution for injection; Humira pre-filled pen; Humira®; Hydroxide; Hydroxychloroquine; Hydroxychloroquine sulphate; Il-2; Immune ablation and hematopoietic stem cell support; Immunonutrition; Immunosuppressor/tnfalpha; Impact; Imuran; Imurel; Increlex; Increlex 10mg/ml solution for injection; Inflectra; Infliximab; Infliximab (ifx alone); Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Injection of iron; Innovator infliximab; Inositol; Interferon alfa; Interferon beta; Interferon beta-1a; Interleukin 2; Interleukin-11; Intralipid; Intralipid 10%; Inulin; Invita d3; Iron; Iron sucrose; Iron sulphate; Iron sulphate 200mg coated tablets; Iron supplement 300-600 mg/day; Iron(iii)- hydroxide dextran complex; Itf2357; J695; Jenapharm; Jnj-40346527; Jnj-40346527-aac; Jnj-64304500; Jnj-64304500-aaa; Jnj-67864238; Kanamycin; Kenacort; Kremezin; Kremezin®, spherical adsorptive carbon; L-carnitine; Lactated ringers; Lactobacillus salivarius ucc118; Lactulose; Lactulose/rhamnose solution; Lap tap bupivacaine/epinephrine; Laquinimod; Laquinimod cápsulas 0.5 mg; Ldp-02; Liposomal bupivacaine; Longum; Losartan; Low dose naltrexone; Low-dose il-2 administration; Lumbar puncture; Maltodextrin; Maltose; Mannitol; Mare´s milk; Masitinib; Masitinib mesylate; Mb-102; Mdgn-002; Mecasermin; Mecasermin [rdna origin] 10mg/ml solution; Medi2070; Medi2070 high dose; Medi2070 high-med dose; Medi2070 low dose; Medi2070 low-med dose; Melphalan; Mensa; Mercaptopurine; Mesalamine; Mesalamine, 5-aminosalicylic acid; Mesalazine; Mesalazine (mesalamine); Mesalazine ec 500 mg; Mesalazine sustained-release tablets; Mesalazine tablets; Mesalazine, tripterygium glycosides; Mesenchymal cell and fibroblast injection; Mesenchymal cell transplantation; Mesenchymal stem cells; Mesenchymal stem cells (msc); Mesenchymal stem cells (mscs); Mesenchymal stromal cells; Mesenchymal stromal cells (msc) for infusion; Mesna; Methacholine; Methotrexate; Methoxsalen; Methoxsalen +ecp; Methyl prednisolone; Methylprednisolone; Methylprednisolone or budesonide; Metronidazol; Metronidazole; Microbiota; Midazolam; Midazolam 2 mg; Midazolam 3 mg; Mirikizumab; Mln0002; Mln0002 (vedolizumab); Mln002; Mobilization of stem cells to prepare for leukapheresis; Moderate oligosaccharide group; Modulen ibd; Modulen ibd (r) (specific enteral nutrition); Mongersen; Monoclonal antibody anti-igg1; Monoclonal antibody ca2; Mosapride; Msc injection 01; Msc injection 02; Msc treatment 01; Msc treatment 02; Msc-afp; Mt-1303; Mva hav; Mycophenolate; Mycophenolate mofetil; Mycophenolic acid; Naltrexone; Naltrexone-hcl; Natalizumab; Neomycin; Ni-0401 (anti-cd3 mab); Nitazoxanide; Nivolumab; Nnc 0142-0000-0002; Nnc0142-0000-0002; Nnc142-0002; None; Normal saline; Null; Nutraceutical combination; Nutrition treat; Nutropinaq 10mg/2ml solution for injection; Nutropinaq®; Ol adalimumab 40 mg; Oligofructose enriched inulin; Olokizumab; Omega-3; Omegaven; Omeprazole; Omeprazole 20 mg; Omeprazole 40 mg; Only 1 arm: treatment with msc-afp; Opc-6535; Opc-6535(tetomilast); Ops-2071 150 mg; Ops-2071 300 mg; Ops-2071 600 mg; Optison; Orencia; Originator (legacy) drug; Other biological agent; Ova-treg; Ovasave; Oxadrop; Oxygen; Ozanimod; Ozanimod hydrochloride; P28gst; Pancrelipase; Pda001; Pectin; Pegylated interferon alfa; Pentasa sachet; Pentasa sachet 1 g; Pentasa sachet 1 g prolonged release granules; Pentoxifylline; Pf-00547659; Pf-00547659 sc injection; Pf-04236921; Pf-04236921 sc injection; Pf-06651600; Pf-06700841; Phosphate; Phylloquinone; Phylloquinone (vitamin k1); Physician standard-of-care; Pioglitazone; Pioglitazone 15 mg; Pl 17901/0122; Pl 20532/0012; Placebo; Placebo ustekinumab; Plaquenil; Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología prgf-system (bti); Pnemovax; Pneumovax; Polaprezinc; Polyethylene glycol; Polyethylene glycol 3350; Pomegranate; Pravastatin; Prebiotics; Prednisolon; Prednisolon jenapharm; Prednisolone; Prednisone; Preparative regimen 4-6 weeks after leukapheresis; Prevenar 13; Probiotic; Probiotic - vsl#3; Probiotic mixture; Probiotics; Prochymal (remestemcel-l); Prochymal adult human mesenchymal stem cells; Prochymal™ adult human mesenchymal stem cells; Promethazine; Prucalopride; Prv-6527; Prv-6527 (jnj-40346527); Prv-6527(jnj-40346527); Qax567; Qax576; Qbeco; Qbeco-ssi; Rabbit; Rabbit antithymocyte globulin; Rad001; Raptiva 100 mg/ml powder and solvent for solution for injection; Rbatg; Rctb-401; Received hormone maintenance therapy; Recombinant growth hormone; Recombinant human insulin-like growth factor; Recombinant human interleukin-11 (rhil-11); Remestemcel-l; Remicade; Remicade (infliximab); Remsima; Remsima (infliximab); Remsima - 100 mg polvere per concentrato per soluzione per infusione - uso endovenoso - flanconcino (vetro) - 1 flaconcino; Remsima and inflectra; Rhamnose; Rhb-104; Rhgh; Rhigf (increlex); Ribavirin; Riboflavin; Riboflavin sodium phosphate injection; Riboflavin supplementation; Rifabutin; Rifabutin, clarithromycin, and clofazimine; Rifaximin; Rifaximin delayed release (dr); Rifaximin delayed release 400 mg film coated tablet; Rifaximin delayed release tablets; Rifaximin eir; Rifaximin+omeprazole+miralax; Rifaximin-eir; Rifaximina; Risankizumab; Risankizumab iv; Risankizumab sc; Risedronate; Rituximab; Ro 549-0261/f04-02; Ro 549-0261/f08-02; Rosuvastatin; Rosuvastatin 10 mg; Routine treatment of cd; Rpc1063; Rpc1063 (equivalent to ozanimod hcl); Rr110 (tamibarotene); Rvg 05565; Rvg 07151; Salofalk 500 mg; Same; Sandostatine; Sargramostim; Sargramostim (leukine); Sc12267; Search for exocrine pancreatic insufficiency at week 0 and 12; Semapimod; Shingrix; Shp647; Shr0302; Simethicone; Sirolimus; Sivelestat; Smoflipid; Smoking cigarettes; Smoking of cannabis; Solid food-based intervention; Somatropin; Somatropin [rdna origin] for injection; Somatropin(rhgh); Sonovue; Soy protein; Soya bean oil; Spesolimab; St10; Sta-5326; Sta-5326 mesylate; Sta-6838, sta-5326 m, s38; Stable isotope infusions; Standard 2 hours-infusion; Standard step-up care; Start adalimumab in monotherapy; Stelara; Stelara, remicade, entyvio, humira, remsima, flixabi, inflectra; Stelara®; Stem cells; Step-up; Steroids; Stromal vascular fraction (svf); Sucrose; Sugar extract; Sulfate; Sulfur hexafluoride; Sulphur hexafluoride; Suspension containing 250 embryonated, viable trichuris suis ova (tso)/15ml; Suspension containing 250 embryonated, viable tso/15ml; Suspension containing 2500 embryonated, viable trichuris suis ova (tso)/15ml; Suspension containing 2500 embryonated, viable tso/15ml; Suspension containing 7500 embryonated, viable trichuris suis ova (tso)/15ml; Suspension of 7500 embryonated, viable tso/15ml; Synbiotic (synergy i / b.longum); Ta-650; Tacrolimus; Tak-018; Tamibarotene; Td-1473; Teduglutide; Teduglutide (alx-0600); Teduglutide 0.05; Teduglutide 0.05 dose; Teduglutide 0.1 mg dose; Teduglutide 0.2 mg; Tetomilast; Thalidomide; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide pharmion; Thc 5mg/ml and cbs 50mg/ml; Thetanix; Thiopurine; Thiotepa; Threonine; Thrx-139060; Thymoglobulin; Ticilimumab; Time and attention; Time and attention + active fructooligosaccharide supplementation; Tnf kinoid; Tnf-alpha antagonists; Tnf-k; Tnf-kinoid; Tnfa kinoid; Tofacitinib; Tolerogenic dendritic cells; Top-down; Tr004 (treg immunotherapy); Treatment with adalimumab; Triamcinolone; Trichuris suis eggs; Trichuris suis ova; Trichuris suis ova (tso); Trichuris trichiura eggs; Tripterygium; Tripterygium glycosides; Trk-170; Tso 250; Tso 2500; Tso 7500; Tu-100; Tv-5600; Ultrasound microbubble contrast agent; Upadacitinib; Ursodeoxycholic acid; Ursofalk; Ursofalk® 250 mg tabletten.; Us tap bupivacaine/epinephrine; Ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab 130 mg iv; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg; Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab sc injection; Uttr1147a; Uvadex; Uvadex and uvar xts photopheresis system; V565; Vancomycin; Vedolizumab; Vedolizumab (genetical recombination); Vedolizumab 300 mg injection [entyvio]; Vedolizumab intravenous injection; Vedolizumab iv; Vedolizumab iv 300 mg; Vedolizumab sc; Vedolizumab sc 108 mg; Vedolizumab subcutaneous injection; Vedolizumab-800cw; Vehice control; Verapamil; Viagra; Vigantol oel; Vigantol oel tm; Visilizumab; Vitamin d; Vitamin d3; Vitamin d3 3000 ui daily; Vitamin d3 4000 ui daily; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; Vitamin e; Vitamin e 800iu; Vitamin k; Vitamin k 10 mg; Vitamin k1; Vorinostat; Vsl#3; Vsl#3 (original de simone formulation); Vsl#3®; Warfarin; Warfarin 10 mg; Wellbutrin (bupropion); Whey protein; Z-206; Zoledronic acid; Zp1848; [14c]-rpc1063 solution (0.1 mg/ml) for oral administration; [18f]fspg; Ácido gadobénico

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04151225	March 3, 2020	11 November 2019	Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease	A Multicentre, Randomised, Double-blind, Placebo-controlled, Repeat Dose, Dose-ranging Phase 2a/2b Study to Evaluate the Safety, Tolerability and Efficacy of an Anti-oncostatin M Monoclonal Antibody (GSK2330811) in Patients With Moderate to Severe Crohn's Disease	Crohns Disease	Drug: GSK2330811;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	280	Phase 2
2	NCT04118088	January 1, 2020	22 October 2019	Postauthorization Safety Study of Darvadstrocel Repeat Administration	Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn's Disease and Complex Perianal Fistula (ASPIRE)	Crohn's Disease;Complex Perianal Fistula	Biological: Darvadstrocel	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	N/A	All	50	Phase 4
3	NCT02677350	December 1, 2019	15 July 2019	AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)	A Phase I, Pilot Trial to Evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients With Fistulizing Crohn's Disease.	Crohn's Disease;Fistulizing Crohn's Disease;Stem Cells	Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)	Joshua M Hare		Not recruiting	18 Years	N/A	All	0	Phase 1	United States
4	NCT04134065	December 1, 2019	4 November 2019	the Effect of Vitamin D in Crohn's Disease	the Effect of Target-oriented Vitamin D Treatment in Refractory Crohn's Disease	Vitamin D Deficiency;Crohn Disease	Drug: Vitamin D;Drug: Placebo oral capsule	Nanjing University School of Medicine	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Not recruiting	20 Years	60 Years	All	30	Early Phase 1
5	NCT03992469	December 2019	4 November 2019	Study to Evaluate Safety, Tolerability and Efficacy of Oral B-FAHF-2 in Mild-to-Moderate Crohn's Disease	Study to Evaluate Safety, Tolerability, and Early Efficacy of Oral B-FAHF-2 in Subjects With Mild-To-Moderate Crohn's Disease	Crohn's Disease	Drug: BFAHF-2;Drug: Placebo	Icahn School of Medicine at Mount Sinai		Not recruiting	18 Years	30 Years	All	28	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT03943446	November 4, 2019	4 November 2019	TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence	Crohn Disease	Drug: TAK-018;Drug: TAK-018 Placebo	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	N/A	All	75	Phase 2	United States;Austria;France;Germany;Netherlands;United Kingdom
7	NCT03961815	November 1, 2019	26 August 2019	Open-label Extension Study of Brazikumab in Crohn's Disease	An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: Brazikumab	Allergan		Recruiting	16 Years	80 Years	All	1000	Phase 3	United States
8	NCT04073472	November 1, 2019	9 September 2019	Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's	A Phase I Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Ileal Anal Anastomosis and Ileal Pouch Fistulas in the Setting of Crohn's Disease of the Pouch	Crohn's Disease;Fistula;Anal Fistula;Pouch, Ileal;Pouches, Ileoanal	Drug: mesenchymal stem cells (MSCs)	The Cleveland Clinic		Not recruiting	18 Years	75 Years	All	15	Phase 1	United States
9	NCT04154735	November 2019	11 November 2019	Autologous Transplant Targeted Against Crohn's	Autologous Hematopoietic Stem Cell Transplant for Crohn's Disease	Crohn's Disease	Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Mesna;Drug: Alemtuzumab;Drug: G-CSF;Drug: Rifaximin;Drug: Tacrolimus	Northwestern University		Not recruiting	18 Years	49 Years	All	0	Phase 2	United States
10	NCT04075825	October 30, 2019	16 September 2019	Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula	A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have Participated in ADMIRE II Study	Crohn's Disease;Complex Perianal Fistula	Biological: Darvadstrocel	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	N/A	All	150	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT04131504	October 16, 2019	11 November 2019	Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)	A Multi-Center, Prospective Study to Discover a Companion Diagnostic for Biologics Targeting TNF	Crohn's Disease;IBD	Drug: Infliximab;Drug: Adalimumab	Children's Hospital Medical Center, Cincinnati	The Leona M. and Harry B. Helmsley Charitable Trust	Recruiting	1 Year	22 Years	All	240	Phase 3	United States
12	NCT04014517	October 1, 2019	29 July 2019	Effect of Peri-operative Immunonutrition on Recurrence and Infections in Crohn's Disease Patients	Effect of Peri-operative Immunonutrition on Recurrence and Infections in Crohn's Disease Patients	Crohn Disease	Other: Standard of Care;Dietary Supplement: Immunonutrition	Istituto Clinico Humanitas		Not recruiting	18 Years	N/A	All	350	N/A
13	NCT04112212	October 1, 2019	14 October 2019	NIR FME of Labelled Vedolizumab to Elucidate the Mechanism of Action and Predicting Response in IBD Patients.	Near-infrared Fluorescence Molecular Endoscopy Imaging of Labelled Vedolizumab-800CW to Elucidate the Mechanism of Action and Predicting Response in IBD Patients. A Prospective Pilot Intervention Study:	Crohn Disease;Colitis, Ulcerative	Drug: Vedolizumab-800CW;Device: Fluorescence endoscopy and spectroscopy	University Medical Center Groningen		Not recruiting	18 Years	N/A	All	35	Phase 1
14	NCT04131322	October 2019	28 October 2019	Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.	Loss of Response of Adalimumab Biosimilar Compared With the Loss of Response of Adalimumab Original: Controlled, Randomized, Non-inferiority Open Study. ADA-SWITCH Study	Crohn Disease;Ulcerative Colitis	Drug: Amgevita 40Mg Solution for Injection;Drug: HUMIRA 40Mg Solution for Injection	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla		Not recruiting	18 Years	N/A	All	216	Phase 4
15	JPRN-jRCT1031190056	30/09/2019	5 November 2019	E6011-CS1 study	Research for medicinal predictive marker on Crohn's disease - E6011-CS1 study	Crohn's disease Crohn's disease;D003424	Study1:Evaluate the disease activity and collect the blood according to the schedule as below. Amount of blood collection should be about 15mL at screening test, after the beginning of the study, about 12.5mL per visit. 1.Adalimumab:At the beginning of the study, after that, 2, 4, 12, 24, 52 weeks after or at the termination 2.Infliximab:At the beginning of the study,after that, 2, 6, 14, 22, 54 weeks after or at the termination 3. Ustekinumab:At the beginning of the study,after that, 2, 8, 20, 32, 56weeks after or at the termination Study2:None.	Kousaku Nanki	EA Pharma Co.,Ltd.(Utilize AMED's funds)	Recruiting	>= 16age old	Not applicable	Both	28	N/A	none
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT04102111	September 23, 2019	11 November 2019	A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: JNJ-67864238;Drug: Placebo	Janssen Research & Development, LLC		Recruiting	18 Years	75 Years	All	90	Phase 2	United States;Argentina;France;Germany;Italy;Poland;Russian Federation;Ukraine
17	NCT03847467	September 20, 2019	22 October 2019	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in Pediatric and Young Adult IBD Patients Receiving Stable Maintenance Anti-TNF Therapy	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Drug: 2'-Fucosyllactose;Other: Placebo	Children's Hospital Medical Center, Cincinnati	Broad Institute;University of Cincinnati;Connecticut Children's Medical Center	Recruiting	11 Years	25 Years	All	216	Phase 1/Phase 2	United States
18	ChiCTR1900026091	2019-09-19	30 September 2019	Development of a predictive nomogram for primary non-response to infliximab in patients with Crhon's disease	Development of a predictive nomogram for primary non-response to infliximab in patients with Crhon's disease: a multicenter study	Crohn's disease	Case series:infliximab;	The First Affiliated Hospital of Sun Yat-sen University		Not Recruiting	9	58	Both	Case series:343;	Retrospective study	China
19	NCT03870334	September 15, 2019	16 September 2019	Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: BT-11 1,000 mg;Drug: Placebo	Landos Biopharma Inc.		Not recruiting	18 Years	75 Years	All	130	Phase 2
20	NCT03885713	September 10, 2019	4 November 2019	Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease	Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Biological: Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa		Recruiting	18 Years	N/A	All	180	Phase 4	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT03917303	September 2019	26 August 2019	Control Crohn Safe Trial	Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study.	Crohn Disease;Inflammatory Bowel Diseases	Drug: Adalimumab;Drug: standard step-up care	Maastricht University Medical Center		Not recruiting	18 Years	70 Years	All	158	Phase 4
22	NCT03962998	September 2019	7 October 2019	Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability	A Randomized Unblinded Feasibility Study Evaluating the Use of Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability in Normal Subjects and Subjects With Active Small Bowel Crohn's Disease	Crohn Disease	Drug: Lactulose/Rhamnose solution;Drug: MB-102	MediBeacon		Recruiting	18 Years	N/A	All	20	Early Phase 1	United States
23	NCT03945019	August 2019	29 July 2019	CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Biological: CT-P13 SC (Infliximab);Other: Placebo SC	Celltrion		Recruiting	18 Years	75 Years	All	600	Phase 3	United States
24	NCT03999580	August 2019	15 July 2019	The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )	A Pragmatic Randomized Controlled Trial on High Dose Vitamin D to Prevent Relapses of Crohn's Disease in Children	Crohn Disease	Drug: vitamin D3	Jantchou Prevost		Not recruiting	4 Years	18 Years	All	316	Phase 3	Canada
25	NCT03926130	July 23, 2019	11 November 2019	A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: Mirikizumab;Drug: Ustekinumab;Drug: Placebo	Eli Lilly and Company		Recruiting	18 Years	80 Years	All	1100	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	NCT04018599	July 15, 2019	30 September 2019	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects	Rheumatoid Arthritis;Polyarticular Juvenile Idiopathic Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis;Crohn Disease;Ulcerative Colitis;Plaque Psoriasis;Pediatric Plaque Psoriasis;Pediatric Crohns Disease;Hidradenitis Suppurativa;Non-infectious Uveitis	Drug: 40 mg MSB11022	Fresenius Kabi SwissBioSim GmbH	PRA Health Sciences	Recruiting	18 Years	55 Years	All	216	Phase 1	United States
27	ChiCTR1900023696	2019-07-01	11 June 2019	Endoscopic balloon dilatation combined with local betamethasone injection to prevent recurrence of anastomotic stenosis after ileocolic resection for Crohn's disease: a single-center prospective randomized controlled trial	Endoscopic balloon dilatation combined with local betamethasone injection to prevent recurrence of anastomotic stenosis after ileocolic resection for Crohn's disease: a single-center prospective randomized controlled trial	Chron's disease	Group 1:EBD;Group 2:EBD combined with local injection of betamethasone;	The Sixth Affiliated Hospital of Sun Yat-sen University		Not Recruiting	18	75	Both	Group 1:45;Group 2:45;	N/A	China
28	JPRN-JapicCTI-194830	01/7/2019	22 July 2019	Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]	Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Crohn's Disease]	Crohn's disease	Intervention name : Vedolizumab (Genetical Recombination) INN of the intervention : Vedolizumab Dosage And administration of the intervention : Vedolizumab (Genetical Recombination) 300 milligrams (mg), intravenous (IV) infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Takeda Pharmaceutical Company Limited		Not Recruiting			BOTH	300	NA	Japan
29	NCT03905109	July 1, 2019	23 April 2019	Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease	A Phase 2a, Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety of ABX464 Compared With Placebo in Patients With Moderate to Severe Active Crohn's Disease Who Have Inadequate Response, Loss of Response, or Intolerance to Prior Amino-salicylates, Immunosuppressant Treatment, Biologics, and/or Corticosteroid Treatment	Crohn Disease	Drug: ABX464;Drug: Placebo	Abivax S.A.		Not recruiting	18 Years	75 Years	All	30	Phase 2	Belgium
30	NCT03935451	July 1, 2019	13 May 2019	Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease	A Randomized Controlled Trial on the Use of Postoperative Extended Venous Thromboprophylaxis in Patients With Inflammatory Bowel Disease: A Pilot Study	IBD;Venous Thromboembolism;Crohn Disease;Ulcerative Colitis;Pulmonary Embolism;Colorectal Disorders	Drug: Apixaban 2.5 milligram;Drug: Placebo Oral Tablet	McMaster University		Not recruiting	18 Years	N/A	All	180	Early Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	NCT04002180	July 1, 2019	29 July 2019	Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]	Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Crohn's Disease]	Crohn's Disease	Drug: Vedolizumab (Genetical Recombination)	Takeda		Recruiting	N/A	N/A	All	300	Phase 3	Japan
32	NCT03950336	July 2019	27 May 2019	Prebiotics and Diet to Reduce Leaky Gut in First Degree Relatives of Crohn's Disease Patients	Influence of Prebiotics on Intestinal Permeability in First Degree Relatives of Crohn's Patients	Healthy First Degree Relatives of Crohn's Disease Patients	Dietary Supplement: Prebiotics;Other: Low n-6 PUFA Diet;Dietary Supplement: Maltodextrin;Other: Control Diet	University of Alberta		Not recruiting	15 Years	50 Years	All	32	N/A
33	NCT04089514	June 30, 2019	28 October 2019	A Real-world Study of Imraldi® Use	Pan-EU Real-World Experience With Imraldi®	Arthritis, Rheumatoid (RA);Axial Spondyloarthritis (axSpA);Arthritis, Psoriatic (PsA);Crohn's Disease (CD);Colitis, Ulcerative (UC)	Drug: Adalimumab	Biogen		Recruiting	18 Years	N/A	All	1400	N/A	Germany;United Kingdom
34	NCT03656627	June 27, 2019	22 October 2019	Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Autoimmune Diseases;Non-small Cell Lung Cancer;Rheumatoid Arthritis;Psoriasis;Giant Cell Arteritis;Polymyalgia Rheumatica;Systemic Lupus Erythematosus;Crohn Disease;Multiple Sclerosis;Ulcerative Colitis	Drug: Nivolumab	Alliance Foundation Trials, LLC.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	72	Phase 1	United States
35	NCT03850509	June 4, 2019	4 March 2019	Efficacy and Safety of Oral OPS-2071 in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation	Efficacy and Safety of Oral OPS-2071 in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation Despite Ongoing Treatment	Crohn's Disease	Drug: OPS-2071 150 mg;Drug: OPS-2071 300 mg;Drug: OPS-2071 600 mg;Drug: Matching Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	IQVIA	Not recruiting	18 Years	70 Years	All	240	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	NCT03941418	June 1, 2019	11 June 2019	Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn Disease	Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn Disease	Ulcerative Colitis;Crohn Disease	Dietary Supplement: Boulardii;Dietary Supplement: Placebo	University Clinic Dr Dragisa Misovic-Dedinje	University Clinic Zvezdara	Not recruiting	18 Years	80 Years	All	150	N/A
37	NCT03915262	June 2019	23 April 2019	Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease	Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease Treated by Biological Therapy	Crohn Disease	Biological: Search for exocrine pancreatic insufficiency at week 0 and 12	Hospices Civils de Lyon		Not recruiting	18 Years	N/A	All	50	N/A	France
38	NCT03798691	May 28, 2019	15 July 2019	Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab	A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Herpes Zoster	Biological: Shingrix	University of Wisconsin, Madison	Boston Medical Center	Recruiting	50 Years	70 Years	All	30	Phase 4	United States
39	NCT03747718	May 1, 2019	25 February 2019	Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in Children	A Study for Evaluation of Clinical Response to Single vs. Maintenance Fecal Microbiota Transplantation in Pediatric Patients With Refractory Crohn's Disease	Crohn Disease	Biological: Fecal Microbiota Transplantation;Other: Placebo	Children's Mercy Hospital Kansas City		Not recruiting	2 Years	25 Years	All	30	Phase 1	United States
40	NCT03808103	May 1, 2019	13 May 2019	Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease	A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia Coli (AIEC) in Patients With Inactive Crohn's Disease (CD)	Crohn Disease	Biological: Placebo;Biological: Bacteriophage preparation	Intralytix, Inc.	MOUNT SINAI HOSPITAL	Recruiting	18 Years	N/A	All	30	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	NCT03733314	April 25, 2019	22 July 2019	A Study of E6011 in Participants With Active Crohn's Disease	Early Phase 2 Clinical Trial of E6011 in Patients With Active Crohn's Disease	Crohn's Disease	Drug: E6011;Drug: Placebo	EA Pharma Co., Ltd.		Recruiting	18 Years	64 Years	All	40	Phase 2	Japan;Poland
42	NCT03942120	April 8, 2019	11 November 2019	Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)	Post-Marketing Surveillance for Crohn's Disease Patients Treated With STELARA	Crohn Disease	Drug: Ustekinumab	Janssen Korea, Ltd., Korea		Recruiting	18 Years	N/A	All	70	Phase 3	Korea, Republic of
43	NCT03816345	April 4, 2019	11 November 2019	Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer	A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	Advanced Malignant Neoplasm;Autoimmune Disease;Crohn Disease;Dermatomyositis;Inflammatory Bowel Disease;Metastatic Malignant Neoplasm;Multiple Sclerosis;Rheumatoid Arthritis;Sjogren Syndrome;Systemic Lupus Erythematosus;Systemic Scleroderma;Ulcerative Colitis;Unresectable Malignant Neoplasm	Biological: Nivolumab	National Cancer Institute (NCI)		Recruiting	18 Years	N/A	All	264	Phase 1	United States
44	NCT03712826	April 2019	25 March 2019	Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease	Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease	Crohn Disease	Drug: Anti-TNF Drug;Drug: Ustekinumab	Hospices Civils de Lyon		Recruiting	18 Years	N/A	All	60	N/A	France
45	NCT03914261	April 2019	23 April 2019	Expanded Access to Risankizumab	Expanded Access to Risankizumab	Crohn's Disease	Drug: Risankizumab	AbbVie		Not recruiting	18 Years	N/A	All		N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	NCT03884439	March 18, 2019	4 November 2019	Infliximab Biosimilar Pfizer Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or Ulcerative Colitis)	Crohn's Disease;Ulcerative Colitis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer		Recruiting	N/A	N/A	All	300	Phase 3	Japan
47	NCT03706456	March 6, 2019	11 November 2019	Phase 3 Study of Cx601 in Subjects With Complex Perianal Fistulising Crohn's Disease	A Phase 3, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Cx601 in the Treatment of Complex Perianal Fistulas in Adult Patients With Crohn's Disease	Complex Perianal Fistulas in Adult Patients With Crohn's Disease	Biological: Darvadstrocel	Takeda		Recruiting	18 Years	N/A	All	20	Phase 3	Japan
48	NCT03901937	March 1, 2019	15 April 2019	The Effects of Parenteral ?-3 Polyunsaturated Fatty Acid on Postoperative Complications of Patients With Crohn's Disease	Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China	Crohn Disease	Drug: ?-3 polyunsaturated fatty acid;Procedure: Intestinal surgery for Crohn's Disease	Sir Run Run Shaw Hospital		Recruiting	18 Years	75 Years	All	158	Phase 4	China
49	EUCTR2017-000574-11-GR	26/02/2019	28 February 2019	Research study to determine whether an investigational drug, SHP647, is safe and effective long term in the treatment of moderate to severe Ulcerative Colitis or Crohn’s Disease (AIDA)	A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (AIDA) - AIDA	Ulcerative colitis or Crohn’s Disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	2453	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Italy;Switzerland;France;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan
50	NCT03681067	February 20, 2019	15 April 2019	A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease	A Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients With Moderate-to-Severe Crohn's Disease	Crohn Disease	Drug: GSK1070806;Drug: Placebo- sodium chloride	University of Birmingham	GlaxoSmithKline;University Hospital Birmingham	Recruiting	16 Years	N/A	All	30	Phase 1/Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	NCT03681652	February 11, 2019	25 February 2019	Post-Operative Crohn's Disease Outcome in Children	Post-Operative Crohn's Disease Outcome in Children (The POPCORN Trial): a Prospective Comparative Non-interventional Open Study	Crohn Disease	Drug: Azathioprine;Drug: Anti-TNF Drug	Schneider Children's Medical Center, Israel		Recruiting	6 Years	18 Years	All	100	N/A	Israel
52	NCT03718182	February 11, 2019	5 November 2018	Can Vitamin D Supplementation in People With Crohn's Disease Improve Symptoms as an Adjunct Therapy?	Can Vitamin D Supplementation in People With Crohn's Disease Improve Symptoms as an Adjunct Therapy? D-CODE Feasibility Randomised Controlled Trial	Crohn Disease;Vitamin D Deficiency	Dietary Supplement: Cholecalciferol	University Hospital Birmingham NHS Foundation Trust	National Institute for Health Research, United Kingdom;University of Birmingham;Clinical Trials Research Centre	Not recruiting	18 Years	N/A	All	50	Phase 4
53	NCT03627091	February 6, 2019	11 November 2019	Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)	Crohn's Disease	Drug: SHP647;Other: Placebo	Shire		Recruiting	16 Years	80 Years	All	983	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Colombia;Croatia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;Bosnia and Herzegovina
54	NCT03752970	February 5, 2019	28 October 2019	A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease	Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease	Crohn Disease	Drug: Spesolimab;Drug: Placebo	Boehringer Ingelheim		Recruiting	18 Years	75 Years	All	28	Phase 2	Austria;Belgium;Germany;Hungary
55	NCT03650413	January 14, 2019	11 November 2019	An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease	A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease	Ulcerative Colitis;Crohn's Disease	Drug: UTTR1147A	Genentech, Inc.		Recruiting	18 Years	80 Years	All	320	Phase 2	United States;Bulgaria;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	EUCTR2018-002629-51-NL	08/01/2019	28 February 2019	A Clinical Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Chronic Inflammatory Bowel Disease That Affects the Lining of the Digestive Tract	A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn’s Disease - Patient Optimization With ustekinumab Re-induction (POWER)	Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: USTEKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Janssen-Cilag International N.V.		Authorised			Female: yes Male: yes	200	Phase 3	France;United States;Spain;Germany;Netherlands;Sweden
57	NCT03773237	December 31, 2018	21 January 2019	Intralipid Versus SMOFlipid in HPN Patients	Randomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients.	Short Bowel Syndrome;Intestinal Fistula;Crohn Disease;Intestinal Obstruction	Dietary Supplement: SMOFLipid;Dietary Supplement: Intralipid	Mayo Clinic		Recruiting	18 Years	75 Years	All	100	N/A	United States
58	EUCTR2018-002925-47-ES	28/12/2018	28 February 2019	prediction of response to therapy in inflammatory bowel disease	Identification of predictive biomarkers for response to biologic therapies in inflammatory bowel disease by proteomic and mass cytometry approaches	Inflammatory bowel disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Adalimumab Pharmaceutical Form: Injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Infliximab Pharmaceutical Form: Infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 5- Trade Name: Golimumab Pharmaceutical Form: Injection INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Ustekinumab Pharmaceutical Form: Injection INN or Proposed INN: USTEKINUMAB CAS Number: 815610-63-0 Other descriptive name: USTEKINUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Trade Name: Vedolizumab Pharmaceutical Form: Infusion INN or Proposed INN: VEDOLIZUMAB CAS Number: 943609-66-3 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	Fundación de Investigación Biomédica del Hospital Universitario de La Princesa		Authorised			Female: yes Male: yes	180	Phase 4	Spain
59	NCT03677648	December 28, 2018	14 October 2019	A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease	A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease	Crohn's Disease	Drug: Placebos;Drug: SHR0302	Reistone Biopharma Company Limited		Recruiting	18 Years	75 Years	All	144	Phase 2	United States;China;Poland;Ukraine
60	JPRN-jRCT1051190043	20/12/2018	10 September 2019	Safety and efficacy of Budesonide administration after endoscopic balloon dilation for Crohn's disease patients with intestinal stenosis	Safety and efficacy of Budesonide administration after endoscopic balloon dilation for Crohn's disease patients with intestinal stenosis - OGF1707	Crohn's disease	At the time of resumption of food after endoscopic balloon dilation, patients receive 9mg/day budesonide orally for 3 weeks, followed by 6mg/day for 1 week.	Tetsuo Takehara	Hideki Iijima	Recruiting	20age	Not applicable	Both	15	Phase 2	none
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	NCT03782376	December 20, 2018	11 November 2019	A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease	A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab approximately 6 mg/kg (IV);Drug: Placebo (SC);Drug: Placebo (IV);Drug: Ustekinumab 90 mg (SC) Group 1;Drug: Ustekinumab 90 mg (SC) Group 2	Janssen-Cilag Ltd.		Recruiting	18 Years	N/A	All	200	Phase 3	United States;Austria;France;Germany;Italy;Netherlands;Spain;Sweden
62	ChiCTR1800019958	2018-12-16	18 December 2018	Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease	Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease	Crohn's disease	Case series:Combining infliximab treatmentwith Hyperbaric Oxygen Therapy;	Daping Hospital, Army Medical University (Third Military Medical University)		Recruiting	18	65	Both	Case series:60;	New Treatment Measure Clinical Study	China
63	EUCTR2018-002629-51-ES	12/12/2018	28 February 2019	A Clinical Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Chronic Inflammatory Bowel Disease That Affects the Lining of the Digestive Tract	A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn’s Disease - Patient Optimization With ustekinumab Re-induction (POWER)	Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: USTEKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Janssen-Cilag International N.V.		Authorised			Female: yes Male: yes	200	Phase 3	France;United States;Spain;Netherlands;Germany;Sweden
64	NCT03759288	December 7, 2018	26 August 2019	An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease	A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease	Crohn's Disease;IBD	Drug: Brazikumab low dose;Drug: Brazikumab high dose;Drug: Humira®;Drug: Placebo	Allergan		Recruiting	16 Years	80 Years	All	1140	Phase 2/Phase 3	United States
65	NCT03574948	December 6, 2018	11 June 2019	5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores	Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores	Crohn Disease;Ulcerative Colitis;Fatigue;Remission	Drug: 5-HTP;Drug: Placebo oral capsule	University Hospital, Ghent		Recruiting	18 Years	60 Years	All	180	Phase 2	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	EUCTR2018-001272-37-DE	04/12/2018	7 January 2019	A clinical trial to investigate the Efficacy and Safety of TD-1473 for the Treatment of Moderately-to-Severely Active Crohn's Disease	A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-to-Severely Active Crohn’s Disease - Efficacy and Safety of TD-1473 in Crohn’s Disease	Moderately-to-Severely Active Crohn’s Disease (CD) MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: TD-1473 Product Code: TD-1473 Pharmaceutical Form: Coated tablet INN or Proposed INN: Not assigned Current Sponsor code: TD-1473 Other descriptive name: THRX-139060 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Product Name: TD-1473 Product Code: TD-1473 Pharmaceutical Form: Coated tablet INN or Proposed INN: Not Assigned Current Sponsor code: TD-1473 Other descriptive name: THRX-139060 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Theravance Biopharma Ireland Limited		Authorised			Female: yes Male: yes	160	Phase 2	Serbia;Portugal;United States;Greece;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;France;Hungary;Poland;Romania;Croatia;South Africa;Bulgaria;Georgia;Germany
67	NCT02834754	December 1, 2018	18 December 2018	Vedolizumab Post Op Study	A Randomized, Double-blind, Placebo Controlled Study of Vedolizumab for the Prevention of Post-operative Crohn's Disease Recurrence	Crohn's Disease	Drug: Vedolizumab;Drug: placebo	Marc Schwartz	Takeda	Recruiting	18 Years	N/A	All	24	Phase 2	United States
68	NCT03378167	December 1, 2018	30 September 2019	PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial	PediCRaFT: Pediatric Crohn's Disease Fecal Microbiota Transplant Pilot Study	Crohn Disease;Pediatric Crohns Disease;Inflammatory Bowel Diseases;Colitis	Biological: MICROBIOTA;Biological: PLACEBO	McMaster Children's Hospital	Hamilton Health Sciences Corporation;McMaster University	Recruiting	3 Years	17 Years	All	45	Phase 1	Canada
69	NCT03944447	December 1, 2018	7 October 2019	Outcomes Mandate National Integration With Cannabis as Medicine	Outcomes Mandate National Integration With Cannabis as Medicine	Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder	Drug: Cannabis, Medical	OMNI Medical Services, LLC		Recruiting	7 Years	N/A	All	100000	Phase 2	United States
70	EUCTR2017-003090-34-BE	28/11/2018	7 January 2019	A study testing how BI 655130 works in patients with fistulizing Crohn’s Disease	Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease - BI 655130 treatment of fistulizing CD	Fistulizing Crohn’s Disease MedDRA version: 20.0 Level: LLT Classification code 10075465 Term: Fistulizing Crohn's disease System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: BI 655130 Pharmaceutical Form: Solution for infusion Current Sponsor code: BI 655130 Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	SCS Boehringer Ingelheim Comm.V		Authorised			Female: yes Male: yes	28	Phase 2	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	NCT03729674	November 26, 2018	3 December 2018	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Rheumatoid Arthritis;Ankylosing Spondylitis;Ulcerative Colitis;Crohn's Disease	Drug: Biosimilar;Drug: Originator (legacy) drug	McGill University Health Center	Université de Sherbrooke;Institut de rhumatologie de Montréal;Hospital for Special Surgery, New York;University of Manitoba;University of Toronto;University of Alberta;University of British Columbia;Alberta Health Services;McMaster University;The Arthritis Program Research Group	Not recruiting	18 Years	N/A	All	800	Phase 3
72	NCT03635112	November 19, 2018	30 September 2019	Efficacy and Safety of TD-1473 in Crohn's Disease	A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo?Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: TD-1473	Theravance Biopharma		Recruiting	18 Years	N/A	All	160	Phase 2	United States;Austria;Bulgaria;Croatia;France;Georgia;Germany;Greece;Hungary;Israel;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom
73	EUCTR2017-005151-83-DE	26/10/2018	6 November 2018	Treatment of Crohn's disease with Ustekinumab in clinical practice	INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE - MUCUS	Crohn's disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: STELARA Product Name: Stelara Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ustekinumab CAS Number: 815610-63-0 Other descriptive name: USTEKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Trade Name: STELARA Product Name: Stelara Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ustekinumab CAS Number: 815610-63-0 Other descriptive name: USTEKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90-	Charité Universitätsmedizin Berlin		Authorised			Female: yes Male: yes	100	Phase 4	Germany
74	NCT03833596	October 25, 2018	25 February 2019	Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD)	Synergistic Effect of Exclusive Enteral Nutrition Formula in Addition to Corticosteroids Therapy to Induce Clinical Remission in Patients With Crohn's Disease: a Pilot Study Involving a Multidimensional Assessment of Potential Mechanisms	Crohn's Disease	Dietary Supplement: Exclusive Enteral Nutrition;Drug: Prednisone	McMaster University	Nestlé	Recruiting	18 Years	75 Years	All	100	Phase 4	Canada
75	NCT03723447	October 23, 2018	11 November 2019	Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)	A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial	Pain, Postoperative;Crohn Disease;Inflammatory Bowel Diseases;Colorectal Cancer;Gastrointestinal Cancer;Gastrointestinal Disease;Digestive System Disease;Pain;Pain, Neuropathic;Intestinal Disease	Drug: Liposomal bupivacaine;Drug: Bupivacaine/epinephrine/dexamethasone	Cedars-Sinai Medical Center		Not recruiting	18 Years	90 Years	All	100	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	EUCTR2017-000617-23-BE	08/10/2018	28 February 2019	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) - CARMEN CD 307	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	983	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Switzerland;Italy;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Germany;Japan
77	NCT03606499	September 26, 2018	22 July 2019	Real-world Effectiveness of Ustekinumab in Participants Suffering From Crohn's Disease With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases	Effectiveness of Ustekinumab in Patients Suffering From Crohn's Disease With Extra-intestinal Manifestations or Immune-Mediated Inflammatory Diseases in a Real-world Setting	Crohn Disease	Drug: Ustekinumab	Janssen Cilag S.A.S.		Recruiting	18 Years	N/A	All	125	Phase 2	France
78	JPRN-JapicCTI-183950	20/9/2018	16 July 2019	A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallelgroup, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	Crohn's Disease	Intervention name : Guselkumab INN of the intervention : Guselkumab Dosage And administration of the intervention : Phase 2 (GALAXI 1): Group 1 (Guselkumab) Guselkumab will be administered by IV infusion. Phase 2 (GALAXI 1): Group 1 and Group 2 (Guselkumab) Guselkumab will be administered by SC injection. Phase 2 (GALAXI 1): Group 2 (Guselkumab) Guselkumab will be administered by IV infusion. Phase 2 (GALAXI 1): Group 3 (Guselkumab) Guselkumab will be administered by IV infusion and SC injection. Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab) Guselkumab will be administered by IV infusion and SC injection Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Phase 2 (GALAXI 1): Group 4 (Ustekinumab) Phase 2 (GALA XI 1): Group 5(Placebo/Ustekinumab) Phase 3 (GALAXI 2 and 3):Group 3 (Ustekinumab) Phase 3 (GALAXI 2 and 3):Group 4 (Placebo/Ustekinumab) Ustekinumab will be administered by IV infusion and SC injection. Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab) Phase 3 (GALAXI 2 and 3):Group 4 (Placebo/Ustekinumab) Placebo will be administered as IV infusion. Control intervention name : Ustekinumab INN of the control intervention : Ustekinumab Dosage And administration of the control intervention : Phase 2 (GALAXI 1): Group 4 (Ustekinumab) Phase 2 (GALA XI 1): Group 5(Placebo/Ustekinumab) Phase 3 (GALAXI 2 and 3):Group 3 (Ustekinumab) Phase 3 (GALAXI 2 and 3):Group 4 (Placebo/Ustekinumab) Ustekinumab will be administered by IV infusion and SC injection. Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab) Phase 3 (GALAXI 2 and 3):Group 4 (Placebo/Ustekinumab) Placebo will be administered as IV infusion.	Janssen Pharmaceutical K.K.		Recruiting	18		BOTH	2000	Phase 2-3	Japan, North America
79	EUCTR2017-000617-23-NL	17/09/2018	1 October 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) - CARMEN CD 307	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	983	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Italy;Switzerland;France;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan
80	EUCTR2017-001976-48-HU	13/09/2018	4 December 2018	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease	Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: LLT Classification code 10011398 Term: Crohn's System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BMS-986165 Product Code: BMS-986165 Pharmaceutical Form: Capsule INN or Proposed INN: BMS-986165 CAS Number: 1609392-28-0 Other descriptive name: BMS986165 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Bristol-Myers Squibb international Corporation		Authorised			Female: yes Male: yes	144	Phase 2	United States;Taiwan;Spain;United Kingdom;Italy;France;Hungary;Czech Republic;Mexico;Canada;Poland;Brazil;Romania;Australia;Germany;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	NCT03623932	September 1, 2018	20 August 2018	Contribution of a Non Medicamentous Approach by Hypnosis on Quality of Life in Crohn Disease	Contribution of a Non Medicamentous Approach by Hypnosis on Quality of Life in Crohn Disease	Crohn Disease	Drug: immunosuppressor/TNFalpha;Behavioral: Hypnosis	University Hospital, Grenoble		Not recruiting	18 Years	65 Years	All	40	N/A
82	NCT03615378	August 30, 2018	26 August 2019	Maintenance Dosing of Vitamin D in Crohn's Disease	A Randomized, Double Blind, Placebo Controlled Trial Evaluating Optimal Maintenance Strategies of Vitamin D Levels in Patients With Crohn's Disease in Remission	Crohns Disease;Vitamin D Deficiency	Dietary Supplement: 5000 IU D3;Dietary Supplement: 1000 IU D3;Dietary Supplement: Placebo	Cedars-Sinai Medical Center		Not recruiting	18 Years	N/A	All	10	Early Phase 1	United States
83	EUCTR2017-004294-14-DE	23/08/2018	28 February 2019	Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Celgene International II Sàrl		Authorised			Female: yes Male: yes	485	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Saudi Arabia;Spain;Ireland;Israel;Russian Federation;Switzerland;Australia;South Africa;Netherlands;China;Slovenia;Finland;Lithuania;Austria;United Kingdom;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Georgia;Germany;Norway;Japan;New Zealand
84	NCT03467958	August 22, 2018	4 November 2019	An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ozanimod	Celgene		Recruiting	12 Years	75 Years	All	1040	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom
85	NCT03546868	August 14, 2018	3 September 2018	Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease	Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Subjects With Inflammatory Bowel Disease.	Inflammatory Bowel Diseases;Ulcerative Colitis;Crohn Disease	Drug: [18F]FSPG	Asan Foundation		Recruiting	19 Years	79 Years	All	20	Phase 2	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
86	NCT03492944	August 6, 2018	20 August 2018	Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason	Contrast-Enhanced Ultrasound Evaluation of Bowel Wall Inflammation in Pediatric Crohn's Disease: Comparison to CT and MRI Enterography	Crohn Disease	Drug: Ultrasound Microbubble Contrast Agent;Device: Ultrasound Imaging	Children's Hospital Medical Center, Cincinnati		Recruiting	10 Years	18 Years	All	25	Phase 1	United States
87	NCT03196427	July 30, 2018	15 July 2019	Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)	A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease	Ulcerative Colitis;Crohn's Disease	Drug: Vedolizumab	Takeda		Recruiting	2 Years	17 Years	All	80	Phase 2	United States;Belgium;Canada;France;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom
88	EUCTR2017-000576-29-HU	24/07/2018	19 November 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)(CARMEN CD 306).	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306) - CARMEN CD 306	Crohn’s disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	1032	Phase 3	Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Colombia;Switzerland;Hungary;Mexico;Canada;Argentina;Belgium;Bulgaria;Japan;Korea, Republic of;Bosnia and Herzegovina
89	NCT03449069	July 23, 2018	26 August 2019	Pediatric MSC-AFP Sub-study for Crohn's Fistula	A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study	Fistula in Ano;Crohn Disease	Drug: MSC-AFP	Mayo Clinic		Recruiting	12 Years	17 Years	All	5	Phase 1	United States
90	EUCTR2017-001737-85-NL	17/07/2018	20 August 2018	Efficacy of AlbenDazole to inDuce mUcosal healing in Patients with Crohn's disease on anti-TNF monotherapy	Efficacy of AlbenDazole to inDuce mUcosal healing in Patients with Crohn's disease on anti-TNF monotherapy - ADD UP	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: albendazole (Eskazole) Product Name: albendazole Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	academic medical centre		Authorised			Female: yes Male: yes	110	Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
91	NCT03476317	July 12, 2018	30 September 2019	Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn Disease	Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Fluconazole	Children's Hospital of Philadelphia	University of Pennsylvania;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	6 Years	18 Years	All	30	Phase 2	United States
92	EUCTR2017-000575-88-AT	06/07/2018	26 November 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn's Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305) - CARMEN CD 305	Crohn's disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	1032	Phase 3	Serbia;United States;Lithuania;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Poland;Brazil;Romania;Croatia;Australia;South Africa;Netherlands;Germany;Japan
93	EUCTR2017-000617-23-AT	06/07/2018	26 November 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) - CARMEN CD 307	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	983	Phase 3	Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Germany;Japan;Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Switzerland;Italy;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina
94	NCT03860571	July 6, 2018	11 March 2019	Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers	A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers	Ulcerative Colitis;Crohn Disease	Drug: BT-11 Placebo;Drug: BT-11 Active	Landos Biopharma Inc.		Not recruiting	18 Years	65 Years	All	70	Phase 1	United States
95	EUCTR2017-002195-13-DE	03/07/2018	7 January 2019	A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease - GALAXI	Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: guselkumab Product Code: CNTO1959 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: GUSELKUMAB Current Sponsor code: CNTO 1959 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection/infusion in pre-filled syringe Route of administration of the placebo: Intravenous use Product Name: guselkumab Product Code: CNTO1959 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Guselkumab Current Sponsor code: CNTO 1959 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection/infusion in pre-filled syringe Route of administration of the placebo: Intravenous use Trade Name: STELARA Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ustekinumab CAS Number: 815610-63-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: STELARA Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ustekinumab CAS Number: 815610-63-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Janssen-Cilag International NV		Authorised			Female: yes Male: yes	2000	Phase 2;Phase 3	Serbia;Portugal;United States;Belarus;Saudi Arabia;Taiwan;Slovakia;Greece;Spain;Ukraine;Lebanon;Russian Federation;Israel;Colombia;Italy;France;Macedonia, the former Yugoslav Republic of;Jordan;Australia;South Africa;Netherlands;Latvia;Tunisia;China;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Croatia;Georgia;Germany;New Zealand;Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
96	NCT03662919	July 2, 2018	17 September 2018	One-year Persistence to Treatment of Participants Receiving Flixabi: a French Cohort Study	PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi®: a French Cohort Study	Arthritis, Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic;Crohn's Disease;Colitis, Ulcerative	Drug: Infliximab	Biogen		Recruiting	6 Years	N/A	All	1500	N/A	France
97	NCT03467620	July 2018	11 June 2018	Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease	Oral Cannabidiol Capsule Usage as an Adjunct Therapy for Crohn's Disease: a Randomized, Placebo-controlled Study	Crohn Disease;Inflammatory Bowel Diseases;Cannabis	Drug: Cannabidiol;Drug: Placebo oral capsule	University of Illinois at Chicago		Not recruiting	18 Years	N/A	All	36	Phase 2/Phase 3
98	NCT03472690	June 25, 2018	23 July 2018	QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease	A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of QBECO SSI for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects With Moderate to Severe Crohn's Disease	Crohn Disease	Biological: QBECO-SSI;Other: Placebo	Qu Biologics Inc.		Recruiting	18 Years	N/A	All	170	Phase 2	Canada
99	NCT03559517	June 25, 2018	11 November 2019	Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)	Crohn's Disease	Biological: SHP647;Other: Placebo	Shire		Recruiting	16 Years	80 Years	All	1032	Phase 3	United States;Australia;Austria;Croatia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom
100	NCT03559660	June 25, 2018	28 October 2019	CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)	Compassionate Use Program Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)	Crohn's Disease	Drug: Certolizumab Pegol	UCB Biopharma S.P.R.L.		Not recruiting	18 Years	N/A	All		Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
101	NCT03599622	June 25, 2018	4 November 2019	An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Crohn's Disease	Granulomatous Colitis;Crohn's Disease;Crohn's Enteritis;Granulomatous Enteritis	Drug: BMS-986165;Other: Placebo	Bristol-Myers Squibb		Recruiting	18 Years	75 Years	All	240	Phase 2	United States;Australia;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom
102	EUCTR2017-000617-23-LT	15/06/2018	23 July 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) - CARMEN CD 307	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	983	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Italy;Switzerland;France;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan
103	NCT03566823	June 11, 2018	11 November 2019	Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)	Crohn's Disease	Biological: SHP647;Other: Placebo	Shire		Recruiting	16 Years	80 Years	All	1032	Phase 3	United States;Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;New Zealand;Portugal;Slovakia;Spain;Ukraine
104	NCT03142321	June 8, 2018	15 July 2019	Defining Predictors of RT Response to Vedolizumab in IBD	Defining Predictors of Radiological Transmural Response to Vedolizumab in Small Bowel Crohn's Disease Through Serum Proteomic Biomarkers	Crohn Disease of Small Intestine	Drug: Vedolizumab 300 MG Injection [Entyvio]	Washington University School of Medicine		Recruiting	18 Years	N/A	All	80	Phase 4	United States
105	NCT03477032	June 1, 2018	11 June 2019	FMT in Inflammatory Bowel Disease	Faecal Transplantation in Inflammatory Bowel Disease	Faecal Microbiota Transplantation;Crohn Disease;Ulcerative Colitis;Microscopic Colitis	Biological: Faecal Microbiota Transplantation	St Vincent's Hospital Melbourne		Recruiting	18 Years	65 Years	All	50	Phase 2	Australia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
106	EUCTR2017-004292-31-LV	21/05/2018	30 April 2019	Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Active Crohn’s Disease	Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Celgene International II Sàrl		Authorised			Female: yes Male: yes	600	Phase 3	Belarus;United States;Taiwan;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;France;Puerto Rico;Australia;Denmark;Latvia;Moldova, Republic of;China;Korea, Republic of;Bosnia and Herzegovina;Turkey;United Kingdom;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Norway;Germany;New Zealand;Japan
107	EUCTR2017-004295-55-LV	21/05/2018	30 April 2019	Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-	Celgene International II Sàrl		Authorised			Female: yes Male: yes	1200	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Saudi Arabia;Spain;Ireland;Israel;Russian Federation;Switzerland;Australia;South Africa;Netherlands;China;Slovenia;Finland;Lithuania;Austria;United Kingdom;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Georgia;Germany;Norway;Japan;New Zealand
108	ChiCTR1800015174	2018-05-01	19 March 2018	Effects of Vitamin D supplementation on clinical prognosis for patients with Crohn's disease	Effects of Vitamin D supplementation on clinical prognosis for patients with Crohn's disease	Crohn's disease	control group:placebo;Vitamin D:800IU Vitamin D;	Gudangdong General Hospital, Guangdong Academy of Medical Sciences		Not Recruiting	18	75	Both	control group:32;Vitamin D:32;	New Treatment Measure Clinical Study	China
109	EUCTR2017-003649-10-DE	30/04/2018	28 February 2019	A Pharmacokinetic, Pharmacodynamic, and Safety Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients From 4 Years to Less Than 18 Years of Age with Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn’s Disease	A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR MODERATE TO SEVERE CROHN’S DISEASE	Moderate to severe ulcerative colitis (UC); moderate to severe Crohn’s disease (CD) MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10009900 Term: Colitis ulcerative System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Etrolizumab Product Code: 549-0261/F02-01 Pharmaceutical Form: Solution for injection INN or Proposed INN: ETROLIZUMAB CAS Number: 1044758-60-2 Current Sponsor code: RO5490261/F02-01 Other descriptive name: ETROLIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150-	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	60	Phase 1	United States;Poland;Belgium;Spain;Germany;United Kingdom
110	EUCTR2017-000574-11-DE	10/04/2018	7 January 2019	Research study to determine whether an investigational drug, SHP647, is safe and effective long term in the treatment of moderate to severe Ulcerative Colitis or Crohn's Disease (AIDA)	A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) - AIDA	Ulcerative colitis or Crohn's Disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	2453	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Italy;Switzerland;France;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
111	NCT03105102	April 9, 2018	4 November 2019	A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989	Crohn's Disease	Drug: placebo for risankizumab SC;Drug: risankizumab IV;Drug: placebo for risankizumab IV;Drug: risankizumab SC	AbbVie		Recruiting	18 Years	80 Years	All	912	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;American Samoa;Brazil;Turkey
112	EUCTR2016-004112-35-SE	04/04/2018	30 April 2018	A comparison between standard treatment with azathioprine and a modified treatment with a lower dose of azathioprine in combination with allopurinol for patients with inflammatory bowel disease	Low-dose azathioprine and allopurinol- versus azathioprine monotherapy in patients with Inflammatory Bowel Disease: An investigator-initiated, open, multicentre, parallel-arm, randomized controlled trial A SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases) study	Patients with inflammatory bowel diseae (Ulcerative colitis or Crohns disease) wh do not responding to first line therapy;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Imurel Product Name: Azathioprine Product Code: NA Pharmaceutical Form: Tablet Trade Name: Allopurinol Product Name: Allopurinol Product Code: NA Pharmaceutical Form: Tablet	SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)		Authorised			Female: yes Male: yes	120	Phase 4	Sweden
113	JPRN-UMIN000031839	2018/04/01	23 April 2019	Safety and efficacy of Budesonide administration after endoscopic ballon dilation for Crohn disease patients with intestinal stenosis	Safety and efficacy of Budesonide administration after endoscopic ballon dilation for Crohn disease patients with intestinal stenosis - Safety and efficacy of Budesonide administration after EBD for CD patients	Crohn's disease	At the time of resumption of food, patients recerve 9mg/day budesonide orally for 3 weeks, followed by 6mg/day for 1 week.	Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology	Japan Community Health care Organizationi Osaka Hospital, Gastroenterology and Hepatology National Hospital Organization Osaka National Hospital, Gastroenterology and Hepatology Osaka Rosai Hospital , Gastroenterology and Hepatology Kansai Rosai Hospital, Gastroenterology and Hepatology Itami City Hospital, Gastroenterology and Hepatology Hyogo Prefectural Nishinomiya Hospital, Gastroenterology and Hepatology	Recruiting	20years-old	Not applicable	Male and Female	15	Not selected	Japan
114	NCT03452501	April 2018	11 June 2018	Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients	An Observational, Prospective Cohort Study to Evaluate the Safety and Effectiveness of Remsima® in the Treatment of Inflammatory Bowel Disease Among Saudi Arabia Patients Diagnosed With Crohn's Disease, Ulcerative Colitis, or Fistulizing CD	Inflammatory Bowel Diseases Including Crohn's Disease, Fistulizing Crohn's Disease and Ulcerative Colitis	Drug: Infliximab	Hikma Pharmaceuticals LLC		Not recruiting	18 Years	N/A	All	150	Phase 3	Saudi Arabia
115	NCT03464136	March 29, 2018	11 November 2019	Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year	A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease	Crohn Disease	Biological: Placebo for Ustekinumab;Biological: Placebo for Adalimumab;Biological: Ustekinumab (6 mg/kg);Biological: Ustekinumab (90 mg);Biological: Adalimumab (40 mg)	Janssen Scientific Affairs, LLC		Recruiting	18 Years	N/A	All	350	Phase 3	United States;Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
116	NCT03478956	March 27, 2018	28 October 2019	A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease	A Phase I, Open-Label, Randomized, Pharmacokinetic, Pharmacodynamic, And Safety Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients From 4 Years To Less Than 18 Years Of Age With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease	Ulcerative Colitis;Crohn's Disease	Drug: Etrolizumab	Hoffmann-La Roche		Not recruiting	4 Years	17 Years	All	24	Phase 1	United States;Belgium;Germany;Poland;Spain;United Kingdom
117	NCT03345823	March 21, 2018	25 March 2019	A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433	Crohn's Disease	Drug: Placebo for Upadacitinib;Drug: Upadacitinib	AbbVie		Recruiting	18 Years	75 Years	All	738	Phase 3	United States;American Samoa;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;Belarus
118	NCT03597971	March 20, 2018	20 August 2018	HMPL004-6599 Phase I Dose-escalating Study	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL004-6599 in Healthy Male Volunteers	Ulcerative Colitis;Crohn Disease	Drug: HMPL004-6599;Drug: Placebo	Nutrition Science Partners Limited	Hutchison Medipharma Limited;Nestlé	Recruiting	18 Years	45 Years	Male	56	Phase 1	Australia
119	NCT03854305	March 20, 2018	6 May 2019	Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease	Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of CSF-1 Receptor, in Subjects With Moderately to Severely Active Crohn's	Crohn's Disease	Drug: PRV-6527;Drug: Placebo	Provention Bio, Inc.		Not recruiting	18 Years	75 Years	All	93	Phase 2	Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine
120	EUCTR2017-004294-14-SK	16/03/2018	7 January 2019	Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Celgene International II Sàrl		Authorised			Female: yes Male: yes	485	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Saudi Arabia;Spain;Ireland;Israel;Russian Federation;Switzerland;Australia;South Africa;Netherlands;China;Slovenia;Finland;Lithuania;Austria;United Kingdom;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Georgia;Germany;Norway;Japan;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
121	EUCTR2017-004295-55-SK	16/03/2018	7 January 2019	Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-	Celgene International II Sàrl		Authorised			Female: yes Male: yes	1200	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Saudi Arabia;Spain;Ireland;Israel;Russian Federation;Switzerland;Australia;South Africa;Netherlands;China;Slovenia;Finland;Lithuania;Austria;United Kingdom;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Georgia;Germany;Norway;Japan;New Zealand
122	EUCTR2017-000574-11-IE	13/03/2018	23 July 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective long term in the treatment of moderate to severe Ulcerative Colitis or Crohn's Disease (AIDA)	A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) - AIDA	Ulcerative colitis or Crohn's Disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-	Shire Human Genetic Therapies, Inc.		Authorised			Female: yes Male: yes	2453	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Italy;Switzerland;France;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan
123	EUCTR2017-004294-14-LT	12/03/2018	30 April 2019	Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Celgene International II Sàrl		Authorised			Female: yes Male: yes	485	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Saudi Arabia;Spain;Ireland;Israel;Russian Federation;Switzerland;Australia;South Africa;Netherlands;China;Slovenia;Finland;Lithuania;Austria;United Kingdom;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Georgia;Germany;Norway;Japan;New Zealand
124	EUCTR2017-004295-55-LT	12/03/2018	30 April 2019	Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-	Celgene International II Sàrl		Authorised			Female: yes Male: yes	1200	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Saudi Arabia;Spain;Ireland;Israel;Russian Federation;Switzerland;Australia;South Africa;Netherlands;China;Slovenia;Finland;Lithuania;Austria;United Kingdom;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Georgia;Germany;Norway;Japan;New Zealand
125	NCT03440385	March 7, 2018	4 November 2019	Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease	Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ozanimod;Other: Placebo	Celgene		Recruiting	12 Years	75 Years	All	675	Phase 3	United States;Australia;Austria;Brazil;Bulgaria;Canada;China;Finland;Georgia;Germany;Greece;Hungary;Israel;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
126	NCT03709628	March 7, 2018	26 November 2018	A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients	An Open-label, Multicenter, Pharmacokinetic Study of a FimH Blocker, EB8018, in Crohn's Disease Patients	Crohn Disease	Drug: EB8018 (First-in-class FimH blocker)	Enterome		Recruiting	18 Years	N/A	All	8	Phase 1	Austria;France;Germany;Italy
127	EUCTR2017-004293-33-HU	06/03/2018	30 April 2019	Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Active Crohn’s Disease	Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimod HCl) Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Other descriptive name: OZANIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Celgene International II Sàrl		Authorised			Female: yes Male: yes	600	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Hong Kong;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;France;Australia;South Africa;Netherlands;China;Korea, Republic of;Slovenia;Finland;Turkey;Lithuania;Austria;Hungary;Mexico;Canada;Poland;Singapore;Bulgaria;Georgia;Germany;Sweden
128	NCT03329209	March 5, 2018	10 September 2018	A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants	An Open-Label, Single-Center, Phase 1 Study to Determine the Pharmacokinetics of Single Intravenous Dose of Vedolizumab 300 mg in Healthy Adult Chinese Subjects	Colitis, Ulcerative;Crohn Disease	Drug: Vedolizumab	Takeda		Not recruiting	18 Years	45 Years	All	16	Phase 1	China
129	JPRN-UMIN000030884	2018/02/27	2 April 2019	A comparison of remission rate at 8 weeks between combination therapy of Ustekinumab and Budesonide and monotherapy of Ustekinumab in moderate to severe Japanese Crohn's disease; A phase III, single-center, double blind, randomized control trial.		Crohn's disease	Ustekinumab monotherapy for 32 weeks. Combination of Budesonide and Ustekinumab for 32 weeks.	Tohoku University Hospital, Division of Gastroenterology		Recruiting	18years-old	75years-old	Male and Female	80	Not selected	Japan
130	NCT03221166	February 27, 2018	22 July 2019	Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors	Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network	Crohn Disease	Drug: Thalidomide;Drug: Infliximab	IRCCS Burlo Garofolo	Centro di Riferimento Oncologico - Aviano;Azienda Ospedaliera Spedali Civili di Brescia	Recruiting	6 Years	17 Years	All	124	Phase 3	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
131	NCT03440372	February 27, 2018	22 October 2019	Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease	Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ozanimod;Other: Placebo	Celgene		Recruiting	12 Years	75 Years	All	675	Phase 3	United States;Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Germany;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Moldova, Republic of;Norway;Poland;Romania;Russian Federation;Saudi Arabia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom
132	NCT03801928	February 23, 2018	21 January 2019	Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease	OBSERVATIONAL, REAL WORLD STUDY OF INFLECTRA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) IN THE UNITED STATES AND CANADA	Inflammatory Bowel Disease (IBD);Crohn's Disease (CD);Ulcerative Colitis (UC)	Drug: Inflectra	Pfizer		Recruiting	18 Years	N/A	All	300	Phase 2	United States
133	NCT03351647	February 14, 2018	5 March 2018	Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease	Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Reactive Protein (CRP), Calprotectin, Ustekinumab Through Levels and Antibodies	Crohn Disease	Biological: Evaluation of biological predictive factors of clinical response to ustekinumab	Hospices Civils de Lyon		Recruiting	18 Years	18 Years	All	50	N/A	France
134	EUCTR2017-003017-25-AT	06/02/2018	7 January 2019	Clinical Study to Evaluation the Efficacy and Safety of PRV-6527 an Inhibitor of Colony Stimulating Factor-1 Receptor, in patients with Moderately to Severely Active Crohn’s Disease	A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of Colony Stimulating Factor-1 Receptor, in Subjects with Moderately to Severely Active Crohn’s Disease - PRovention INvestigation in Crohn’s DiseasE (PRINCE)	Moderately to severely Active Crohn's Disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 MedDRA version: 20.0 Level: LLT Classification code 10011403 Term: Crohn's disease aggravated System Organ Class: 100000004856 MedDRA version: 20.1 Level: LLT Classification code 10058815 Term: Crohn's disease acute episode System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: JNJ-40346527-AAC Product Code: PRV-6527 (JNJ-40346527) Pharmaceutical Form: Capsule, hard CAS Number: 1142364-35-9 Current Sponsor code: PRV-6527 (JNJ-40346527) Other descriptive name: JNJ-40346527-AAC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Provention Bio, Inc.		Authorised			Female: yes Male: yes	90	Phase 2	Hungary;Poland;Spain;Ukraine;Austria;Russian Federation;Germany
135	EUCTR2017-002258-36-BE	05/02/2018	4 December 2018	Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’s disease recurrence	A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Crohn’s disease recurrence - STOP-Postoperative Endoscopic Recurrence Study (STOP-PER)	Post-operative endoscopic Crohn’s disease recurrence MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin delayed release 400 mg film coated tablet Product Code: Rifaximin-EIR Pharmaceutical Form: Coated tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: Rifaximin-EIR Other descriptive name: RIFAXIMINA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1600- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	ALFASIGMA S.P.A.		Authorised			Female: yes Male: yes	180	Phase 2	Spain;Belgium;Netherlands;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
136	NCT03358706	February 2, 2018	11 November 2019	A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease	A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease.	Crohn Disease	Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg	Janssen Research & Development, LLC		Recruiting	18 Years	75 Years	All	51	Phase 1	United States;Belgium;Germany;Sweden;United Kingdom;Austria;Denmark
137	NCT03395184	February 2, 2018	4 November 2019	Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease	A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN'S DISEASE	Crohn's Disease	Drug: Placebo PF-06651600;Drug: Placebo PF-06700841;Drug: PF-06651600;Drug: PF-06700841	Pfizer		Recruiting	18 Years	75 Years	All	250	Phase 2	United States;Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates
138	NCT03185000	February 2018	16 December 2017	Treg Immunotherapy in Crohn's Disease	A Double-blind, Placebo Controlled, First Into Human Clinical Trial of T Regulatory Cells (TR004) for Inflammatory Bowel Disease Using (ex Vivo) Treg Expansion	Crohn Disease	Drug: TR004 (Treg immunotherapy);Other: Placebo	King's College London	Guy's and St Thomas' NHS Foundation Trust;Medical Research Council;Imperial College London;St. George's Hospital, London;Miltenyi biotech	Not recruiting	18 Years	80 Years	All	24	Phase 1/Phase 2
139	NCT03901235	January 15, 2018	15 April 2019	MSC Intratissular Injection in Crohn Disease Patients	Treatment of Refractory Crohn's Disease Lesions by Local Injection of Mesenchymal Stem Cells	Efficacy and Safety	Biological: Mesenchymal Stromal Cells	University Hospital of Liege	Laboratoire de Thérapie Cellulaire et Génétique from CHU de Liège	Recruiting	18 Years	N/A	All	60	Phase 1/Phase 2	Belgium
140	EUCTR2017-002231-41-BE	10/01/2018	20 August 2018	A study to investigate how the body responds to the study drug Vedolizumab in child patients with Ulcerative Colitis or Crohn’s Disease	A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease (A Phase 2, Randomized, Double-Blind, Dose-Ranging Study With Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease) - Hubble	Ulcerative Colitis and Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Entyvio Product Name: Vedolizumab IV Product Code: MLN0002 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Vedolizumab CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Entyvio Product Name: Vedolizumab IV Product Code: MLN0002 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Vedolizumab CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Trade Name: Entyvio Product Name: Vedolizumab IV Product Code: MLN0002 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Vedolizumab CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Entyvio Product Name: Vedolizumab IV Product Code: MLN0002 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Vedolizumab CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Takeda Development Centre Europe, Ltd.		Authorised			Female: yes Male: yes	80	Phase 2	United Kingdom;Germany;Netherlands;Israel;Ukraine;Belgium;Poland;Canada;Hungary;United States;France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
141	EUCTR2017-003017-25-HU	08/01/2018	22 January 2018	Clinical Study to Evaluation the Efficacy and Safety of PRV-6527 an Inhibitor of Colony Stimulating Factor-1 Receptor, in patients with Moderately to Severely Active Crohn’s Disease	A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of Colony Stimulating Factor-1 Receptor, in Subjects with Moderately to Severely Active Crohn’s Disease - PRovention INvestigation in Crohn’s DiseasE (PRINCE)	Moderately to severely Active Crohn's Disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 MedDRA version: 20.0 Level: LLT Classification code 10011403 Term: Crohn's disease aggravated System Organ Class: 100000004856 MedDRA version: 20.1 Level: LLT Classification code 10058815 Term: Crohn's disease acute episode System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: JNJ-40346527-AAC Product Code: PRV-6527(JNJ-40346527) Pharmaceutical Form: Capsule, hard CAS Number: 1142364-35-9 Current Sponsor code: PRV-6527(JNJ-40346527) Other descriptive name: JNJ-40346527-AAC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Provention Bio, Inc.		Authorised			Female: yes Male: yes	90	Phase 2	Germany;Russian Federation;Austria;Ukraine;Spain;Poland;Hungary
142	EUCTR2016-003179-23-DE	19/12/2017	28 February 2019	This trial will test the drug filgotinib for the treatment of small bowel Crohn’s disease.	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD)	Small Bowel Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Gilead Sciences, Inc.		Authorised			Female: yes Male: yes	100	Phase 2	United States;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Belgium;Poland;Germany
143	NCT03104413	December 18, 2017	22 October 2019	A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Crohn's Disease	Drug: risankizumab SC;Drug: placebo for risankizumab IV;Drug: risankizumab IV	AbbVie		Recruiting	16 Years	80 Years	All	579	Phase 3	United States;American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;Brazil;Turkey
144	NCT03345849	December 7, 2017	4 November 2019	A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies	Crohn's Disease	Drug: Upadacitinib;Drug: Placebo for Upadacitinib	AbbVie		Recruiting	18 Years	75 Years	All	501	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;American Samoa;Belarus
145	EUCTR2017-002258-36-ES	04/12/2017	26 March 2018	Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’s disease recurrence	A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Crohn’s disease recurrence - STOP-Postoperative Endoscopic Recurrence Study (STOP-PER)	Post-operative endoscopic Crohn’s disease recurrence MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000016693 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin delayed release 400 mg film coated tablet Product Code: Rifaximin-EIR Pharmaceutical Form: Coated tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: Rifaximin-EIR Other descriptive name: RIFAXIMINA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1600- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	ALFASIGMA S.P.A.		Not Recruiting			Female: yes Male: yes	180	Phase 2	Spain;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
146	NCT03362736	December 4, 2017	22 October 2019	An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease	An Early Access Program for Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab	Janssen Research & Development, LLC		Not recruiting	18 Years	N/A	All		Phase 1	Brazil
147	NCT02974322	December 1, 2017	16 December 2017	A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease	A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease	Crohn Disease	Drug: GED-0301;Drug: Placebo	Celgene		Not recruiting	12 Years	N/A	All	0	Phase 3	United States;Australia;Austria;Belgium;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;Bosnia and Herzegovina;Czech Republic
148	NCT02559713	November 29, 2017	11 March 2019	Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease	An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically	Colitis, Ulcerative;Crohn Disease	Drug: Vedolizumab	Takeda		Not recruiting	18 Years	N/A	Female	11	Phase 4	United States
149	NCT03345836	November 29, 2017	11 November 2019	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy	Crohn's Disease	Other: Matching placebo for upadacitinib;Drug: upadacitinib	AbbVie		Recruiting	18 Years	75 Years	All	645	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;American Samoa;Belarus
150	EUCTR2017-002258-36-DE	21/11/2017	28 February 2019	Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’s disease recurrence	A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Crohn’s disease recurrence - STOP-Postoperative Endoscopic Recurrence Study (STOP-PER)	Post-operative endoscopic Crohn’s disease recurrence MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin delayed release 400 mg film coated tablet Product Code: Rifaximin-EIR Pharmaceutical Form: Coated tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: Rifaximin-EIR Other descriptive name: RIFAXIMINA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	ALFASIGMA S.P.A.		Authorised			Female: yes Male: yes	180	Phase 2	Spain;Belgium;Netherlands;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
151	NCT03537157	November 16, 2017	24 September 2018	A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention	A Phase II, Multicentre, Double-blind, Randomised, Placebo-controlled Study of Rifaximin Delayed Release 400 mg Tablet: Clinical Efficacy and Safety in the Prevention of Post-operative Endoscopic Crohn's Disease Recurrence	Crohn Disease	Drug: Rifaximin delayed release tablets;Other: Placebo	Alfasigma S.p.A.	Cromsource	Recruiting	18 Years	75 Years	All	156	Phase 2	Italy
152	NCT03266484	November 13, 2017	18 March 2019	Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease	Effect of Dietary Therapy With a Probiotic Mixture on the Gut Microbiome and Fatigue Symptoms in Patients With Quiescent Inflammatory Bowel Disease - A Clinical Trial	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Dietary Supplement: Probiotic Mixture;Dietary Supplement: Placebo	Massachusetts General Hospital	Winclove Bio Industries BV	Recruiting	18 Years	75 Years	All	100	N/A	United States
153	NCT03357471	November 3, 2017	10 September 2018	Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondylitis;Moderately to Severely Active Crohn's Disease	Drug: e-Device	UCB Biopharma S.P.R.L.		Not recruiting	18 Years	N/A	All	70	Phase 3	United States
154	NCT03755583	November 1, 2017	21 January 2019	Effect of Exclusive Enteral Nutrition on Disease Process, Nutritional Status and Gastrointestinal Microbiota for Chinese Children With Crohn's Disease	Effect of Exclusive Enteral Nutrition on Disease Process, Nutritional Status and Intestinal Microbiota for Chinese Children With Crohn's Disease	Crohn Disease;Enteral Nutrition;Gastrointestinal Microbiome	Dietary Supplement: Exclusive Enteral Nutrition	Children's Hospital of Fudan University		Recruiting	1 Year	17 Years	All	40	N/A	China
155	NCT03167437	October 30, 2017	8 April 2019	Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease	An Open-Label, Phase I/II Pilot Study to Assess the Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease	Crohn's Disease	Drug: Vorinostat	National Institute of Allergy and Infectious Diseases (NIAID)		Recruiting	18 Years	65 Years	All	35	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
156	NCT03495973	October 25, 2017	22 October 2019	Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease	Prospective Observational Study on Stelara Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)	Crohn Disease	Drug: Ustekinumab	Janssen-Cilag Ltd.		Not recruiting	18 Years	N/A	All	110	Phase 2	Sweden
157	NCT03171246	October 23, 2017	11 June 2018	CD-TREAT Diet: a Novel Therapy for Active Luminal Crohn's Disease	An Open Label Pilot Study of the CD-TREAT Diet as a Novel Therapy for Active Luminal Crohn's Disease	Crohn Disease	Dietary Supplement: Solid food-based intervention	NHS Greater Glasgow and Clyde	University of Glasgow	Recruiting	6 Years	65 Years	All	20	N/A	United Kingdom
158	NCT03220243	October 19, 2017	26 August 2019	Stem Cell Coated Fistula Plug in Patients With Crohn's RVF	A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Rectovaginal Fistulizing Crohn's Disease	Fistula Vagina;Crohn Disease	Drug: MSC-AFP	Mayo Clinic		Not recruiting	18 Years	65 Years	Female	5	Phase 1	United States
159	NCT03220841	October 9, 2017	16 September 2019	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study	Crohn Disease;Inflammatory Bowel Diseases;Stricture; Bowel	Drug: Adalimumab Injection;Drug: Thiopurine;Procedure: Endoscopic balloon dilatation	St Vincent's Hospital Melbourne	Australasian Gastro Intestinal Research Foundation;AbbVie	Recruiting	18 Years	N/A	All	78	Phase 4	Australia
160	NCT03279081	September 15, 2017	7 October 2019	Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)	A Phase-III Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow up Period up to 52 Weeks	Crohn's Disease	Drug: Cx601;Other: Placebo	Tigenix S.A.U.		Recruiting	18 Years	N/A	All	600	Phase 3	United States;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Puerto Rico;Spain;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
161	EUCTR2016-003191-50-CZ	13/09/2017	28 February 2019	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: RISANKIZUMAB CAS Number: 1612838-76-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: RISANKIZUMAB CAS Number: 1612838-76-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for infusion INN or Proposed INN: RISANKIZUMAB CAS Number: 1612838-76-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for infusion INN or Proposed INN: RISANKIZUMAB CAS Number: 1612838-76-2 Concentration unit: mg milligram(s) Concentration type: equal	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	959	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Chile;Italy;France;Puerto Rico;Denmark;Latvia;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Estonia;Spain;Ireland;Russian Federation;Israel;Colombia;Switzerland;Malaysia;Australia;South Africa;Netherlands;Slovenia;Finland;Lithuania;Austria;United Kingdom;Egypt;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Germany;Norway;Japan;New Zealand
162	JPRN-JapicCTI-184152	01/9/2017	16 July 2019	Investigation of the safety and efficacy of Budesonide ( Zentacort Capsules ) in patients with Crohn's disease	Investigation of the safety and efficacy of Budesonide ( Zentacort Capsules ) in patients with Crohn's disease	Crohn's disease	Intervention name : Budesonide ( Zentacort Capsules 3mg ) INN of the intervention : Budesonide Dosage And administration of the intervention : Oral	ZERIA Pharmaceutical Co., Ltd.		Recruiting			BOTH	200	NA
163	EUCTR2017-000725-12-CZ	08/08/2017	23 July 2018	A clinical research study of an investigational new drug to treat perianal fistulas in patients with Crohn’s disease (CD).	A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn’s disease over a period of 24 weeks and a follow-up period up to 52 weeks. ADMIRE-CD II study.	Perianal fistulising Crohn´s disease MedDRA version: 20.0 Level: PT Classification code 10002156 Term: Anal fistula System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Allogenic eASCs 5 million cells/ml suspension for injection CX601 Product Code: Cx601 Pharmaceutical Form: Suspension for injection INN or Proposed INN: nap Current Sponsor code: Allogenic eASCs Other descriptive name: Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs) Concentration unit: Other Concentration type: equal Concentration number: 5000000- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intralesional use	TiGenix, S.A.U.		Authorised			Female: yes Male: yes	326	Phase 3	Italy;Israel;Spain;Belgium;Poland;Canada;Czech Republic;Hungary;United States;France
164	NCT03234907	August 3, 2017	11 June 2019	Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: Vedolizumab IV;Drug: Placebo	Takeda		Not recruiting	18 Years	80 Years	All	215	Phase 3	China
165	NCT03162432	August 1, 2017	30 September 2019	High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade	High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade	IBD;Ulcerative Colitis;Crohn Disease	Drug: Vitamin D3	Boston Children’s Hospital		Recruiting	7 Years	25 Years	All	50	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
166	NCT03185624	July 25, 2017	16 December 2017	Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease	Effectiveness of Rifaximin on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients Without Risk Factor for Recurrence: A Multicenter Randomized Controlled Trial	Crohn Disease	Drug: Rifaximin	Sixth Affiliated Hospital, Sun Yat-sen University	First Affiliated Hospital, Sun Yat-Sen University;Peking Union Medical College Hospital;Xijing Hospital;Shanghai 10th People's Hospital;RenJi Hospital;Sir Run Run Shaw Hospital	Not recruiting	18 Years	65 Years	All	80	Phase 3	China
167	NCT02330211	July 17, 2017	21 January 2019	Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's Colitis	A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Crohn's Colitis	Inflammatory Bowel Diseases;Crohn Disease	Biological: Fecal Microbiota Transplant;Biological: Placebo	Stacy A. Kahn		Not recruiting	5 Years	30 Years	All	4	Phase 1/Phase 2	United States
168	NCT03169894	July 14, 2017	18 March 2019	Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease	Phase Ib Escalating Dose, Open-Label, Signal-Finding Study to Evaluate the Safety, Tolerability, and Short-Term Efficacy of the Anti-Light Monoclonal Antibody MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease Who Previously Failed Treatment With an Anti-TNFa Agent, With and Without Loss of Function Mutations in Decoy Receptor 3 (Anti-LIGHT in Anti-TNFa-Resistant Crohn's Disease [TRaCk LIGHT])	Crohn Disease	Drug: MDGN-002	Aevi Genomic Medicine		Recruiting	18 Years	65 Years	All	8	Phase 1	United States
169	NCT03219359	July 12, 2017	23 April 2019	Autologous Stem Cell Transplant for Crohn's Disease	Maintenance in Autologous Stem Cell Transplant for Crohn's Disease (MASCT - CD)	Crohn Disease	Drug: Vedolizumab;Drug: Methylprednisolone;Drug: Thymoglobulin;Drug: Cyclophosphamide;Procedure: Autologous stem cell transplant	Icahn School of Medicine at Mount Sinai		Recruiting	18 Years	N/A	All	50	Phase 2	United States
170	JPRN-UMIN000028139	2017/07/04	2 April 2019	Therapeutic reactivity of Ustekinumab in moderate to severe active stage Crohn's disease		Crohn's disease	Treatment with Ustekinumab	Graduate School of Medical Sciences, Kyushu University		Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
171	NCT03014219	July 2017	16 December 2017	Phase 1 Crohn's Pediatric Sub-study of MSC AFP	A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study	Perianal Fistula	Drug: Only 1 arm: treatment with MSC-AFP	William A. Faubion, M.D.		Not recruiting	12 Years	17 Years	All	0	Phase 1	United States
172	NCT03235180	June 16, 2017	14 October 2019	Ultrasound Evaluation of Crohn's Disease	Ultrasound Evaluation of Crohn's Disease	Crohn Disease	Drug: Sulfur Hexafluoride;Device: Ultrasound Elastography;Device: Ultrasound Vascularity;Device: Magnetic Resonance Enterography (MRE)	Mayo Clinic		Recruiting	18 Years	N/A	All	100	Phase 4	United States
173	NCT03267238	June 16, 2017	4 November 2019	Fecal Microbial Transplantation in Patients With Crohn's Disease	Fecal Microbial Transplantation in Patients With Crohn's Disease	Crohn Disease	Biological: Fecal Microbial Transplantation	Stony Brook University		Not recruiting	7 Years	N/A	All	9	Early Phase 1	United States
174	NCT02764762	June 12, 2017	11 November 2019	Triple Combination Therapy in High Risk Crohn's Disease (CD)	An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications	Crohn Disease	Drug: Vedolizumab;Drug: Adalimumab;Drug: Methotrexate	Takeda		Recruiting	18 Years	65 Years	All	60	Phase 4	United States;Canada
175	NCT03393247	June 1, 2017	18 January 2018	The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on CD	The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on Crohn Disease:a Randomized, Open Label, Single-center Cohort Study	Crohn Disease	Drug: infliximab and azathioprine combination at week 0;Drug: infliximab and azathioprine combination at week 14	Sixth Affiliated Hospital, Sun Yat-sen University		Recruiting	14 Years	60 Years	All	160	N/A	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
176	JPRN-UMIN000025961	2017/05/21	10 September 2019	The study of effect of Alfacalcidol treatment on Crohn's disease	The study of effect of Alfacalcidol treatment on Crohn's disease - The study of effect of Alfacalcidol treatment on Crohn's disease	Crohn's disease	Oral treatment of Alfacalcidol 1 microgram/day for 3 month	Nagoya University Hospital		Recruiting	18years-old	Not applicable	Male and Female	31	Not selected	Japan
177	JPRN-jRCTs041180126	21/05/2017	10 September 2019	CD Alfacalcidol study	The study of effect of Alfacalcidol treatment on Crohn's disease	Crohn's disease	administration of alfacalcidol for patietns with active lesion of small intestine by CE and low 25OHD level.	Masanao Nakamura		Recruiting	18age	Not applicable	Both	36	Phase 2	none
178	NCT03155945	May 18, 2017	16 September 2019	Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain	A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain	Crohn's Disease;Abdominal Pain	Drug: APD371	Arena Pharmaceuticals		Not recruiting	18 Years	80 Years	All	14	Phase 2	United States
179	NCT03185611	May 18, 2017	16 December 2017	Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease	Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients With Risk Factor for Recurrence: A Multicenter Randomized Controlled Trial	Crohn Disease	Drug: Rifaximin;Drug: Azathioprine	Sixth Affiliated Hospital, Sun Yat-sen University	First Affiliated Hospital, Sun Yat-Sen University;Peking Union Medical College Hospital;Xijing Hospital;Shanghai 10th People's Hospital;RenJi Hospital;Sir Run Run Shaw Hospital	Recruiting	18 Years	65 Years	All	120	Phase 3	China
180	NCT03105128	May 10, 2017	4 November 2019	A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: placebo for risankizumab;Drug: risankizumab IV;Drug: risankizumab SC	AbbVie		Recruiting	16 Years	80 Years	All	940	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;Finland;France;Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
181	NCT03172377	May 3, 2017	24 September 2018	Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients	Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients	Crohn Disease in Remission;Crohn Disease	Other: Lengthening adalimumab dosing interval	Radboud University	Erasmus Medical Center	Recruiting	18 Years	N/A	All	174	Phase 4	Netherlands
182	NCT03059849	May 1, 2017	16 December 2017	Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD	Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD	Crohn Disease;Ulcerative Colitis	Drug: Adalimumab	McMaster University		Not recruiting	18 Years	80 Years	All	290	Phase 4
183	NCT02994836	April 21, 2017	27 May 2019	GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )	Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation	Crohn's Disease;Inflammatory Bowel Disease;Ulcerative Colitis	Drug: Anti-TNF discontinuation: Physiological saline solution;Biological: Anti-TNF:Adalimumab (Subcutaneus);Biological: Anti-TNF: Infliximab (Infusion)	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa		Recruiting	18 Years	N/A	All	194	Phase 4	Spain
184	NCT03107793	April 19, 2017	11 November 2019	Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab	Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab	Crohn Disease	Drug: Ustekinumab	Janssen-Cilag Ltd.		Not recruiting	18 Years	N/A	All	500	Phase 3	Belgium;Czechia;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom
185	NCT03108326	April 15, 2017	23 July 2018	Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease	Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease in Conjunction With Long-term Outcome	Crohn Disease	Biological: Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra	Ced Service GmbH		Recruiting	18 Years	80 Years	All	900	Phase 1	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
186	NCT02953275	April 13, 2017	22 July 2019	Synergistic Effect of Vedolizumab and Pentoxifylline	Synergistic Effect of Vedolizumab and Pentoxifylline in the Management of Patients With Inflammatory Bowel Disease	Crohn Disease	Drug: vedolizumab;Drug: Pentoxifylline;Drug: placebo	University of Miami	Takeda	Not recruiting	18 Years	80 Years	All	37	Early Phase 1	United States
187	NCT03046056	April 11, 2017	11 November 2019	Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)	Small Bowel Crohn's Disease	Drug: Filgotinib;Drug: Placebo to match filgotinib	Gilead Sciences	Galapagos NV	Recruiting	18 Years	75 Years	All	100	Phase 2	United States;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Spain;Ukraine;United Kingdom
188	NCT03077412	April 6, 2017	14 October 2019	Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease	Fistulizing Crohn's Disease	Drug: Filgotinib;Drug: Placebo to match filgotinib	Gilead Sciences	Galapagos NV	Recruiting	18 Years	75 Years	All	75	Phase 2	United States;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;Poland
189	EUCTR2016-002939-15-DE	05/04/2017	30 April 2019	A clinical study testing the efficacy and safety of V565 in patients with Crohn's Disease	A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn’s disease. - A six week efficacy, safety and tolerability study of V565 in Crohn's disease (the HarbOR study).	Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: V565 Product Code: V565 Pharmaceutical Form: Capsule INN or Proposed INN: not applied for Current Sponsor code: V565 Other descriptive name: V565 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 185- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	VHsquared Ltd		Not Recruiting			Female: yes Male: yes	126	Phase 2	United States;Slovakia;Ukraine;Austria;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Germany;Netherlands;Norway
190	NCT03078803	March 28, 2017	25 February 2019	Fecal Transplant for Crohn's Disease	A Prospective Multicenter Randomized Controlled Trial Comparing Fecal Microbiota Transplantation (FMT) to Placebo in the Treatment of Mild to Moderate Crohn's Disease	Crohn Disease	Biological: Fecal Microbiota Transplant (FMT);Biological: Placebo	University of Alberta	University of Calgary;McMaster University	Recruiting	18 Years	N/A	All	126	Phase 2	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
191	NCT03090139	March 28, 2017	2 July 2018	Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets	Indicators of Sub-Optimal Response to Anti-Tumor Necrosis Factor (TNF) Therapy in Patients With Crohn's Disease (CD) and Ulcerative Colitis (UC): A Retrospective Chart Review in the Emerging Market (EM) Region (EXPLORE)	Colitis, Ulcerative;Crohn Disease;Inflammatory Bowel Diseases	Drug: Anti-TNF Therapy	Takeda		Not recruiting	18 Years	N/A	All	1731	Phase 3	Argentina;China;Colombia;Korea, Republic of;Mexico;Russian Federation;Saudi Arabia;Singapore;Taiwan;Turkey
192	NCT03009396	March 18, 2017	11 March 2019	Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease	An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study	Crohn Disease	Drug: RHB-104; a fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine	RedHill Biopharma Limited		Not recruiting	18 Years	76 Years	All	331	Phase 3	United States;Canada;Czechia;Israel;New Zealand;Poland;Serbia
193	NCT02914600	March 17, 2017	22 October 2019	Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease	A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease	Crohn's Disease	Drug: Filgotinib;Drug: Placebo	Gilead Sciences	Galapagos NV	Recruiting	18 Years	N/A	All	1000	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;Czech Republic
194	NCT03027193	March 15, 2017	11 November 2019	A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers	A Phase I Clinical Trial to Determine the Safety and Immunogenicity of the Candidate Mycobacterium Avium Subspecies Paratuberculosis (MAP) Vaccines ChAdOx2 HAV and MVA HAV in Healthy Adult Volunteers	Crohn Disease;Mycobacterium Avium Subspecies Paratuberculosis	Biological: ChAdOx2 HAV;Biological: MVA HAV	University of Oxford		Recruiting	18 Years	50 Years	All	28	Phase 1	United Kingdom
195	EUCTR2016-002918-43-GB	28/02/2017	26 February 2018	Study to compare 2 treatment strategies in Crohn's Disease patients treated with Ustekinumab	Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn’s Disease Patients Treated with Ustekinumab	Moderately to severely active Crohn's disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for infusion INN or Proposed INN: ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: USTEKINUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 130- Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: USTEKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90-	Janssen-Cilag International N.V.		Authorised			Female: yes Male: yes	650	Phase 3	United Kingdom;Germany;Netherlands;Spain;Belgium;Portugal
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
196	JPRN-UMIN000026330	2017/02/27	10 September 2019	Efficacy and safety of the biosimilar Infliximab in the patients with Crohn's disease	Efficacy and safety of the biosimilar Infliximab in the patients with Crohn's disease - Efficacy and safety of IFX-BS in CD patients	Crohn disease	Infliximab (5 or 10mg/kg, every 8 weeks, for 12 months) Biosimilar Infliximab (5 or 10mg/kg, every 8 weeks, for 12 months)	University of Toyama		Not Recruiting	20years-old	Not applicable	Male and Female	30	Not selected	Japan
197	EUCTR2016-003797-40-BE	23/02/2017	23 October 2017	A clinical study to investigate the effectiveness and safety of treatment with the drug APD334 in ulcerative colitis and crohn's disease patients with skin conditions	A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations	Active Skin Extra-Intestinal Manifestations in Inflammatory Bowel Disease.;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: APD334 Pharmaceutical Form: Tablet INN or Proposed INN: Not yet available CAS Number: 1206123 97 8 Current Sponsor code: APD334 Other descriptive name: APD334 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2-	Arena Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	20	Phase 2	United States;Belgium;Germany
198	EUCTR2015-001924-40-AT	21/02/2017	6 November 2017	A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn's disease in adults and adolescents.	A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with active Crohn’s disease - A Study of Efficacy and Safety of GED-0301 in Adults and Adolescents with Crohn's Disease	Active Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 100000016693 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Mongersen Product Code: GED-0301 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: mongersen CAS Number: 1443994-98-6 Current Sponsor code: GED-0301 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Mongersen Product Code: GED-0301 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: mongersen CAS Number: 1443994-98-6 Current Sponsor code: GED-0301 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Celgene Corporation		Not Recruiting			Female: yes Male: yes	798	Phase 3	Serbia;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Norway;Germany;Sweden;Austria;Turkey;Finland;Bosnia and Herzegovina;Korea, Republic of;Latvia;Netherlands;Denmark;Australia;Malaysia;France;Switzerland;Italy;Colombia;Chile;Israel;Russian Federation;Ukraine;Spain;Greece;Slovakia;Taiwan;United States;Portugal
199	EUCTR2016-003797-40-DE	21/02/2017	15 October 2018	A clinical study to investigate the effectiveness and safety of treatment with the drug APD334 in ulcerative colitis and crohn's disease patients with skin conditions	A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations	Active Skin Extra-Intestinal Manifestations in Inflammatory Bowel Disease.;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: APD334 Pharmaceutical Form: Tablet INN or Proposed INN: Not yet available CAS Number: 1206123 97 8 Current Sponsor code: APD334 Other descriptive name: APD334 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2-	Arena Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	20	Phase 2	United States;Belgium;Germany
200	JPRN-UMIN000025846	2017/02/01	2 April 2019	A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease		ulcerative colitis, Crohn's disease	Administration of the fecal material from healthy donors to patients after taking three kinds of antibiotics (Amoxicillin, fosmycin, metronidazole) for two weeks	Juntendo university school of medicine Department of gastroenterology		Recruiting	16years-old	Not applicable	Male and Female	60	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
201	JPRN-jRCTs031180415	01/02/2017	22 July 2019	A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease	Single center non-randomized study: A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease	Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease)	AFM therapy arm : three antibiotics, amoxicillin (1500 mg/day), fosfomycin (3000 mg/day) and metronidazole (750 mg/day) are administered orally to patients for 2 weeks. For pediatric patients, amoxicillin (50mg/kg), fosfomycin (120mg/kg) and metronidazole (20mg/kg) are administered orally for 2 weeks (the upper limit is the same amount as adults). FMT arm : Approximately 150 to 250 g of donor stool is diluted with saline (500 mL) and filtered to remove crude components. The diluted and filtered fecal suspension is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site. A-FMT arm : Patient undergoes FMT two days after AFM therapy.	Dai Ishikawa		Recruiting	>=6 age old		Both	120	N/A	none
202	EUCTR2015-001179-36-CZ	30/01/2017	28 February 2019	Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate to Severely Crohn’s disease. Subjects will be separated in two groups that will be treated in parallel to receive study drug or placebo. Neither the treating physician nor the subject will be aware of the actual treatment received.	A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn’s Disease. - RHB-104-01	Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: RHB-104 Pharmaceutical Form: Capsule INN or Proposed INN: Clarithromycin CAS Number: 81103-11-9 Other descriptive name: CLARITHROMYCIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- INN or Proposed INN: Rifabutin CAS Number: 72559-06-9 Other descriptive name: RIFABUTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 45- INN or Proposed INN: Clofazimine CAS Number: 2030-63-9 Other descriptive name: CLOFAZIMINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	RedHill Biopharma Ltd.		Not Recruiting			Female: yes Male: yes	324	Phase 3	Serbia;United States;Czech Republic;Slovakia;Canada;Poland;Romania;Australia;Israel;Bulgaria;New Zealand
203	EUCTR2016-002939-15-CZ	24/01/2017	3 September 2018	A clinical study testing the efficacy and safety of V565 in patients with Crohn's Disease.	A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn’s disease. - English A six week efficacy, safety and tolerability study of V565 in Crohn’s disease (HarbOR study)	Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: V565 Product Code: V565 Pharmaceutical Form: Capsule INN or Proposed INN: not applied for Current Sponsor code: V565 Other descriptive name: V565 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 185- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	VHsquared Ltd		Authorised			Female: yes Male: yes	126	Phase 2	United States;Hungary;Czech Republic;Slovakia;Canada;Poland;Belgium;Ukraine;Austria;Netherlands;Germany;United Kingdom
204	NCT03000101	January 19, 2017	21 January 2019	Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease	New Insight and Knowledge on Anti-inflammatory Effectiveness of Dietary Phenolics (NIKE)	Crohn's Disease;Ulcerative Colitis	Other: placebo beverage;Other: 100% pomegranate juice	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi	University of Bologna;Conserve Italia;GAT Foods	Not recruiting	18 Years	80 Years	All	18	N/A	Italy
205	EUCTR2016-003321-42-NL	18/01/2017	10 April 2017	Stepwise extention of the adalimumab injection interval in patients with stable Crohn's disease.	Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients: the LADI study.	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira (adalimumab) Product Name: Adalimumab Pharmaceutical Form: Injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Radboud University Medical Centre		Authorised			Female: yes Male: yes		Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
206	NCT02968108	January 18, 2017	27 May 2019	A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease	A Randomized Double-blind Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab	Janssen Research & Development, LLC		Not recruiting	2 Years	17 Years	All	45	Phase 1	United States;Belgium;Canada;France;Germany;Poland
207	NCT03261102	January 17, 2017	25 March 2019	TDM Guided Early Optimization of ADAL in Crohn's Disease	Therapeutic Drug Monitoring Guided Early Optimization of Adalimumab in Crohn's Disease; A Randomized Open Label Study	Crohn Disease;Drug Monitoring;Inflammatory Bowel Diseases	Biological: Adalimumab	waqqas.afif	AbbVie	Recruiting	18 Years	N/A	All	200	N/A	Canada
208	EUCTR2015-001179-36-SK	13/01/2017	28 February 2019	Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate to Severely Crohn’s disease. Subjects will be separated in two groups that will be treated in parallel to receive study drug or placebo. Neither the treating physician nor the subject will be aware of the actual treatment received.	A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn’s Disease. - RHB-104-01	Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: RHB-104 Pharmaceutical Form: Capsule INN or Proposed INN: Clarithromycin CAS Number: 81103-11-9 Other descriptive name: CLARITHROMYCIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- INN or Proposed INN: Rifabutin CAS Number: 72559-06-9 Other descriptive name: RIFABUTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 45- INN or Proposed INN: Clofazimine CAS Number: 2030-63-9 Other descriptive name: CLOFAZIMINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	RedHill Biopharma Ltd.		Not Recruiting			Female: yes Male: yes	324	Phase 3	Serbia;United States;Czech Republic;Slovakia;Canada;Poland;Romania;Australia;Israel;Bulgaria;New Zealand
209	EUCTR2016-002763-34-GB	04/01/2017	28 February 2019	A Long Term Study to Follow the Safety of a New Treatment in Patients with Crohn’s Disease	A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease	Moderately to Severely Active Crohn's Disease (CD) MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: Filgotinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: Filgotinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Gilead Sciences, Inc.		Authorised			Female: yes Male: yes	1000	Phase 3	Serbia;Portugal;United States;Belarus;Taiwan;Hong Kong;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Sri Lanka;Italy;Switzerland;India;France;Malaysia;Australia;South Africa;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Romania;Croatia;Bulgaria;Georgia;Norway;Iceland;Germany;New Zealand;Japan;Sweden
210	NCT02862132	January 2017	28 January 2019	Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases	Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)	Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease	Drug: Vedolizumab	Shaare Zedek Medical Center		Recruiting	N/A	18 Years	All	120	N/A	United States;Denmark;Finland;Ireland;Israel;Slovenia;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
211	NCT03012542	January 2017	11 June 2018	Diet as Essential Therapy (DIET) for Inflammatory Bowel Disease	Randomized Trial of Diet for Crohn's Disease and Impact on Disease Activity and the Microbiome	Crohn Disease	Dietary Supplement: Diet 1;Dietary Supplement: Diet 2	University of Washington		Recruiting	18 Years	N/A	All	32	N/A	United States
212	NCT03056664	January 2017	16 December 2017	The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease	The Safety and Efficiacy of Local MSC Injection in the Treatment of Fistulas in Patients With Perianal Crohn's Disease	Crohn's Disease;Fistula	Procedure: Routine drainage surgery;Biological: MSC injection 01;Biological: MSC injection 02;Other: placebo	Sixth Affiliated Hospital, Sun Yat-sen University		Not recruiting	18 Years	65 Years	All	3	Phase 2/Phase 3
213	EUCTR2017-000576-29-IE		18 June 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)(CARMEN CD 306).	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306) - CARMEN CD 306	Crohn’s disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Not Available			Female: yes Male: yes	1032	Phase 3	Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Colombia;Switzerland;France;Hungary;Mexico;Canada;Argentina;Belgium;Bulgaria;Japan;Korea, Republic of;Bosnia and Herzegovina
214	EUCTR2017-000617-23-IE		18 June 2018	Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) - CARMEN CD 307	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SHP647 Product Code: SHP647 Pharmaceutical Form: Solution for injection INN or Proposed INN: Anti-MAdCAM antibody Current Sponsor code: SHP647 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Shire Human Genetic Therapies, Inc.		Not Available			Female: yes Male: yes	983	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Colombia;Italy;Switzerland;France;Australia;South Africa;Netherlands;Korea, Republic of;Bosnia and Herzegovina;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan
215	EUCTR2017-003649-10-PL		28 February 2019	A Pharmacokinetic, Pharmacodynamic, and Safety Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients From 4 Years to Less Than 18 Years of Age with Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn’s Disease	A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR MODERATE TO SEVERE CROHN’S DISEASE	Moderate to severe ulcerative colitis (UC); moderate to severe Crohn’s disease (CD) MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10009900 Term: Colitis ulcerative System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Etrolizumab Product Code: 549-0261/F02-01 Pharmaceutical Form: Solution for injection INN or Proposed INN: ETROLIZUMAB CAS Number: 1044758-60-2 Current Sponsor code: RO5490261/F02-01 Other descriptive name: ETROLIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150-	F. Hoffmann-La Roche Ltd		Not Available			Female: yes Male: yes	60	Phase 1	United States;Belgium;Spain;Poland;Germany;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
216	NCT02891226	December 14, 2016	9 September 2019	A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease	A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)	Crohn's Disease	Drug: Mirikizumab;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	75 Years	All	180	Phase 2	United States;Australia;Belgium;Canada;Czechia;Hungary;Japan;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;Austria;Czech Republic;France
217	NCT02231814	December 2016	24 September 2018	Pilot Study of Partial Enteral Nutrition With a Unique Diet for the Treatment of Adult Patients With Crohn's Disease	Dietary Therapy Using Partial Enteral Nutrition and the Crohn's Disease Exclusion Diet (CDED) for Induction and Maintenance of Remission in Mild to Moderate Crohn's Disease in Adults- A Pilot Study	Crohn's Disease	Dietary Supplement: Crohns Disease Exclusion Diet + PEN;Other: Crohns Disease Exclusion Diet	Prof. Arie Levine		Recruiting	18 Years	55 Years	All	40	N/A	Israel
218	NCT02704624	December 2016	9 July 2018	Effects of Supplementation of Vitamin D in Patients With Crohn`s Disease	The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial	Crohn Disease;Vitamin D Deficiency;Fatigue;Sarcopenia;Muscle Weakness;Disorder of Bone Density and Structure, Unspecified	Dietary Supplement: Vitamin D;Other: Placebo	Federal University of Juiz de Fora	Fundação de Amparo à Pesquisa do estado de Minas Gerais	Recruiting	18 Years	50 Years	All	110	Phase 4	Brazil
219	NCT03183661	November 16, 2016	16 December 2017	A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial	Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101)	Crohn Disease	Biological: ALLO-ASC-CD	Anterogen Co., Ltd.		Recruiting	18 Years	65 Years	All	9	N/A
220	EUCTR2016-000634-21-DE	08/11/2016	3 September 2018	A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s Disease	A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease	Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: JNJ-64304500 Pharmaceutical Form: Lyophilisate for solution for injection INN or Proposed INN: JNJ-64304500 Current Sponsor code: JNJ-64304500 Other descriptive name: JNJ-64304500-AAA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: USTEKINUMAB CAS Number: 815610-63-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for infusion INN or Proposed INN: USTEKINUMAB CAS Number: 815610-63-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Janssen-Cilag International NV		Authorised			Female: yes Male: yes	693	Phase 2	United States;Ukraine;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Belgium;Poland;Romania;Bulgaria;Germany;Japan;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
221	JPRN-UMIN000024566	2016/11/01	2 April 2019	Study on the selection of appropriate patients for the dose escalation of adalimumab in Crohn's disease therapy.		Crohn'disease	Dose escalation group Administration of Adalimumab 80 mg every other week Non-dose escalation group Administration of Adalimumab 40 mg every other week	Toho University Medical Center Sakura Hospital		Not Recruiting	16years-old	Not applicable	Male and Female	60	Not applicable	Japan
222	NCT02760615	November 1, 2016	10 December 2018	Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study	An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease	Colitis, Ulcerative;Crohn Disease	Drug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: Vedolizumab	Takeda		Recruiting	18 Years	55 Years	All	60	Phase 4	United States
223	NCT02998827	November 2016	9 January 2017	Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients		Crohn Disease	Drug: Thalidomide;Drug: infliximab, azathioprine;Other: enteral nutrition	Sixth Affiliated Hospital, Sun Yat-sen University		Recruiting	N/A	N/A	Female	90	N/A
224	JPRN-UMIN000023735	2016/10/31	23 April 2019	Does changing every other week (eow)- to every week (ew)-injection of adalimumab influence trough and efficacy in patients with Crohn's disease?-Trough of adalimumab evaluation-TRADE study	Does changing every other week (eow)- to every week (ew)-injection of adalimumab influence trough and efficacy in patients with Crohn's disease?-Trough of adalimumab evaluation-TRADE study - TRADE study	Crohn's disease	EW or EOW injection of adalimumab	Saitama Medical Center, Saitama Medical University		Not Recruiting	15years-old	75years-old	Male and Female	10	Not selected	Japan
225	NCT02914561	October 31, 2016	22 October 2019	Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease	Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: Filgotinib;Drug: Placebo to match filgotinib	Gilead Sciences	Galapagos NV	Recruiting	18 Years	75 Years	All	1320	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
226	EUCTR2016-002061-54-IT	13/10/2016	7 January 2019	Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases.	Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases. Evaluation of immunogenicity and clinical response - Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®)	Rheumatoid arthritis, seronegative spondylo arthritis, Crohn's Disease, Ulcerative Colitis MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10075634 Term: Acute haemorrhagic ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO Product Name: Remsima Product Code: 42942019 Pharmaceutical Form: Powder for solution for infusion	UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI		Not Recruiting			Female: yes Male: yes	250	Phase 4	Italy
227	NCT02772965	October 2016	28 October 2019	Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Pragmatic Clinical Trial To Evaluate The Effectiveness Of Low Dose Oral Methotrexate In Patients With Pediatric Crohn's Disease Initiating Anti-TNF Therapy	Pediatric Crohn's Disease	Drug: Methotrexate;Other: Sugar pill (placebo)	University of North Carolina, Chapel Hill	Patient-Centered Outcomes Research Institute;ImproveCareNow (ICN);The Leona M. and Harry B. Helmsley Charitable Trust;Children's Hospital Medical Center, Cincinnati;Grifols Diagnostics Solutions, Inc;National Institutes of Health (NIH);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Recruiting	N/A	20 Years	All	425	Phase 3	United States
228	NCT02956538	October 2016	14 November 2016	Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide	Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Study	Crohn Disease	Drug: Thalidomide;Drug: placebo(for thalidomide)	Sixth Affiliated Hospital, Sun Yat-sen University		Recruiting	18 Years	50 Years	Both	72	Phase 0	China
229	EUCTR2016-003073-18-GB	29/09/2016	3 April 2017	A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body	A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults - ADME study of [14C]-RPC1063 in healthy male subjects (QCL117686)	The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for adult patients with moderately to severely active inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856 MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration Pharmaceutical Form: Oral solution INN or Proposed INN: Ozanimod hydrochloride CAS Number: 1618636-37-5 Current Sponsor code: RPC1063HCL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.1-	Celgene International II Sàrl		Authorised			Female: no Male: yes	6	Phase 1	United Kingdom
230	NCT02871635	September 28, 2016	27 May 2019	BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity	BI 695501 Versus Humira® in Patients With Active Crohn's Disease: a Randomized, Double-blind, Multicenter, Parallel Group, Exploratory Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity	Crohn Disease	Drug: BI 695501;Drug: HUMIRA	Boehringer Ingelheim		Not recruiting	18 Years	80 Years	All	147	Phase 3	United States;Belarus;Bosnia and Herzegovina;Croatia;Czechia;Germany;Greece;Israel;Poland;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
231	EUCTR2014-004904-31-BE	21/09/2016	20 August 2018	A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remsima (infliximab) Pharmaceutical Form: Powder for concentrate for solution for injection/infusion	Mundipharma Pharmaceuticals B.V.		Not Recruiting			Female: yes Male: yes	156	Phase 4	Belgium;Netherlands
232	NCT02883452	September 12, 2016	26 August 2019	A Phase I Study to Evaluate PK, Efficacy and Safety of CT-P13 SC in Patients With Active CD and UC	An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis	Crohn's Disease;Ulcerative Colitis	Biological: Infliximab	Celltrion		Not recruiting	18 Years	75 Years	All	170	Phase 1	Korea, Republic of
233	JPRN-UMIN000023871	2016/09/01	2 April 2019	Comparison of efficacy between adalimumab 80mg every other week vs 40mg every week in Crohn's disease(WAVE-K study)		Crohn's disease	Administration of Adalimumab 80 mg every 2 weeks. Administration of Adalimumab 40 mg every week.	Fukuoka University Chikushi Hospital		Recruiting	16years-old	Not applicable	Male and Female	100	Not applicable	Japan
234	NCT02820493	September 2016	11 June 2018	Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF	Effectiveness of Vedolizumab Therapy in Inducing Clinical Remission in CD Patients Naïve to Anti-TNF and Its Capability to Halt Disease Progression	Crohn Disease	Drug: vedolizumab	Universita degli Studi di Genova		Not recruiting	18 Years	80 Years	All	0	Phase 4
235	NCT02630966	August 10, 2016	3 December 2018	Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease	A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)	Crohn Disease	Drug: Vedolizumab;Drug: Placebo	Takeda		Not recruiting	18 Years	80 Years	All	34	Phase 4	United States;Canada;France;Italy;Netherlands;Spain;United Kingdom;Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
236	NCT02743806	August 1, 2016	11 November 2019	Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease	Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease	Colitis, Ulcerative;Crohn Disease	Drug: Vedolizumab	Takeda		Not recruiting	18 Years	90 Years	All	331	Phase 4	Australia;Bulgaria;Czechia;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;Turkey;Ukraine;Czech Republic;Slovakia;Taiwan
237	NCT02765256	August 2016	26 August 2019	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn's Disease	Drug: Fluconazole;Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Promethazine	University of Pennsylvania	Children's Hospital of Philadelphia;Crohn's and Colitis Foundation	Not recruiting	18 Years	75 Years	All	30	Phase 2	United States
238	NCT02897661	August 2016	16 December 2017	Fecal Microbiota Transplantation Improves Nutritional State of Patients With Crohn's Disease	Fecal Microbiota Transplantation Combined Enteral Nutrition Therapy Contribute to Nutritional Improvement of Patients With Crohns' Disease	Crohn's Diseases	Procedure: FMT;Drug: Metronidazole;Dietary Supplement: EN	The Second Hospital of Nanjing Medical University		Recruiting	18 Years	65 Years	All	60	Phase 2/Phase 3	China
239	NCT02641392	July 25, 2016	11 February 2019	A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease	A Phase 3, Long-term Active Treatment Extension Study of Mongersen (GED-0301) in Subjects With Crohn's Disease	Crohn's Disease	Drug: GED-0301;Other: Placebo	Celgene		Not recruiting	12 Years	N/A	All	310	Phase 3	United States;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;Bosnia and Herzegovina;Czech Republic;Estonia;Finland;Malaysia;New Zealand;South Africa
240	EUCTR2016-000205-36-DE	11/07/2016	14 November 2016	A Clinical Trial to Evaluate Activity, Safety and Tolerability of FE 999301 by Intravenous Infusions in Patients with Active Inflammatory Bowel Disease (IBD).	A Single-Centre, Exploratory Trial to Assess the Mechanisms of Molecular Activity, Safety and Tolerability of One Dose Level of FE 999301 by Intravenous Infusions in Patients with Active Inflammatory Bowel Disease (IBD) - FUTURE	Inflammatory Bowel Disease (Crohn`s Disease and Ulcerative Colitis) MedDRA version: 19.0 Level: PT Classification code 10009900 Term: Colitis ulcerative System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: FE 999301 Pharmaceutical Form: Concentrate for solution for infusion	University Hospital Schleswig-Holstein (UKSH)		Authorised			Female: yes Male: yes		Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
241	EUCTR2016-001638-84-NL	08/07/2016	23 October 2017	Thiopurines with Low Dose Allopurinol: a prospective one way cross-over study	Thiopurines with Low Dose Allopurinol: a prospective one way cross-over study - ThiLDA-study	Crohn's disease & Colitis Ulcerosa;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Allopurinol Sandoz 100 mg, tabletten Pharmaceutical Form: Tablet INN or Proposed INN: ALLOPURINOL CAS Number: 315-30-0 Current Sponsor code: allopurinol Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 50- INN or Proposed INN: ALLOPURINOL CAS Number: 315-30-0 Current Sponsor code: allopurinol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Meander Medical Center		Not Recruiting			Female: yes Male: yes		Phase 4	Netherlands
242	JPRN-UMIN000019958	2016/07/02	2 April 2019	Research for biomarkers of inflammatory bowel disease. - Investigation of the usefulness of LRG for evaluation of disease condition after adalimumab treatments		Crohn's disease, ulcerative colitis	Patients with Crohn's disease or ulcerative colitis Adalimumab administration subcutaneously for 52 weeks using the recommended dosing regimens.	Iwate Medical University Kochi Medical School Hospital Keio University School of Medicine		Not Recruiting	15years-old	Not applicable	Male and Female	100	Not applicable	Japan
243	NCT02768532	July 1, 2016	26 August 2019	Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease	VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease	Crohn Disease	Drug: Vedolizumab	Centre Hospitalier Universitaire de Saint Etienne	Theradiag;Takeda	Recruiting	18 Years	N/A	All	93	Phase 4	France
244	NCT02793778	July 2016	15 July 2019	Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness of a Nutritional Intervention in Improving the Intestinal Mucosal Health Status in Subjects With Crohn's Disease (CD) Receiving Anti-TNF Therapy	Crohn's Disease	Drug: CROWN;Drug: CROWN Placebo	Prometheus Laboratories	Nestlé Health Science Spain;Nestec Ltd.	Not recruiting	18 Years	85 Years	All	42	Phase 2	United States
245	NCT02806206	July 2016	8 August 2016	Prucalopride Prior to Small Bowel Capsule Endoscopy	The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial	Gastrointestinal Hemorrhage;Crohn Disease;Celiac Disease;Intestinal Diseases;Inflammatory Bowel Diseases	Drug: Prucalopride;Drug: Placebo	University of British Columbia		Not recruiting	19 Years	N/A	Both	122	Phase 4	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
246	JPRN-UMIN000022270	2016/06/30	23 April 2019	Evaluation of the effects and predictive factors of double dose of adalimumab for the patients with Crohn's disease	Evaluation of the effects and predictive factors of double dose of adalimumab for the patients with Crohn's disease - ADA2 study	Crohn's disease	double dose of adalimumab	Saitama Medical Center		Not Recruiting	15years-old	80years-old	Male and Female	20	Not selected	Japan
247	EUCTR2016-000678-40-CZ	27/06/2016	28 February 2019	Program to allow continuation of treatment with Entyvio (Vedolizumab IV) for patients with ulcerative colitis and Chron´s disease who previously participated in a clinical trial with this same treatment	Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease	Ulcerative Colitis and Crohn’s Disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856 MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Entyvio Product Name: vedolizumab IV Product Code: MLN002 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: vedolizumab CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	Takeda Development Centre Europe Limited		Authorised			Female: yes Male: yes	385	Phase 4	Serbia;Taiwan;Estonia;Slovakia;Ukraine;Turkey;Russian Federation;Italy;India;Czech Republic;Hungary;Poland;Malaysia;Romania;Australia;South Africa;Bulgaria;Latvia;New Zealand;Korea, Republic of
248	EUCTR2015-000555-24-NL	16/06/2016	8 August 2016	Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Effectiveness and Safety of Vedolizumab in Prevention of Recurrence of Crohn's Disease of the mucosa in Patients with Surgical Removel of the area between the small and the large bowel.	Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-colonic Surgical Resection and Ileocolonic Anastamosis : REPREVIO (recurrence prevention with Entyvio) - REPREVIO	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Entyvio Product Name: Vedolizumab IV Product Code: MLN0002 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: vedolizumab CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Other descriptive name: VEDOLIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Concentrate and solvent for solution for infusion Route of administration of the placebo: Intravenous use	Academic Medical Center Amsterdam		Authorised			Female: yes Male: yes	80	Phase 4	Netherlands
249	EUCTR2016-001278-13-FI	08/06/2016	27 June 2016	Immunologic, genetic and bowel microbes as predictors of the treatment response for TNFalpha-blocking drugs in patients with Crohn’s disease or ulcerative colitis	Immunologic, genetic and microbiomic predictors of the treatment response for TNFalpha-blocking drugs – prospective follow-up cohort of patients with Crohn’s disease or ulcerative colitis - PROSIBD	Ulcerative colitis and Crohn's disease MedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10058815 Term: Crohn's disease acute episode System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10057035 Term: Crohn's ileocolitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011405 Term: Crohn's enteritis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011406 Term: Crohn's ileitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10076318 Term: Crohn's disease relapse System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10075466 Term: Fistulising Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10066678 Term: Acute ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10075465 Term: Fistulizing Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011400 Term: Crohn's colitis System Organ Class: 10017947 - Gastrointe;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remsima Product Name: Remsima Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3	Taina Sipponen		Authorised			Female: yes Male: yes		Phase 4	Finland
250	NCT02782663	May 18, 2016	1 April 2019	A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease	A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease	Crohn's Disease (CD)	Drug: ABT-494	AbbVie		Not recruiting	18 Years	75 Years	All	107	Phase 2	United States;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Romania;Slovakia;Spain;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
251	ChiCTR-OPC-16008655	2016-05-01	18 April 2017	Efficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from China	Efficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from China	Crohn‘s Disease	1:Thalidomide 75-100mg qd;2:Thalidomide 150-200mg qd;3:Thalidomide 75-100mg qd+MTX 20-25mg /W;	Peking Union Medical College Hospital		Recruiting	16	70	Both	1:90;2:90;3:90;	Post-market	China
252	NCT02538341	May 2016	15 April 2019	Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)	Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)	Rheumatoid Arthritis;Inflammatory Arthritis;Arthritis;Psoriatic Arthritis;Psoriasis;Ankylosing Spondylitis;Enteropathic Arthritis;Crohn's Disease	Biological: Herpes Zoster Vaccine;Drug: Placebo	University of Alabama at Birmingham	Oregon Health and Science University	Not recruiting	50 Years	N/A	All	617	Phase 2	United States
253	EUCTR2015-004618-10-BE	19/04/2016	8 August 2016	PhArmaCo-kinetics of InFliximab during treatment Induction	Study of the inter-individual variation of PhArmaCo-kinetics of InFliximab during treatment Induction in patients with Crohn’s disease and Ulcerative Colitis	Patients with Crohn disease or Ulcerative Colitis which need biotherapy (antibody against TNF-a);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remsima INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Other descriptive name: Remsima Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Concentration number: 5-10 Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Other descriptive name: Remicade Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Concentration number: 5-10 Trade Name: Inflectra Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Other descriptive name: Inflectra Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Concentration number: 5-10	CUB- Hopital Erasme		Authorised			Female: yes Male: yes		Phase 4	Belgium
254	NCT02620046	April 15, 2016	20 May 2019	Vedolizumab Subcutaneous Long-Term Open-Label Extension Study	A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease	Colitis, Ulcerative;Crohn Disease	Drug: Vedolizumab SC	Takeda		Recruiting	18 Years	80 Years	All	692	Phase 3	Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;Colombia;Czech Republic;Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland
255	EUCTR2015-001963-37-SK	14/04/2016	19 November 2018	A long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease	A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn’s disease - A long-term study to explore the safety of GED-0301 in Crohn's disease	Active Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Mongersen Product Code: GED-0301 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: mongersen CAS Number: 1443994-98-6 Current Sponsor code: GED-0301 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Celgene Corporation		Not Recruiting			Female: yes Male: yes	1414	Phase 3	Portugal;Serbia;United States;Taiwan;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia;Italy;Switzerland;France;Malaysia;Australia;Denmark;Netherlands;Latvia;Korea, Republic of;Bosnia and Herzegovina;Finland;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Norway;Germany;New Zealand;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
256	NCT02749630	April 11, 2016	11 November 2019	A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)	An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis and Crohn's Disease	Ulcerative Colitis;Crohn's Disease	Drug: Placebo;Drug: UTTR1147A	Genentech, Inc.		Not recruiting	18 Years	80 Years	All	90	Phase 1	Germany;United Kingdom;Canada
257	NCT02685683	April 4, 2016	20 August 2018	Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease	A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease	Crohn's Disease	Drug: GED-0301	Celgene		Not recruiting	18 Years	N/A	All	18	Phase 2	Italy
258	JPRN-UMIN000020029	2016/04/01	22 July 2019	The significance of serum HBs-antigen as a monitoring examination for viral reactivation during immunesuppressive therapy in patients with previously resolved hepatitis B virus infection	The significance of serum HBs-antigen as a monitoring examination for viral reactivation during immunesuppressive therapy in patients with previously resolved hepatitis B virus infection - Monitoring by HBs antigen for HBV Reactivation	Collagen disease, collagen disease related disease, ulcerative colitis, Crohn's disease, intestinal Behcet's disease (simple ulcers included), psoriasis, and diseases that require other immunosuppressive therapies.	Entecavir administration is initiated when serum HBV-DNA levels increased up to 3.0 Log/IU/mL and/or serum HBs-antigen becomes detectable.	Saitama Medical University		Recruiting	16years-old	Not applicable	Male and Female	300	Not selected	Japan
259	NCT02324699	April 2016	3 September 2018	Corticosteroids With Vedolizumab in Crohn's Disease	Corticosteroids as Co-Induction Agents With Vedolizumab in Crohn's Disease: a Double-blind Placebo Controlled Randomized Trial	Crohn's Disease	Drug: Prednisone;Drug: Placebo;Drug: Vedolizumab	Icahn School of Medicine at Mount Sinai	Takeda	Not recruiting	18 Years	70 Years	All	1	Phase 4	United States
260	NCT02538354	March 2016	13 June 2016	The Effect of Riboflavin in Crohn's Disease	The Effect of Riboflavin Supplementation on Faecalibacterium Prausnitzii in Crohn's Disease	Crohn Disease	Dietary Supplement: Riboflavin supplementation	University Medical Center Groningen		Recruiting	18 Years	65 Years	Both	84	N/A	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
261	NCT02769494	March 2016	23 May 2016	The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer	The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease	Crohn's Disease;Oral Ulcer	Drug: Mesalazine Sustained-Release Tablets;Drug: Riboflavin Sodium Phosphate Injection	Xijing Hospital of Digestive Diseases		Recruiting	18 Years	65 Years	Both	40	Phase 3	China
262	EUCTR2015-001925-18-GB	24/02/2016	2 October 2017	A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn’s disease	A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease. - A randomized, double-blind, study to explore the efficacy and safety o	Active Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 100000016693 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Mongersen Product Code: GED-0301 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: mongersen CAS Number: 1443994-98-6 Current Sponsor code: GED-0301 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Celgene Corporation		Authorised			Female: yes Male: yes	1064	Phase 3	Serbia;Portugal;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;France;Australia;Denmark;South Africa;Netherlands;Latvia;Korea, Republic of;Finland;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Canada;Poland;Belgium;Romania;Croatia;Bulgaria;Norway;Germany;New Zealand;Sweden
263	EUCTR2015-001963-37-LV	18/02/2016	29 January 2018	A long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease	A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn’s disease - A long-term study to explore the safety of GED-0301 in Crohn's disease	Active Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Mongersen Product Code: GED-0301 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: mongersen CAS Number: 1443994-98-6 Current Sponsor code: GED-0301 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Celgene Corporation		Not Recruiting			Female: yes Male: yes	1414	Phase 3	Portugal;Serbia;United States;Taiwan;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia;Italy;Switzerland;France;Malaysia;Australia;Denmark;Netherlands;Latvia;Korea, Republic of;Bosnia and Herzegovina;Finland;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Norway;Germany;New Zealand;Sweden
264	NCT02186275	February 2016	16 December 2017	The Vitamin D in Pediatric Crohn's Disease	Randomized Controlled Trial of High Dose Vitamin D in Children With Newly Diagnosed Crohn's Disease for the Prevention of Relapses	Crohn's Disease	Drug: Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day;Drug: Vitamin D3 800 UI/day then 800 UI/day	St. Justine's Hospital	Canadian Institutes of Health Research (CIHR)	Recruiting	9 Years	18 Years	All	316	Phase 3	Canada
265	EUCTR2015-002025-19-PL	28/01/2016	28 February 2019	An open-label study to assess improvement in patients with Moderate to Severe Crohn’s Disease taking RPC1063 orally	A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy - Open-Label Endoscopic Improvement Trial of RPC1063 for Moderate to Severe Crohn’s Disease	Moderately to Severely Active Crohn's Disease MedDRA version: 20.1 Level: LLT Classification code 10058815 Term: Crohn's disease acute episode System Organ Class: 100000004856 MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 MedDRA version: 20.0 Level: LLT Classification code 10011403 Term: Crohn's disease aggravated System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod CAS Number: 1306760-87-1 Other descriptive name: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: 1mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod CAS Number: 1306760-87-1 Other descriptive name: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-	Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation		Authorised			Female: yes Male: yes	60	Phase 2	United States;Hungary;Canada;Poland;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
266	NCT02925351	January 25, 2016	11 November 2019	Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases	The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases	Autoimmune Disease;Crohn Disease;Inflammatory Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Takayasu Arteritis	Procedure: Computed Tomography;Radiation: Fluorine F 18 Clofarabine;Procedure: Positron Emission Tomography	Jonsson Comprehensive Cancer Center	National Cancer Institute (NCI)	Not recruiting	18 Years	N/A	All	8	N/A	United States
267	NCT02742597	January 12, 2016	8 January 2018	Patient-Centred Innovations for Persons With Multimorbidity - Ontario	Patient-Centred Innovations for Persons With Multimorbidity - Ontario	Hypertension;Depression;Anxiety;Musculoskeletal Pain;Arthritis;Rheumatoid Arthritis;Osteoporosis;Chronic Obstructive Pulmonary Disease (COPD);Asthma;Chronic Bronchitis;Cardiovascular Disease;Heart Failure;Stroke;Transient Ischemic Attacks;Ulcer;Gastroesophageal Reflux;Irritable Bowel;Crohn's Disease;Ulcerative Colitis;Diverticulosis;Chronic Hepatitis;Diabetes;Thyroid Disorder;Cancer;Kidney Disease;Urinary Tract Problem;Dementia;Alzheimer's Disease;Hyperlipidemia;HIV;Multimorbidity	Behavioral: TIP / IMPACT Plus Care Coordination	Lawson Health Research Institute	Western University, Canada;Université de Sherbrooke;Canadian Institutes of Health Research (CIHR);Sunnybrook Health Sciences Centre;St. Michael's Hospital, Toronto;University Health Network, Toronto;Toronto East General Hospital;Providence HealthCare;Mount Sinai Hospital, Canada;Toronto Central Community Care Access Centre;Women's College Hospital	Not recruiting	18 Years	80 Years	All	1980	N/A	Canada
268	NCT02574637	January 5, 2016	20 August 2018	Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease	A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy	Crohn's Disease	Drug: MEDI2070 High dose;Drug: MEDI2070 High-Med dose;Drug: MEDI2070 Low-Med dose;Drug: MEDI2070 Low dose;Drug: Placebo	Allergan		Not recruiting	18 Years	80 Years	All	29	Phase 2	United States;Australia;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Russian Federation;Spain;Bulgaria;Czech Republic;Korea, Republic of;Poland;Turkey;United Kingdom
269	NCT02611817	January 4, 2016	1 July 2019	Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy	Crohn's Disease	Drug: Vedolizumab SC 108 mg;Drug: Placebo;Drug: Vedolizumab IV 300 mg	Takeda		Not recruiting	18 Years	80 Years	All	644	Phase 3	United States;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;Argentina;Czech Republic;Spain
270	ChiCTR-IIR-16007751	2016-01-01	18 April 2017	Clinical study of acupuncture and moxibustion treatment for Cohn's disease	Molecular regulation mechanism of acupuncture and moxibustion therapy in inhibiting epithelial-mesenchymal transition of intestinal fibrosis in Crohn's disease	Crohn's disease	Acupuncture Group:Acupuncture, Moxibustion, Prednisone and azathioprine;Placebo acupuncture group:Placebo acupuncture, moxibustion, Prednisone and azathioprine;Drug Group:Prednisone and azathioprine;	Shanghai Research Institute of Acupuncture and Meridian		Recruiting	16	70	Both	Acupuncture Group:40;Placebo acupuncture group:40;Drug Group:40;	Phase 1 study	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
271	ChiCTR1800020305	2016-01-01	14 January 2019	A follow-up study for infliximab or combine with azathioprine in the treatment of Crohn's disease	Infliximab or combine with azathioprine in the treatment of Crohn's disease and relationship with ATI	crohn's disease;K50.900	Group 2:infliximab + azathioprine;Group 1:infliximab alone;	Department of Gastroenterology, Nanfang Hospital, Southern Medical University		Recruiting	12	80	Both	Group 2:41;Group 1:45;	Retrospective study	China
272	NCT02465944	January 2016	5 September 2016	A Pilot Study of FFP104 in Subjects With Crohn's Disease	A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease	Crohn's Disease	Drug: FFP104;Drug: Placebo	Fast Forward Pharmaceuticals		Recruiting	18 Years	75 Years	Both	24	Phase 1/Phase 2	Belgium;Netherlands
273	NCT02532738	January 2016	7 September 2015	The Efficiency of MSC in Refractory Crohn's Disease	A Stage II Clinical Trial Comparing the Efficiacy of Routine Treatment Combined With or Without MSC Therapy in Refractory Crohn's Disease	Crohn's Disease	Drug: Routine Treatment of CD;Biological: MSC treatment 01;Biological: MSC treatment 02;Other: NS	Sixth Affiliated Hospital, Sun Yat-sen University	Third Affiliated Hospital, Sun Yat-Sen University;Nanfang Hospital of Southern Medical University	Not recruiting	18 Years	65 Years	Both	3	Phase 2/Phase 3
274	NCT02680756	January 2016	18 June 2018	Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD	A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease	Anemia, Iron-Deficiency;Inflammatory Bowel Disease;Crohn's Disease	Drug: Ferric Maltol;Drug: Ferric Carboxy Maltose	Shield Therapeutics		Recruiting	18 Years	N/A	All	242	Phase 3	United States;Belgium;France;Germany;Hungary;Spain
275	EUCTR2016-000522-18-FR		2 October 2017	Risk stratified randomized controlled trial in paediatric Crohn’s Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive disease course, respectively – a treatment strategy	Risk stratified randomized controlled trial in paediatric Crohn’s Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive disease course, respectively – a treatment strategy - REDUCE-RISKincd-PIBD-TRIAL	Crohn’s disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: humira Pharmaceutical Form: Solution for infusion INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- Product Name: Imurel Pharmaceutical Form: Coated tablet INN or Proposed INN: azathioprine CAS Number: 446-86-6 Other descriptive name: AZATHIOPRINE Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 2.5- Trade Name: Methotrexate Product Name: methotrexate Pharmaceutical Form: Solution for injection	PIBDNet		Not Available			Female: yes Male: yes	312	Phase 4	France;Hungary;Czech Republic;Canada;Poland;Belgium;Israel;Netherlands;Germany;Italy;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
276	EUCTR2016-000786-24-IT		5 March 2018	Efficacy and safety of thalidomide in pediatric patients with Crohn's disease	Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network - Talidomide in Crohn disease in Pediatrics	Crohn's Disease MedDRA version: 19.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: THALIDOMIDE CELGENE - 50 MG CAPSULA RIGIDA - USO ORALE - BLISTER (PVC/PE/ACLAR/ALU) 28 CAPSULE Pharmaceutical Form: Capsule, hard Product Name: INFLIXIMAB Pharmaceutical Form: Powder for infusion	IRCCS Burlo Garofolo		Not Available			Female: yes Male: yes	124	Phase 3	Italy
277	EUCTR2016-003190-17-CZ		28 February 2019	A Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease.	A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for infusion INN or Proposed INN: RISANKIZUMAB CAS Number: ABBV-066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for infusion INN or Proposed INN: RISANKIZUMAB CAS Number: ABBV-066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: RISANKIZUMAB CAS Number: ABBV-066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection/infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Risankizumab Product Code: ABBV-066 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: RISANKIZUMAB CAS Number: ABBV-066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal	AbbVie Deutschland GmbH & Co. KG		Not Available			Female: yes Male: yes	579	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Chile;Italy;France;Puerto Rico;Denmark;Latvia;Bosnia and Herzegovina;Korea, Republic of;Turkey;Czech Republic;Mexico;Canada;Brazil;Croatia;Romania;Sweden;Serbia;United States;Estonia;Spain;Ireland;Israel;Russian Federation;Colombia;Switzerland;Malaysia;Australia;South Africa;Netherlands;Slovenia;Finland;Lithuania;Austria;United Kingdom;Egypt;Hungary;Argentina;Belgium;Poland;Singapore;Bulgaria;Germany;Norway;New Zealand
278	NCT02596893	December 8, 2015	2 September 2019	Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease	Crohn Disease	Drug: GED-0301;Drug: Placebo	Celgene		Not recruiting	18 Years	N/A	All	701	Phase 3	United States;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;Bosnia and Herzegovina;Czech Republic;Former Serbia and Montenegro;South Africa
279	NCT02678052	December 1, 2015	26 August 2019	OTIS Vedolizumab Pregnancy Exposure Registry	Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry	Colitis, Ulcerative;Crohn's Disease	Drug: Vedolizumab;Biological: Other Biological Agent	Takeda		Recruiting	18 Years	44 Years	Female	200	N/A	United States;Canada
280	NCT02620007	December 2015	4 March 2019	Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease	Multicenter Double Blind Randomized Clinical Trial Assessing the Benefit of Adherent Invasive E. Coli Eradication in Adult Ileal and Ileo-colonic Crohn Disease	Crohn Disease;Adherent-invasive E. Coli	Drug: Ciprofloxacin;Drug: Rifaximin;Drug: Ciprofloxacin Placebo;Drug: Rifaximin Placebo	Assistance Publique - Hôpitaux de Paris		Recruiting	18 Years	80 Years	All	62	Phase 2	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
281	NCT02636517	December 2015	18 December 2018	Fecal Microbiome Transplant	Fecal Microbiome Transplant in Pediatric C. Difficile	Clostridium Difficile;Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Biological: Fecal Microbiota Transplant	Children's Hospital of Philadelphia		Recruiting	3 Years	21 Years	All	50	N/A	United States
282	NCT02597829	November 2015	17 November 2015	Does Clinical Response Correlate With Serum Certolizumab Levels?	Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO)	Crohn's Disease	Drug: Certolizumab Pegol	Shafran Gastroenterology Center	UCB Pharma;UCB Pharma	Not recruiting	18 Years	70 Years	Both	20	Phase 4	United States
283	NCT02622763	November 2015	25 February 2019	Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment	Safety and Clinical Efficacy Evaluation of Intralesional Administration of Tolerogenic Dendritic Cells in Patients With Refractory Crohn's Disease	Crohn's Disease	Biological: Tolerogenic Dendritic Cells	Fundacion Clinic per a la Recerca Biomédica		Recruiting	18 Years	65 Years	All	20	Phase 1	Spain
284	NCT02926300	November 2015	16 December 2017	Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)	Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease	Crohn's Disease	Biological: stem cells	Kang Stem Biotech Co., Ltd.		Recruiting	19 Years	70 Years	All	24	N/A	Korea, Republic of
285	EUCTR2014-005666-29-GB	16/10/2015	21 August 2017	A study to investigate Thetanix (Bacteroides thetaiotaomicron) in young people aged 16 to 18 years with stable Crohn's disease	A Phase 1 randomised, double-blind, placebo-controlled study to assess the safety and tolerability of Bacteroides thetaiotaomicron in young people aged 16 to 18 years with stable Crohn's disease. - A study of Thetanix in young people with stable Crohn's disease	Crohn's disease in young persons MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Thetanix Product Code: B. theta Pharmaceutical Form: Capsule INN or Proposed INN: Colony-purified Bacteroides thetaiotaomicron (B.theta) Current Sponsor code: MRx1233 (previously LBP001) Other descriptive name: B. theta Concentration unit: CFU/g colony forming unit(s)/gram Concentration type: range Concentration number: 1E+7 to 1E+10-CFU/g Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	4D Pharma		Authorised			Female: yes Male: yes		Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
286	NCT02531113	October 9, 2015	30 September 2019	Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease	A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy	Crohn's Disease	Drug: RPC1063	Celgene		Not recruiting	18 Years	75 Years	All	69	Phase 2	United States;Canada;Hungary;Poland;Ukraine;Italy
287	NCT02177071	October 2015	21 January 2019	A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy	A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy	Crohn's Disease	Drug: INFLIXIMAB;Drug: AZATHIOPRINE;Drug: MERCAPTOPURINE;Drug: Methotrexate	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Saint-Louis Hospital, Paris, France	Recruiting	18 Years	65 Years	All	300	Phase 4	Australia;Belgium;France
288	NCT02520843	October 2015	28 January 2019	An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF	An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and Stromal Vascular Fraction	Crohn Disease	Drug: stromal vascular fraction (SVF)	Assistance Publique Hopitaux De Marseille		Not recruiting	18 Years	N/A	All	10	Phase 1/Phase 2	France
289	NCT02847884	October 2015	11 June 2019	IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study	IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study	Inflammatory Bowel Disease;Crohn's Disease	Biological: Infliximab	University of Alberta	The Hospital for Sick Children;The Children's Hospital of Winnipeg;Alberta Children's Hospital;Provincial Health Services Authority;Children's Hospital of Eastern Ontario	Not recruiting	2 Years	17 Years	All	28	Phase 2	Canada
290	EUCTR2013-003199-11-BE	25/09/2015	28 May 2018	CURE	Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study. - CURE	Crohn's disease;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]	Trade Name: Adalimumab Product Name: Humira Pharmaceutical Form: Injection	GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives		Authorised			Female: yes Male: yes	200	Phase 4	France;Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
291	EUCTR2015-001834-15-ES	24/09/2015	12 October 2015	A long term extension trial of BI 655066 in patients with moderately to severely active Crohn's disease	An open label, single group, long term safety extension trial of BI 655066, in patients with moderately to severely active Crohn's disease	Crohn's disease MedDRA version: 18.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: BI 655066 10 mg/ml Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: not available yet Current Sponsor code: BI 655066 Other descriptive name: BI 655066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Product Code: BI 655066 90 mg/ml Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: not available yet Current Sponsor code: BI 655066 Other descriptive name: BI 655066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90-	Boehringer Ingelheim España, S.A.		Authorised			Female: yes Male: yes	62		United States;Canada;Spain;Germany;Korea, Republic of
292	NCT02513459	September 16, 2015	15 July 2019	A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease	An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: ABBV-066	AbbVie	Boehringer Ingelheim	Not recruiting	18 Years	75 Years	All	65	Phase 2	United States;Belgium;Canada;Germany;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom
293	NCT02417974	September 2015	24 June 2019	Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)	Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)	Crohn's Disease	Biological: Fecal Microbiota Transplant (FMT)	Beth Israel Deaconess Medical Center	Brigham and Women's Hospital;Boston Medical Center;Massachusetts Institute of Technology	Recruiting	18 Years	N/A	All	44	Phase 2	United States
294	NCT02522169	September 2015	24 August 2015	TOPIT; Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease	Verbessertes Therapiemanagement für pädiatrische CED-Patienten Mit Chronisch-entzündlicher Darmerkrankung: Eine Randomisierte Multizentrische Studie, Welche Die Effektivität Einer Talspiegel-gesteuerten Infliximab-Erhaltungsphase Mit Dem herkömmlichen Dosierungsregime Vergleicht Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Randomized Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease	Pediatric Crohns Disease	Drug: Infliximab	Klinikum Westbrandenburg GmbH		Not recruiting	6 Years	17 Years	Both	120	N/A
295	NCT03010787	September 2015	16 December 2017	A First Time in Human Study in Healthy Volunteers and Patients	A Four Part, Phase 1, First Time in Human, Single Centre Study in Healthy Male Subjects, Patient Volunteers With Crohn's Disease and in Healthy Patient Volunteers With a Terminal Ileostomy	Crohn's Disease	Drug: V565;Drug: Placebo	VHsquared Ltd.		Not recruiting	18 Years	65 Years	All	47	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
296	EUCTR2014-004108-31-HU	27/08/2015	29 August 2016	Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate Crohn’s disease. Subjects will be separated in two groups that will be treated in parallel to receive study drug or placebo. Neither the treating physician nor the subject will be aware of the actual treatment received.	A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately Active Crohn’s Disease - MAP EU	Moderately Active Crohn's Disease MedDRA version: 18.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: RHB-104 Pharmaceutical Form: Capsule INN or Proposed INN: Clarithromycin CAS Number: 81103-11-9 Other descriptive name: CLARITHROMYCIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- INN or Proposed INN: Rifabutin CAS Number: 72559-06-9 Other descriptive name: RIFABUTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 45- INN or Proposed INN: Clofazimine CAS Number: 2030-63-9 Other descriptive name: CLOFAZIMINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	RedHill Biopharma Ltd.		Not Recruiting			Female: yes Male: yes	360	Phase 3	Czech Republic;Hungary;Slovakia;Belgium;Spain;Ukraine;Ireland;Russian Federation;Netherlands;Germany;United Kingdom
297	EUCTR2014-003824-36-SE	12/08/2015	17 September 2018	A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's disease	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE	Crohn`s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Etrolizumab Product Code: Ro 549-0261/F04-02 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Etrolizumab CAS Number: 1044758-60-2 Current Sponsor code: RO5490261 Other descriptive name: ETROLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 105- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Etrolizumab Product Code: Ro 549-0261/F08-02 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Etrolizumab CAS Number: 1044758-60-2 Current Sponsor code: RO5490261 Other descriptive name: ETROLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 210- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	1250	Phase 3	Serbia;United States;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;France;Australia;South Africa;Netherlands;Latvia;Korea, Republic of;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Sweden
298	EUCTR2014-003855-76-SE	12/08/2015	17 September 2018	An Open-Label Extension Study to assess the long-term safety and effective of etrolizumab treatment for patients with moderately to severely active Crohn's disease	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Crohn`s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Etrolizumab Product Code: Ro 549-0261/F04-02 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Etrolizumab CAS Number: 1044758-60-2 Current Sponsor code: RO5490261 Other descriptive name: ETROLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 105-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	1250	Phase 3	Serbia;United States;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;France;Australia;South Africa;Netherlands;Latvia;Korea, Republic of;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Sweden
299	NCT02538679	August 7, 2015	16 December 2017	A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques	A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Technique Versus Laparoscopic Transversus Abdominis Plane Nerve Block Technique Versus No Block on Postoperative Opioid Consumption After Major Colorectal Surgery	Crohn's Disease;Inflammatory Bowel Disease;Postoperative Pain	Other: Placebo;Drug: US TAP Bupivacaine/Epinephrine;Drug: Lap TAP Bupivacaine/Epinephrine	Cedars-Sinai Medical Center		Not recruiting	18 Years	90 Years	All	127	N/A
300	NCT02193750	August 2015	11 June 2018	Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease	Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease: A Randomized, Controlled Trial	Crohn's Disease	Dietary Supplement: Placebo;Dietary Supplement: Moderate Oligosaccharide Group;Dietary Supplement: High Oligosaccharide Group	University of British Columbia	The Alfred;Melbourne Health	Recruiting	19 Years	N/A	All	48	N/A	Australia;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
301	NCT02389790	August 2015	16 December 2017	Extension Study of MT-1303 in Subjects With Crohn's Disease	A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease Who Have Completed the MT 1303-E13 Study	Crohn's Disease	Drug: MT-1303	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	65 Years	All	46	Phase 2	Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;Czech Republic
302	NCT02452151	August 2015	1 June 2015	Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial	Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission.	Colitis, Ulcerative;Crohn's Disease	Drug: Infliximab-Biosimilar;Drug: Infliximab-Innovator	Onze Lieve Vrouwe Gasthuis	Santeon	Not recruiting	18 Years	N/A	Both	300	Phase 4
303	NCT02499783	July 27, 2015	29 January 2018	Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein	Crohn's Disease	Biological: Adalimumab;Other: Placebo	AbbVie		Not recruiting	18 Years	70 Years	All	205	Phase 3	China
304	EUCTR2015-001179-36-PL	24/07/2015	30 April 2019	Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate to Severely Crohn’s disease. Subjects will be separated in two groups that will be treated in parallel to receive study drug or placebo. Neither the treating physician nor the subject will be aware of the actual treatment received.	A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn’s Disease	Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: RHB-104 Pharmaceutical Form: Capsule INN or Proposed INN: Clarithromycin CAS Number: 81103-11-9 Other descriptive name: CLARITHROMYCIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 95- INN or Proposed INN: Rifabutin CAS Number: 72559-06-9 Other descriptive name: RIFABUTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 45- INN or Proposed INN: Clofazimine CAS Number: 2030-63-9 Other descriptive name: CLOFAZIMINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	RedHill Biopharma Ltd.		Not Recruiting			Female: yes Male: yes	324	Phase 3	Serbia;United States;Czech Republic;Slovakia;Canada;Poland;Romania;Australia;Israel;Bulgaria;New Zealand
305	NCT02646683	July 2015	13 May 2019	A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study	An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOw Countries VEdolizumab in CD Study)	Crohn Disease	Drug: vedolizumab	Geert D'Haens	Takeda	Recruiting	18 Years	80 Years	All	260	Phase 4	Belgium;Hungary;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
306	EUCTR2014-005376-29-NL	29/06/2015	4 August 2015	An open-label study to evaluate the effectiveness, safety and the healing of the mucosa of the bowel of vedolizumab in subject with early onset on Crohn's disease versus subject with longer exisiting Crohn's disease.	An open-label observational phase 4 study to evaluate efficacy , safety and mucosal healing of early versus late use of vedolizumab in Crohn's disease: the LOVE-CD study (LOw countries VEdolizumab in CD study) - LOVE-CD	Active Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Entyvio Pharmaceutical Form: Powder for concentrate for dispersion for infusion	Academic Medical Center, Gastroenterology		Authorised			Female: yes Male: yes	260	Phase 4	Netherlands
307	EUCTR2014-001050-41-DE	12/06/2015	28 February 2019	Randomized Evaluation of an Algorithm for Crohn's Treatment - Study 2	A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease - REACT2	Crohn's Disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection	Robarts Clinical Trials		Authorised			Female: yes Male: yes	1200	Phase 4	United States;Canada;Germany;United Kingdom
308	NCT02403323	June 8, 2015	4 November 2019	Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Crohn Disease	Drug: etrolizumab	Hoffmann-La Roche		Recruiting	18 Years	N/A	All	900	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;Czech Republic
309	EUCTR2014-004904-31-NL	19/05/2015	5 September 2016	A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remsima (infliximab) Pharmaceutical Form: Powder for concentrate for solution for injection/infusion	Mundipharma Pharmaceuticals B.V.		Authorised			Female: yes Male: yes		Phase 4	Netherlands
310	NCT02256462	May 1, 2015	25 February 2019	Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial	Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial	Crohn's Disease	Drug: Adalimumab	Schneider Children's Medical Center, Israel		Not recruiting	6 Years	17 Years	All	82	Phase 4	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
311	NCT02413047	May 2015	16 December 2017	Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator	A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained With the Addition of an Immunomodulator	Inflammatory Bowel Disease;Ulcerative Colitis;Crohn's Disease	Drug: Azathioprine;Drug: 6 mercaptopurine;Drug: Methotrexate	Indiana University		Recruiting	18 Years	80 Years	All	20	N/A	United States
312	NCT02423460	May 2015	19 November 2018	Threonine Requirement in IBD Adults and Healthy Adult Controls	Threonine Requirement in Healthy Adult Subjects and in Patients With Crohn's Disease and With Ulcerative Colitis Using the Indicator Amino Acid Oxidation (IAAO) Methodology	Ulcerative Colitis;Crohn's Disease;Healthy	Other: Threonine	Nestlé	The Hospital for Sick Children;Mount Sinai Hospital, Canada	Not recruiting	18 Years	40 Years	Male	86	N/A	Canada
313	NCT02575040	May 2015	26 October 2015	Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel Disease	Efficacy of Fecal Microbiota Transplantation for Refractory Inflammatory Bowel Disease	Ulcerative Colitis;Crohn Disease;Constipation (Excl Faecal Impaction)	Biological: Fecal microbiota transplantation	Gulhane Military Medical Academy		Recruiting	18 Years	N/A	Both	60	Phase 3	Turkey
314	NCT02405442	April 30, 2015	23 April 2019	Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease	A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: Andecaliximab;Drug: Placebo	Gilead Sciences		Not recruiting	18 Years	75 Years	All	187	Phase 2	United States;Australia;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;Czech Republic;Iceland
315	NCT02539368	April 22, 2015	26 August 2019	Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease	POST-MARKETING OBSERVATIONAL COHORT STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) TREATED WITH CT-P13 IN USUAL CLINICAL PRACTICE (CONNECT-IBD)	Inflammatory Bowel Diseases;Ulcerative Colitis;Crohn's Disease	Drug: CT-P13;Drug: Remicade	Pfizer	Hospira, now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	All	2565	Phase 3	Belgium;Czechia;Finland;France;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;Czech Republic;Ireland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
316	NCT02425111	April 13, 2015	16 December 2017	Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease	An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV	Crohn's Disease	Drug: Vedolizumab	Takeda		Not recruiting	18 Years	80 Years	All	101	Phase 3	United States;Belgium;Canada;Czechia;France;Hungary;Italy;Poland;Czech Republic
317	NCT02367183	April 8, 2015	21 January 2019	A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease	A Randomized, Double-blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects With Active Crohn's Disease.	Crohn Disease	Drug: GED-0301;Drug: Placebo	Celgene		Not recruiting	18 Years	N/A	All	64	Phase 1	United States;Australia;Canada;Hungary;Slovakia
318	NCT02208310	April 2015	16 December 2017	Trial of High Dose Vitamin D in Patient's With Crohn's Disease	A Randomized Controlled Trial of High-Dose Vitamin D in Crohn's Disease	Crohn's Disease;Vitamin D Deficiency	Drug: Cholecalciferol 10,000 IU;Drug: Cholecalciferol 400 IU	University of Michigan	Crohn's and Colitis Foundation	Not recruiting	18 Years	75 Years	All	11	Phase 4	United States
319	NCT02517684	April 2015	25 February 2019	Top-down Infliximab Study in Kids With Crohn's Disease	Top-down Infliximab Study in Kids With Crohn's Disease	Crohn's Disease	Drug: Infliximab;Drug: Prednisolone;Other: Exclusive enteral nutrition;Drug: Azathioprine	Erasmus Medical Center	ZonMw: The Netherlands Organisation for Health Research and Development;Hospira, now a wholly owned subsidiary of Pfizer	Not recruiting	3 Years	17 Years	All	100	Phase 4	Belgium;Finland;Netherlands;Denmark;Italy;Poland
320	NCT02580617	April 2015	22 January 2018	A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease	A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Crohn's Disease	Crohn's Disease	Biological: ALLO-ASC	Anterogen Co., Ltd.		Recruiting	18 Years	65 Years	All	9	Phase 1	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
321	NCT02851134	April 2015	11 March 2019	Search for New Genetic Mutations Major Effect in Crohn's Disease	Search for New Genetic Mutations Major Effect in Crohn's Disease	Crohn Disease	Genetic: genetic analysis;Biological: blood and stools samples	University Hospital, Lille		Not recruiting	5 Years	80 Years	All	20	N/A	France
322	NCT02674308	March 31, 2015	14 October 2019	Entyvio (Vedolizumab) Long Term Safety Study	Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease	Ulcerative Colitis and Crohn's Disease	Drug: Vedolizumab;Other: Other Biologic Agents	Takeda		Not recruiting	18 Years	N/A	All	5302	N/A	United States;Austria;Belgium;Canada;Croatia;Denmark;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom
323	NCT02394028	March 20, 2015	4 November 2019	A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Etrolizumab;Drug: Placebo	Hoffmann-La Roche		Recruiting	18 Years	80 Years	All	1150	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;Czech Republic
324	NCT02365649	March 17, 2015	16 December 2017	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy	Crohn's Disease	Drug: ABT-494;Drug: Placebo	AbbVie		Not recruiting	18 Years	75 Years	All	219	Phase 2	United States;Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;United Kingdom;Czech Republic;Sweden
325	NCT03306446	March 17, 2015	8 April 2019	Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab	Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab	CD	Drug: Start adalimumab in monotherapy	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives		Not recruiting	18 Years	75 Years	All	203	Phase 4	Belgium;France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
326	NCT02675153	March 1, 2015	16 December 2017	To Evaluate the Efficacy and Safety of Sirolimus for Crohn's Disease With Stenosis	Efficacy and Safety of Sirolimus in the Treatment of Crohn's Disease With Stenosis	Crohn's Diseases	Drug: Sirolimus;Drug: 5-ASA, Prednisone, Azathioprine or Remicade	The Second Hospital of Nanjing Medical University	Xijing Hospital of Digestive Diseases	Recruiting	18 Years	70 Years	All	50	Phase 4	China
327	NCT01836289	March 2015	20 August 2018	High-dose Cyclophosphamide for Severe Refractory Crohn Disease	High-dose Cyclophosphamide for Severe Refractory Crohn Disease	Crohn's Disease;Crohn Disease	Drug: High-dose Cyclophosphamide	Johns Hopkins University		Not recruiting	18 Years	100 Years	All	0	Phase 1/Phase 2	United States
328	NCT02378688	March 2015	24 October 2016	Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease	A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease	Crohn's Disease	Drug: MT-1303;Drug: Placebo	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	65 Years	Both	78	Phase 2	Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine
329	NCT02392286	March 2015	18 January 2018	Corticosteroid Dosage for Crohn's Disease Flare	A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares	Crohn's Disease;Inflammatory Bowel Disease	Drug: Corticosteroid	Yale University		Recruiting	18 Years	N/A	All	182	Phase 4	United States
330	EUCTR2014-001645-24-DE	09/02/2015	28 February 2019	A Study to Assess Treatment Efficacy and Safety of Rifaximin DR Twice Daily in Subjects with Active Crohn's Disease for 52 weeks.	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease	Treatment of active Crohn’s disease MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin Delayed Release (DR) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: Rifaxmin DR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Salix Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	660	Phase 3	France;United States;Hungary;Czech Republic;Canada;Poland;Russian Federation;Israel;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
331	EUCTR2014-001644-38-DE	02/02/2015	28 February 2019	A Study to Assess Treatment Efficacy and Safety of Rifaximin DR Twice Daily in Subjects with Active Crohn's Disease for 52 weeks.	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease	Treatment of active Crohn’s disease MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin Delayed Release (DR) Pharmaceutical Form: Tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: Rifaxmin DR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Salix Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	660	Phase 3	France;United States;Hungary;Czech Republic;Canada;Poland;Russian Federation;Israel;Germany
332	NCT02061163	February 2015	29 June 2015	Contrast-Enhanced Ultrasound in Human Crohn's Disease	Evaluation of Contrast-Enhanced Ultrasound in Human Crohn's Disease	Crohn's Disease	Device: Contrast Enhanced Ultrasound;Drug: Optison	University of Michigan		Not recruiting	10 Years	N/A	Both	0	Phase 1/Phase 2	United States
333	NCT02321280	February 2015	22 October 2018	The Efficacy of Denosumab in Active Crohn's Disease	Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease	Crohn Disease	Drug: Denosumab	University of Manitoba	University of Toronto;McMaster University	Not recruiting	18 Years	80 Years	All	2	Phase 1/Phase 2	Canada
334	JPRN-UMIN000032485	2015/01/01	2 April 2019	efficacy of early adalimumab or immunomodulator on postoperative remission maintenance in patients with Crohn's disease		Cron's disease	adalimumab azathiopurine	Sakura medical center, Toho university		Recruiting	20years-old	70years-old	Male and Female	20	Not selected	Japan
335	NCT02272868	January 2015	11 June 2018	Fecal Microbial Transplant in Pediatric Crohn's Disease	Fecal Microbial Transplant in Pediatric Crohn's Disease: A Double Blind Placebo Control Study	Crohn's Disease	Biological: Fecal Microbial transplant;Drug: Normal Saline;Drug: rifaximin+omeprazole+miralax	Seattle Children's Hospital		Not recruiting	12 Years	21 Years	All	7	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
336	NCT02335281	January 2015	19 February 2015	Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease	Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Inflammatory Bowel Disease	Inflammatory Bowel Disease;Ulcerative Colitis;Crohn's Disease	Procedure: FMT;Drug: Mesalazine	Yanling Wei		Recruiting	16 Years	70 Years	Both	40	Phase 2	China
337	EUCTR2015-002882-41-AT		1 February 2016	A Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease	Sono-Response-Study A Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease	Inflammatory bowel disease (Crohn's disease) MedDRA version: 18.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: SonoVue Product Name: SonoVue Pharmaceutical Form: Gas and solvent for dispersion for injection/infusion INN or Proposed INN: sulphur hexafluoride CAS Number: 2551-62-4 Other descriptive name: SULFUR HEXAFLUORIDE Concentration unit: µl/ml microlitre(s)/millilitre Concentration type: equal Concentration number: 8-	Medical University of Vienna (MUW)		Authorised			Female: yes Male: yes			Austria
338	NCT02201693	December 12, 2014	29 April 2019	Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease	Randomised Trial Comparing 12 Months of Cyclic Enteral Nutrition to Supplementary Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease	Crohn's Disease	Dietary Supplement: MODULEN IBD	Assistance Publique - Hôpitaux de Paris	GETAID Pediatric	Not recruiting	6 Years	18 Years	All	100	N/A	France
339	EUCTR2014-001295-65-AT	01/12/2014	14 November 2016	Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's Disease	A phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, single-dose and multi-injection, parallel groups study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (ova-Treg)) in patients with active refractory Crohn’s Disease (Crohn’s And Treg Study: CATS29) - CATS29	Moderately to severely active Crohn's Disease MedDRA version: 18.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Ovasave Pharmaceutical Form: Suspension for injection INN or Proposed INN: Ova-Treg CAS Number: - Current Sponsor code: Ova-Treg Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population Concentration unit: Other Concentration type: equal Concentration number: 10e6- Pharmaceutical form of the placebo: Suspension for injection Route of administration of the placebo: Intravenous use	TxCell		Not Recruiting			Female: yes Male: yes	170	Phase 2	Belgium;Austria;Germany;Italy
340	NCT02249078	December 2014	17 November 2015	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease	A Multicenter, Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease	Crohn's Disease	Drug: E6011;Drug: Placebo	Eisai Inc.		Not recruiting	18 Years	N/A	Both	0	Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
341	NCT02255370	December 2014	8 August 2016	Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease	Controlled, Randomized, Double Blind Study, Comparing Curcumin to Thiopurines in the Prevention of Post-op Recurrence in Crohn Disease	Crohn's Disease	Drug: Curcumin	University Hospital, Clermont-Ferrand	3i nature;Naturopôle Nutrition santé	Recruiting	18 Years	N/A	Both	122	Phase 3	France
342	NCT02539849	December 2014	12 February 2018	Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease	Effect of Prebiotic Fructo-oligosaccharides (FOS) on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease	Crohn Disease	Dietary Supplement: FOS;Drug: Adalimumab	Hospital Universitari Vall d'Hebron Research Institute	AbbVie	Not recruiting	18 Years	65 Years	All	38	N/A	Spain
343	EUCTR2014-001295-65-BE	28/11/2014	31 October 2016	Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's Disease	A phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, single-dose and parallel-group study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (Ova-Treg)) in patients with active refractory Crohn's Disease (Crohn's And Treg Study: CATS29) - CATS29	Moderately to severely active Crohn's Disease MedDRA version: 19.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Ovasave Pharmaceutical Form: Suspension for injection INN or Proposed INN: Ova-Treg CAS Number: - Current Sponsor code: Ova-Treg Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population Concentration unit: Other Concentration type: equal Concentration number: 10e6- Pharmaceutical form of the placebo: Suspension for injection Route of administration of the placebo: Intravenous use	TxCell		Not Recruiting			Female: yes Male: yes	117	Phase 2	Belgium;Austria;Germany;Italy
344	EUCTR2014-002556-77-CZ	27/11/2014	21 November 2016	A clinical study to assess the safety, tolerability and clinical effects of MT 1303 in subjects with moderate to severe active Crohn’s Disease	A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Active Crohn’s Disease	Subjects with moderate to severe crohn's disease MedDRA version: 18.1 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule, hard INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Mitsubishi Tanabe Pharma Corporation (MTPC)		Not Recruiting			Female: yes Male: yes	80	Phase 2	France;Hungary;Czech Republic;Slovakia;Poland;Ukraine;Israel;Netherlands;Germany;Japan;Italy
345	EUCTR2014-002557-19-CZ	27/11/2014	6 November 2017	A clinical study to assess the safety and clinical effects of MT-1303 in subjects with moderate to severe active Crohn’s Disease who have completed the main MT-1303-E13 study	A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects with Moderate to Severe Active Crohn’s Disease who have Completed the MT-1303-E13 Study	Subjects with moderate to severe crohn's disease MedDRA version: 18.1 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule, hard INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4-	Mitsubishi Tanabe Pharma Corporation (MTPC)		Not Recruiting			Female: yes Male: yes	80	Phase 2	France;Hungary;Czech Republic;Slovakia;Poland;Ukraine;Israel;Netherlands;Germany;Japan;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
346	EUCTR2014-001892-30-BE	24/11/2014	17 August 2015	Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate Crohn's disease	Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate Crohn’s Disease	Crohn’s Disease MedDRA version: 17.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GLPG1205 Product Code: G321605 Pharmaceutical Form: Capsule, hard Current Sponsor code: G321605 Other descriptive name: GLPG1205 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Galapagos NV		Not Recruiting			Female: yes Male: yes	120	Phase 2	France;Hungary;Czech Republic;Poland;Spain;Belgium;Ukraine;Russian Federation;Germany;United Kingdom
347	EUCTR2014-001644-38-HU	18/11/2014	28 February 2019	A Study to Assess Treatment Efficacy and Safety of Rifaximin DR Twice Daily in Subjects with Active Crohn's Disease for 52 weeks.	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease	Treatment of active Crohn’s disease MedDRA version: 17.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin Delayed Release (DR) Pharmaceutical Form: Tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: Rifaxmin DR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Salix Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	660	Phase 3	France;United States;Czech Republic;Hungary;Canada;Poland;Russian Federation;Israel;Germany
348	EUCTR2014-001645-24-HU	18/11/2014	28 February 2019	A Study to Assess Treatment Efficacy and Safety of Rifaximin DR Twice Daily in Subjects with Active Crohn's Disease for 52 weeks.	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease	Treatment of active Crohn’s disease MedDRA version: 17.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin Delayed Release (DR) Pharmaceutical Form: Tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: Rifaxmin DR Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Salix Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	660	Phase 3	France;United States;Czech Republic;Hungary;Canada;Poland;Russian Federation;Israel;Germany
349	NCT02453607	November 17, 2014	16 December 2017	The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease	The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease	Inflammatory Bowel Disease;Crohn's Disease	Drug: Infliximab;Drug: thiopurine	Ernest Seidman	University of Toronto;University of Calgary;University of Alberta	Recruiting	18 Years	70 Years	All	225	N/A	Canada
350	NCT02240108	October 28, 2014	30 September 2019	One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease	Crohn's Disease	Drug: Rifaximin EIR;Drug: Placebo	Bausch Health Americas, Inc.	Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC	Not recruiting	18 Years	N/A	All	81	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
351	EUCTR2013-001746-33-DK	23/10/2014	28 February 2019	A Blinded Study to Evaluate Higher Versus Standard Adalimumab doses for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration	A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration	Crohn's disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira 40 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	500	Phase 3	United States;Slovakia;Spain;Austria;Israel;Switzerland;Italy;France;Czech Republic;Hungary;European Union;Canada;Belgium;Denmark;Germany;Netherlands
352	EUCTR2013-001746-33-DE	08/10/2014	28 February 2019	A Blinded Study to Evaluate Higher Versus Standard Adalimumab doses for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration	A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration	Crohn's disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira 40 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	500	Phase 3	United States;Slovakia;Spain;Austria;Israel;Switzerland;Italy;France;Hungary;Czech Republic;European Union;Canada;Belgium;Denmark;Germany;Netherlands
353	NCT02148640	October 2014	16 December 2017	The NOR-SWITCH Study	A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY	Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis;Ulcerative Colitis;Crohn's Disease;Psoriasis Chronic	Drug: Innovator infliximab;Drug: Biosimilar infliximab	Diakonhjemmet Hospital	South-Eastern Norway Regional Health Authority	Not recruiting	18 Years	N/A	All	482	Phase 4	Norway
354	EUCTR2014-003141-10-BE	29/09/2014	6 January 2015	Invloed van UDCA op fecale galzoutensamenstelling van IBD patiënten: piloot studie.	Invloed van UDCA op fecale galzoutensamenstelling van IBD patiënten: piloot studie.	Crohn's disease or colitis ulcerosa MedDRA version: 17.1 Level: PT Classification code 10009900 Term: Colitis ulcerative System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 17.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: UrsoFalk® 250 mg tabletten. Product Name: UrsoFalk Pharmaceutical Form: Tablet INN or Proposed INN: ursodeoxycholic acid CAS Number: 128-13-2 Other descriptive name: URSODEOXYCHOLIC ACID Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-	Ghent University Hospital		Authorised			Female: yes Male: yes			Belgium
355	NCT02096861	September 19, 2014	11 June 2018	Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease	A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease	Crohn's Disease	Biological: CT-P13;Biological: Remicade	Celltrion	Pfizer	Not recruiting	18 Years	75 Years	All	220	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
356	JPRN-UMIN000015770	2014/09/01	7 October 2019	Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease.	Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease.	Crohn's disease (180 <= CDAI < 450) CDAI: Crohn's disease Activity Index	Standard therapy for Crohn's disease (Pentasa 3 g/day) Patients take curcumin or placebo	Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research		Not Recruiting	20years-old	70years-old	Male and Female	30	Not selected	Japan
357	NCT02108821	September 2014	16 December 2017	Fecal Microbiota Transplantation in Pediatric Patients	A Study of Fecal Microbiota Transplantation in Pediatric Patients With Relapsed Inflammatory Bowel Disease.	Inflammatory Bowel Diseases (IBD);Crohn's Disease (CD);Ulcerative Colitis (UC)	Biological: Fecal Microbiota Transplantation (FMT)	Children's Mercy Hospital Kansas City	University of Pittsburgh	Not recruiting	2 Years	22 Years	All	23	Phase 1	United States
358	NCT02154425	September 2014	11 June 2018	A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)	Axial Spondyloarthritis (AxSpA);Non-radiographic Evidence-AxSpA;Ankylosing Spondylitis;Crohn's Disease;Psoriatic Arthritis;Rheumatoid Arthritis	Procedure: Breast milk sampling;Biological: Certolizumab Pegol	UCB BIOSCIENCES, Inc.	PPD;Parexel	Not recruiting	18 Years	N/A	Female	17	Phase 1	United States;Netherlands;Switzerland;France
359	NCT02332356	September 2014	23 April 2019	Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease	Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease	Crohn Disease	Drug: azathioprine or adalimumab and infliximab	Tokyo Medical and Dental University		Recruiting	16 Years	65 Years	All	100	Phase 3	Japan
360	NCT02240121	August 21, 2014	30 September 2019	One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease	Crohn's Disease	Drug: Rifaximin EIR;Drug: Placebo	Bausch Health Americas, Inc.	Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC	Not recruiting	18 Years	N/A	All	80	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
361	EUCTR2013-005629-21-HU	14/08/2014	28 August 2014	Diagnostic use of 99mTecnetium labeled infliximab in Crohn’s disease	Diagnostic use of 99mTecnetium labeled infliximab in Crohn’s disease	Crohn’s disease MedDRA version: 17.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Infliximab (Remicade): 100 mg of lyophilized infliximab Pharmaceutical Form: Lyophilisate for solution for injection INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	First Department of Medicine, University of Szeged		Authorised			Female: yes Male: yes			Hungary
362	NCT02185014	August 12, 2014	16 December 2017	Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115	A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease	Crohn's Disease	Drug: Adalimumab	AbbVie		Not recruiting	18 Years	75 Years	All	246	Phase 3	United States;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;Czech Republic
363	JPRN-UMIN000014006	2014/08/01	2 April 2019	Exploratory study of relation between efficacy and serum infliximab level, and predictors of response to infliximab dose escalation in patients with crohn's disease		Crohn's disease	dose escalation of infliximab	IBD Center, Sapporo Kosei General Hospital		Recruiting	18years-old	Not applicable	Male and Female	20	Not selected	Japan
364	NCT02000362	August 2014	16 December 2017	Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)	An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease	Crohn's Disease	Biological: Stem cells	Kang Stem Biotech Co., Ltd.		Recruiting	19 Years	70 Years	All	24	Phase 1/Phase 2	Korea, Republic of
365	NCT02199561	July 2014	9 January 2017	Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease	A Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease	Crohn's Disease	Biological: Fecal Microbiota Transplant	University of Alberta		Not recruiting	18 Years	65 Years	Both	3	Phase 1/Phase 2	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
366	EUCTR2013-001746-33-ES	23/06/2014	28 February 2019	A Blinded Study to Evaluate the Efficacy and Safety of Two Adalimumab Doses in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration	A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regimens in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration	Crohn's disease MedDRA version: 16.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	AbbVie Deutschland GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	300	Phase 3	United States;Slovakia;Spain;Austria;Israel;Switzerland;Italy;France;Hungary;Czech Republic;European Union;Canada;Belgium;Denmark;Germany;Netherlands
367	NCT02164877	June 2014	11 June 2018	Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease	A Randomized, Controlled Study of Soluble Dietary Fiber on Bacterial Translocation in Adults Patients With Crohn's Disease	Crohn's Disease	Drug: pectin	Jinling Hospital, China		Not recruiting	17 Years	40 Years	All	3	Phase 2	China
368	NCT02179372	June 2014	12 December 2016	Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases	Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases	Ulcerative Colitis;Crohn's Disease	Dietary Supplement: Eicosapentaenoic acid;Dietary Supplement: Medium chain fatty acid (placebo)	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi		Not recruiting	18 Years	80 Years	Both	60	N/A	Italy
369	NCT01881464	May 2014	19 February 2015	Anti TNF a Improves Endothelial Dysfunction in IBD Patients	Anti TNF a Improves Endothelial Dysfunction in IBD Patients	Crohn's Disease	Device: Endopath from Itamar medical - FDA approved device.;Drug: Anti TNF Alfa.	Carmel Medical Center		Recruiting	18 Years	40 Years	Both	20	Phase 4	Israel
370	NCT02148185	May 2014	19 February 2015	Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease	A Phase I, Open-label Study to Evaluate PK, PD, and Safety of a Single Oral Dose of MT-1303 in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: MT-1303	Mitsubishi Tanabe Pharma Corporation		Not recruiting	20 Years	65 Years	Both	1	Phase 1	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
371	EUCTR2013-004781-34-ES	16/04/2014	13 February 2017	Rapidity of response to adalimumab treatment in patients with Crohn´s Disease.	Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.	Crohn's disease MedDRA version: 16.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: ADALIMUMAB Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Product Name: ADALIMUMAB Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Product Name: ADALIMUMAB Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	AbbVie Farmacéutica S.L.U.		Not Recruiting			Female: yes Male: yes		Phase 4	Spain
372	NCT02065570	April 9, 2014	18 December 2018	Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease	A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration	Crohn's Disease	Drug: Adalimumab	AbbVie		Not recruiting	18 Years	75 Years	All	514	Phase 3	Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;United States;Czech Republic
373	EUCTR2013-005013-13-LT	08/04/2014	16 November 2015	A Study Comparing SB5 to Humira® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy	Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB5 is rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), adult Crohn's disease (CD), paediatric CD, ankylosing spondylitis (AS), psoriasis (Ps), psoriatic arthritis (PsA), ulcerative colitis (UC), and psoriasis. MedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: SB5 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: SB5 Other descriptive name: SB5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira® Product Name: Humira® Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: not applicable Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Samsung Bioepis Co., Ltd.		Not Recruiting			Female: yes Male: yes	490		Czech Republic;Mexico;Poland;Ukraine;Lithuania;Russian Federation;Bulgaria;United Kingdom;Korea, Republic of;Bosnia and Herzegovina
374	EUCTR2013-001029-17-NL	01/04/2014	14 April 2014	Dose reduction of infliximab in Crohn’s disease, based on serum infliximab concentration	Efficacy and safety of trough level-based dose reduction during infliximab maintenance treatment in Crohn’s disease - REDIX	Crohn's disease MedDRA version: 16.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Infliximab Pharmaceutical Form: Powder for concentrate for solution for infusion	Academic Medical Center		Authorised			Female: yes Male: yes			Netherlands
375	JPRN-UMIN000013369	2014/04/01	2 April 2019	Efficacy of preoperative oral antibiotics prophylaxis for prevention of surgical site infections in patients with Crohn's disease		Crohn's disease	Oral antibiotics will be administrated on the day before surgery (500mg of kanamycin and 500mg of metronidazole at 14:00, 15:00, and 21:00) without oral antibiotics	Hyogo college of medicine		Not Recruiting	20years-old	70years-old	Male and Female	240	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
376	NCT01960426	April 2014	23 May 2016	Evaluation of Health Costs and Resource Utilization	A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease.	Ulcerative Colitis;Crohn's Disease	Other: Measurement of drug (Adalimumab/Infliximab);Other: Intensify treatment with the existing drug	University of Western Ontario, Canada	Prometheus Laboratories	Not recruiting	18 Years	N/A	Both	51	Phase 4	United States
377	NCT02913508	April 2014	3 October 2016	Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease	A Randomized, Open Label Phase 2 Study to Assess Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Exploratory Efficacy of Vedolizumab Subcutaneous Compared to Vedolizumab Intravenous in Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease	Ulcerative Colitis;Crohn's Disease	Drug: Vedolizumab subcutaneous injection;Drug: Vedolizumab intravenous injection	Takeda		Not recruiting	18 Years	80 Years	Both	0	Phase 2
378	ChiCTR-DDT-14004402	2014-03-28	18 April 2017	The study of small bowel cleaning by using senna, 20% mannitol, simethicone and three days fasting	The study of small bowel cleaning by using senna, 20% mannitol, simethicone and three days fasting	Obscure gastrointestinal bleeding, iron deficiency anemia , Suspected Crohn’s disease, Suspected small bowel tumors, Surveillance of polyposis syndromes, malabsorption? Celiac disease, nonsteroidal a	Group A:20%Mannitol, 0.9% saline;Group B:20%Mannitol, 0.9% saline?simethicone;Group C:20%Mannitol, 0.9% saline?simethicone;	Sanming First Affiliated Hospital of Fujian Medical University		Not Recruiting	10	85	Both	Group A:60;Group B:60;Group C:60;	Phase 4 study	China
379	JPRN-UMIN000014205	2014/03/25	16 July 2019	Examination of the medical treatment by the pancrelipase to the refractory inflammatory bowel disease patient	Examination of the medical treatment by the pancrelipase to the refractory inflammatory bowel disease patient - Validity of pancrelipase in patients with inflammatory bowel disease	Crohn's disease Ulcerative colitis	Administration of pancrelipase	Department of Gastroenterology Osaka City University Graduate School of Medicine		Not Recruiting	20years-old	Not applicable	Male and Female	30	Not selected	Japan
380	NCT02039063	March 14, 2014	21 January 2019	A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease	A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease	Crohn's Disease	Drug: E6011 2 mg/kg;Drug: E6011 5 mg/kg;Drug: E6011 10 mg/kg;Drug: E6011 15 mg/kg	EA Pharma Co., Ltd.		Not recruiting	20 Years	64 Years	All	28	Phase 1/Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
381	NCT01908283	March 2014	9 January 2017	Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease	Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease	Inflammatory Bowel Diseases;Crohn Disease;Colitis, Ulcerative	Biological: 13-valent pneumococcal conjugated vaccine (PCV13)	Klara M. Pósfay Barbe	Swiss IBD Cohort Study;Foundation for liver and gut studies (FLAGS);Schweizerische Morbus Crohn / Colitis ulcerosa Vereinigung (SMCCV)	Not recruiting	18 Years	99 Years	Both	300	Phase 4	Switzerland
382	NCT02088944	March 2014	19 February 2015	a Single-center Registered Clinical Research of Chinese Patients With Moderate to Severe Crohn's Disease		Serological C Reactive Protein or Erythrocyte Sedimentation Rate	Drug: Infliximab	Nanfang Hospital of Southern Medical University		Not recruiting	18 Years	75 Years	Both	142	N/A
383	NCT02281916	March 2014	18 June 2018	Safety Study of P28GST Treatment in Crohn's Disease Patients	Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial	Crohn's Ileocolitis	Drug: P28GST	University Hospital, Lille	National Research Agency, France;Institut National de la Santé Et de la Recherche Médicale, France	Not recruiting	18 Years	N/A	All	10	Phase 2	France
384	EUCTR2013-002857-32-DE	20/02/2014	28 November 2016	A Study to Investigate the Efficacy and Safety of the study drug, GLPG0634, in Subjects With Active Crohn’s Disease With Evidence of Mucosal Ulceration	Double-Blind, Randomized, Placebo-Controlled, Multi Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn’s Disease With Evidence of Mucosal Ulceration	Crohn’s Disease With Evidence of Mucosal Ulceration MedDRA version: 18.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GLPG0634 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB CAS Number: 1206161-97-8 Current Sponsor code: GLPG0634 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Galapagos NV		Not Recruiting			Female: yes Male: yes	180	Phase 2	France;Hungary;Czech Republic;Poland;Belgium;Romania;Russian Federation;Germany;United Kingdom
385	NCT01986127	February 14, 2014	18 December 2018	Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients	A Randomized, Double-blinded, Placebo-controlled Study on the Effects of Adalimumab Intralesional Intestinal Strictures of Crohn's Disease Patients	Crohn's Disease	Drug: Adalimumab;Drug: placebo	Sara Varea	Hospital Clinic of Barcelona	Not recruiting	18 Years	N/A	All	26	Phase 3	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
386	NCT02060318	February 11, 2014	16 December 2017	Regulatory T-cells and Crohn's Disease	The Effect of Infliximab Therapy in Crohn Patients on Regulatory T-cells	Crohn Disease	Drug: Infliximab	Hvidovre University Hospital		Not recruiting	18 Years	N/A	All	47	N/A	Denmark
387	JPRN-UMIN000012790	2014/02/01	2 April 2019	Prospective Pilot study of Infliximab Dose-intensification determined by Capsule Endoscopic Evaluation of Small Intestinal Involvements in Patients with Crohn's Disease		Crohn's disease	dose intensification of 10mg/kg infliximab with additional treatment with thiopurines in case of aggravation at 6 months	Saitama Medical center		Not Recruiting	20years-old	65years-old	Male and Female	20	Not selected	Japan
388	NCT01783106	February 1, 2014	4 November 2019	Antibiotics and Hydroxychloroquine in Crohn's	A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease	Crohn's Disease	Drug: Ciprofloxacin;Drug: Doxycycline;Drug: Hydroxychloroquine;Drug: Budesonide	Royal Liverpool University Hospital	National Association for Colitis and Crohn's Disease;National Institute for Health Research, United Kingdom	Not recruiting	18 Years	N/A	All	59	Phase 2	United Kingdom
389	NCT01765439	February 2014	20 August 2018	The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	The Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	Crohn Disease;Ulcerative Colitis	Dietary Supplement: VSL#3 (Original De Simone formulation)	Charles University, Czech Republic	Iscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La Sapienza	Recruiting	N/A	N/A	All	80	N/A	Czechia;Czech Republic
390	NCT01932658	February 2014	25 April 2016	Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment	Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment	Crohn's Disease	Biological: Hematopoietic stem cell transplantation	University of California, Los Angeles		Not recruiting	7 Years	70 Years	Both	0	Phase 0	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
391	JPRN-JapicCTI-142402	28/1/2014	16 July 2019	Phase III study of MLN0002 (300 mg) in treatment of Crohn's disease	Phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and pharmacokinetics of intravenous MLN0002 (300 mg) infusion in induction and maintenance therapy in Japanese subjects with moderate or severe Crohn's disease	Crohn's disease	Intervention name : MLN0002 (Vedolizumab) INN of the intervention : Vedolizumab Dosage And administration of the intervention : Vedolizumab (300 mg) administered by intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Vedolizumab Placebo administered by intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter.	Takeda Pharmaceutical Company Limited		Not Recruiting	15	80	BOTH	157	Phase 3	Japan
392	EUCTR2013-002902-29-BE	09/01/2014	9 January 2017	Efficacy, safety and pharmacokinetics of BI 655066 in patients with active, moderate-to-severe Crohn's disease.	A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist monoclonal antibody, in patients with moderately to severely active Crohn's disease, who are naïve to, or were previously treated with anti-TNF therapy.	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: BI 655066 10 mg/ml Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: BI 655066 Other descriptive name: BI 655066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Product Code: BI 655066 90 mg/ml Pharmaceutical Form: Solution for injection in pre-filled syringe Current Sponsor code: BI 655066 Other descriptive name: BI 655066 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90-	SCS Boehringer Ingelheim Comm.V		Not Recruiting			Female: yes Male: yes	120	Phase 2	United States;Canada;Poland;Spain;Belgium;Ireland;Netherlands;Germany;United Kingdom;Korea, Republic of
393	NCT01988506	January 6, 2014	27 August 2018	Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases	Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach	Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis	Drug: Interleukin 2	Assistance Publique - Hôpitaux de Paris	Iltoo Pharma	Recruiting	18 Years	N/A	All	132	Phase 2	France
394	NCT02019602	January 2014	16 December 2017	A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta	A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia® (Certolizumab Pegol)	Axial Spondyloarthritis (AxSpA);Non-radiographic Evidence-AxSpA;Ankylosing Spondylitis;Crohn's Disease;Psoriatic Arthritis;Rheumatoid Arthritis	Procedure: Blood sampling from mother;Procedure: Blood sampling from infant;Procedure: Blood sampling from umbilical cord;Biological: Certolizumab Pegol	UCB BIOSCIENCES, Inc.	PPD;Parexel	Not recruiting	18 Years	N/A	All	16	Phase 1	United States;France;Netherlands;Switzerland
395	NCT02044952	January 2014	19 February 2015	Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission	Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission	Inflammatory Bowel Diseases;Crohn's Disease;Gastrointestinal Diseases;Digestive System Diseases;Intestinal Diseases	Drug: Mesalazine, Tripterygium glycosides	Zhu Weiming		Recruiting	18 Years	75 Years	Both	40	Phase 2/Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
396	NCT02056418	January 2014	19 February 2015	Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult	A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult	Crohn Disease	Dietary Supplement: enteral nutrition;Drug: corticosteroid	Jinling Hospital, China		Not recruiting	18 Years	75 Years	Both	30	Phase 4	China
397	NCT02615288	January 2014	7 December 2015	High Dose Vitamin D3 in Crohn's Disease	Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohn's Disease in Remission: A Randomized Double-blind Controlled Study	Crohn's Disease	Dietary Supplement: Vitamin D3	McMaster University	Canadian Association of Gastroenterology	Not recruiting	18 Years	70 Years	Both	40	N/A
398	EUCTR2011-001332-29-AT	02/12/2013	27 October 2014	The degradation and elimination of Infliximab	Pharmacokinetics of Infliximab	Inflammatory bowel disease (Ulcerative Colitis, Crohn's disease) MedDRA version: 17.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 17.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for solution for injection/infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Other descriptive name: Remicade Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie		Authorised			Female: yes Male: yes			Austria
399	NCT02015793	December 2013	11 June 2018	Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease	A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein	Crohn's Disease	Biological: Adalimumab;Biological: Placebo for adalimumab	AbbVie		Not recruiting	18 Years	70 Years	All	30	Phase 2	China
400	EUCTR2012-004222-25-BE	26/11/2013	16 August 2016	Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease	A 12-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 4-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to placebo, in the treatment of moderate Crohn’s disease in patients intolerant or with unsatisfactory response to immunosuppressive drugs and/or TNF-inhibitors - AB1010 in treatement of patients with moderate Crohn's disease	Crohn's disease MedDRA version: 18.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: not applicable Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: not applicable Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AB Science		Authorised			Female: yes Male: yes	450	Phase 3	United States;Central African Republic;Slovakia;Greece;Spain;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Romania;South Africa;Netherlands;Tunisia;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
401	EUCTR2013-002838-20-NL	12/11/2013	29 January 2018	The effect of Vitamin D to prevent post-operative relapse of Crohn's Disease	The effect of Vitamin D3 to prevent post-operative relapse of Crohn’s Disease: a placebo-controlled randomized trial (DETECT) - DETECT	Crohn's Disease MedDRA version: 18.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: InVita D3 Pharmaceutical Form: Oral solution INN or Proposed INN: Colecalciferol Other descriptive name: CHOLECALCIFEROL CONCENTRATE Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 25000- Pharmaceutical form of the placebo: Oral drops, solution Route of administration of the placebo: Oral use	Academic Medical Center		Not Recruiting			Female: yes Male: yes	142	Phase 3	Belgium;Netherlands
402	EUCTR2012-001723-12-ES	07/10/2013	4 December 2018	adalimumab intralesional in intestinal strictures of Crohn's disease patients	A randomized, double-blinded, placebo-controlled study on the effects of adalimumab intralesional intestinal strictures of Crohn's disease patients	Crohn disease MedDRA version: 16.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]	Trade Name: Humira Product Name: Adalimumab Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intralesional use	Fundació Clínic per a la Recerca Biomèdica		Not Recruiting			Female: yes Male: yes	102	Phase 3	Spain
403	NCT02859675	October 7, 2013	26 August 2019	Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease	Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease	Crohn's Disease;Olfactogustatory Perception	Other: triangular test;Biological: blood sampling;Other: Questionnaires	Centre Hospitalier Universitaire Dijon		Recruiting	18 Years	60 Years	Female	75	N/A	France
404	NCT01674413	October 2013	16 December 2017	Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)	Calprotectin-Directed Humira® Maintenance Therapy, a Double-blind, Double-dummy, Randomized Controlled Trial in Crohn's Disease	Crohn's Disease	Drug: Adalimumab;Drug: Adalimumab PRN;Drug: Placebo	Peter Higgins	AbbVie	Not recruiting	18 Years	N/A	All	0	Phase 3	United States
405	NCT02538757	October 2013	21 August 2017	Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)	Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)	Arthritis;Rheumatoid Arthritis;Psoriatic Arthritis;Psoriasis;Ankylosing Spondylitis;Enteropathic Arthritis;Crohn's Disease;Inflammatory Arthritis	Biological: Herpes Zoster Vaccine;Drug: Placebo	University of Alabama at Birmingham	Oregon Health and Science University	Not recruiting	50 Years	N/A	All	125	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
406	JPRN-JapicCTI-142426	01/9/2013	2 April 2019	A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease	A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics after Dose Escalation in Japanese Subjects with Crohn's Disease	Crohn's Disease	Intervention name : adalimumab INN of the intervention : adalimumab Dosage And administration of the intervention : adalimumab 80mg every other week Control intervention name : null	AbbVie GK			15		BOTH	28	Phase 3
407	NCT01951326	September 2013	11 March 2019	Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease	A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: RHB-104;Drug: Placebo	RedHill Biopharma Limited		Not recruiting	18 Years	75 Years	All	330	Phase 3	United States;Australia;Bulgaria;Canada;Czechia;Israel;New Zealand;Poland;Serbia;Slovakia;Czech Republic
408	NCT01958827	September 2013	19 October 2017	A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease	A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics After Dose Escalation in Japanese Subjects With Crohn's Disease	Crohn's Disease	Biological: Adalimumab	AbbVie		Not recruiting	15 Years	N/A	All	28	Phase 3	Japan
409	EUCTR2013-002932-25-NL	21/08/2013	28 February 2019	A randomized clinical trial: treatment of perianal fistulas in Crohn's disease	Multimodal treatment of perianal fistulas in Crohn's disease: seton vs anti-TNF vs advancement plasty - PISA-trial	Perianal fistulas in Crohn's Disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Infliximab Pharmaceutical Form: Powder for concentrate for solution for infusion Trade Name: Humira Product Name: Adalimumab Pharmaceutical Form: Powder for concentrate for solution for infusion	Academic Medical Center		Not Recruiting			Female: yes Male: yes	126	Phase 4	Netherlands
410	EUCTR2013-000971-34-DK	01/08/2013	30 April 2019	High dose vitamin D treatment in Crohn's disease affects the gut immune cells	Mucosal immune regulation by high dose vitamin D treatment in Crohn’s disease - MirViDiC	Active Crohn's Disease in colon and/or terminal ileum MedDRA version: 19.0 Level: LLT Classification code 10011408 Term: Crohns disease aggravated System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Dekristol 20.000 ie Pharmaceutical Form: Capsule, soft INN or Proposed INN: cholecalciferol Other descriptive name: CHOLECALCIFEROL Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 20000- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Remsima Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Jørgen Agnholt		Not Recruiting			Female: yes Male: yes	50	Phase 3	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
411	NCT01523106	August 2013	19 February 2015	L-carnitine to Treat Fatigue Associated With Crohn's Disease	L-carnitine to Treat Fatigue Associated With Crohn's Disease	Crohn's Disease;Fatigue	Drug: L-carnitine;Other: Placebo	University of California, San Francisco		Not recruiting	18 Years	70 Years	Both	0	N/A	United States
412	EUCTR2013-001212-30-NL	04/07/2013	4 November 2013	Immune modulation by parenteral Fish oil in patients with Crohn’s disease	Modulation of immune function by parenteral fish oil in patients with Crohn’s disease and high inherent Tumor Necrosis Factor-alfa production, a randomized, single blinded, cross-over study	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Omegaven Pharmaceutical Form: Emulsion for infusion Trade Name: Intralipid 10% Pharmaceutical Form: Solution for infusion			Authorised			Female: yes Male: yes			Netherlands
413	NCT01864616	July 2013	11 June 2018	The Impact of Vitamin D on Disease Activity in Crohn's Disease		Crohn Disease	Dietary Supplement: Vitamin D3	University of Saskatchewan	Dania Alrefai;Dr.Jennifer Jones;Dr.Hani Jawa;Dr.Wael El-matary;Saudi Arabian Cultural Bureau	Not recruiting	16 Years	70 Years	All	9	N/A	Canada;Saudi Arabia
414	NCT01915927	July 2013	26 August 2019	Stem Cell Fistula Plug in Perianal Crohn's Disease	A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease.	Perianal Crohn's Disease	Drug: MSC-AFP	William A. Faubion, M.D.		Not recruiting	18 Years	65 Years	All	20	Phase 1	United States
415	NCT01947010	July 2013	19 February 2015	Pneumococcal Vaccination of Crohn Patients	Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease	Crohns Disease	Biological: Prevenar 13;Biological: Pneumovax	Statens Serum Institut	Hvidovre University Hospital;Herlev Hospital	Not recruiting	18 Years	N/A	Both	151	Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
416	EUCTR2013-001503-37-DK	31/05/2013	10 July 2015	Effect of low-dose Azathioprine and Allopurinol compared to Azathioprine on clinical outcomes in Inflammatory Bowel Disease	Effect of low-dose Azathioprine and Allopurinol compared to Azathioprine on clinical outcomes in Inflammatory Bowel Disease	Inflammatory Bowel Disease, (Ulcerativ colitis, Crohns disease) MedDRA version: 14.1 Level: PT Classification code 10021972 Term: Inflammatory bowel disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Imurel Pharmaceutical Form: Tablet INN or Proposed INN: azathioprine CAS Number: 446-86-6 Other descriptive name: AZATHIOPRINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Allopurinol Pharmaceutical Form: Tablet INN or Proposed INN: allopurinol CAS Number: 17795-21-0 Other descriptive name: ALLOPURINOL SODIUM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Marianne Kiszka-Kanowitz		Not Recruiting			Female: yes Male: yes	46		Denmark
417	NCT01827631	May 27, 2013	16 December 2017	Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects	Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects	Crohn's Disease	Drug: GSK1605786 capsule	GlaxoSmithKline		Not recruiting	18 Years	45 Years	All	21	Phase 1	China
418	NCT01847170	May 2013	16 December 2017	Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease		Crohn's Disease	Biological: Fecal Microbial Transplantation	Beth Israel Deaconess Medical Center	The Broad Foundation;Brigham and Women's Hospital	Not recruiting	18 Years	N/A	All	22	Phase 1	United States
419	NCT02073526	May 2013	9 January 2017	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Infliximab, adalimumab, certolizumab pegol	Oslo University Hospital		Not recruiting	18 Years	N/A	Both	1230	N/A	Norway
420	NCT02233062	May 2013	19 February 2015	Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease	Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Male Patients With Crohn's Disease	Crohn's Disease	Dietary Supplement: Exclusive Enteral Nutrition Therapy	Jinling Hospital, China		Not recruiting	18 Years	40 Years	Male	12	N/A	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
421	NCT02676622	April 2013	16 December 2017	Autologous Stem Cell Transplant for Refractory Crohn's Disease	A Pilot Study of Autologous Hematopoietic Stem Cell Transplantation With Post-Transplant Ultra Low-Dose IL-2 for Refractory Crohn's Disease	Crohn's Disease	Drug: mobilization of stem cells to prepare for Leukapheresis;Other: Leukapheresis- Collection of stem cells;Drug: Preparative regimen 4-6 weeks after Leukapheresis;Other: Stem Cell Transplant;Drug: Low-dose IL-2 administration	Nationwide Children's Hospital		Not recruiting	12 Years	29 Years	All	0	Phase 2
422	JPRN-UMIN000010524	2013/03/29	2 April 2019	Optimization of adalimumab switch therapy for loss of response with infliximab in Crohn's disease -OASISstudy		Crohn's disease	Adalimubab is administered continuously starting with 160 mg, then 80 mg after 2 weeks and 40 mg from 2 weeks onwards. Continous administration of azathioprine concomitantly with adalimubab at the initial dose of 160 mg, then 80 mg after 2 weeks and 40 mg from 2 weeks onwards. The target dose for azathioprine is 2.0-2.5mg/kg/day and the dose is increased at the discretion of the attending physician.	Tokyo Medical & Dental University Gastroenterology		Not Recruiting	15years-old	Not applicable	Male and Female	20	Not selected	Japan
423	NCT01804166	March 21, 2013	30 September 2019	A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)	A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)	Hepatosplenic T-Cell Lymphoma	Drug: Infliximab;Drug: Golimumab	Janssen Scientific Affairs, LLC		Recruiting	N/A	N/A	All	40	Phase 4	United States
424	NCT01769755	March 2013	12 March 2018	A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease	A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease	Crohns Disease	Biological: PDA001;Drug: Vehicle Controlled Placebo	Celularity Incorporated		Not recruiting	18 Years	75 Years	All	14	Phase 1	United States
425	NCT01809275	March 2013	29 August 2016	Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease	A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease;Inflammatory Bowel Disease	Drug: QBECO;Drug: Placebo	Qu Biologics Inc.		Not recruiting	18 Years	N/A	Both	68	Phase 1/Phase 2	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
426	NCT01810185	March 2013	19 February 2015	Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease	Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Low dose naltrexone;Drug: Placebo	Santa Barbara Cottage Hospital		Not recruiting	18 Years	N/A	Both	0	Phase 2	United States
427	NCT01817972	March 2013	19 February 2015	Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease	A Phase III, Randomized, Double-blind Trial in the Comparison of Cimzia Versus Cimzia Plus Azathioprine in the Change in Mean SES-CD (Simple Endoscopic Scores-Crohn's Disease) Scores in the Treatment of Active, Moderate to Severe Crohn's Disease	Crohn's Disease	Biological: Certolizumab pegol;Drug: Azathioprine	Gastroenterology Research of America	UCB Pharma	Not recruiting	18 Years	70 Years	Both	65	Phase 3	United States
428	NCT01826188	March 2013	18 March 2019	Combined THC and CBD Drops for Treatment of Crohn's Disease	Combined THC and CBD Drops for Treatment of Crohn's Disease, a Phase II Double Blind Placebo Controlled Trial	Crohn's Disease	Drug: THC 5mg/ml and CBS 50mg/ml;Drug: Placebo	Meir Medical Center		Not recruiting	20 Years	85 Years	All	50	Phase 1/Phase 2	Israel
429	NCT01828190	March 2013	19 February 2015	The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers	Prospective Open-label Study of the Efficacy of the Addition of Hyperbaric Oxygen to the Treatment of Patients With Perianal Fistulas Already Treated With TNF Alpha Blockers	Crohn's Disease;Perianal Fistulas	Other: Hyperbaric oxygen	Assaf-Harofeh Medical Center		Recruiting	18 Years	70 Years	Both	50	N/A	Israel
430	EUCTR2012-002867-86-DK	13/02/2013	31 August 2015	Prevention of serious pneumococcal infections in people with Crohn's disease	Pneumococcal vaccination of Crohn patients - A randomized, non-blinded phase 4 clinical trial with the purpose of investigating the immune response against two different pneumococcal vaccines in patients with Crohn's disease - PneuVac	Crohn's Disease MedDRA version: 15.1 Level: LLT Classification code 10069594 Term: Pneumococcal immunization System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Pnemovax Product Name: Pneumovax Pharmaceutical Form: Solution for injection/infusion Trade Name: Prevenar 13 Product Name: Prevenar 13 Pharmaceutical Form: Solution for injection	Statens Serum Institut		Not Recruiting			Female: yes Male: yes		Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
431	NCT01768858	February 5, 2013	11 February 2019	Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice	Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice	Crohn´s Disease;Ulcerative Colitis;Plaque Psoriasis;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: Adalimumab	AbbVie	Raffeiner GmbH	Not recruiting	18 Years	99 Years	All	96	Phase 2	Austria
432	NCT01714726	February 1, 2013	18 March 2019	Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.	A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy	Crohn's Disease	Drug: MEDI2070;Drug: placebo	Allergan		Not recruiting	18 Years	65 Years	All	121	Phase 2	United States;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Spain;Czech Republic
433	NCT01696942	February 2013	16 December 2017	Cimzia Versus Mesalamine for Crohn's Recurrence	Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine	Crohn's Disease	Drug: Cimzia;Drug: Mesalamine	Milton S. Hershey Medical Center	UCB Pharma	Not recruiting	18 Years	N/A	All	10	Phase 4	United States
434	NCT01765998	February 2013	19 February 2015	The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)	The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation	Crohn's Disease	Drug: Probiotic;Drug: Placebo	The Baruch Padeh Medical Center, Poriya		Not recruiting	18 Years	60 Years	Both	60	Phase 4	Israel
435	NCT01802593	February 2013	4 January 2016	Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure	Phase 4, Open Label Multicenter Randomized Controlled Trial. Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Immunomodulator Failure	Crohn's Disease	Drug: AZATHIOPRINE or METHOTREXATE	Prof. Arie Levine		Not recruiting	6 Years	18 Years	Both	20	Phase 4	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
436	NCT01874015	February 2013	16 December 2017	Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease	Transplantation of Bone Marrow Mesenchymal Stem Cell in Moderate to Severe Fistulizing Crohn's Disease	Crohn's Disease	Biological: mesenchymal cell transplantation;Biological: mesenchymal cell and fibroblast injection	Royan Institute		Recruiting	18 Years	65 Years	All	10	Phase 1	Iran, Islamic Republic of
437	NCT02010762	February 2013	16 December 2017	The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease	The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial	Crohn's Disease	Drug: Vitamin D;Drug: Placebo	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)		Not recruiting	18 Years	N/A	All	142	Phase 4	Netherlands
438	EUCTR2012-002432-93-CZ	18/01/2013	24 August 2015	A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn’s disease	A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn’s disease	Crohns disease MedDRA version: 17.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: 0114-0006B Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: N/A Current Sponsor code: NNC0114-0006 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	114		Serbia;United States;Hungary;Czech Republic;Slovakia;Poland;Spain;Russian Federation;Bulgaria
439	JPRN-UMIN000009596	2013/01/01	2 April 2019	Withdrawal of immunomodulator in Crohn's disease treated with adalimumab and immnomodulator : a multicenter randomized trial(Diamond2 study).		Crohn`s disease	Withdrawal of the concomitant immunomodulator (azathioprine or 6-mercaptoprine) while under adalimumab 40 mg/every other week continued treatment. Non-withdrawal of the concomitant immunomodulator (azathioprine or 6-mercaptoprine) while under adalimumab 40 mg/every other week continued treatment.	Department of Internal Medicine, School of Medicine, Keio University		Not Recruiting	15years-old	Not applicable	Male and Female	200	Not selected	Japan
440	NCT02501291	January 2013	14 March 2016	Thalidomide in Treating Crohn's Disease	Thalidomide in Inducing and Maintaining Remission of Crohn's Disease	Crohn's Disease	Drug: Thalidomide	First Affiliated Hospital, Sun Yat-Sen University		Not recruiting	18 Years	75 Years	Both	47	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
441	NCT01696396	December 4, 2012	20 August 2018	AMG 181 in Subjects With Moderate to Severe Crohn's Disease	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: AMG 181;Other: Placebo	Amgen		Not recruiting	18 Years	65 Years	All	254	Phase 2	United States;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Netherlands;Switzerland;United Kingdom;Czech Republic
442	NCT01078935	December 2012	19 February 2015	The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation	The Effect of Probiotics on Bowel Disease	Crohn's Disease;Ulcerative Colitis	Dietary Supplement: probiotics;Dietary Supplement: placebo	The Baruch Padeh Medical Center, Poriya	Ministry of Health, Israel	Not recruiting	18 Years	80 Years	Both	100	Phase 4
443	NCT01735461	December 2012	11 June 2018	Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients	Oral Calcium Supplementation, a Strategy to Reduce Kidney Stones in Crohn's Patients Living With a Small Bowel Resection	Kidney Calculi;Crohn's Disease	Dietary Supplement: Calcium Carbonate	University of British Columbia	University of Texas Southwestern Medical Center	Recruiting	19 Years	N/A	All	40	N/A	Canada
444	NCT01752790	December 2012	19 February 2015	Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease	Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial	Pediatric Crohn's Disease	Drug: Top-down;Drug: Step-up	University of Roma La Sapienza		Not recruiting	6 Years	18 Years	Both	0	Phase 4	Italy
445	NCT01757964	December 2012	16 December 2017	Bacteriotherapy in Pediatric Inflammatory Bowel Disease	Bacteriotherapy in Pediatric Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis;CD	Biological: Bacteriotherapy	David Suskind	Seattle Children's Hospital	Not recruiting	12 Years	21 Years	All	13	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
446	NCT01820247	December 2012	19 February 2015	Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission	Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission	Crohn's Disease	Drug: enteral nutrition;Drug: Tripterygium glycosides	Zhu Weiming		Recruiting	18 Years	75 Years	Both	100	N/A	China
447	JPRN-UMIN000009284	2012/11/20	21 May 2019	The Study for Efficacy of Adalimumab Maintenance Therapy Initiated Following Resection of Active Lesions in Crohn's Disease Patients	The Study for Efficacy of Adalimumab Maintenance Therapy Initiated Following Resection of Active Lesions in Crohn's Disease Patients - The Efficacy of Adalimumab Maintenance Therapy for Post-Operative Crohn's Disease	Crohn's disease Patients who has been treated with following surgical removal of active lesions(intestinal resection)	adalimumab injected immediately(within 3months) after surgical removal Crohn's disease lesions(intestinal resection). Inject SC 160mg,80mg,40mg in every other week.	Sakura Medical Center,Toho university		Not Recruiting	18years-old	65years-old	Male and Female	20	Phase 2	Japan
448	EUCTR2012-000529-31-BE	09/11/2012	11 June 2018	A study to find out more about the effect of AMG 181 in people with moderate to severe Crohn's Disease	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease	Moderate to severe Crohn's Disease MedDRA version: 17.1 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: AMG 181 Product Code: AMG 181 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG 181 Current Sponsor code: AMG 181 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Not Recruiting			Female: yes Male: yes	252	Phase 2	France;United States;Hungary;Czech Republic;Canada;Belgium;Denmark;Austria;Netherlands;Germany;United Kingdom
449	NCT01349920	November 2012	19 October 2017	Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)	An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)	Crohn Disease	Drug: Infliximab	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	60 Years	All	15	N/A	Moldova, Republic of;United Kingdom
450	NCT01817426	November 2012	19 February 2015	Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission	Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study	Crohn Disease	Drug: Infliximab;Other: Placebo	Copenhagen University Hospital at Herlev		Recruiting	18 Years	N/A	Both	136	Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
451	NCT01823029	November 2012	19 February 2015	Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia		Crohn's Disease	Drug: erythropoietin;Drug: enteral nutrition.;Drug: injection of iron	Jinling Hospital, China	Ministry of Health, China	Not recruiting	18 Years	75 Years	Both	387	N/A	China
452	EUCTR2012-000645-13-NL	17/10/2012	5 August 2014	Infliximab as first treatment instead of second line treatment in Crohns disease	Infliximab Top-down Study in Kids with Crohn’s disease - ITSKIDS	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion	ErasmusMC		Authorised			Female: yes Male: yes	90		Belgium;Netherlands;Italy
453	EUCTR2011-006084-22-GB	04/10/2012	16 October 2012	Usefulness of the measurement of blood levels of infliximab and adalimumab in inflammatory bowel disease patients in predicting response to treatment	Utilising drug levels and anti-drug antibodies to predict response to treatment in patients with Inflammatory Bowel Disease - Trough levels of anti-TNF agents in inflammatory bowel disease	Inflammatory bowel disease MedDRA version: 14.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Infliximab Pharmaceutical Form: Infusion INN or Proposed INN: Infliximab CAS Number: 170277-31-3 Current Sponsor code: Centocor Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 10mg/kg body wt- Trade Name: Humira Product Name: adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Current Sponsor code: EU/1/03/256/001 Concentration unit: mg milligram(s) Concentration type: not less then Concentration number: 40-mg	Royal Liverpool University Hospital		Authorised			Female: yes Male: yes	0		United Kingdom
454	NCT01562951	October 2012	17 May 2016	Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants	cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants	Crohn's Disease;Mucosal Inflammation	Drug: ADALIMUMAB;Drug: Placebo	Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa	Abbott;TFS Trial Form Support	Not recruiting	18 Years	75 Years	Both	15	Phase 3	Belgium;France;Spain
455	NCT01596894	October 2012	16 December 2017	Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease	A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone.	Crohn's Disease	Drug: Azithromycin + Metronidazole;Drug: Metronidazole	Prof. Arie Levine		Not recruiting	5 Years	17 Years	All	73	Phase 4	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
456	NCT01692808	October 2012	17 November 2015	Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease	Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease.	Crohn's Disease	Drug: Vitamin D3 3000 UI daily;Drug: Vitamin D3 4000 UI daily	St. Justine's Hospital		Not recruiting	10 Years	18 Years	Both	20	Phase 2	Canada
457	NCT01823042	October 2012	19 February 2015	The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)	A Randomized, Controlled, Open-label Study to Assess the the Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD).	Crohn's Disease	Drug: azathioprine+enteral nutrition;Drug: Azathioprine	Jinling Hospital, China		Recruiting	18 Years	75 Years	Both	100	N/A	China
458	EUCTR2011-006064-43-DE	27/09/2012	22 May 2017	Study to assess efficacy and safety of stem cells derived from allogeneic adipose tissue for the treatment of perianal fistulas in patients with Crohn’s disease.	A phase III, randomised, double blind, parallel group, placebo controlled, multicentre study to assess efficacy and safety of expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of perianal fistulising Crohn's disease over a period of 24 weeks and an extended follow-up period up to 104 weeks. ADMIRE-CD study.	Perianal fistulising Crohn´s disease MedDRA version: 17.1 Level: PT Classification code 10002156 Term: Anal fistula System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Allogenic eASCs 5 million cells/ml suspension for injection. CX601 Product Code: Cx601 Pharmaceutical Form: Suspension for injection INN or Proposed INN: Not applicable Current Sponsor code: Allogenic eASCs Other descriptive name: Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs) Concentration unit: U/ml unit(s)/millilitre Concentration type: equal Concentration number: 5000000 - Pharmaceutical form of the placebo: Suspension for injection Route of administration of the placebo: Intralesional use	TiGenix S.A.U.		Not Recruiting			Female: yes Male: yes	208	Phase 3	France;Belgium;Spain;Austria;Israel;Netherlands;Germany;Italy
459	EUCTR2012-000529-31-GB	27/09/2012	28 February 2019	A study to find out more about the effect of AMG 181 in people with moderate to severe Crohn's Disease	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease	Moderate to severe Crohn's Disease MedDRA version: 17.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: AMG 181 Product Code: AMG 181 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG 181 Current Sponsor code: AMG 181 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Not Recruiting			Female: yes Male: yes	252	Phase 2	France;United States;Hungary;Czech Republic;Canada;Belgium;Denmark;Austria;Netherlands;Germany;United Kingdom
460	EUCTR2012-002702-51-DK	24/09/2012	5 February 2018	Discontinuation of biologic therapy (infliximab) in patients with Crohn’s disease during sustained complete absence of disease activity: A Nordic multi-center, double blinded, randomized, placebo controlled study	Discontinuation of infliximab therapy in patients with Crohn’s disease during sustained complete remission: A Nordic multi-center, double blinded, randomized, placebo controlled study - STOP IT	Patients with Crohn's disease with absence of disease activity during biologic therapy (infliximab) MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Concentration number: 5-10 Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use Trade Name: Remsima Product Name: Remsima Pharmaceutical Form: Concentrate for solution for infusion	Department of medical gastroenterology S, Odense University Hospital		Authorised			Female: yes Male: yes	136	Phase 4	Finland;Denmark;Norway;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
461	JPRN-UMIN000015297	2012/09/19	23 April 2019	The feasibility study of accelated infliximab infusion from initial administration	The feasibility study of accelated infliximab infusion from initial administration - The feasibility study of accelated infliximab infusion from initial administration	patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)	Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable patient continue to receive more five treatment with 60min procedure.	Chiba University Hospital		Recruiting	20years-old	70years-old	Male and Female	54	Phase 2	Japan
462	NCT01632462	September 2012	19 February 2015	A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	Crohn's Disease	Drug: VSL#3	Federico II University		Recruiting	5 Years	17 Years	Both	30	Phase 4	Italy
463	NCT03079700	August 1, 2012	16 December 2017	Immune Modulation From Trichuris Suis	Mucosal and Systemic Immune Modulation From Trichuris Suis in a Self-infected Individual	Crohn Disease;Ulcerative Colitis;Intestinal Helminthiasis	Biological: Trichuris suis eggs	University of Aarhus		Not recruiting	18 Years	70 Years	Male	1	N/A
464	EUCTR2011-005846-36-DK	31/07/2012	7 April 2015	Bloodflow measurements in stenotic inflammatory bowel disease.	Safe evaluation of obstructive crohns disease using bloodflow Time-intensity curves and Elastography correlated to Neutrocytes and collagen counts and biomechanical properties Obtained in Stenotic Intestine after Surgery (STENOSIS) - STENOSIS	Crohns Disease undergoing elective surgery for intestinal stenosis. MedDRA version: 14.1 Level: PT Classification code 10058829 Term: Elective surgery System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 14.1 Level: PT Classification code 10059696 Term: Scan with contrast System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: LLT Classification code 10028049 Term: MRI System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: PT Classification code 10045434 Term: Ultrasound scan System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: PT Classification code 10022699 Term: Intestinal stenosis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Trade Name: SonoVue Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: sulphur hexafluoride CAS Number: 2551-62-4 Other descriptive name: SULFUR HEXAFLUORIDE Concentration unit: µl/ml microlitre(s)/millilitre Concentration type: equal Concentration number: 8-	Gastroenterology MIDT		Not Recruiting			Female: yes Male: yes			Denmark
465	EUCTR2011-005886-19-DK	31/07/2012	7 April 2015	Correlation between intestinal blOod flow assessed by magNetic resonance imaging and ulTRASound Techniques (CONTRAST)	Correlation between intestinal blOod flow assessed by magNetic resonance imaging and ulTRASound Techniques (CONTRAST) - CONTRAST	Crohns Disease with active disease MedDRA version: 14.1 Level: PT Classification code 10059696 Term: Scan with contrast System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: LLT Classification code 10011403 Term: Crohn's disease aggravated System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: LLT Classification code 10028049 Term: MRI System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: PT Classification code 10045434 Term: Ultrasound scan System Organ Class: 10022891 - Investigations ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Trade Name: SonoVue Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: sulphur hexafluoride CAS Number: 2551-62-4 Other descriptive name: SULFUR HEXAFLUORIDE Concentration unit: µl/ml microlitre(s)/millilitre Concentration type: equal Concentration number: 8-	Gastroenterology MIDT		Not Recruiting			Female: yes Male: yes			Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
466	NCT01570348	July 2012	11 March 2019	Crohn's Allogeneic Transplant Study	Allogeneic Hematopoietic Cell Transplantation for Patients With Treatment-Refractory Crohn's Disease: A Phase 2 Study	Crohn Disease	Procedure: Allogeneic Bone Marrow Transplantation;Drug: Cyclophosphamide;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Drug: Mycophenolate Mofetil;Drug: Mycophenolic Acid;Other: Quality-of-Life Assessment;Drug: Tacrolimus;Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center	National Cancer Institute (NCI);National Institutes of Health (NIH)	Not recruiting	18 Years	60 Years	All	2	Phase 2	United States
467	NCT01576471	July 2012	16 December 2017	Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo	A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Biological: Trichuris suis ova (TSO);Biological: Placebo	Coronado Biosciences, Inc.		Not recruiting	18 Years	65 Years	All	250	Phase 2	United States
468	NCT01629628	July 2012	19 February 2015	Adalimumab for the Management of Post-operative Crohn's Disease (CD)	An Investigator Initiated Prospective, Single Center, Randomized, Open Label Study to Assess the Efficacy of Adalimumab for the Maintenance of Remission in Post-operative CD Patients	Crohn Disease	Drug: Adalimumab;Drug: 6 Mercaptopurine	Tel-Aviv Sourasky Medical Center	Abbott	Not recruiting	18 Years	70 Years	Both	100	Phase 3	Israel
469	NCT01659762	July 2012	24 October 2016	A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.	A Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stromal (MSC) Cells in Adults With Moderate to Severe Crohn's Disease.	Crohn's Disease	Biological: autologous mesenchymal stromal cell	Emory University	Atlanta Clinical and Translational Science Institute;Atlanta Clinical and Translational Science Institute	Not recruiting	18 Years	65 Years	Both	16	Phase 1	United States
470	NCT00692939	June 26, 2012	26 August 2019	Autologous Stem Cell Transplantation for Crohn's Disease	Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients With Severe Crohn's Disease	Crohn's Disease	Biological: autologous CD34-selected peripheral blood stem cells transplant;Drug: Alemtuzumab;Drug: ATG;Drug: Melphalan;Drug: Thiotepa;Drug: Rituximab;Drug: Cyclophosphamide;Drug: G-CSF;Drug: Mesna	Paul Szabolcs		Recruiting	10 Years	60 Years	All	20	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
471	EUCTR2011-003038-14-NL	21/06/2012	3 July 2012	A RANDOMIZED CONTROLLED TRIAL INVESTIGATING TAILORED TREATMENT WITH INFLIXIMAB FOR ACTIVE LUMINAL CROHN'S DISEASE	A RANDOMIZED CONTROLLED TRIAL INVESTIGATING TAILORED TREATMENT WITH INFLIXIMAB FOR ACTIVE LUMINAL CROHN'S DISEASE - TAILORIX	Luminal active Crohn's Disease MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]	Trade Name: INFLIXIMAB Product Name: INFLIXIMAB Pharmaceutical Form: Suspension for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: INFLIXIMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	GETAID		Authorised			Female: yes Male: yes	120		Netherlands
472	EUCTR2011-004820-37-ES	13/06/2012	26 June 2012	Experimental study in humans to evaluate the efficacy and safety of blood products rich in proteins for the treatment of anal fistulas in Crohn's patients	Phase II, open-label clinical trial to evaluate the safety and efficacy of platelet-rich plasma and fibrin clot processed with PRGF-System tecnology in the treatment of anal fistulas in Crohn's patients	Perianal fistulas in Crohn's Disease Patients MedDRA version: 14.1 Level: LLT Classification code 10068659 Term: Perianal fistula System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Product Name: Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI) Pharmaceutical Form: Rectal solution INN or Proposed INN: Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI) Other descriptive name: HUMAN PLASMA FOR FRACTIONATION Concentration unit: % percent Concentration type: equal Concentration number: 100-	Fundación FISEVI		Authorised			Female: yes Male: yes		Phase 2	Spain
473	EUCTR2012-000729-28-ES	13/06/2012	26 June 2012	Imaging study in patients with Crohn`s Disease	MULTICENTER STUDY IN PATIENTS WITH CROHN?S DISEASE FOR CHARACTERIZATION OF MAGNETIC RESONANCE ENTEROGRAPHY ASSAYS FOR ASSESSMENT OF DISEASE ACTIVITY	Investigation of magnetic resonance enterography (MRE) with/without dye for evaluation of disease status in Crohn's disease MedDRA version: 14.1 Level: HLGT Classification code 10017969 Term: Gastrointestinal inflammatory conditions System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]	Product Name: / Product Code: / Pharmaceutical Form: Solution for injection INN or Proposed INN: ÁCIDO GADOBÉNICO CAS Number: 113662-23-0 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mmol/kg millimole(s)/kilogram Concentration type: equal Concentration number: 0.1-	Genentech, Inc.		Authorised			Female: yes Male: yes	54		Belgium;France;Spain;United States
474	EUCTR2009-017998-37-BE	08/06/2012	2 May 2016	Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFa-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy.	Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFa-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy.	Patients with an active spondyloarthropathy and with an active rheumatoid arthritis; who were diagnosed according to the classic ACR-criteria (American College of Rheumatology) for rheumatoid arthritis and according the ASAS-criteria (Assessment of SpondyloArthritis international Society) for spondylarthropathy. Patients with an active rheumatoid arthritis or with an active axial and peripheral spondyloarthropathy. Patients with erosive hand arthrosis. Patients with an active Crohn's disease. MedDRA version: 19.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: HLT Classification code 10052775 Term: Spondyloarthropathies System Organ Class: 100000004859 MedDRA version: 19.0 Level: HLT Classification code 10039078 Term: Rheumatoid arthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia 200 mg solution for injection Product Name: Certolizumab pegol Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Product Name: 99mTc-S-HYNIC Certolizumab pegol Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25-	Ghent University Hospital		Authorised			Female: yes Male: yes			Belgium
475	EUCTR2011-001754-28-DE	05/06/2012	8 August 2016	A randomized, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the safety and efficacy of CP-690,550 for maintenance therapy in subjects with moderate to severe Crohn’s disease	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE	Crohn's disease MedDRA version: 17.1 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Tofacitinib Product Code: CP-690,550-10 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Tofacitinib CAS Number: 540737-29-9 Current Sponsor code: CP-690,550-10 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA		Not Recruiting			Female: yes Male: yes	108	Phase 2	United States;Greece;Spain;Ukraine;Austria;Israel;France;Hungary;Czech Republic;Canada;Croatia;Australia;South Africa;Bulgaria;Netherlands;Germany;Japan;Sweden;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
476	EUCTR2011-006127-38-ES	05/06/2012	26 June 2012	Experimental study in humans to evaluate the efficacy and safety of blood products rich in proteins for the treatment of anal fistulas in Crohn's patients without subsidiary drug treatment.	Phase II, open-label clinical trial to evaluate the safety and efficacy of platelet-rich plasma and fibrin clot in processed with PRGF-system technology, in the treatment of anal fistulas in Crohn's patients with no concomitant therapy with second-line drugs.	Perianal fistulas in Crohn's Disease Patients MedDRA version: 14.1 Level: PT Classification code 10002156 Term: Anal fistula System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Product Name: Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI) Pharmaceutical Form: Rectal solution INN or Proposed INN: Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI) Other descriptive name: HUMAN PLASMA FOR FRACTIONATION Concentration unit: % percent Concentration type: equal Concentration number: 100-	Fundación FISEVI		Authorised			Female: yes Male: yes		Phase 2	Spain
477	JPRN-UMIN000007806	2012/06/01	2 April 2019	The feasibility study of accelated infliximab infusion during maintenance phase		patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)	Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable patient continue to receive more five treatment with 60min procedure.	Chiba University Hospital		Not Recruiting	Not applicable	Not applicable	Male and Female	54	Phase 2	Japan
478	JPRN-UMIN000008199	2012/06/01	2 April 2019	The investigations for improving successful judgment rate with PillCam Patency Capsule and differential diagnosis in Crohn's disease patients with following capsule endoscopy.		Crohn's disease, Patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin more than 3 months	Patients administered with mosapride Patients administered with no mosapride	Department of Gastroenterology, Graduate School of Medicine, Osaka City University		Not Recruiting	12years-old	85years-old	Male and Female	40	Not selected	Japan
479	NCT01181765	June 2012	19 February 2015	The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy	The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)	Crohn's Disease	Biological: Infliximab 5 mg/kg body weight infused over 2 hours	Janssen Inc.		Not recruiting	18 Years	N/A	Both	1	Phase 4	Canada
480	NCT01442025	June 2012	24 August 2015	Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease	A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease	Crohn's Disease	Drug: Infliximab	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives		Not recruiting	18 Years	N/A	Both	121	Phase 4	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
481	NCT01545050	June 2012	11 June 2018	Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease	A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease	Biological: Placebo matching with BMS-945429;Biological: BMS-945429	Vitaeris INC		Not recruiting	18 Years	N/A	All	72	Phase 2	United States;Austria;Canada;Czechia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Switzerland;Taiwan;United Kingdom;Australia;Brazil;Czech Republic;Russian Federation;Singapore
482	NCT01564823	June 2012	30 March 2015	Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease	Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease	Crohn´s Disease	Drug: Metronidazole;Drug: Azathioprine;Drug: Adalimumab	Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa	Effice Servicios Para la Investigacion S.L.	Not recruiting	18 Years	N/A	Both	86	Phase 3	Spain
483	NCT01624376	June 2012	19 February 2015	Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease	A Randomized, Double-blind, Placebo-controlled Phase I/IIa Study in Patients With Abdominal or Perianal Fistulizing Crohn's Disease to Explore the Safety, Tolerability and Preliminary Efficacy of Locally Administered DLX105.	Fistulizing Crohn's Disease	Drug: DLX105;Drug: Placebo	Delenex Therapeutics AG		Not recruiting	18 Years	65 Years	Both	18	Phase 2	Switzerland
484	NCT02445547	June 2012	16 December 2017	Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease	Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial	Crohn Disease	Other: UC-MSCs by peripheral intravenous infusion;Drug: received hormone maintenance therapy	Fuzhou General Hospital	Shaanxi Provincial People's Hospital	Not recruiting	18 Years	70 Years	All	82	Phase 1/Phase 2	China
485	JPRN-UMIN000009631	2012/05/02	2 April 2019	Efficacy and safety of a selective neutrophil elastase inhibitor in surgery for patients with Crohn's disease: A randomized controlled study		Crohn's disease	In the intervention group, sivelestat sodium will be continuously administered intravenously at 4.8 mg/kg from introduction of anesthesia until a maximum of 2 days after surgery. In the control group, sivelestat sodium will not be administered and conventional treatment will be given.	Department of Surgery 2,Tokyo Women's Medical University		Recruiting	16years-old	Not applicable	Male and Female	20	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
486	JPRN-UMIN000008043	2012/05/01	22 July 2019	The influence of medication for Crohn's disease on serological response to the influenza vaccination	The influence of medication for Crohn's disease on serological response to the influenza vaccination - Influence of Crohn's disease medication on influenza vaccination	Crohn's disease	Influenza Vaccination to Crohn's disease patients treated with Infliximab Influenza Vaccination to Crohn's disease patients treated with Elemental diet Influenza Vaccination to patients with upper-alimentary tract disorders (Disease-control)	The Jikei University School of Medicine Division of Gastroenterology and Hepatology		Not Recruiting	16years-old	60years-old	Male and Female	150	Phase 4	Japan
487	NCT01387594	May 2012	16 December 2017	Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs	A Multi-Center, Phase 1, Open-Label Evaluation Of The Effect Of PF-00547659 (Anti Madcam Monoclonal Antibody) On Cerebrospinal Fluid (CSF) Lymphocytes In Volunteers With Crohns Disease Or Ulcerative Colitis Who Are Anti-TNFInadequate Responders (TOSCA)	Crohn's Disease;Ileitis;Ileo-colonic and Colonic Crohn's Disease;Granulomatous Colitis;Regional Enteritis;Ulcerative Colitis	Procedure: lumbar puncture;Drug: lumbar puncture	Shire		Not recruiting	18 Years	75 Years	All	49	Phase 1	Austria;Belgium;France;Germany;Netherlands
488	NCT01369667	April 2012	24 August 2015	Vitamin D Supplementation in Adult Crohn's Disease	Vitamin D and Immunomodulation: Effects in Crohn's Disease	Crohn's Disease	Dietary Supplement: Vitamin D3;Other: Placebo	University of Dublin, Trinity College	Queen Mary University of London	Not recruiting	18 Years	75 Years	Both	117	Phase 4	Ireland
489	NCT01470599	April 2012	16 December 2017	A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease	A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn's Disease	Crohn's Disease	Drug: CP-690,550	Pfizer		Not recruiting	18 Years	76 Years	All	150	Phase 2	United States;Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;Croatia;Czech Republic
490	NCT01556672	April 2012	11 July 2016	Adalimumab-psoriasis and Small Bowel Lesions	Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab	Plaque Psoriasis;Crohn's Disease	Drug: Adalimumab;Device: Capsule endoscopy	Innovaderm Research Inc.	Abbott;Abbott	Not recruiting	18 Years	80 Years	Both	100	Phase 4	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
491	NCT01877577	April 2012	19 February 2015	Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D	Supplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.	Crohn's Disease (CD);Ulcerative Colitis (UC)	Dietary Supplement: Vitamin D3	University of California, San Francisco		Not recruiting	18 Years	N/A	Both	30	N/A	United States
492	EUCTR2011-005966-39-BE	08/03/2012	7 October 2014	Therapeutic effect of mesenchymal cells in patients suffering from a disease characterized by a severe inflammation and/or in whom the immune system attacks their own tissues.	Mesenchymal stem cell therapy for the treatment of severe or refractory inflammatory and/or autoimmune disorders.	Crohn's disease MedDRA version: 14.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.0 Level: HLGT Classification code 10003816 Term: Autoimmune disorders System Organ Class: 10021428 - Immune system disorders MedDRA version: 14.0 Level: PT Classification code 10064147 Term: Gastrointestinal inflammation System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: mesenchymal stem cells Product Code: MSC Pharmaceutical Form: Infusion	CHU-ULg		Authorised			Female: yes Male: yes	20		Belgium
493	NCT01393899	March 2012	19 October 2017	The Safety And Efficacy Of Maintenance Therapy With CP-690,550	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: CP-690,550	Pfizer		Not recruiting	18 Years	75 Years	All	180	Phase 2	United States;Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;Croatia;India
494	NCT01540292	March 2012	19 February 2015	Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders	Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders	Crohn's Disease	Biological: Mesenchymal Stem Cells (MSC)	University Hospital of Liege		Recruiting	18 Years	75 Years	Both	20	Phase 1/Phase 2	Belgium
495	NCT01580670	March 2012	15 July 2019	Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease	Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease	Pediatric Crohn's Disease	Drug: TA-650	Mitsubishi Tanabe Pharma Corporation		Not recruiting	6 Years	17 Years	All	14	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
496	NCT01647412	March 2012	20 April 2015	Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease	Growth Hormone and Nutrition Therapy in Juvenile Crohn's Disease, a Randomized Clinical Trial	Crohn's Disease	Drug: Growth Hormone;Dietary Supplement: Nutraceutical Combination;Other: Exclusion Diet;Other: Placebo Growth Hormone	Columbia University		Not recruiting	10 Years	17 Years	Both	0	Phase 2	United States
497	NCT01957423	March 2012	19 February 2015	Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients.	Immune Response Regulation and Nutritional Status of Crohn's Disease Patients Under Anti-TNF-alpha and Azathioprine Therapy.	Crohn's Disease	Dietary Supplement: Whey protein;Dietary Supplement: Soy protein	University of Campinas, Brazil	Fundação de Amparo à Pesquisa do Estado de São Paulo	Not recruiting	N/A	N/A	Both	41	N/A	Brazil
498	NCT02450513	March 2012	13 June 2016	Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study	Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study	Crohn's Disease	Drug: Adalimumab	Universitaire Ziekenhuizen Leuven		Recruiting	18 Years	65 Years	Both	30	N/A	Belgium
499	EUCTR2011-002517-11-DE	22/02/2012	5 November 2012	The aim of the study is to evaluate the clinical response and the remission in subjects with moderate to severe Crohn’s disease following 8 weeks of treatment with OKZ relative to placebo	A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetic of olokizumab administered subcutaneously to subjects with moderate to severe Crohn’s disease - Olokizumab	Moderate to severe Crohn’s disease MedDRA version: 15.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 15.0 Level: LLT Classification code 10011403 Term: Crohn's disease aggravated System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: olokizumab Product Code: CDP6038 Pharmaceutical Form: Solution for injection INN or Proposed INN: olokizumab CAS Number: 1007223-17-7 Current Sponsor code: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	UCB BIOSCIENCES GmbH		Not Recruiting			Female: yes Male: yes	96		Germany;Hungary;Czech Republic;Serbia
500	JPRN-UMIN000006882	2012/02/01	2 April 2019	Evaluation of Concomitant Adalimumab and Cytapheresis in Patients who lose Response to Adalimumab Therapy		Crohn's disease	Adalimumab therapy (40 mg/dose, every other week) combined with Granulocyte/ Monocyte Apheresis (GMA), once weekly for 5 comsecutive weeks. If responses are noted, GMA is applied for another 5 sessions (once weekly).	Department of Lower Gastroenterology, Hyogo College of Medicine	Hyogo College of Medicine (Hyogo, Japan), Osaka City Univ. (Osaka, Japan), Osaka Medical College (Osaka, Japan), Kyoto Univ. (Kyoto, Japan), Shiga University of Medical Science (Shiga, Japan)	Not Recruiting	15years-old	Not applicable	Male and Female	20	Phase 4	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
501	JPRN-UMIN000007343	2012/02/01	10 September 2019	The study of the effectiveness of anti-TNF antibody maintenance treatment combined with elemental diet for Crohn's disease patients	The study of the effectiveness of anti-TNF antibody maintenance treatment combined with elemental diet for Crohn's disease patients - The study of the effectiveness of anti-TNF antibody maintenance treatment combined with elemental diet for Crohn's disease patients	Crohn's disease	Patients in monotherapy group receive; 1) intravenous infusion of infliximab (10mg/kg) at every 8 weeks (dose escalation of anti-TNF antibody), or 2) intravenous infusion of infliximab (5mg/kg) at week 0, 2, and 6 and then every 8 weeks, or subcutaneous injection of adalimumab at week 0 (160mg), 2 (80mg) and then every 2 weeks (40mg) (first time or switch of anti-TNF antibody). Patients in combination therapy group take half the amount of their daily allowance of calories (900-1,200kcal) by elemental diet and the remaining half by usual unrestricted meals, in addition to above anti-TNF antibody therapy.	Tohoku University Graduate School of Medicine (Tohoku University Hospital)		Not Recruiting	20years-old	Not applicable	Male and Female	90	Not applicable	Japan
502	NCT01514240	February 2012	19 October 2017	Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan	A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan	Crohn's Disease	Drug: D9421-C capsule 3 mg;Drug: Mesalazine tablets	AstraZeneca		Not recruiting	15 Years	130 Years	All	123	Phase 3	Japan
503	NCT02399683	February 2012	28 November 2016	Immune Modulation From Trichuris Trichiura	Mucosal and Systemic Immune Modulation From Trichuris Trichiura in a Self-infected Individual	Crohn Disease;Colitis, Ulcerative;Intestinal Helminthiasis	Biological: Trichuris trichiura eggs	University of Aarhus		Not recruiting	18 Years	70 Years	Male	1	N/A
504	EUCTR2011-005678-47-IT	19/01/2012	18 March 2013	A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn’s disease in remission.	A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn’s disease in remission. - IGON 2	CROHN'S DISEASE IN REMISSION PHASE MedDRA version: 14.1 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GED-0301 Product Code: NA Pharmaceutical Form: Modified-release capsule, hard Current Sponsor code: GED-0301 Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Modified-release capsule, hard Route of administration of the placebo: Oral use	GIULIANI		Not Recruiting			Female: yes Male: yes		Phase 2	Italy
505	EUCTR2011-003966-34-ES	10/01/2012	10 March 2014	Biomarkers in diagnosis & treatment of patients with Crohn?s disease treated with immunosuppressants	The ADACAL Study: cAlprotectin and hsCRP as markers of a new Diagnostic-therapeutic strAtegy that assesses muCosal Activity to individuaLize treatment and improve the prognosis of patients with Crohn?s disease treated with immunosuppressants - not applicable	Crohn's disease (CD) is an inflammatory disease of the intestines that primarily causes abdominal pain, diarrhea, vomiting, or weight loss.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 40-160 Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)		Not Recruiting			Female: yes Male: yes	180		Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
506	EUCTR2011-002817-12-GR	09/01/2012	28 October 2013	A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease	A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease	Moderately-to-Severely Active Crohn’s Disease MedDRA version: 14.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GSK1605786A Product Code: GSK1605786A Pharmaceutical Form: Capsule, hard Current Sponsor code: GSK1605786A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-	GlaxoSmithKline Research and Development Limited		Not Recruiting			Female: yes Male: yes	900		Argentina;Canada;Hungary;Czech Republic;United Kingdom;Austria;Korea, Republic of;China;Netherlands;South Africa;Australia;Denmark;France;Italy;Switzerland;Russian Federation;Israel;Spain;Greece;Slovakia;Hong Kong;Taiwan;Estonia;Portugal;United States;Brazil;Belgium;Poland;Bulgaria;Germany;Norway;Japan;New Zealand;Sweden
507	JPRN-UMIN000006889	2012/01/01	2 April 2019	Evaluation of Concomitant Infliximab and Granulocyte/ Monocyte Adsorption Apheresis in Crohn's disease Patients who lose Response to 5mg/kg/dose Infliximab Therapy		Crohn's disease	Repeat 3 sets of the concomitant therapy with IFX and GMA. Each set is consisted from a single 5mg/kg/dose of infliximab infusion plus 3 times of weekly GMA at 5, 6, and 7 weeks after IFX infusion. Repeat 3 infusions of the 10mg/kg/dose infliximab in 8 weeks interval.	Department of Lower Gastroenterology, Hyogo College of Medicine		Not Recruiting	16years-old	75years-old	Male and Female	50	Phase 4	Japan
508	JPRN-UMIN000007514	2012/01/01	2 April 2019	Phase ll Study of Postoperative Adalimumab Maintenance Therapy for Crohn's Disease Recurrence		Crohn's disease	Adalimumab (HUMIRA 40mg for SC Injection) Inject SC 160mg on Day 1, then inject SC 80 mg on Day 15, and inject SC 40 mg every other week, beginning on Day 29.	Nagoya University Gradeate School of Medicine Department of Gastroenterology		Not Recruiting	20years-old	Not applicable	Male and Female	25	Phase 2	Japan
509	EUCTR2011-000885-36-ES	26/12/2011	16 February 2015	Adalimub treatment to prevent recurrency post-surgery in Crohn disease.	Multicentric, randomized double blind clinical trial and paralell groups to compare Adalimub vs Azatioprina efficacy prevention in Crhon disease post-surgical recurrency after 52 weeks of treatment - APPRECIA	Compare efficay of Adalimub vs Azatioprina to prevent surgical intervention in Chron disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Current Sponsor code: NA Other descriptive name: Adalimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- Trade Name: Imurel Product Name: Imurel Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Azatioprina CAS Number: 6336-41-0 Other descriptive name: Imurel Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Flagyl Product Name: Flagyl Pharmaceutical Form: Oral suspension INN or Proposed INN: Metronidazol CAS Number: 99616-64-5 Other descriptive name: Flagyl Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125-	GETECCU		Not Recruiting			Female: yes Male: yes			Spain
510	EUCTR2011-003966-34-BE	06/12/2011	21 August 2017	Biomarkers in diagnosis & treatment of patients with Crohn’s disease treated with immunosuppressants	The ADACAL Study: cAlprotectin and hsCRP as markers of a new Diagnostic-therapeutic strAtegy that assesses muCosal Activity to individuaLize treatment and improve the prognosis of patients with Crohn’s disease treated with immunosuppressants	Crohn's disease (CD) is an inflammatory disease of the intestines that primarily causes abdominal pain, diarrhea, vomiting, or weight loss.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 40-160 Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)		Not Recruiting			Female: yes Male: yes	180	Phase 3	Spain;Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
511	NCT01438151	December 2011	19 October 2017	Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease	Association of Serum Infliximab and Antibodies Toward Infliximab (ATI) to Clinical Outcomes in Crohn's Disease	Crohn's Disease	Drug: Remicade	Shradha Agarwal	Prometheus Laboratories	Not recruiting	7 Years	N/A	All	11	N/A	United States
512	NCT01453946	December 2011	19 October 2017	Safety and Maintenance Study of Entocort for Children With Crohn's Disease	A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive	Crohn's Disease	Drug: Entocort	Perrigo Company		Not recruiting	5 Years	17 Years	All	55	Phase 3	Italy;Poland;United States;Canada;Germany
513	NCT01466374	December 2011	28 September 2015	Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease	A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: BMS-936557 (Anti-IP-10 Antibody)	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	Both	121	Phase 2	United States;Belgium;France;Hungary;Israel;Poland;Puerto Rico;South Africa
514	NCT01496053	December 2011	28 April 2015	Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)	Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study	Ulcerative Colitis;Crohn's Disease;Inflammatory Bowel Disease	Dietary Supplement: AndoSan;Dietary Supplement: Sugar Extract	Oslo University Hospital	ImmunoPharma	Recruiting	18 Years	60 Years	Both	100	Phase 2/Phase 3	Norway
515	NCT01505855	December 2011	19 February 2015	Efficacy Study of Pneumococcal Vaccination in Crohn's Disease	Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study	Crohn's Disease	Drug: 23-valent polysaccharide pneumococcal vaccine	Kyunghee University Medical Center	Wonju Severance Christian Hospital;Seoul National University Hospital;Asan Medical Center;Soonchunhyang University Hospital;Ewha Womans University;Kosin University Gospel Hospital;Chung-Ang University Hospital;Inje University;The Catholic University of Korea;Keimyung University Dongsan Medical Center;Korea University;Wonkwang University;Severance Hospital;Konkuk University Hospital	Not recruiting	18 Years	N/A	Both	197	Phase 4	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
516	NCT01792388	December 2011	19 February 2015	Vitd and Barrier Function in IBD	Vitamin D and Its Effects on Inflammation and Intestinal Permeability in Crohn's Disease in Remission	Crohn's Disease	Dietary Supplement: Vitamin D;Dietary Supplement: Soya Bean oil	University of Dublin, Trinity College	University of Calgary;Queen Mary University of London	Not recruiting	18 Years	70 Years	Both	30	Phase 4	Ireland
517	NCT01536418	November 11, 2011	5 February 2018	An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease	A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease	Crohn's Disease	Drug: GSK1605786A	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	255	Phase 3	United States;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;Argentina;Brazil;China;Czech Republic;Ireland;South Africa
518	NCT01218360	November 2011	30 March 2015	Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)	Observational Study on Disease Severity, Evaluation Tools and the Long Term Impact of Each Treatment Strategy in the Daily Clinical Practice in Patients With Moderate to Severe Active Crohn's Disease (Protocol P06484)	Crohn Disease	Drug: Physician standard-of-care	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	65 Years	Both	71	N/A	Greece
519	NCT01434693	November 2011	19 October 2017	Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease	A Sequential Dose-Escalation, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Single Doses of 3 Different Doses of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease	Crohn's Disease	Biological: Trichuris suis ova;Other: Placebo	Coronado Biosciences, Inc.		Not recruiting	18 Years	55 Years	All	36	Phase 1	United States
520	NCT01442363	November 2011	19 February 2015	A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease		Perianal Crohn's Disease	Drug: BLI-1300 low dose;Drug: BLI-1300 high dose;Drug: placebo	Braintree Laboratories		Not recruiting	18 Years	N/A	Both	8	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
521	NCT01444092	November 2011	19 October 2017	Safety Study of Entocort for Children With Crohn's Disease	A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive	Crohn's Disease	Drug: Entocort	Perrigo Company		Not recruiting	5 Years	17 Years	All	123	Phase 3	United States;Canada;Germany;Italy;Poland
522	NCT01540942	November 2011	19 February 2015	Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease	A Randomized, Controlled, Open-label Study to Investigate the Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease	Crohn's Disease	Dietary Supplement: nutrition treat;Other: surgery	Jinling Hospital, China		Not recruiting	18 Years	75 Years	Both	91	N/A	China
523	JPRN-UMIN000006232	2011/10/01	2 April 2019	Evaluation of efficacy of high dose infliximab with azathiopurine add-on therapy for patients with Crohn's disease refractory to low dose infliximab		Crohn's disease	treatment with high dose infliximab and azathiopurine(6MP can be used in case of refractory patients to azatioupurine) treatment with only high dose infliximab	Saitama Medical University		Not Recruiting	15years-old	70years-old	Male and Female	40	Not selected	Japan
524	NCT01393626	October 2011	16 December 2017	A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: CP-690,550	Pfizer		Not recruiting	18 Years	75 Years	All	280	Phase 2	United States;Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;India;Romania;Sweden
525	NCT01433432	October 2011	19 February 2015	Open Label Extension Study to Protocol C2/13/DR-6MP-02	Clinical Efficacy and Safety of Delayed Release 6-Mercaptopurine (DR-6MP) for Targeted Ileal Delivery in Patients With Moderately Active Crohn's Disease - Open Label Extension Study	Crohn's Disease	Drug: 80 mg DR-6MP	Teva GTC		Not recruiting	18 Years	75 Years	Both	0	Phase 2	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
526	NCT01489943	September 19, 2011	16 December 2017	A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects	A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects	Crohn's Disease	Drug: GSK1605786 500 mg;Drug: Midazolam 3 mg;Drug: Pioglitazone 15 mg;Drug: Omeprazole 40 mg;Drug: Rosuvastatin 10 mg	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	24	Phase 1	United States
527	EUCTR2010-022760-12-DE	13/09/2011	5 March 2018	A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohn’s Disease - IMUNITI	Moderately to severely active Crohn's disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Stelara Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: N/A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: N/A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 77-104 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Janssen-Cilag International N.V.		Authorised			Female: yes Male: yes	1310	Phase 3	New Zealand;Japan;Germany;Iceland;Bulgaria;Croatia;Belgium;Brazil;Canada;European Union;Hungary;Czech Republic;United Kingdom;Austria;Korea, Republic of;Netherlands;South Africa;Denmark;Australia;Italy;Russian Federation;Israel;Ireland;Spain;Serbia;United States
528	NCT01369355	September 13, 2011	22 October 2019	A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease	Crohn's Disease;Colitis;IBD;Inflammatory Bowel Disease	Drug: Placebo SC;Drug: Placebo IV;Drug: Ustekinumab 90 mg SC q8w;Drug: Ustekinumab 130 mg IV;Drug: Ustekinumab 90 mg SC q12w	Janssen Research & Development, LLC		Not recruiting	18 Years	99 Years	All	1282	Phase 3	Spain;United Kingdom;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;South Africa;United States;Czech Republic
529	JPRN-UMIN000005689	2011/09/01	2 April 2019	GMA (Granulocyte and Monocyte Adsorption) early combined with azathioprine vs Infliximab plus azathioprine for induction of remission in active Crohn's disease : an open randomized trial		Crohn's disease	Patients in the combination therapy of GMA with azathioprine receive intensive GMA (twice per week, total 10 sessions) and oral azathioprine. Patients in the combination therapy of Infliximab and azathioprine receive infusion of IFX (at week 0, 2, 6) and oral azathioprine.	Department of Gastroenterology and Hepatology, Kyoto University Hospital		Not Recruiting	12years-old	75years-old	Male and Female	60	Not applicable	Japan
530	NCT01388933	September 2011	19 February 2015	A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease	A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects With Moderate Crohn's Disease	Crohn's Disease	Drug: TU-100;Drug: Matching Placebo	Tsumura USA	INC Research	Not recruiting	18 Years	75 Years	Both	79	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
531	EUCTR2010-022759-42-DE	29/08/2011	16 November 2015	A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease - UNITI 2	Moderately to severely active Crohn's disease MedDRA version: 17.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Stelara Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: N/A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Janssen-Cilag International N.V.		Not Recruiting			Female: yes Male: yes	612	Phase 3	United States;Spain;Israel;Russian Federation;Italy;United Kingdom;Hungary;European Union;Canada;Brazil;Croatia;Australia;Bulgaria;South Africa;Iceland;Netherlands;Germany;Japan;New Zealand;Korea, Republic of
532	EUCTR2010-022758-18-DE	24/08/2011	26 October 2015	Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy - UNITI 1	Moderately to severely active Crohn's disease MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Stelara Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection INN or Proposed INN: Ustekinumab CAS Number: 815610-63-0 Current Sponsor code: CNTO1275 Other descriptive name: N/A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Janssen-Cilag International N.V.		Not Recruiting			Female: yes Male: yes	703	Phase 3	Korea, Republic of;Japan;New Zealand;Iceland;Germany;South Africa;Australia;Denmark;Brazil;Belgium;Canada;European Union;Czech Republic;Hungary;United Kingdom;Italy;Israel;Austria;Ireland;Spain;United States;Serbia
533	EUCTR2010-023797-39-GB	12/08/2011	28 January 2013	TREATMENT OF IRON DEFICIENCY ANAEMIA IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE	TREATMENT OF IRON DEFICIENCY ANAEMIA IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE USING FERROUS SULPHATE OR COSMOFER: TOLERANCE AND EFFECTS ON HAEMOGLOBIN, DISEASE ACTIVITY, MOOD, QUALITY OF LIFE AND AUTONOMIC NERVOUS SYSTEM ACTIVITY. AN OPEN LABEL PHASE IV NON-INFERIORITY STUDY. - TREATMENT OF IRON DEFICIENCY ANAEMIA IN ADOLESCENTS WITH IBD.	Inflammatory bowel disease MedDRA version: 14.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders	Trade Name: Iron sulphate 200mg coated tablets Product Name: Ferrous sulphate Product Code: Ferrous sulphate Pharmaceutical Form: Tablet INN or Proposed INN: Iron sulphate CAS Number: 7720-78-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: CosmoFer Product Name: CosmoFer 50mg/ml solution for infusion or injection Pharmaceutical Form: Solution for infusion INN or Proposed INN: iron(III)- hydroxide dextran complex CAS Number: 9004-66-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Barts Health NHS Trust		Authorised			Female: yes Male: yes		Phase 4	United Kingdom
534	NCT01352221	August 2011	16 December 2017	Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)	A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Crohn's Disease Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 2)	Iron Deficiency Anaemia;Inflammatory Bowel Disease;Crohn's Disease	Drug: ST10;Drug: Placebo oral capsule	Shield Therapeutics		Not recruiting	18 Years	N/A	All	128	Phase 3	Austria;United Kingdom
535	NCT02619552	August 2011	26 August 2019	Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease	Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease	Crohn's Disease;IBD	Drug: Anti-TNF;Drug: Steroids	University of Maryland, Baltimore	Vanderbilt University;Milton S. Hershey Medical Center;Mercy Medical Center	Not recruiting	18 Years	N/A	All	50	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
536	EUCTR2010-022215-19-GB	21/07/2011	3 December 2012	Combined growth hormone and IGF1 therapy in paediatric Crohn'd disease	A Pharmacokinetic Study Of The Combined Use Of Recombinant Human GH And IGF-1 In Children With Inflammatory Bowel (Crohn’s) Disease - Combination rhGH + rhIGF-1 in childhood/adolescent Crohn’s	Impaired growth in Paediatric Crohn's disease MedDRA version: 14.1 Level: LLT Classification code 10011398 Term: Crohn's System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Increlex Product Name: Increlex 10mg/ml solution for injection Pharmaceutical Form: Solution for injection INN or Proposed INN: Mecasermin [rDNA Origin] 10mg/ml solution CAS Number: 67763-96-6 Other descriptive name: Recombinant human Insulin-like Growth Factor Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: NutropinAq® Product Name: NutropinAq 10mg/2ml solution for injection Pharmaceutical Form: Solution for injection INN or Proposed INN: Somatropin(rhGH) CAS Number: 12629-01-5 Other descriptive name: recombinant growth hormone Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5-1	Greater Glasgow & Clyde NHS		Authorised			Female: yes Male: yes	24		United Kingdom
537	EUCTR2011-002821-24-IT	21/07/2011	25 March 2013	Study on patients with moderate, active Crohn’s disease treated with Rifaximin-EIR 400 mg tablets.	Prospective pharmacodynamic study on patients with moderate, active Crohn’s disease treated with Rifaximin-EIR 400 mg tablets. - RETIC-PD/006/2011	Treatment of active, moderate Crohn’s disease MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Rifaximin-EIR Product Code: NA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: RIFAXIMIN CAS Number: 80621-81-4 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: range Concentration number: 380-420	ALFA WASSERMANN		Not Recruiting			Female: yes Male: yes			Italy
538	EUCTR2011-002640-27-IT	14/07/2011	28 October 2013	A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn’s disease (Ileo-Colitis)	A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn?s disease (Ileo-Colitis) - I.G.O.N. 1 STUDY	ACTIVE CROHN'S DISEASE MedDRA version: 14.1 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GED-0301 Product Code: NA Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: NA CAS Number: NA Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg/g milligram(s)/gram Concentration type: up to Concentration number: 160-	GIULIANI		Not Recruiting			Female: yes Male: yes		Phase 2	Germany;Italy
539	JPRN-UMIN000005970	2011/07/01	2 April 2019	Investigation on the remission maintaining effect of Polaprezinc in patients with Crohn's disease in remission phase.		Patients with Crohn's disease in remission phase	Polaprezinc administration group: patients has Polaprezinc 150mg/day for xxx months with Crohn's disease maintenance therapy. Polaprezinc non administration group: patients treated with Crohn's disease maintenance therapy only.	Kawasaki Medical School		Recruiting	20years-old	Not applicable	Male and Female	100	Not selected	Japan
540	NCT01298492	July 1, 2011	16 December 2017	A Study To Monitor Long-Term Treatment With PF-00547659	A Multicenter Open-label Extension Study To Assess Long-term Safety Of PF-00547659 In Subjects With Crohn's Disease OPERA II	Crohn's Disease	Drug: PF-00547659	Shire		Not recruiting	18 Years	75 Years	All	268	Phase 2	United States;Austria;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Bulgaria;Portugal;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
541	EUCTR2011-002061-38-BE	29/06/2011	21 August 2017	Treating patients with infliximab based on their trough levels	A randomised prospective trough level monitoring study with real-time therapeutic adaptations: Trough level Adapted infliXImab Treatment scheme (TAXIT). - TAXIT	2) Crohn's disease and ulcerative colitis MedDRA version: 13.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 13.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remicade Product Name: Remicade Product Code: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Katholieke Universiteit Leuven		Not Recruiting			Female: yes Male: yes		Phase 4	Belgium
542	JPRN-UMIN000005251	2011/06/01	2 April 2019	A prospective open-label study to investigate the efficacy and safety of methotrexate in Crohn's disease patients who lost response or showed intolerance to infliximab		Crohn's disease	Administration of oral methotrexate 15mg divided after breakfast and dinner weekly for 16 weeks.If remission(CDAI<150) cannot be obtained at week 8, the dose of methotrexate can be increased to 25mg weekly.	Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University		Not Recruiting	16years-old	Not applicable	Male and Female	14	Not selected	Japan
543	NCT01345318	June 2011	16 December 2017	B0151005 Open-Label Extension Study	A Multicenter Open-label Extension Study For Subjects Who Participated In Study B0151003 (Andante Ii)	Crohn's Disease	Biological: PF-04236921	Pfizer		Not recruiting	N/A	N/A	All	191	Phase 2	United States;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;New Zealand;Switzerland;United Kingdom
544	NCT01582568	June 2011	14 March 2016	EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment	EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment	Crohns Disease	Drug: Certolizumab	Baylor College of Medicine	UCB Pharma	Not recruiting	18 Years	70 Years	Both	1	Phase 4	United States
545	EUCTR2011-000854-44-SE	02/05/2011	17 November 2014	A clinical study for treatment of Crohns Disease with the new drug substance TRK-170. The study consists of two parts and are conducted at servral hopsitals in Europe. Patients in the study may receive placebo (drug with no effect) but either the doctor or the patient will know during the study.	A Two Part, Multi Centre, Randomized, Placebo Controlled, Double Blind Study of TRK 170 for the Treatment of Crohn's Disease	Crohn's disease MedDRA version: 14.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: TRK-170 Product Code: TRK-170 Pharmaceutical Form: Film-coated tablet CAS Number: 894404-71-8 Current Sponsor code: TRK-170 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: TRK-170 Product Code: TRK-170 Pharmaceutical Form: Film-coated tablet CAS Number: 894404-71-8 Current Sponsor code: TRK-170 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Toray Industries Inc		Not Recruiting			Female: yes Male: yes	609		Netherlands;Norway;Sweden;Czech Republic;Hungary;Poland;Belgium;Bulgaria;Latvia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
546	ChiCTR-TRC-11001321	2011-05-01	18 April 2017	Effect of ?-3 Fish Oil Fat on Perioperative Immunity in Patients with Crohn's Disease	Effect of ?-3 Fish Oil Fat on Perioperative Immunity in Patients with Crohn's Disease	Crohn's disease;ICD:K50.9	control group:Total parenteral nutrition (TPN) will be administrated to patients from day1 to day7 after the operation. Non-protein energy of the TPN is 120kJ/kg/d, of which 60% is supplied by glucose and 40% by fat emulsion. Amino acid of the TPN is 0.8-1.0g/kg/d. Electrolyte, vitamins, trace elements will be added into the TPN. Glucose/insulin ratio is 5:1. In this group, medium-long chain triglyceride will be used.;?-3 Fat group:Total parenteral nutrition (TPN) will be administrated to patients from day1 to day7 after the operation. Non-protein energy of the TPN is 120kJ/kg/d, of which 60% is supplied by glucose and 40% by fat emulsion. Amino acid of the TPN is 0.8-1.0g/kg/d. Electrolyte, vitamins, trace elements will be added into the TPN. Glucose-insulin ratio is 5:1. In this group, medium-long chain triglyceride and ?-3 fish oil fat (Omegaven);	The First Affiliated Hospital of Sun Yat-sen University		Not Recruiting	14	75	Both	control group:30;?-3 Fat group:30;	Post-market	China
547	NCT01346826	May 2011	8 August 2016	Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)	Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial	Crohn's Disease;Ulcerative Colitis	Drug: Standard 2 hours-infusion;Drug: Accelerated 1 hour-infusion;Drug: Accelerated 30 minutes-infusion	Asan Medical Center		Not recruiting	16 Years	80 Years	Both	145	Phase 4	Korea, Republic of
548	NCT01276509	April 6, 2011	16 December 2017	Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease	A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)	Crohn's Disease	Drug: PF-00547659 SC injection	Shire		Not recruiting	18 Years	75 Years	All	265	Phase 2	United States;Austria;Belgium;Bulgaria;Canada;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Croatia;Portugal;Sweden
549	NCT01338740	April 2011	19 February 2015	Switching From Adalimumab to Infliximab	Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab	Crohn's Disease	Drug: Adalimumab and Infliximab	University Hospital, Ghent	Abbott	Recruiting	18 Years	75 Years	Both	40	N/A	Belgium
550	NCT01341808	April 2011	19 February 2015	Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients	Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis;Hepatitis A	Biological: Epaxal Berna (virosomal hepatitis A vaccine)	Asan Medical Center		Not recruiting	18 Years	40 Years	Both	493	Phase 4	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
551	NCT01345799	April 2011	19 February 2015	A Study of TRK-170 for the Treatment of Crohn's Disease	A Two Part, Multi-Centre, Randomized, Placebo-Controlled, Double-Blind Study of TRK-170 for the Treatment of Crohn's Disease	Crohn's Disease	Drug: TRK-170;Drug: Placebo	Toray Industries, Inc		Not recruiting	18 Years	50 Years	Both	123	Phase 2	Belgium;Bulgaria;Czech Republic;France;Hungary;Latvia;Netherlands;Norway;Poland;Romania;Serbia;Sweden;Ukraine
552	NCT02504255	April 2011	3 August 2015	Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease	Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease : A Multicenter Cohort	Crohn Disease	Biological: Biological samplings;Other: Questionnaires	Hospices Civils de Lyon		Not recruiting	18 Years	N/A	Both	144	Phase 3	France
553	EUCTR2010-023347-14-BE	02/03/2011	17 February 2014	Treatment of Crohn’s disease-associated refractory diarrhoea with octreotide LAR An open pilot study	Treatment of Crohn’s disease-associated refractory diarrhoea with octreotide LAR An open pilot study	Crohn Disease refractory diarrhoea MedDRA version: 12.1 Level: LLT Classification code 10066533 Term: Diarrhea recurrent	Trade Name: Sandostatine Product Name: sandostatine Pharmaceutical Form: Injection* Trade Name: Sandostatine Product Name: sandostatine Pharmaceutical Form: Injection*	Gastroenterology CHC Liege		Authorised			Female: yes Male: yes			Belgium
554	JPRN-UMIN000005146	2011/03/01	2 April 2019	Study of Combination Therapy of Adalimumab and an Immunomodulator for Crohn's Disease(Diamond study)		Crohn's disease	Administration of Adalimumab 160 mg at baseline, 80 mg at 2 weeks and 40 mg every 2 weeks. In addition to Adalimumab Therapy, co-administration of 25-100mg Azathioprine once a day.Fixed dosage of Azathioprine up to 4 weeks and not increase in dosage later	Department of Internal Medicine, School of Medicine, Keio University		Not Recruiting	15years-old	Not applicable	Male and Female	200	Phase 4	Japan
555	NCT01258205	February 28, 2011	16 December 2017	Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects	A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease, and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease	Crohn's Disease	Drug: AMG 139	Allergan		Not recruiting	18 Years	55 Years	All	48	Phase 1	United States;Australia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
556	EUCTR2010-022383-12-NL	16/02/2011	12 May 2014	A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn’s Disease	A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn’s Disease	Subjects with Crohn's Disease MedDRA version: 16.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GSK1605786A Product Code: GSK1605786A Pharmaceutical Form: Capsule, hard INN or Proposed INN: GSK1605786A CAS Number: na Current Sponsor code: GSK1605786A Other descriptive name: na Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	750		United States;Portugal;Estonia;Taiwan;Hong Kong;Slovakia;Greece;Spain;Russian Federation;Israel;Switzerland;Italy;France;Australia;Denmark;Netherlands;Korea, Republic of;Austria;United Kingdom;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Bulgaria;Norway;Germany;Japan;New Zealand;Sweden
557	EUCTR2010-024528-12-DK	14/02/2011	22 July 2013	Kontrast UltraLydsskanning af Tyndtarmen hos patienter med Crohns sygdom – et pilotstudie (KULT) - KULT	Kontrast UltraLydsskanning af Tyndtarmen hos patienter med Crohns sygdom – et pilotstudie (KULT) - KULT	Morbus Crohn disease with signs of activity in the small bowel. MedDRA version: 12.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: SonoVue Pharmaceutical Form: Powder for solution for injection CAS Number: 2551-62-4 Other descriptive name: SULFUR HEXAFLUORIDE Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 45-	Henning Glerup		Not Recruiting			Female: yes Male: yes	5		Denmark
558	EUCTR2010-022384-35-DE	02/02/2011	14 April 2014	A 25 month study of a potential new medicine (GSK1605786A) for the treatment of Crohn’s disease	An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn’s Disease - Open label extension study	Subjects with Crohn’s Disease MedDRA version: 16.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GSK1605786A Product Code: GSK1605786A Pharmaceutical Form: Capsule, hard Current Sponsor code: GSK1605786A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	800		Portugal;United States;Estonia;Slovakia;Greece;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;Bulgaria;Germany;Netherlands;Norway;Japan;Sweden
559	NCT01203631	February 2011	8 August 2016	Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease	A Randomised, Double-blind, Parallel-group, Placebo Controlled Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease	Inflammation;Crohn's Disease	Drug: NNC 0142-0000-0002;Drug: Placebo	Janssen Research & Development, LLC		Not recruiting	18 Years	75 Years	Both	78	Phase 2	United States;Belgium;Canada;France;Hungary;Israel;Poland;Russian Federation
560	NCT01287897	February 2011	19 October 2017	A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy	A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Crohn's Disease Who Are Anti-tnf Inadequate Responders (Andante)	Crohn's Disease	Drug: PF-04236921 SC injection	Pfizer		Not recruiting	18 Years	75 Years	All	250	Phase 2	United States;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;New Zealand;Romania;Switzerland;United Kingdom;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
561	NCT01290042	February 2011	23 March 2015	Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.	A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.	Ulcerative Colitis;Crohn's Disease	Drug: AMG 181;Other: Placebo for AMG 181	Amgen		Not recruiting	18 Years	65 Years	Both	43	Phase 1	United States;Australia
562	NCT01291810	February 2011	19 February 2015	Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety and Immunogenicity of Neovacs' TNFa-Kinoid in Adult Subjects With Crohn's Disease	Crohn's Disease	Biological: TNF Kinoid;Biological: WFI	Neovacs		Not recruiting	18 Years	65 Years	Both	66	Phase 2	Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Netherlands;Romania
563	EUCTR2010-019973-13-DE	14/01/2011	3 September 2012	A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients	A multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tolerability of the anti-IL13 monoclonal antibody QAX576 in the treatment of perianal fistulas in patients suffering from Crohn’s disease	Treatment of perianal fistulas in patients suffering from Crohn's Disease. MedDRA version: 14.0 Level: PT Classification code 10016717 Term: Fistula System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders	Product Code: QAX576 Pharmaceutical Form: Powder and solvent for solution for infusion Current Sponsor code: QAX576 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Novartis Pharma AG		Not Recruiting			Female: yes Male: yes	23	Phase 2	Germany;Switzerland
564	EUCTR2010-019996-32-BE	12/01/2011	21 August 2017	A phase II, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety and immunogenicity of Neovacs’TNFa-Kinoid in adult subjects with Crohn’s Disease	A phase II, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety and immunogenicity of Neovacs’TNFa-Kinoid in adult subjects with Crohn’s Disease	Crohn’s Disease MedDRA version: 14.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: TNF-Kinoid Product Code: TNF-K Pharmaceutical Form: Emulsion for injection INN or Proposed INN: Not assigned yet Current Sponsor code: TNFa-Kinoid or TNFa-K or Kinoid Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Emulsion for injection Route of administration of the placebo: Intramuscular use	Neovacs SA		Not Recruiting			Female: yes Male: yes	132	Phase 2	France;Hungary;Czech Republic;Belgium;Croatia;Romania;Bulgaria;Netherlands;Germany
565	EUCTR2010-020836-21-BE	07/01/2011	21 August 2017	A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s disease	A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s disease	Crohn’s disease MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: NNC0142-0000-0002 Product Code: NNC142-0002 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: N/A Current Sponsor code: NNC142-0002 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Novo Nordisk A/S		Not Recruiting			Female: yes Male: yes	100	Phase 2	United States;Hungary;European Union;Canada;Poland;Belgium;Israel;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
566	EUCTR2010-022017-26-GB	07/01/2011	28 February 2019	A pilot study on the effects of an alternate-day corticosteroid regimen in children with active crohn’s disease - Alternate-day corticosteroid regimen in children with Crohn’s disease	A pilot study on the effects of an alternate-day corticosteroid regimen in children with active crohn’s disease - Alternate-day corticosteroid regimen in children with Crohn’s disease	Crohn's disease MedDRA version: 12. Level: LLT Classification code 10013099 Term: Disease Crohns	Product Name: Prednisolone Pharmaceutical Form: Soluble tablet INN or Proposed INN: Prednisolone CAS Number: 125-02-0 Concentration unit: mg milligram(s) Concentration type: equal	Central Manchester University Hospitals Foundation Trust		Not Recruiting			Female: yes Male: yes	27	Phase 2	United Kingdom
567	EUCTR2010-022382-10-GB	06/01/2011	2 October 2012	A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease	A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease	Subjects with Moderately-to-Severely Active Crohn’s Disease MedDRA version: 14.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GSK1605786A Product Code: GSK1605786A Pharmaceutical Form: Capsule, hard Current Sponsor code: GSK1605786A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Authorised			Female: yes Male: yes	600		Hungary;Germany;Netherlands;Norway;France;Italy;Austria;Sweden;Australia;United Kingdom;Czech Republic;Canada;Belgium;Denmark;Spain;Japan;United States
568	JPRN-UMIN000007047	2011/01/01	2 April 2019	Effect of adacolumn and adalimumab combination therapy for the active stage Crohn's disease		Crohn's disease	Adacolumn and adalimumab combination therapy for 10 weeks. Adalimumab single therapy for remain 94 weeks. Adacolumn single therapy for 104 weeks.	Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology		Recruiting	12years-old	75years-old	Male and Female	40	Not applicable	Japan
569	NCT01245088	January 2011	19 February 2015	Chondroitin Sulfate for Crohn's Disease	A Pilot Study of Chondroitin Sulfate (CS) for the Treatment of Mild to Moderate Crohn's Disease	Crohn's Disease	Drug: chondroitin sulfate	University Hospital Case Medical Center		Not recruiting	18 Years	80 Years	Both	0	Phase 1/Phase 2	United States
570	NCT01275508	January 2011	19 February 2015	Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut	Prospective, Monocentric, Open-label, Clinical Phase 1 Study to Demonstrate the Safety and Tolerability of FITC-Adalimumab After Single Topical Administration to the Intestinal Mucosa During Endomicroscopy in Patients With Crohn's Disease	Crohn's Disease	Drug: FITC-Adalimumab	University of Erlangen-Nürnberg Medical School	Abbott	Not recruiting	18 Years	70 Years	Both	25	Phase 1/Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
571	NCT01316601	January 2011	8 June 2015	A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease		Crohn's Disease	Drug: QAX567	Gerhard Rogler	Novartis Pharmaceuticals	Not recruiting	18 Years	N/A	Both	3	Phase 2	Switzerland
572	EUCTR2011-003742-40-DE		23 February 2015	A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort™ EC as a Maintenance Treatment for Crohn’s Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive	A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort™ EC as a Maintenance Treatment for Crohn’s Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive	Crohn's Disease MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]	Trade Name: Entocort® Kapseln Product Name: budesonide Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3-	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	50		United States;Canada;Poland;Germany;Italy
573	EUCTR2011-003743-22-DE		10 July 2015	A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive	A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive	Crohn's Disease;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]	Trade Name: Entocort® Kapseln Product Name: budesonide Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: budesonide CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3-	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	110		United States;Canada;Poland;Germany;Italy
574	NCT01277666	December 20, 2010	16 December 2017	A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease	A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease	Crohn's Disease	Drug: GSK1605786A;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	608	Phase 3	United States;Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;Czech Republic
575	NCT01199302	December 2010	11 May 2015	Safety Study in Subjects With Crohn's Disease	A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease	Crohn's Disease	Drug: AMG 827	Amgen		Not recruiting	N/A	N/A	Both	67	Phase 2	United States;Australia;Belgium;Canada;France;Netherlands;Poland;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
576	NCT01266785	December 2010	20 May 2019	Infliximab, Regulatory T Cells, IL2 and Crohn's Disease	Analysis of Relationship Between Infliximab Treatment Response, Regulatory T Cells, and Interleukin-2 in Crohn's Disease	Crohn's Disease	Drug: Infliximab	Oregon Health and Science University	Centocor, Inc.	Not recruiting	18 Years	70 Years	All	0	N/A	United States
577	NCT01094613	November 2010	19 February 2015	Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease	MultiCTR Randomized Double-Blind Double-Dummy Study to Evaluate Clinical Efficacy/Safety of DR 6MP for Targeted Ileal Delivery vs Purinethol in Patients w/Moderately Active Crohn's Disease	Crohn's Disease	Drug: Delayed Release 6 mercaptopurine;Drug: 6 Mercaptopurine	Teva GTC		Not recruiting	18 Years	75 Years	Both	70	Phase 1/Phase 2	Israel
578	NCT01224171	November 2010	19 October 2017	Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease	A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: vedolizumab;Other: Placebo	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	80 Years	All	416	Phase 3	United States;Canada;Puerto Rico
579	EUCTR2006-000720-13-DE	27/10/2010	16 November 2015	Study to evaluate the effectiveness and safety of 3 doses of embryonated eggs of the porcine whipworm compared to placebo (dummy drug) in the treatment of active Crohn's disease.	Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease - TSO vs. placebo in active Crohn’s disease	Induction of remission in active Crohn´s disease MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml Product Code: TSO 250 Pharmaceutical Form: Oral suspension Current Sponsor code: TSO 250 Other descriptive name: Suspension containing 250 embryonated, viable TSO/15ml Concentration unit: ml millilitre(s) Concentration type: equal Concentration number: 17- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use Product Name: Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml Product Code: TSO 2500 Pharmaceutical Form: Oral suspension Current Sponsor code: TSO 2500 Other descriptive name: Suspension containing 2500 embryonated, viable TSO/15ml Concentration unit: ml millilitre(s) Concentration type: equal Concentration number: 167- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use Product Name: Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml Product Code: TSO 7500 Pharmaceutical Form: Oral suspension Current Sponsor code: TSO 7500 Other descriptive name: Suspension of 7500 embryonated, viable TSO/15ml Concentration unit: ml millilitre(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Dr. Falk Pharma GmbH		Not Recruiting			Female: yes Male: yes	400	Phase 2	Czech Republic;Denmark;Austria;Germany;Switzerland
580	JPRN-UMIN000005761	2010/10/27	2 April 2019	The Study for Efficacy and Safety of Adalimumab for Crohn's Disease with Loss of Response to Infliximab		Crohn's Disease patient as following 1)or 2) 1)the patient who treated with IFX infusion of interval every 4-6 weeks. 2)the patient who could not keep to treat with IFX due to side effect or ineffectiveness.	Adalimumab (HUMIRA 40mg for SC Injection) Inject SC 160mg on Day 1, then inject SC 80 mg on Day 15, and inject SC 40 mg every other week, beginning on Day 29.	Kenji Watanabe		Not Recruiting	Not applicable	Not applicable	Male and Female	50	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
581	JPRN-UMIN000005762	2010/10/27	2 April 2019	The Study for Efficacy of Adalimumab Conbined Elemental Diet Therapy for Crohn's Disease		Crohn's Disease patient who was ineffective for present therapy and who has not been treated with anti TNF alpha antibody.	1)Adalimumab (HUMIRA 40mg for SC Injection) Inject SC 160mg on Day 1, then inject SC 80 mg on Day 15, and inject SC 40 mg every other week, beginning on Day 29. 2)Elental(1 kcal/ml; 80g/300ml)	Kenji Watanabe		Not Recruiting	Not applicable	Not applicable	Male and Female	40	Not selected	Japan
582	NCT01111292	October 2010	19 October 2017	Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia	Myo-Inositol Chemoprevention in Colitis-Associated Dysplasia	Colon Carcinoma;Dysplasia in Crohn Disease;Low Grade Dysplasia in Ulcerative Colitis;Rectal Carcinoma	Drug: Inositol;Other: Placebo	National Cancer Institute (NCI)		Not recruiting	18 Years	N/A	All	5	Phase 1/Phase 2	United States
583	NCT01203254	October 2010	19 February 2015	Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease	Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease	Crohns Disease;Bile Acid Malabsorption	Drug: Colesevelam;Drug: Placebo	Florian Beigel		Not recruiting	18 Years	65 Years	Both	34	Phase 4	Germany
584	NCT01231217	October 2010	19 February 2015	Green Tea in Crohn's Disease		Crohn's Disease	Other: Green tea (Camellia sinensis);Other: Coffee	University Hospital Heidelberg		Recruiting	18 Years	N/A	Both	80	N/A	Germany
585	EUCTR2010-020137-10-GB	20/09/2010	30 April 2019	Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM)	An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects with Moderate to Severe Crohn's Disease - CALM	Crohn's disease MedDRA version: 17.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira 40 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Azathioprin-ratiopharm 25mg Filmtabletten Product Name: azathioprine Pharmaceutical Form: Tablet INN or Proposed INN: Azathioprine CAS Number: 446-86-6 Other descriptive name: AZATHIOPRINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Azathioprin-ratiopharm 50 mg Filmtabletten Product Name: azathioprine Pharmaceutical Form: Tablet INN or Proposed INN: Azathioprine CAS Number: 446-86-6 Other descriptive name: AZATHIOPRINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Decortin 5 mg Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISONE CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Decortin 20 mg Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISONE CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	AbbVie Deutschland GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	240	Phase 3	United States;Spain;Lithuania;Austria;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Germany;Netherlands;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
586	NCT01187459	September 2010	19 February 2015	Vitamin D in Pediatric Crohn's Disease	Vitamin D in Pediatric Crohn's Disease	Vitamin D Deficiency	Dietary Supplement: Vitamin D	University of British Columbia	McMaster University	Not recruiting	8 Years	18 Years	Both	87	Phase 4	Canada
587	NCT01215890	September 2010	19 February 2015	Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease	A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients	Crohn's Disease;Low Bone Mineral Density	Drug: risedronate;Drug: placebo	University of Alberta		Not recruiting	18 Years	N/A	Both		Phase 4	Canada
588	NCT01233570	September 2010	19 February 2015	Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease	Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease	Crohn Disease	Drug: Tacrolimus	University of Aberdeen		Not recruiting	12 Years	N/A	Both	20	Phase 2	United Kingdom
589	NCT01233960	September 2010	16 December 2017	Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease	A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: adult human mesenchymal stem cells	Mesoblast International Sàrl		Not recruiting	18 Years	70 Years	All	120	Phase 3	United States;Australia;New Zealand
590	EUCTR2010-018431-18-DE	23/08/2010	16 February 2015	A Multicenter Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence	Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE® (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence - PREVENT	Crohn’s disease (CD) MedDRA version: 16.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: REMICADE Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: INFLIXIMAB Other descriptive name: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Powder for concentrate for solution for infusion Route of administration of the placebo: Intravenous use	Janssen Biologics B.V.		Not Recruiting			Female: yes Male: yes	290		Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Australia;Denmark;Germany;Netherlands;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
591	NCT01155362	August 2010	4 March 2019	A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease	A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease	Crohn's Disease	Biological: Human Placenta-Derived Cells PDA001 Intravenous Infusion;Drug: Vehice Control	Celularity Incorporated	Celgene Corporation	Not recruiting	18 Years	75 Years	All	50	Phase 2	United States
592	NCT01190410	August 2010	23 July 2018	Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol	An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035	Crohn's Disease	Drug: certolizumab pegol	UCB Pharma		Not recruiting	6 Years	17 Years	All	16	Phase 2	United States;Canada;Australia
593	NCT01261286	August 2010	19 February 2015	Drug-Disease Interaction in Crohn's Disease	Pharmacodynamics and Pharmacokinetics of Verapamil in Crohn's Disease Patients	Crohn's Disease	Drug: verapamil	University of Alberta		Not recruiting	18 Years	65 Years	Both		Phase 1	Canada
594	NCT01611805	July 22, 2010	16 December 2017	Japanese Phase I of GSK1605786	A Placebo-Controlled, Four-Period Crossover, Single Ascending Oral Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of the CCR9 Receptor Antagonist GSK1605786 in Japanese Healthy Male Subject	Crohn's Disease	Drug: GSK1605786;Drug: GSK1605786 Placebo	GlaxoSmithKline		Not recruiting	20 Years	55 Years	Male	30	Phase 1	Australia
595	NCT01150890	July 2010	25 May 2015	AMG 827 in Subjects With Moderate to Severe Crohn's Disease	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: AMG 827 350 MG;Drug: AMG 827 210 MG;Drug: AMG 827 700 MG;Drug: Placebo	Amgen		Not recruiting	18 Years	65 Years	Both	130	Phase 2	United States;Australia;Belgium;Canada;France;Netherlands;Poland;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
596	EUCTR2009-015680-14-NL	18/05/2010	16 February 2015	Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients with Refractory Perianal Crohn’s Disease - allo bmMSCs CD fistula	Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients with Refractory Perianal Crohn’s Disease - allo bmMSCs CD fistula	single or multiple draining perianal fistulas as a result of Crohn's Disease MedDRA version: 12.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: Bone Marrow Derived Mesenchymal Stem cells (MSCs) Product Code: NA Pharmaceutical Form: Injection*	Leiden University Medical Center		Not Recruiting			Female: yes Male: yes			Netherlands
597	NCT01114607	May 5, 2010	16 December 2017	A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects	A Single Dose, Randomized, Five-Period Crossover Study to Assess the Relative Bioavailability of Four New Formulations of the CCR9 Receptor Antagonist GSK1605786A (CCX282) in Healthy Male and Female Subjects	Crohn's Disease	Drug: GSK1605786 ChemoCentryx: formulation A;Drug: GSK1605786 GSK: formulation B;Drug: GSK1605786 GSK direct-fill: formulation C;Drug: GSK1605786 GSK modified-process: formulation D;Drug: GSK1605786 GSK tablet: formulation E	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	24	Phase 1	United States
598	NCT00737932	May 2010	30 March 2015	Laquinimod Phase IIa Study in Active Crohn's Disease	A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn's Disease.	Crohn's Disease	Drug: Laquinimod;Other: placebo	Teva Pharmaceutical Industries		Not recruiting	18 Years	75 Years	Both	180	Phase 2	Belgium;France;Israel;Italy;Netherlands;Poland;South Africa;Spain;United Kingdom
599	NCT00988832	February 2010	19 October 2017	An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)	A UK Retrospective Audit of Patients With Crohn's Disease Treated With Infliximab	Crohn's Disease	Biological: Infliximab	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	380	N/A	United Kingdom
600	NCT01037322	January 2010	19 February 2015	Cannabidiol for Inflammatory Bowel Disease	Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease	Crohn's Disease;Ulcerative Colitis	Drug: cannabidiol;Drug: placebo in drops	Meir Medical Center		Not recruiting	20 Years	80 Years	Both	20	Phase 1/Phase 2	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
601	NCT01040910	January 2010	19 February 2015	Cannabis for Inflammatory Bowel Disease	A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease	Crohn's Disease;Ulcerative Colitis	Drug: smoking of cannabis;Drug: smoking cigarettes with placebo	Meir Medical Center		Recruiting	20 Years	70 Years	Both	20	Phase 1/Phase 2	Israel
602	NCT01046773	January 2010	19 February 2018	Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease	Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease	Crohn's Disease;Vitamin D Deficiency	Drug: Cholecalciferol	University of California, Los Angeles	The Broad Foundation	Not recruiting	8 Years	18 Years	All	3	Phase 1	United States
603	NCT01053559	January 2010	19 February 2015	Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy	Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients With Small Bowel Crohn's Disease Treated With Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy	Crohn's Disease	Drug: certolizumab pegol	Shafran Gastroenterology Center	UCB Pharma	Not recruiting	18 Years	70 Years	Both	15	N/A	United States
604	NCT01090817	January 2010	29 June 2015	An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease	A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn's Disease	Crohn Disease	Drug: Mesenchymal stromal cells (MSC) for infusion	R.P.Herrmann	The Queen Elizabeth Hospital;Concord Hospital;Sir Charles Gairdner Hospital;The Alfred	Not recruiting	18 Years	55 Years	Both	21	Phase 2	Australia
605	NCT01288053	January 2010	20 August 2018	Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease	Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease	Crohn's Disease	Biological: Allogeneic Stem Cell Therapy	Northwestern University		Not recruiting	18 Years	45 Years	All	9	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
606	NCT01548014	January 2010	19 February 2015	The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease	Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study	Crohn's Disease	Dietary Supplement: VSL#3	Samsung Medical Center		Recruiting	13 Years	17 Years	Both	1	Phase 3	Korea, Republic of
607	JPRN-UMIN000010293	2009/12/19	2 April 2019	Parallel-group, multicenter, comparative study on the usefulness of nutrition therapy for patients with Crohn's disease Infliximab maintenance therapy		Crohn's disease	Infliximab maintenance therapy for 48 weeks in, Racol daily nutritional interventions during the study period as a target intake of 800kcal per day, in the implementation group nutrition therapy is used in conjunction with a diet and Racol. In the group of non-nutritional therapy is carried out aggressive nutritional intervention is not performed, and only the normal diet	Graduate School of Medical Sciences, Kyushu University	Oita Red Cross Hospital Takano Hospital	Recruiting	20years-old	Not applicable	Male and Female	80	Not applicable	Japan
608	EUCTR2008-005237-30-NL	01/12/2009	7 December 2015	A Multicenter, Prospective, Long-term Registry of children with Crohn's Disease or Ulcerative Colitis	A Multicenter, Prospective, Long-term Registry of Pediatric Patients with Crohn's Disease or Ulcerative Colitis - DEVELOP	Pediatric patients with a confirmed diagnosis of CD or UC . MedDRA version: 18.1 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Other descriptive name: Remsima and Inflectra Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Janssen Biologics B.V.		Authorised			Female: yes Male: yes	6000		United States;Canada;Netherlands;Sweden
609	NCT01024647	December 2009	19 February 2015	Optimizing Cimzia in Crohn's Patients	Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy	Crohn's Disease	Biological: certolizumab pegol	Atlanta Gastroenterology Associates	UCB Pharma	Recruiting	18 Years	N/A	Both	50	Phase 4	United States
610	EUCTR2009-011621-14-AT	12/11/2009	19 March 2012	A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease - A2202E1	A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease - A2202E1	Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: AIN457 Product Code: AIN457 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Not available CAS Number: None Current Sponsor code: AIN457 Other descriptive name: None Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	72		Germany;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
611	JPRN-UMIN000002796	2009/11/01	2 April 2019	Effect of tacrolimus for patients with refractory Crohn's disease: A randomized, placebo-controlled trial.		Crohn's disease	We randomly assigned patients into either placebo or tacrolimus group at a ratio of 1:1 by use of stratified block randomization. Patients assigned to tacrolimus received for four weeks. For induction of remission, the dose of tacrolimus is increased with aiming at high trough level (10~15ng/ml). placebo control	Department of Gastroenterology and Hepatology, Kyoto University		Recruiting	16years-old	65years-old	Male and Female	50	Phase 2	Japan
612	NCT01015391	November 2009	19 February 2015	Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease	A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection	Crohn's Disease	Drug: T2;Drug: Azathioprine	Jinling Hospital, China		Recruiting	18 Years	N/A	Both	100	N/A	China
613	EUCTR2008-006957-42-DE	30/10/2009	11 March 2013	Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s disease	Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s disease	Induction of remission in active Crohn´s disease MedDRA version: 14.1 Level: LLT Classification code 10058815 Term: Crohn's disease acute episode System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders	Product Name: Budenofalk 9mg gastro-resistant granules Product Code: Budenofalk 9mg gastro-resistant granules Pharmaceutical Form: Gastro-resistant granules INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Gastro-resistant granules Route of administration of the placebo: Oral use Trade Name: Budenofalk 3mg gastro-resistant capsules Product Name: Budenofalk 3mg gastro-resistant capsules Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Gastro-resistant capsule, hard Route of administration of the placebo: Oral use	Dr. Falk Pharma GmbH		Not Recruiting			Female: yes Male: yes	500	Phase 3	Hungary;Czech Republic;Slovakia;Ukraine;Romania;Lithuania;Russian Federation;Bulgaria;Latvia;Germany
614	EUCTR2009-011220-62-NL	26/10/2009	19 March 2012	A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesalazine: the CROWN study	A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesalazine: the CROWN study	1. Patients with a diagnosis of quiscent (CDAI < 150) Crohn's Disease (CD) according to established clinical, endoscopic, radiological and histological criteria. 2. Patients will be aged 18 years or older. 3. Patients with mesalazine maintenance therapy > 1 year. MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: mesalazine Pharmaceutical Form: Tablet INN or Proposed INN: mesalazine CAS Number: 65-49-6 Other descriptive name: AMINOSALICYLIC ACID Concentration unit: mg milligram(s) Concentration type: range Concentration number: 3000-3200	University Medical Center Utrecht		Not Recruiting			Female: yes Male: yes			Netherlands
615	NCT00989573	October 2009	19 February 2015	A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease	A Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: OPC-6535	Otsuka Pharmaceutical Co., Ltd.		Not recruiting	18 Years	64 Years	Both	191	Phase 2/Phase 3	Japan;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
616	NCT01661257	October 2009	19 February 2015	Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-a Therapy	Expression of T-cell Immunoglobulin- and Mucin-domain-containing Molecule 3 (TIM-3)and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-a Therapy	Crohn's Disease	Drug: Infliximab	Samsung Medical Center		Not recruiting	13 Years	17 Years	Both	20	Phase 3	Korea, Republic of
617	NCT00999115	September 2009	19 February 2015	Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA)	Clinical Trial in Phase I-IIa to Study the Feasibility and Security of the Allogenic Use of Adipose-derived Stem Cells for the Local Treatment of Recto-vaginal Fistula in Crohn´s Disease	Rectovaginal Fistula;Crohn Disease	Drug: Expanded allogenic adipose-derived adult stem cells	Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz		Not recruiting	18 Years	N/A	Female	10	Phase 1/Phase 2	Spain
618	NCT02322008	September 2009	19 February 2015	Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice	Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice	Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease	Biological: infliximab and adalimumab	Regionshospitalet Viborg, Skive		Not recruiting	18 Years	N/A	Both	1035	N/A
619	EUCTR2009-013348-35-NL	04/08/2009	19 March 2012	(Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease	(Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease	Patients with quiescent Crohn’s colitis, defined as a Crohn’s Disease Activity Index <150 ; non-IBD patients will serve as disease controls. MedDRA version: 9.1 Level: LLT Classification code 10011400 Term: Crohn's colitis MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10011402 Term: Crohn's disease (colon)	Trade Name: Chenofalk Product Name: Chenofalk Product Code: RVG 07151 Pharmaceutical Form: Capsule* INN or Proposed INN: CHENODEOXYCHOLIC ACID CAS Number: 474259 Other descriptive name: Chenodiol Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 15-	University Medical Center Utrecht		Not Recruiting			Female: yes Male: yes			Netherlands
620	NCT00367705	August 2009	19 February 2015	VSL#3 Treatment in Children With Crohn's Disease	Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease	Crohn's Disease	Dietary Supplement: VSL#3®;Dietary Supplement: Placebo	Hadassah Medical Organization		Not recruiting	6 Years	18 Years	Both	300	Phase 4	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
621	NCT01012570	August 2009	19 February 2015	The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients		Crohn's Disease	Drug: Application of Adalimumab	Gerhard Rogler		Not recruiting	18 Years	65 Years	Both	34	Phase 2	Switzerland
622	EUCTR2009-011763-37-IT	22/07/2009	28 August 2012	THE ANTI-ANGIOGENIC EFFECTS OF ADALIMUMAB IN CROHN`S DISEASE - ND	THE ANTI-ANGIOGENIC EFFECTS OF ADALIMUMAB IN CROHN`S DISEASE - ND	Crohn`s Disease MedDRA version: 9.1 Level: LLT Classification code 10038283 Term: Regional enteritis of small intestine with large intestine	Pharmaceutical Form: Solution for injection INN or Proposed INN: Adalimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	ISTITUTO CLINICO HUMANITAS		Not Recruiting			Female: yes Male: yes			Italy
623	JPRN-UMIN000002074	2009/07/01	2 April 2019	Rosuvastatin for Acute Systemic Crohn's disease: A mono-center randomized triaL		Crohn's disease	Rosuvastatin (Crestor) 0mg/day: Control group Rosuvastatin (Crestor) 5mg/day: Low-dose group Rosuvastatin (Crestor) 20mg/day: High-dose group	Department of lower gastroenterology, Hyogo College of Medicine		Not Recruiting	20years-old	65years-old	Male and Female	45	Phase 2	Japan
624	NCT00944736	July 2009	19 February 2015	Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease	Effect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in Remission	Crohn's Disease	Dietary Supplement: VSL#3;Dietary Supplement: Placebo	Children's Mercy Hospital Kansas City	VSL Pharmaceuticals	Not recruiting	11 Years	17 Years	Both	12	Phase 3	United States
625	NCT00950105	July 2009	19 February 2015	Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)	A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy Subjects	Crohn's Disease	Drug: CPSI-2364 or placebo	Ferring Pharmaceuticals		Not recruiting	18 Years	55 Years	Both	30	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
626	NCT00972218	July 2009	26 September 2016	Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease	Efficacy of Adalimumab (Humira®) in Spondyloarthritis Related to Crohn's Disease	Spondyloarthritis;Crohn's Disease	Biological: Adalimumab	University of Alberta	Abbott	Not recruiting	18 Years	N/A	Both	0	Phase 4	Canada
627	NCT00851565	June 2009	19 February 2015	Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy	Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy	Crohn's Disease	Procedure: Measurement of serum infliximab and anti-infliximab antibodies;Procedure: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status	Copenhagen University Hospital at Herlev	Aase and Ejnar Danielsens Foundation;Beckett Foundation;the Danish Biotechnology Program;Danish Colitis-Crohn Society;Danish Medical Association Research Fund;Frode V. Nyegaard and wife’s Foundation;Health Science Research Foundation of Region of Copenhagen;Herlev Hospital Research Council;Lundbeck Foundation;P. Carl Petersens Fund;Biomonitor A/S;Prometheus Inc.;The Danish Institute for Health Services Research	Not recruiting	18 Years	N/A	Both	120	Phase 4	Denmark
628	NCT01372969	June 2009	23 April 2019	Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.	Multicenter Phase I/IIa Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.	Crohn's Disease;Anal Fistula	Drug: Cx601	Tigenix S.A.U.		Not recruiting	18 Years	N/A	All	24	Phase 1/Phase 2	Spain
629	NCT00790933	May 22, 2009	26 February 2018	An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease	A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease	Ulcerative Colitis;Crohn's Disease	Drug: Vedolizumab	Takeda		Not recruiting	18 Years	N/A	All	2243	Phase 3	United States;Australia;Belgium;Canada;Czechia;Germany;Hungary;Israel;Korea, Republic of;Malaysia;Czech Republic
630	EUCTR2008-008359-40-AT	07/05/2009	19 March 2012	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease - A2202	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease - A2202	Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: AIN457 Product Code: AIN457 Pharmaceutical Form: Powder for solution for infusion Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	72		Germany;Poland;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
631	JPRN-UMIN000002604	2009/05/01	2 April 2019	Combined therapy of infliximab with surgery in maintenance of remission in Crohn's disease		Crohn's disease	Patients are randomly divided into two groups, groups treated with or without infliximab by staffs of Keio Clinical Research Center at 2 to 4 weeks after surgery. Patients receive infliximab 5 mg/kg at 0, 2, 6 weeks, followed by every 8 weeks for 2 years. Alternatively, patients continue to receive infliximab with intervals of 8 weeks if they received infliximab within 8 weeks from the time point 0. Patients without infliximab receive maintenance therapy without immunomodulators.	Clinical Research Group of inflammatory bowel disease in Japan		Not Recruiting	18years-old	Not applicable	Male and Female	100	Phase 4	Japan
632	NCT00742781	May 2009	19 October 2017	Vitamin D Supplementation in Crohn's Patients	Vitamin D and Crohn's Disease From the Bench to the Clinic	Inflammatory Bowel Disease	Dietary Supplement: Vitamin D	Penn State University		Not recruiting	18 Years	70 Years	All	21	Phase 1	United States
633	NCT00889161	May 2009	19 February 2015	Curcumin in Pediatric Inflammatory Bowel Disease	Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study	Inflammatory Bowel Disease;Ulcerative Colitis;Crohn's Disease	Drug: Curcumin	Seattle Children's Hospital		Not recruiting	8 Years	18 Years	Both	11	Phase 1	United States
634	NCT01510431	May 2009	24 October 2016	Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease	An Open-label Compassionate Treatment Protocol to Evaluate the Safety and Treatment Outcomes of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease	Crohn's Disease	Drug: PROCHYMAL (remestemcel-L)	Mesoblast International Sàrl		Not recruiting	18 Years	70 Years	Both	11	N/A	United States
635	EUCTR2008-001137-99-GB	28/04/2009	20 March 2012	CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease	CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease	Crohn's Disease MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders	Product Name: Ciprofloxacin Product Code: PL 20532/0012 Pharmaceutical Form: Tablet INN or Proposed INN: Ciprofloxacin hydrochloride CAS Number: 86393-32-0 Current Sponsor code: 3591 Concentration unit: mg milligram(s) Concentration type: not less then Product Name: Budesonide Product Code: PL 17901/0122 Pharmaceutical Form: Capsule INN or Proposed INN: Budesonide Current Sponsor code: 3591 Other descriptive name: Entocort CR Concentration unit: mg milligram(s) Concentration type: range Concentration number: 9-3 Trade Name: DOXYCYCLINE Product Name: DOXYCYCLINE Pharmaceutical Form: Tablet INN or Proposed INN: DOXYCYCLINE HYCLATE CAS Number: 564-25-0 Current Sponsor code: 3591 Other descriptive name: DOXYCYCLINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-200 Trade Name: HYDROXYCHLOROQUINE Product Name: HYDROXYCHLOROQUINE SULPHATE Pharmaceutical Form: Coated tablet INN or Proposed INN: HYDROXYCHLOROQUINE SULPHATE CAS Number: 747-36-4 Current Sponsor code: PL17907/0017 Other descriptive name: PLAQUENIL Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 200-600	Royal Liverpool & Broadgreen University Hospitals Trust	University of Liverpool	Authorised			Female: yes Male: yes	100		United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
636	EUCTR2008-002784-14-EE	28/04/2009	5 February 2018	An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease	A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease	Ulcerative Colitis and Crohn’s Disease MedDRA version: 14.1 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: VEDOLIZUMAB Product Code: MLN0002 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: VEDOLIZUMAB CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	Millennium Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	2200	Phase 3	Portugal;Serbia;United States;Hong Kong;Estonia;Taiwan;Slovakia;Greece;Spain;Ukraine;Ireland;South Africa;Netherlands;Latvia;Korea, Republic of;Turkey;Austria;Malta;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Romania;Bulgaria;Iceland;Germany;Norway;New Zealand;Sweden;Israel;Russian Federation;Italy;Switzerland;India;France;Malaysia;Australia
637	EUCTR2008-007519-34-SE	17/04/2009	19 March 2012	Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST - FAST VERSION	Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST - FAST VERSION	This is a open label, prospective, multicenter trial in patients recieving one hour infusions of infliximab (i.e. Remicade)as part of their daily practice. Main objective: Is to assess the tolerability of Remicade with an infusionsrate of 30 minutes. Patients: eligible patients are those with intestinal fistulas Mb Crohn disease or Ulcerative colitis/IBD. or patietns with	Trade Name: Remicade Pharmaceutical Form: Powder and solvent for solution for infusion	University of Leuven Hospitals, Division of Gastroenterology		Authorised			Female: yes Male: yes	200		Sweden
638	EUCTR2008-006484-36-IT	16/04/2009	23 May 2012	MULTICENTER COMPARATIVE STUDY BETWEEN NUTRITIONAL THERAPY ALONE AND ANTI-TNF-alpha MONOCLONAL ANTIBODY IN INDUCING AND MAINTAINING REMISSION IN PEDIATRIC CROHN`S DISEASE: A RANDOMIZED CONTROLLED TRIAL - NUTRITION AND BIOLOGICS IN CROHN`S DISEASE	MULTICENTER COMPARATIVE STUDY BETWEEN NUTRITIONAL THERAPY ALONE AND ANTI-TNF-alpha MONOCLONAL ANTIBODY IN INDUCING AND MAINTAINING REMISSION IN PEDIATRIC CROHN`S DISEASE: A RANDOMIZED CONTROLLED TRIAL - NUTRITION AND BIOLOGICS IN CROHN`S DISEASE	Moderate-to-severe active Crohn`s disease. MedDRA version: 9.1 Level: LLT Classification code 10011398 Term: Crohn's	Trade Name: REMICADE Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: INFLIXIMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA		Not Recruiting			Female: yes Male: yes			Italy
639	NCT00899678	April 2009	19 October 2017	The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents	A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)	Crohn's Disease	Drug: Certolizumab Pegol	UCB Celltech		Not recruiting	6 Years	17 Years	All	99	Phase 2	United States;Australia;Canada;New Zealand
640	EUCTR2009-009926-94-DK	26/03/2009	8 August 2016	Use of combined measurements of serum infliximab and anti-infliximab antibodies in the treatment of patients with Crohns disease failing infliximab therapy	Use of combined measurements of serum infliximab and anti-infliximab antibodies in the treatment of patients with Crohns disease failing infliximab therapy	Patients with Crohns diseases failing treatment with infliximab MedDRA version: 13.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders	Trade Name: Remicade Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Humira Pharmaceutical Form: Solution for injection	Department of medical gastroenterology, Herlev Hospital		Not Recruiting			Female: yes Male: yes		Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
641	EUCTR2008-002783-33-ES	02/03/2009	11 September 2012	A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Disease Estudio multicéntrico, ciego, controlado con placebo, aleatorizado, de fase 3, sobre la inducción y el mantenimiento de la respuesta clínica y la remisión con MLN0002 en pacientes con enfermedad de Crohn moderada o grave.	A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Disease Estudio multicéntrico, ciego, controlado con placebo, aleatorizado, de fase 3, sobre la inducción y el mantenimiento de la respuesta clínica y la remisión con MLN0002 en pacientes con enfermedad de Crohn moderada o grave.	Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave MedDRA version: 9.1 Level: LLT Classification code 10013099 Term: Disease Crohns ;Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave MedDRA version: 9.1 Level: LLT Classification code 10013099 Term: Disease Crohns	Product Name: VEDOLIZUMAB Product Code: MLN0002 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: VEDOLIZUMAB CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Code: MLN0002 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: VEDOLIZUMAB CAS Number: 943609-66-3 Current Sponsor code: MLN0002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Millennium Pharmaceuticals, Inc.		Authorised			Female: yes Male: yes	1060	Phase 3	Hungary;Portugal;Germany;Netherlands;Bulgaria;France;Ireland;Italy;Latvia;Austria;Sweden;United Kingdom;Slovakia;Czech Republic;Iceland;Malta;Belgium;Denmark;Estonia;Spain;Greece
642	EUCTR2007-005455-42-NL	26/02/2009	23 December 2013	ENDO ACE TRIAL Endoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk; a randomized controlled trial - ENDO ACE TRIAL	ENDO ACE TRIAL Endoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk; a randomized controlled trial - ENDO ACE TRIAL	Crohn's disease. Patients with Crohn's disease with status after ileocecal resection. Stenotic ileocecal anastomosis with symptoms of obstruction. MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders	Trade Name: Budenofalk Product Name: Budenofalk Pharmaceutical Form: Capsule, soft INN or Proposed INN: BUDESONIDE CAS Number: 51333223 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3 -mg Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Kenacort Product Name: Kenacort Pharmaceutical Form: Solution for injection INN or Proposed INN: TRIAMCINOLONE CAS Number: 124947 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40-mg/ml Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intraileal use (Noncurrent)	University Medical Center Utrecht		Not Recruiting			Female: yes Male: yes	42		Netherlands
643	EUCTR2008-000649-77-NL	06/02/2009	19 March 2012	A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Previously Treated with TNF Antagonist Therapy - CERTIFI	A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Previously Treated with TNF Antagonist Therapy - CERTIFI	Moderately to Severely Active Crohn’s Disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: Ustekinumab Product Code: CNTO 1275 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ustekinumab Current Sponsor code: CNTO 1275 Other descriptive name: Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40; Anti-IL-12; Human Anti-IL-12 Antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Ustekinumab Product Code: CNTO 1275 Pharmaceutical Form: Solution for injection INN or Proposed INN: Ustekinumab Current Sponsor code: CNTO 1275 Other descriptive name: Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40; Anti-IL-12; Human Anti-IL-12 Antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90 - Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Centocor BV		Not Recruiting			Female: yes Male: yes	500	Phase 2b	United Kingdom;Germany;Netherlands;Belgium;France;Spain;Austria
644	EUCTR2008-007329-38-IT	06/02/2009	19 March 2012	Multicenter, randomized, double-blind, parallel-group study of intra-erythrocyte dexamethasone versus placebo in patients with steroid-dependent Crohn?s disease - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s Disease	Multicenter, randomized, double-blind, parallel-group study of intra-erythrocyte dexamethasone versus placebo in patients with steroid-dependent Crohn?s disease - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s Disease	Patients with steroid-dependent Crohn?s Disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: dexamethasone sodium phosphate 250 mg/ 10 ml Product Code: ERY-DEX Pharmaceutical Form: Solution for infusion INN or Proposed INN: dexamethasone sodium phosphate CAS Number: 2392-39-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Route of administration not applicable	ERYDEL S.P.A.		Not Recruiting			Female: yes Male: yes	184		Spain;Italy
645	NCT00245505	February 2009	19 February 2015	The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active Drug: Crohn's Disease	The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s Disease, Evaluated by Video Capsule Endoscopy After 6 and 12 Weeks Treatment. A Pilot Study	Crohn's Disease	Drug: Mesalazine (Mesalamine)	Ferring Pharmaceuticals		Not recruiting	18 Years	70 Years	Both	3	Phase 3	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
646	EUCTR2008-002100-26-BE	28/01/2009	27 January 2014	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE	Active mild to moderate crohn's disease. MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: PENTASA Sachet Pharmaceutical Form: Prolonged-release granules INN or Proposed INN: MESALAZINE CAS Number: 89576 Current Sponsor code: FE999907 Other descriptive name: Mesalamine, 5-aminosalicylic acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2000- Pharmaceutical form of the placebo: Granules Route of administration of the placebo: Oral use	Ferring Pharmaceuticals A/S		Not Recruiting			Female: yes Male: yes	510		France;Belgium;Denmark;Germany;United Kingdom;Sweden
647	EUCTR2008-005903-25-DE	08/01/2009	4 March 2013	Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)	Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)	inflammatory bowel disease (Crohn’s disease and ulcerative colitis) MedDRA version: 12.0 Level: LLT Classification code 10021973 Term: Inflammatory bowel disease NOS	Product Name: SC12267 Product Code: SC12267 Pharmaceutical Form: Film-coated tablet Current Sponsor code: SC12267 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 35- Trade Name: Prednisolon Jenapharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Prednisolon CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Prednisolon Jenapharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Prednisolon CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: Prednisolon Jenapharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Prednisolon CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	4SC AG		Not Recruiting			Female: yes Male: yes	35		Bulgaria;Germany
648	NCT00844285	January 2009	4 November 2019	SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry	A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease	Crohn's Disease	Drug: Cimzia	UCB Pharma		Not recruiting	18 Years	N/A	All	3045	Phase 1	United States
649	NCT01429922	January 2009	19 February 2015	Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose	Double Blind Placebo-controlled,Safety and Tolerability of ZP1848 Administered as Ascending Single Dose SUBCUTANEOUS Bolus Injections in Healthy Subjects Followed by Multiple Dose Cohort of Patients With Stable Crohn's Disease in Remission	Crohns Disease	Drug: ZP1848	MDS Pharma Services		Not recruiting	18 Years	50 Years	Both	60	Phase 1/Phase 2	United States
650	NCT00771667	December 2008	19 October 2017	A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy	A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy	Crohn's Disease	Drug: Placebo (IP);Drug: Ustekinumab 1mg/kg (IP);Drug: Ustekinumab 3 mg/kg (IP);Drug: Ustekinumab 6 mg/kg (IP);Drug: Placebo IV - Responder - Placebo SC (MP);Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP);Drug: Ustekinumab IV - Responder - Placebo SC (MP);Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP);Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP);Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)	Centocor, Inc.		Not recruiting	18 Years	N/A	All	526	Phase 2	United States;Australia;Austria;Belgium;Canada;France;Germany;Israel;Netherlands;New Zealand;Spain;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
651	NCT00774982	December 2008	19 February 2015	Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients	Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease	Crohns Disease	Drug: Delayed Release 6 mercaptopurine;Drug: 6 Mercaptopurine	Teva GTC		Not recruiting	18 Years	50 Years	Both	12	Phase 1	Israel
652	NCT00783692	December 2008	19 October 2017	Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease	A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: vedolizumab;Other: Placebo	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	80 Years	All	1116	Phase 3	United States;Canada;Puerto Rico
653	NCT00801125	December 2008	27 June 2016	Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-a Therapy	A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-a Therapy	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	N/A	Both	0	Phase 4
654	NCT00805766	December 2008	8 January 2018	Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)	Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650 in Patients With Crohn's Disease (CD)	Crohn's Disease	Drug: TA-650	Mitsubishi Tanabe Pharma Corporation		Not recruiting	16 Years	75 Years	All	39	Phase 3	Japan
655	NCT01378390	December 2008	23 April 2019	Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease	Randomized, Single-blind, Placebo Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Expanded Autologous Adipose-derived Stem Cells (ASCs) (CX-401), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease	Complex Perianal Fistula;Crohn Disease	Drug: Expanded autologous adipose-derived adult stem cells (eASCs);Drug: Placebo	Tigenix S.A.U.		Not recruiting	18 Years	N/A	All	56	Phase 3	Austria;Netherlands;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
656	EUCTR2008-003571-45-BE	05/11/2008	19 March 2012	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE	CROHN’S DISEASE MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: CP-690,550 Pharmaceutical Form: Tablet CAS Number: 540-737-29-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: CP-690,550 Pharmaceutical Form: Tablet CAS Number: 540737-29-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ		Not Recruiting			Female: yes Male: yes	136		Hungary;Czech Republic;United Kingdom;Netherlands;Belgium;France;Spain;Italy
657	NCT00603616	November 2008	18 December 2018	Induction of Clinical Response Using Rifaximin in Crohn's Disease	A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: Placebo Comparator;Drug: Rifaximin	Scott Lee	Valeant Pharmaceuticals International, Inc.	Not recruiting	18 Years	80 Years	All	36	Phase 2	United States
658	NCT00752622	November 2008	16 December 2017	Treatment With Infliximab in a Medical Setting (Study P05587)	Optimization of Treatment With Infliximab in a Medical Setting	Crohn's Disease	Biological: Infliximab 5 mg/kg;Biological: Infliximab 5 mg/kg every 6 weeks;Biological: Infliximab 7 mg/kg every 8 weeks	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	100	Phase 4	Canada
659	NCT01559142	November 2008	19 February 2015	Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease	Efficacy and Safety of Induction Therapy With Three Doses of Infliximab in Patients With Crohn Disease Aged 7-17 Years-multicenter Open Study. Efficacy and Safety of Two Regimens of Maintenance Therapy in Patients With Crohn Disease Aged 7-17 Years-multicenter Randomized Study	Crohn Disease	Drug: Infliximab with azathioprine (IIFX + AZA);Drug: Infliximab (IFX alone)	Children's Memorial Health Institute, Poland		Not recruiting	7 Years	17 Years	Both	100	Phase 3	Poland
660	EUCTR2008-004926-18-DE	30/10/2008	19 March 2012	Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease - CHAMP	Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease - CHAMP	Moderate to severe Crohn’s disease	Trade Name: Humira Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Remicade Pharmaceutical Form: Powder for infusion*	IBD Center LMU Munich		Authorised			Female: yes Male: yes			Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
661	NCT00764699	October 2008	5 March 2018	Effect of Increlex® on Children With Crohn Disease	Effect of Increlex® on Children With Crohn Disease	Crohn Disease	Drug: rhIGF (Increlex)	Nationwide Children's Hospital	Tercica	Not recruiting	5 Years	15 Years	All	3	Phase 2/Phase 3	United States
662	NCT00791557	October 2008	19 October 2017	Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease	An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum	Pyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease	Drug: Infliximab	University Hospitals Cleveland Medical Center	Centocor, Inc.	Not recruiting	18 Years	75 Years	All	2	N/A	United States
663	NCT00808262	October 2008	19 February 2015	Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease	A Phase I/II, Open-label, Escalating Dose, Optimal Two-stage, Study of TNFa-Kinoid (TNF- K) Immunization in Crohn's Disease Patients	Crohn's Disease	Biological: TNFa Kinoid	Neovacs		Not recruiting	18 Years	65 Years	Both	21	Phase 1/Phase 2	South Africa;Switzerland
664	NCT00810030	October 2008	19 February 2015	FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR	Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease	Inflammatory Bowel Disease;Anemia;Iron Deficiency;Iron-Deficiency Anemia;Crohn's Disease;Ulcerative Colitis	Drug: Ferric carboxymaltose;Drug: Iron Sucrose	Vifor Inc.	Parexel;ClinStar	Not recruiting	18 Years	N/A	Both	484	Phase 3	Austria;Russian Federation
665	EUCTR2008-003167-39-BE	17/09/2008	7 October 2014	Effet du fluconazole sur le taux d'anticorps anti-Saccharomyces cerevisiae (ASCSA) après résection chirurgicale pour maladie de Crohn.	Effet du fluconazole sur le taux d'anticorps anti-Saccharomyces cerevisiae (ASCSA) après résection chirurgicale pour maladie de Crohn.	Crohn' disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: diflucan Pharmaceutical Form: Capsule* INN or Proposed INN: FLUCONAZOLE CAS Number: 86386734 Concentration unit: mg milligram(s) Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Cliniques Universitaires Saint Luc		Authorised			Female: yes Male: yes	60		Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
666	EUCTR2008-004276-49-ES	16/09/2008	19 March 2012	Estudio de fase IIa, multicéntrico, randomizado, doble ciego, controlado con placebo, de cohortes secuenciales, de búsqueda de rango de dosis para evaluar la seguridad, tolerabilidad y el efecto clínico de escalada de dosis de laquinimod en la Enfermedad de Crohn activa de moderada a grave.	Estudio de fase IIa, multicéntrico, randomizado, doble ciego, controlado con placebo, de cohortes secuenciales, de búsqueda de rango de dosis para evaluar la seguridad, tolerabilidad y el efecto clínico de escalada de dosis de laquinimod en la Enfermedad de Crohn activa de moderada a grave.	Enfermedad de Crohn activa de moderada a grave MedDRA version: 9.1 Level: PT Classification code 10011401 Term: Crohn's disease	Product Name: Laquinimod Cápsulas 0.5 mg Product Code: TV-5600 Pharmaceutical Form: Capsule* INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Teva Pharmaceutical Industries Ltd.		Authorised			Female: yes Male: yes	199		United Kingdom;Netherlands;Belgium;France;Spain;Italy
667	NCT00731172	September 2008	19 February 2015	A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease	A Pilot Single Center,Randomized,Double Blind Placebo Controlled Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Inducing Remission in Patients With Moderately Active Crohn's Disease.	Crohns Disease	Drug: glatiramer acetate;Drug: placebo	Tel-Aviv Sourasky Medical Center	Teva Pharmaceutical Industries;Given Imaging Ltd.	Recruiting	18 Years	70 Years	Both	50	Phase 2	Israel
668	NCT00736983	September 2008	19 February 2015	Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's	Adalimumab for the Treatment of Perianal Fistulas in Crohn's Disease More Effective Alone or Combined to Ciprofloxacin	Crohn's Disease With Perianal Fistulas	Drug: adalimumab;Drug: ciprofloxacin	Foundation for Liver Research		Not recruiting	18 Years	70 Years	Both	76	Phase 3	Netherlands
669	NCT00584740	August 2008	19 October 2017	Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single iv Infusions of AIN457 10 mg/kg (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Active Crohn's Disease	Crohn's Disease	Drug: AIN457;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	75 Years	All	59	Phase 2	Germany;Canada;United States
670	NCT00720538	August 2008	19 February 2015	Thalidomide in Pediatric Inflammatory Bowel Diseases.	Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.	Inflammatory Bowel Diseases;Crohn's Disease;Ulcerative Colitis	Drug: Thalidomide;Drug: placebo	IRCCS Burlo Garofolo	Ospedale Meyer;Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.;Vittore Buzzi Children's Hospital;University of Pisa;Pediatric Gastroenterology Unit, University of Messina.;Università degli Studi di Brescia;University of Trieste	Not recruiting	2 Years	18 Years	Both	84	Phase 3	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
671	NCT00715117	July 2008	17 September 2018	The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease	The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease	Crohn's Disease	Drug: Naltrexone;Other: Placebo, sugar pill	Milton S. Hershey Medical Center		Not recruiting	6 Years	17 Years	All	14	Phase 2	United States
672	NCT01235325	July 2008	19 February 2015	The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients	The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease	Supplementation;Bone Health;Crohn's Disease	Dietary Supplement: phylloquinone (vitamin K1);Dietary Supplement: placebo	University College Cork	Health Research Board, Ireland	Not recruiting	18 Years	70 Years	Both	70	Phase 4	Ireland
673	NCT02997059	July 2008	9 January 2017	Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.	Effect of Fluconazole on the Levels of Anti-Saccharomyces Cerevisiae Antibodies (ASCA) After Surgical Resection for Crohn's Disease. Multicenter, Randomized, and Controlled in Two Parallel Groups Versus Placebo	Crohn's Disease Aggravated	Drug: Fluconazole;Other: Placebo	University Hospital, Lille	Ministry of Health, France	Not recruiting	18 Years	N/A	Both	35	Phase 2	France
674	EUCTR2007-001377-28-FR	11/06/2008	19 March 2012	Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL	Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL	Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously, -- AND who developed adverse events (AEs) corresponding to pre-specified newly diagnosed autoimmune disorders OR who developed severe thrombocytopenia. MedDRA version: 9.1 Level: LLT Classification code 10061664 Term: Autoimmune disorder MedDRA version: 9.1 Level: LLT Classification code 10025139 Term: Lupus erythematosus systemic MedDRA version: 9.1 Level: LLT Classification code 10047888 Term: Wegener's granulomatosis MedDRA version: 9.1 Level: LLT Classification code 10002817 Term: Antiphospholipid syndrome MedDRA version: 9.1 Level: LLT Classification code 10040767 Term: Sjogren's syndrome MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10009900 Term: Colitis ulcerative MedDRA version: 9.1 Level: LLT Classification code 10003827 Term: Autoimmune hepatitis MedDRA version: 9.1 Level: LLT Classification code 10049046 Term: Autoimmune thyroiditis MedDRA version: 9.1 Level: LLT Classification code 10003822 Term: Autoimmune haemolytic anaemia NOS MedDRA version: 9.1 Level: LLT Classification code 10034697 Term: Pernicious anemia MedDRA version: 9.1 Level: LLT Classification code 10028417 Term: Myasthenia gravis MedDRA version: 9.1 Level: LLT Classification code 10018620 Term: Goodpasture's syndrome MedDRA version: 9.1 Level: LLT Classification code 10	Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Efalizumab Other descriptive name: EFALIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	Merck Serono International S.A.		Authorised			Female: yes Male: yes	92	Phase 4	Portugal;Germany;Netherlands;France;Austria
675	NCT00707512	June 2008	3 August 2015	CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring	INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring	Crohn's Disease	Drug: natalizumab	Biogen		Not recruiting	18 Years	N/A	Both	87	N/A	United States;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
676	EUCTR2008-001131-35-NL	14/05/2008	19 March 2012	Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial - Azorix-trial	Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial - Azorix-trial	this study is designed as a multicenter radomized trial comparing azathioprine maintenance treatment to infliximab maintenance treatment in Crohn's disease patients that are in remission for at least 6 months while being treated with a combined therapy of infliximab and azathioprine for at least 6 months	Trade Name: Remicade Product Name: Infliximab Product Code: EU/1/99/116/003 Pharmaceutical Form: Intravenous infusion Trade Name: Imuran Product Name: Azathioprine Product Code: RVG 05565 Pharmaceutical Form: Oral drops*	Academic Medical Center, department of Gastroenterology and hepatology		Authorised			Female: yes Male: yes			Netherlands
677	NCT00686374	May 1, 2008	11 June 2018	Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806	A Multi-center, Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Crohn's Disease Who Have Demonstrated a Clinical Response in the M06-806 Study	Crohn's Disease	Biological: Adalimumab	AbbVie (prior sponsor, Abbott)		Not recruiting	7 Years	18 Years	All	100	Phase 3	Belgium;Canada;Czech Republic;Czechia;France;Netherlands;Poland;United Kingdom;United States
678	NCT00609973	May 2008	19 October 2017	Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease	Double-blind, Placebo Controlled, Randomized, Multicentre, Pilot Study on the Safety and Efficacy of Ciprofloxacin for Prophylactic Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease Patients	Crohn's Disease	Drug: Ciprofloxacin;Drug: Placebo	University of North Carolina, Chapel Hill	Crohn's and Colitis Foundation;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Not recruiting	18 Years	70 Years	All	33	Phase 2	United States
679	NCT01297907	May 2008	19 February 2015	Bronchial Hyperreactivity in Children With Crohn Disease		Crohn's Disease	Other: Methacholine Challenge Test;Other: Fractional Exhaled NO (FENO);Other: Blood Test;Other: PCDAI	Rambam Health Care Campus		Not recruiting	6 Years	25 Years	Both	47	N/A	Israel
680	EUCTR2008-001466-93-GB	30/04/2008	24 July 2012		Trial of adjuvant vitamin D with Infliximab in active Crohn's Disease (IBDVit2). - IBDVit2	Active Crohn's Disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: Vigantol Oel Product Name: Vigantol Oel TM Pharmaceutical Form: Oral liquid Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use	Imperial College London		Not Recruiting			Female: yes Male: yes	40		United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
681	EUCTR2008-001467-10-GB	30/04/2008	24 July 2012		Trial of Adjuvant Vitamin D with Standard Maintenance Therapy in Preventing Relapse of Inflammatory Bowel Disease - IBDVit3	Ulcerative colitis - in remission Crohn's Disease - in remission MedDRA version: 9.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: Vigantol Oel Product Name: Vigantol Oel TM Pharmaceutical Form: Oral liquid Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use	Imperial College London		Not Recruiting			Female: yes Male: yes	120		United Kingdom
682	EUCTR2007-006692-37-GB	10/04/2008	19 March 2012	The Immunomodulatory Role of Vitamin D in Inflammatory Bowel Disease (IBDVit): IBDVit1 - Trial of Adjuvant Vitamin D with Corticosteroids in Active Crohn’s Disease; IBDVit2 - Trial of Adjuvant Vitamin D with Infliximab in Active Crohn's Disease; IBDVit3 - Trial of Adjuvant Vitamin D with standard maintenance therapy in preventing relapse of Inflammatory Bowel Disease. - IBDVit	The Immunomodulatory Role of Vitamin D in Inflammatory Bowel Disease (IBDVit): IBDVit1 - Trial of Adjuvant Vitamin D with Corticosteroids in Active Crohn’s Disease; IBDVit2 - Trial of Adjuvant Vitamin D with Infliximab in Active Crohn's Disease; IBDVit3 - Trial of Adjuvant Vitamin D with standard maintenance therapy in preventing relapse of Inflammatory Bowel Disease. - IBDVit	IBDVit1 - Active Crohn's Disease IBDVit2 - Active Crohn's Disease IBDVit3 - Crohn's Disease in remission / Ulcerative Colitis in remission MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis	Trade Name: Vigantol Oel Product Name: Vigantol Oel TM Pharmaceutical Form: Oral liquid Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use	Imperial College London		Authorised			Female: yes Male: yes	210		United Kingdom
683	NCT01487759	March 2008	19 February 2015	Prebiotic Effect on Metabolites in Crohn's Disease	Metabolite Profiling of the Impact of Oligofructose Enriched Inulin in Crohn's Disease Patients	Crohn Disease	Dietary Supplement: Oligofructose enriched inulin;Dietary Supplement: Maltodextrin	Katholieke Universiteit Leuven		Not recruiting	18 Years	N/A	Both	67	N/A	Belgium
684	EUCTR2007-004269-16-GB	28/02/2008	19 March 2012	Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation. - IGF-I in growth-retarded Crohn's disease children	Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation. - IGF-I in growth-retarded Crohn's disease children	Growth failure in children with Crohn's disease	Trade Name: Increlex Product Name: Increlex 10mg/ml solution for injection Pharmaceutical Form: Solution for injection	Queen Mary, University of London		Not Recruiting			Female: yes Male: yes			United Kingdom
685	EUCTR2007-003239-21-FR	05/02/2008	19 March 2012	A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when treatment is administered in two different settings : either at hospital or at home - PERFECT	A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when treatment is administered in two different settings : either at hospital or at home - PERFECT	Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: Certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Certolizumab pegol (rINN) CAS Number: 428863-50-7 Current Sponsor code: CDP870 Other descriptive name: Anti TNF humanized antibody Fab fragment-PEG conjugate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 150-+/- 15	UCB PHARMA S.A.		Authorised			Female: yes Male: yes		Phase 3b	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
686	NCT00609752	February 2008	19 February 2015	Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease	Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease	Crohn Disease	Drug: prednisolone;Dietary Supplement: Alicalm (polymeric liquid formula)	University Hospital Birmingham	SHS International;Children's Memorial Research Foundation;St George's University Hospital Research Foundation	Recruiting	7 Years	17 Years	Both	80	Phase 4	United Kingdom
687	NCT00517296	January 2008	16 December 2017	Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas	EUS Guided Treatment With Humira for Crohn's Perianal Fistulas	Crohn Disease;Rectal Fistula	Procedure: EUA with seton placement if necessary;Drug: adalimumab;Procedure: EUS	Vanderbilt University Medical Center		Not recruiting	18 Years	N/A	All	21	Phase 4	United States
688	NCT00615199	January 2008	19 October 2017	A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Safety And Efficacy Of CP-690,550 In Subjects With Moderate To Severe Crohn's Disease.	Crohn's Disease	Drug: CP-690,550;Drug: Placebo	Pfizer		Not recruiting	18 Years	N/A	All	139	Phase 2	United States;Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom
689	NCT00621257	January 2008	16 December 2017	Vitamin D Levels in Children With IBD	Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Dietary Supplement: ergocalciferol;Dietary Supplement: Cholecalciferol	Boston Children’s Hospital	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Crohn's and Colitis Foundation;NASPGHAN Foundation	Not recruiting	5 Years	21 Years	All	134	N/A	United States
690	NCT02185183	January 2008	19 October 2017	Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)	Phase 2 Clinical Trial for Oral Administration of Alequel for Patients With IBD	Crohn's Disease	Drug: Alequel	Hadassah Medical Organization		Not recruiting	18 Years	70 Years	All	22	Phase 1/Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
691	EUCTR2007-001913-41-FI	12/12/2007	19 March 2012	A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease	A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease	Crohn`s disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: certolizumab pegol CAS Number: 428863-50-7 Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 150-+/-15 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	UCB Celltech		Not Recruiting			Female: yes Male: yes	550	Phase 3b	Hungary;Finland;Czech Republic;Germany;Belgium;Estonia;Italy;Latvia;Austria
692	EUCTR2007-002716-26-FI	12/12/2007	26 June 2012	A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn’s disease who have participated in study C87085	A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn’s disease who have participated in study C87085	Crohn`s disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: certolizumab pegol CAS Number: 428863-50-7 Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 150-+/- 15	UCB Celltech		Not Recruiting			Female: yes Male: yes	200	Phase 3b	Hungary;Finland;Czech Republic;Belgium;Estonia;Italy;Latvia;Austria
693	NCT00619489	December 2007	19 October 2017	Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease	Phase 2, Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease	Ulcerative Colitis;Crohn's Disease	Drug: vedolizumab	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	75 Years	All	72	Phase 2	Canada
694	NCT00358683	November 2007	19 February 2015	A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease	Open Label Long Term Clinical Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87055 Study.	Crohn's Disease	Drug: Certolizumab pegol	UCB Pharma		Not recruiting	18 Years	N/A	Both	0	Phase 3
695	NCT00562887	November 2007	19 February 2015	Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease	A Phase 2B, Multi-Center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects With Moderately to Severely Active Crohn's Disease.	Crohn's Disease	Biological: Placebo;Biological: ABT-874	Abbott		Not recruiting	18 Years	74 Years	Both	246	Phase 2	United States;Australia;Austria;Belgium;Canada;Denmark;Puerto Rico;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
696	NCT00543374	October 2007	24 October 2016	Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease	A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: PROCHYMAL adult human mesenchymal stem cells	Mesoblast International Sàrl		Not recruiting	18 Years	70 Years	Both	98	Phase 3	United States;Canada
697	NCT00774969	October 2007	19 February 2015	Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease	Phase 1 Study to Evaluate the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri-Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease	Perianal Crohns'	Drug: Metronidazole	S.L.A. Pharma AG		Not recruiting	18 Years	65 Years	Both	19	Phase 1	United Kingdom
698	NCT00792740	October 2007	19 February 2015	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease	Crohn's Disease	Drug: ITF2357;Drug: Placebo capsules	Italfarmaco		Not recruiting	18 Years	88 Years	Both	51	Phase 1/Phase 2	Belgium
699	NCT00521950	September 2007	19 February 2015	Cost-effectiveness of TPMT Pharmacogenetics	Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis	Genetic: TPMT genotyping; Drug: azathioprine or 6-mercaptopurine;Drug: azathioprine (AZA) or 6-mercaptopurine (6-MP)	ZonMw: The Netherlands Organisation for Health Research and Development	Radboud University	Not recruiting	18 Years	N/A	Both	853	N/A	Netherlands
700	EUCTR2007-000189-19-NL	06/08/2007	19 March 2012	Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease	Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease	Moderate-to-severe active Crohn’s Disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Code: ITF2357 Pharmaceutical Form: Capsule, hard Current Sponsor code: ITF2357 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Italfarmaco S.p.A.		Not Recruiting			Female: yes Male: yes	80		Netherlands;Belgium;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
701	NCT00511329	August 2007	11 June 2018	Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease	Growth and the Effect of Genotropin in Chronically Ill Children With Juvenile Rheumatoid Arthritis and With Crohn's Disease	Arthritis, Juvenile Rheumatoid;Crohn Disease	Drug: somatropin [rDNA origin] for injection	Nationwide Children's Hospital	Pfizer	Not recruiting	5 Years	17 Years	All	10	Phase 2/Phase 3	United States
702	EUCTR2007-001014-17-FR	26/07/2007	19 March 2012	A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s disease	A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s disease	Treatment of moderate, active Crohn’s disease: induction of remission. MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Product Name: Rifaximin-EIR Pharmaceutical Form: Gastro-resistant tablet CAS Number: 80621-81-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Alfa Wassermann S.p.A.		Authorised			Female: yes Male: yes	424	Phase 2	Hungary;Germany;France;Italy
703	EUCTR2006-003371-13-DE	17/07/2007	19 March 2012	A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy. Revised Protocol 04 incorporating Amendments 02, 03, 08 & 09 (v1.0, date 09-Mar-2009) + administrative letters 01 & 02. And Pharmacogenetics Blood Sample Amendment 01 - Site Specific (Version 2.0, Date: 26-Oct-2006).	A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy. Revised Protocol 04 incorporating Amendments 02, 03, 08 & 09 (v1.0, date 09-Mar-2009) + administrative letters 01 & 02. And Pharmacogenetics Blood Sample Amendment 01 - Site Specific (Version 2.0, Date: 26-Oct-2006).	Crohn's disease, NOS MedDRA version: 8.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: Orencia Product Name: Abatacept Product Code: BMS-188667 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Current Sponsor code: BMS-188667 Other descriptive name: CTLA4Ig Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Bristol-Myers Squibb International Corporation		Not Recruiting			Female: yes Male: yes	709	Phase 3	Czech Republic;United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Ireland;Italy;Poland
704	NCT01144156	July 2007	19 February 2015	Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy	Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy	Crohn's Disease	Drug: Treatment with Adalimumab	Rabin Medical Center	Abbott	Not recruiting	18 Years	N/A	Both	30	N/A	Israel
705	EUCTR2006-004784-58-BE	22/06/2007	19 March 2012	Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease - ACTIF	Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease - ACTIF	Crohn's disease MedDRA version: 8.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: remicade Product Name: remicade Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277313 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 5-	University of Leuven		Authorised			Female: yes Male: yes	25		United Kingdom;Germany;Belgium;France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
706	JPRN-UMIN000004427	2007/06/01	2 April 2019	A Prospective Randomized Open Trial to Assess the Efficiency of Infliximab for Crohn's Patients after Intestinal Resection		Crohn's disease	Non-infliximab arm: Conventional medicine is administered, excluding Infliximab, Azathioprine, and 6-Mercaptopurine, to subjects during the study period (for 60 months, maximum). Infliximab arm: Infliximab is administered to subjects during the study period (for 60 months, maximum) together with other conventional medications, such as 5-aminosalicylic acid. Infliximab is administered every 8 weeks to subjects during study period after the start of protocol treatment as a rule. Immunomodulators, such as Azathioprine and 6-Mercaptopurine, are not permitted during the trial.	Lower GI disease, Hyogo College of Medicine		Not Recruiting	16years-old	65years-old	Male and Female	30	Phase 2,3	Japan
707	NCT00495521	June 2007	16 December 2017	High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children	A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease	Crohn's Disease	Drug: 4-Aminosalicylic acid extended release granules	Jacobus Pharmaceutical		Not recruiting	2 Years	18 Years	All	2	Phase 2	United States;Israel
708	NCT00724529	June 2007	19 February 2015	Post Marketing Surveillance of Remicade	Post Marketing Surveillance of Remicade in Inflammatory Bowel Disease (IBD)	Crohn's Disease;Ankylosing Spondylitis	Biological: Infliximab	Janssen Korea, Ltd., Korea		Not recruiting	N/A	N/A	Both	938	Phase 4	Korea, Republic of
709	NCT00606346	May 31, 2007	11 November 2019	A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease	A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease	Crohn's Disease;Ulcerative Colitis;Indeterminate Colitis;Inflammatory Bowel Diseases	Biological: Anti TNF therapy including infliximab;Drug: No Biologics	Janssen Biotech, Inc.		Not recruiting	1 Month	17 Years	All	4970	N/A	United States;Canada
710	NCT00467922	May 2007	19 February 2015	An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy	A Randomized Prospective Double Blind Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care Versus Either Colloid and Crystalloid	Crohn's Disease;Ulcerative Colitis;Rectal Cancer;Colon Cancer;Colon Polyps;Rectal Polyps;Diverticulitis	Drug: Hextend;Drug: Lactated Ringers	Spectrum Health Hospitals	Deltex Medical, Inc.	Not recruiting	18 Years	80 Years	Both	69	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
711	NCT00482092	May 2007	16 December 2017	Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease	A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: adult human mesenchymal stem cells;Drug: Placebo	Mesoblast International Sàrl		Not recruiting	18 Years	70 Years	All	330	Phase 3	United States;Australia;Canada;New Zealand
712	NCT00307931	April 2007	19 October 2017	Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab	Certolizumab Pegol in the Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Have Been Previously Treated Successfully With Infliximab But Who Have Subsequently Lost Response or Developed Intolerance to Infliximab	Crohn's Disease	Biological: Certolizumab pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	16	Phase 3	Greece
713	NCT00409682	April 2007	19 October 2017	Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease	A Multi-Center, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease	Biological: Adalimumab	Abbott		Not recruiting	6 Years	17 Years	All	192	Phase 3	United States;Belgium;Canada;Czech Republic;France;Netherlands;Poland;United Kingdom;Italy
714	JPRN-JapicCTI-070367	01/3/2007	2 April 2019	A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects with Crohn's Disease	A Multi-Center, Randomized, Double-Blind, Placebo-controlled study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects with Crohn's Disease	Crohn's disease	Intervention name : adalimumab INN of the intervention : adalimumab Dosage And administration of the intervention : Subcutaneous Control intervention name : Placebo Dosage And administration of the control intervention : Subcutaneous	Abbott Japan Co., Ltd.	Eisai Co., Ltd.		15	75	BOTH	80	Phase 2-3
715	NCT00445432	March 2007	19 October 2017	A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease	A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease	Crohn's Disease	Biological: adalimumab;Other: Placebo	Abbott	Eisai Co., Ltd.	Not recruiting	15 Years	75 Years	All	82	Phase 2/Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
716	NCT00462072	March 2007	19 October 2017	Centocor Microarray Study of Patients	Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases	Rheumatoid Arthritis;Psoriatic Arthritis;Psoriasis;Crohn's Disease	Drug: Infliximab	University of Rochester	Centocor, Inc.	Not recruiting	12 Years	N/A	All	31	Phase 4	United States
717	JPRN-JapicCTI-070366	01/2/2007	2 April 2019	A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects with Crohn's Disease	A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects with Crohn's Disease	Crohn's disease	Intervention name : adalimumab INN of the intervention : adalimumab Dosage And administration of the intervention : Subcutaneous Control intervention name : Placebo Dosage And administration of the control intervention : Subcutaneous	Abbott Japan Co., Ltd.	Eisai Co., Ltd.		15	75	BOTH	80	Phase 2-3
718	NCT00445939	February 2007	19 October 2017	A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease	A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease	Crohn's Disease	Biological: adalimumab;Biological: placebo	Abbott	Abbott Japan Co.,Ltd;Eisai Co., Ltd.	Not recruiting	15 Years	75 Years	All	90	Phase 2/Phase 3	Japan
719	EUCTR2006-006632-22-BE	26/01/2007	19 March 2012	Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study. - Infliximab to adalimumab switch trial	Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study. - Infliximab to adalimumab switch trial	Luminal Crohns Disease, moderate to severe, refractory to steroids and/or antimetabolitets and controlled with anti-TNF therapy MedDRA version: 8.1 Level: LLT Classification code 10011401 Term: Crohn's disease	Trade Name: HUMIRA Pharmaceutical Form: Injection* Trade Name: REMICADE Pharmaceutical Form: Intravenous infusion	University of Leuven, Division of Gastroenterology		Authorised			Female: yes Male: yes			Belgium
720	NCT00354367	January 2007	19 February 2015	Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas	A Phase IIIB Multicenter, Open Label, Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor (TNF) in Crohn's Disease Patients With Draining Fistulas.	Crohn Disease	Drug: Certolizumab pegol	UCB Pharma		Not recruiting	18 Years	N/A	Both	0	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
721	NCT00356408	January 2007	19 October 2017	Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease	An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).	Crohn's Disease	Biological: Certolizumab pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	106	Phase 3	United States;Canada;Germany
722	NCT00417690	January 2007	19 February 2015	High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease	A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease	Crohn's Disease	Drug: 4-Aminosalicylic acid;Drug: PASER placebo granules	Jacobus Pharmaceutical		Not recruiting	18 Years	65 Years	Both	54	Phase 2	United States;Israel
723	NCT00427804	January 2007	19 October 2017	Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption	Tumor Necrosis Factor-a Induces Vitamin D Resistance in Small Intestinal Calcium Absorption	Rheumatoid Arthritis;Crohn's Disease	Drug: calcitriol	Atlanta VA Medical Center	Emory University	Not recruiting	18 Years	50 Years	Male	9	N/A	United States
724	NCT00427921	January 2007	19 October 2017	Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)	A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)	Crohn's Disease	Biological: adalimumab	Abbott		Not recruiting	18 Years	N/A	All	304	Phase 3	United States
725	NCT00513552	January 2007	19 February 2015	Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis	Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis	Crohn's Disease	Drug: Rifabutin, Clarithromycin, and Clofazimine	Medstar Research Institute		Recruiting	18 Years	90 Years	Both	20	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
726	NCT00406653	December 2006	19 October 2017	A Study of Abatacept in Patients With Active Crohn's Disease	A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Crohn's Disease (CD) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy	Crohn's Disease	Drug: abatacept;Drug: placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	451	Phase 3	United States;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;India;Italy;Mexico;Netherlands;Poland;Puerto Rico;South Africa;Switzerland;Argentina;Ireland;Korea, Republic of;Spain;United Kingdom
727	NCT00417391	December 2006	19 February 2015	Phase II Study of RR110 in Patients With Active Crohn's Disease	Phase II Study of RR110 in Patients With Active Crohn's Disease	Crohn's Disease	Drug: RR110 (Tamibarotene)	R&R Inc.		Not recruiting	20 Years	N/A	Both	24	Phase 2	Japan
728	NCT00349752	November 2006	19 October 2017	Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease	A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.	Crohn's Disease	Biological: certolizumab pegol 400 mg;Other: Placebo	UCB Pharma		Not recruiting	18 Years	N/A	All	174	Phase 3	United States;Canada;Germany;Belgium
729	EUCTR2006-002078-23-NL	12/10/2006	5 August 2013	A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease.	A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease.	Moderate to severe Crohn's Disease (Harvey Bradshaw Index score greater or equal to7). MedDRA version: 8.1 Level: LLT Classification code 10013099 Term: Disease Crohns	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Injection* INN or Proposed INN: adalimumab Concentration unit: mg milligram(s) Concentration type: range Concentration number: 40-160 Product Name: Humira pre-filled PEN Pharmaceutical Form: Injection* INN or Proposed INN: adalimumab Concentration unit: mg milligram(s) Concentration type: range Concentration number: 40-160	Abbott GmbH & Co. KG (Abbott)		Not Recruiting			Female: yes Male: yes	1000		Portugal;Slovakia;Greece;Finland;Spain;Ireland;Austria;Italy;United Kingdom;France;Czech Republic;Belgium;Denmark;Netherlands;Norway;Germany;Sweden
730	EUCTR2005-000496-17-SE	06/10/2006	19 March 2012	Atorvastatin in moderat active Crohns disease	Atorvastatin in moderat active Crohns disease	Crohn's disease is an idiopathic chronic inflammatory bowel disease thought to result from inappropriate and ongoing activation of the mucosal immune system driven by the presence of normal luminal flora. It may affect the hole gastrointestinal tract, from mouth to rectum, with symptoms such as diarrhea, weight lose, malabsorption, abdominal pain and fever.	Product Name: atorvastatin Pharmaceutical Form: Tablet	Region Skåne		Not Recruiting			Female: yes Male: yes	12		Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
731	NCT00333788	October 2006	19 October 2017	Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease	Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.	Crohn's Disease	Biological: Certolizumab pegol (CDP870)	UCB Pharma		Not recruiting	18 Years	N/A	All	233	Phase 3	United States;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom
732	NCT00454545	October 2006	19 February 2015	Atorvastatin in Moderate Active Crohns Disease		Crohns Disease	Drug: Atorvastatin	Skane University Hospital		Not recruiting	18 Years	65 Years	Both	12	Phase 2	Sweden
733	NCT00573469	October 2006	19 October 2017	Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease	A Multicentre, Double-blind, Randomised, Parallel-group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease	Crohn's Disease	Drug: D9421-C, 9mg;Drug: D9421-C, 15mg;Drug: Placebo	AstraZeneca		Not recruiting	18 Years	65 Years	All	75	Phase 2	Japan
734	NCT00897312	October 2006	2 May 2016	Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease	Title: Evaluation of Systemic IDO Levels After Various Immunotherapeutics	Melanoma	Biological: infliximab;Biological: pegylated interferon alfa;Biological: ticilimumab;Drug: ribavirin;Other: high performance liquid chromatography;Other: laboratory biomarker analysis	Vanderbilt-Ingram Cancer Center	National Cancer Institute (NCI)	Not recruiting	N/A	N/A	Both	7	N/A
735	EUCTR2006-002494-48-GB	27/09/2006	19 March 2012	Sildenafil in Crohn’s disease: an open label pilot study of Sildenafil in 15 patients with active colonic Crohn’s disease - Sildenafil in active colonic Crohn’s disease	Sildenafil in Crohn’s disease: an open label pilot study of Sildenafil in 15 patients with active colonic Crohn’s disease - Sildenafil in active colonic Crohn’s disease	Active colonic Crohn's disease MedDRA version: 8.1 Level: LLT Classification code 10011402 Term: Crohn's disease (colon)	Trade Name: Viagra Pharmaceutical Form: Film-coated tablet	University College London / University College London Hospitals NHS Foundation Trust		Not Recruiting			Female: yes Male: yes	15		United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
736	NCT00343642	September 2006	19 February 2015	Dietary Treatment of Crohn's Disease	Dietary Treatment of Crohn's Disease	Crohn's Disease;Inflammatory Bowel Disease	Dietary Supplement: Time and attention + fructo-oligosaccharide placebo;Dietary Supplement: dietary therapy + fructo-oligosaccharide placebo;Drug: Time and attention + active fructooligosaccharide supplementation	Rush University Medical Center	National Center for Complementary and Integrative Health (NCCIH)	Not recruiting	18 Years	80 Years	Both	73	Phase 1/Phase 2	United States
737	NCT00353756	September 2006	19 February 2015	Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease	A Placebo-Controlled, Phase 1, Single and Multiple IV Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of C326 in Adults With Crohn’s Disease	Crohn's Disease	Drug: C326, IL-6 Inhibitory Avimer protein	Avidia		Recruiting	18 Years	65 Years	Both	52	Phase 1	Australia
738	NCT00588393	September 2006	19 February 2015	FolateScan in Autoimmune Disease	Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases	Rheumatoid Arthritis;Osteoarthritis;Multiple Sclerosis;Crohn's Disease;Systemic Lupus Erythematosus	Drug: FolateScan (Technetium Tc 99mEC20)	Mayo Clinic	Endocyte	Not recruiting	18 Years	N/A	Both	75	Phase 2	United States
739	NCT00663117	September 2006	19 October 2017	The Effects of Naltrexone on Active Crohn's Disease	The Effects of Naltrexone in Active Crohn's Disease	Inflammation;Crohn's Disease	Drug: Naltrexone-HCl;Drug: Placebo	Penn State University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);The Broad Foundation	Not recruiting	18 Years	75 Years	All	40	Phase 2	United States
740	NCT00348283	August 2006	19 October 2017	Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon	Crohn's Disease	Biological: adalimumab;Biological: placebo	Abbott		Not recruiting	18 Years	75 Years	All	135	Phase 3	United States;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
741	EUCTR2005-005291-32-BE	20/07/2006	19 March 2012	A Multi-Center, Randomized, Double-Blind, Placebo - Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects with Crohn's Disease Involving the Colon.	A Multi-Center, Randomized, Double-Blind, Placebo - Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects with Crohn's Disease Involving the Colon.	Crohn's Disease MedDRA version: 8.1 Level: LLT Classification code 10057035	Product Name: Humira Pharmaceutical Form: Injection* INN or Proposed INN: Adalimumab Concentration unit: mg milligram(s) Concentration type: range Concentration number: 40-160 Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use	Abbott GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	130		Germany;Netherlands;Belgium;Italy;Austria;Sweden
742	EUCTR2005-005363-28-GB	11/07/2006	19 March 2012	A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF AST-120 IN MILD TO MODERATELY ACTIVE CROHN’S PATIENTS WITH FISTULAS	A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF AST-120 IN MILD TO MODERATELY ACTIVE CROHN’S PATIENTS WITH FISTULAS	The two main categories of inflammatory bowel disease (IBD) are ulcerative colitis and Crohn’s disease. Crohn’s disease is characterized by recurring episodes of suppurative inflammation of any part of the bowel, from the mouth to the anus. This can result in strictures, microperforations, and fistulas. Crohn’s patients typically expetience fever, weight loss, stomatitis, perianal fistulae and/or fissures, arthritis, and erythema nodosum.	Trade Name: Kremezin Product Name: AST-120 Product Code: AST-120 Pharmaceutical Form: Granules INN or Proposed INN: AST-120 Current Sponsor code: AST-120 Other descriptive name: Kremezin®, Spherical Adsorptive Carbon Concentration unit: g gram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Granules Route of administration of the placebo: Oral use	Ocera Therapeutics, Inc.		Authorised			Female: yes Male: yes	240		Hungary;Germany;Czech Republic;United Kingdom;Belgium;Austria
743	NCT00287170	July 2006	19 February 2015	Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease	Pilot, Open-Label, Randomized, Parallel Group Study to Evaluate Clinical/ and Immunological Efficacy/Safety of Locally Delivered 6-MP or Calcitriol vs Purinethol in Non-Steroid Dependent Patients With Active CD	Crohn's Disease	Drug: Delayed Release 6MP or Calcitriol vs. Purinethol	Teva GTC		Not recruiting	18 Years	75 Years	Both	15	Phase 1/Phase 2	Israel
744	NCT00305409	June 2006	19 February 2015	Synbiotic Treatment in Crohn's Disease Patients	Synbiotic Treatment in Crohn's Disease Patients	Crohn's Disease	Drug: Synbiotic (Synergy I / B.longum)	University of Dundee		Not recruiting	18 Years	79 Years	Both	50	N/A	United Kingdom
745	NCT00329537	June 2006	19 February 2015	Study of Sargramostim in Moderately to Severely Active Crohn's Disease	Open-Label Phase 1 Study to Assess the Tolerability, Pharmacokinetics and Safety of 2 and 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 4 Weeks, and Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease (Sargramostim Phase 1/2 Study)	Crohn's Disease	Drug: Sargramostim (Leukine);Drug: Placebo	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	Both	11	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
746	NCT00338650	June 2006	19 February 2015	Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)	A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab	Crohn's Disease	Drug: adalimumab	Abbott		Not recruiting	18 Years	75 Years	Both	1000	Phase 3	United States
747	EUCTR2005-003827-38-GB	02/05/2006	18 April 2012	A Multinational Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects with Moderate to Severe Crohn’s Disease	A Multinational Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects with Moderate to Severe Crohn’s Disease	Subjects will be enrolled suffering from active, moderate to severe Crohn´s disease with a history of small or large bowel disease, with or without colonic disease. Their screening Crohn´s Disease Activity Index (CDAI) shall be between 250 and 450 inclusive and their fasting serum CRP concentration shall be above 7.5 mg/L.	Product Name: CCX282-B Product Code: CCX282-B Pharmaceutical Form: Capsule* Current Sponsor code: CCX282-B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	ChemoCentryx, Inc		Authorised			Female: yes Male: yes	598		Hungary;Czech Republic;United Kingdom;Belgium;Denmark;France;Bulgaria;Austria;Sweden
748	NCT00257699	May 2006	19 February 2015	Study of Antibiotics in the Treatment of Colonic Crohn's Disease	Metronidazole and Ciprofloxacin in the Treatment of Colonic Crohn's Disease: The MACINTOCC Trial.	Crohn's Disease	Drug: Metronidazole placebo;Drug: ciprofloxacin placebo;Drug: ciprofloxacin;Drug: metronidazole	Mount Sinai Hospital, Canada	Crohn's and Colitis Foundation	Not recruiting	16 Years	N/A	Both	12	Phase 2	Canada
749	NCT00317369	May 2006	19 February 2015	A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease	A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease	Crohn Disease	Drug: OPC-6535(Tetomilast)	Otsuka Pharmaceutical Co., Ltd.		Not recruiting	16 Years	65 Years	Both	60	Phase 2	Japan
750	NCT00329420	May 2006	19 October 2017	Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)	A Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed no Clinical Efficacy in a Remission Induction Study (Study C87037) But Showed Clinical Efficacy After Additional Remission Induction Therapy Was Applied, at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals	Crohn's Disease	Biological: Certolizumab pegol	UCB Pharma		Not recruiting	16 Years	64 Years	All	46	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
751	NCT00329550	May 2006	19 October 2017	Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease	A 26-week, Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed Clinical Efficacy in a Remission Induction Study (Study C87037 [NCT00291668]), at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals	Crohn's Disease	Biological: Certolizumab pegol (CZP)	UCB Japan Co. Ltd.		Not recruiting	16 Years	64 Years	All	40	Phase 2	Japan
752	NCT00655733	April 2006	19 October 2017	Phase II Study of HMPL-004 in Subjects With Crohn's Disease		Crohn's Disease	Drug: HMPL004;Drug: Placebo	Hutchison Medipharma Limited		Not recruiting	18 Years	N/A	All	101	Phase 2	United States
753	EUCTR2005-004104-37-BE	23/03/2006	3 April 2012	A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab fragment of humanized antibody to tumor necrosis factor (TNF) over 26 weeks in patients suffering from Crohn’s Disease with prior loss of response or intolerance to infliximab.	A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab fragment of humanized antibody to tumor necrosis factor (TNF) over 26 weeks in patients suffering from Crohn’s Disease with prior loss of response or intolerance to infliximab.	Patients with Crohn's Disease with prior loss of response or intolerance to infliximab Classification code 10011401	Product Name: certolizumab pegol Product Code: CDP870 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: certolizumab pegol Current Sponsor code: CDP870 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 150-+/- 15 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	UCB S.A.		Not Recruiting			Female: yes Male: yes	600	Phase 3b	Germany;United Kingdom;Belgium;Spain;Italy;Austria;Sweden
754	EUCTR2005-005414-20-IT	06/03/2006	19 March 2012	Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD	Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD	Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis MedDRA version: 6.1 Level: PT Classification code 10021972	Trade Name: Thalidomide Pharmion Pharmaceutical Form: Capsule, hard INN or Proposed INN: Thalidomide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	ISTITUTO PER L INFANZIA BURLO GAROFOLO		Authorised			Female: yes Male: yes	124		Italy
755	NCT00291668	March 2006	16 March 2015	Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease	A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Active Crohn's Disease	Crohn's Disease	Biological: Certolizumab Pegol;Other: Placebo	UCB Japan Co. Ltd.		Not recruiting	16 Years	65 Years	Both	94	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
756	NCT00306215	March 2006	19 February 2015	A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease	A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: CCX282-B	ChemoCentryx		Not recruiting	18 Years	N/A	Both	436	Phase 2	Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Netherlands;Poland;South Africa;Sweden;United Kingdom
757	EUCTR2005-003337-40-GB	13/02/2006	19 March 2012	Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTIC	Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTIC	Patients with Crohn's disease who have not responded to immunosupressant medication	Product Name: Cyclophosphamide Product Code: N/A Pharmaceutical Form: Intravenous infusion INN or Proposed INN: cyclophosphamide CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Concentration number: 4000- INN or Proposed INN: cyclophosphamide CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 200- Product Name: Filgrastim Product Code: N/A Pharmaceutical Form: Injection* INN or Proposed INN: Filgrastim CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: µg/kg microgram(s)/kilogram Concentration type: range Concentration number: 50-100 Product Name: rabbit antithymocyte globulin Product Code: rbATG Pharmaceutical Form: Intravenous infusion INN or Proposed INN: rabbit antithymocyte globulin CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 7.5- Product Name: Mesna Product Code: N/A Pharmaceutical Form: Intravenous infusion INN or Proposed INN: mensa CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg/m2 milligram(s)/square meter Concentration type: range Concentration number: 3200-4800 Product Name: methyl prednisolone Product Code: N/A Pharmaceutical Form: Intravenous infusion INN or Proposed INN: methyl prednisolone CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 3- Product Name: ciprofloxacin Product Code: N/A Pharmaceutical Form: Tablet INN or Proposed INN: ciprofloxacin CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: g gram(s) Concentration type: range Concentration number: 1-90	European Group for Blood and Marrow Transplantation (EMBT)		Authorised			Female: yes Male: yes	48		United Kingdom
758	NCT00286689	February 3, 2006	18 December 2018	Effects of Growth Hormone in Chronically Ill Children		Hurler Syndrome;Cerebral Palsy;Juvenile Rheumatoid Arthritis;Crohn Disease;HIV Infections	Drug: Growth Hormone;Procedure: Whole body Protein turnover;Procedure: DEXA scan	University of Texas Southwestern Medical Center		Not recruiting	3 Years	17 Years	All	0	N/A	United States
759	NCT00294112	February 2006	19 February 2015	Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease	A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants	Crohn's Disease	Drug: Prochymal™ adult human mesenchymal stem cells;Drug: adult human mesenchymal stem cells	Mesoblast International Sàrl		Not recruiting	18 Years	70 Years	Both	10	Phase 2	United States
760	NCT00297648	February 2006	19 October 2017	Mucosal Healing Study in Crohn's Disease (CD)	A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFa) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.	Crohn's Disease	Biological: Certolizumab pegol	UCB Pharma		Not recruiting	18 Years	N/A	All	89	Phase 3	Belgium;France;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
761	NCT00583232	February 2006	16 December 2017	Protein and Energy Metabolism in Pediatric Crohn's Disease	Protein and Energy Metabolism in Pediatric Crohn's Disease	Crohn's Disease;Protein Metabolism;Energy Metabolism	Drug: Stable isotope infusions	Indiana University	GlaxoSmithKline;Crohn's and Colitis Foundation;National Center for Research Resources (NCRR)	Not recruiting	6 Years	18 Years	All	15	Phase 1	United States
762	NCT00587041	February 2006	19 October 2017	Use of Oral Probiotics to Reduce Urinary Oxalate Excretion	Use of Oral Probiotics to Reduce Urinary Oxalate Excretion	Nephrolithiasis;Hyperoxaluria;Crohn's Disease	Dietary Supplement: Oxadrop;Dietary Supplement: Agri-King Synbiotic (AKSB);Other: Placebo	Mayo Clinic	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH);National Center for Complementary and Integrative Health (NCCIH);National Center for Research Resources (NCRR)	Not recruiting	18 Years	N/A	All	40	Phase 1/Phase 2	United States
763	NCT00727298	February 2006	19 October 2017	Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)	Post Marketing Surveillance Study of the Labeled Use of Remicade® (Infliximab) in Patients With Chronic Inflammatory Diseases	Arthritis, Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic;Psoriasis;Crohn's Disease	Biological: Infliximab	Merck Sharp & Dohme Corp.	Centocor, Inc.	Not recruiting	18 Years	N/A	All	4485	N/A	Germany
764	EUCTR2005-002857-29-HU	04/01/2006	19 March 2012	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease	Moderate to severe, active Crohn’s disease MedDRA version: 3.2 Level: LLT Classification code 10011401	Product Name: STA-5326 mesylate Product Code: S38 Pharmaceutical Form: Coated tablet Current Sponsor code: STA-5326 mesylate Other descriptive name: STA-6838, STA-5326 m, S38 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Synta Pharmaceutical Corporation		Not Recruiting			Female: yes Male: yes	282		Hungary
765	NCT00295165	January 2006	19 February 2015	Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease	Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease	Crohn Disease	Drug: Sargramostim (Leukine);Drug: Placebo	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	Both	33	Phase 3	United States;Australia;Brazil;Bulgaria;Canada;Israel;New Zealand;Romania;Russian Federation;South Africa;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
766	NCT00630643	January 2006	19 February 2015	NI-0401 in Active Crohn's Disease	A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn´s Disease	Moderate to Severe Crohn's Disease	Biological: NI-0401 (anti-CD3 mAB);Drug: Placebo	NovImmune SA		Not recruiting	18 Years	70 Years	Both	40	Phase 1/Phase 2
767	EUCTR2005-002319-26-DE	20/12/2005	19 March 2012	Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study	Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study	Crohn's disease	Product Code: AZD9056 Pharmaceutical Form: Tablet Current Sponsor code: AZD9056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AstraZeneca AB		Not Recruiting			Female: yes Male: yes	40	Phase 2	Hungary;Germany;Belgium;Austria
768	JPRN-C000000300	2005/12/01	2 April 2019	Z-206 Phase III Clinical Trial - Investigation on the remission-inducing effect in patients with Crohn's disease in active phase -		Patients with Crohn's disease in active phase	Z-206 group:Three tablets of Z-206 400mg tablet, 4 tablets of Pentasa placebo tablet per time (total 7 tablets). 3 times a day (t.i.d.) after each meal for 12 weeks. Mesalazine group:Four tablets of Pentasa 250mg tablet, 3 tablets of Z-206 placebo tablet per time (total 7 tablets). 3 times a day (t.i.d.) after each meal for 12 weeks. Placebo group:Three tablets of Z-206 placebo tablet, 4 tablets of Pentasa placebo tablet per time (total 7 tablets). 3 times a day (t.i.d.) after each meal for 12 weeks.	Zeria Pharmaceutical Co.,LTD		Not Recruiting	16years-old	64years-old	Male and Female	60	Phase 3	Japan
769	JPRN-C000000301	2005/12/01	2 April 2019	Z-206 Phase III Clinical Trial -Investigation on the remission–maintaining effect in patients with Crohn's disease in remission phase-		Patients with Crohn's disease in remission phase	Z-206 group:Three tablets of Z-206 400mg tablet, 4 tablets of Pentasa placebo tablet per time (total 7 tablets). 3 times a day (t.i.d.) after each meal for 48 weeks. Mesalazine group:Four tablets of Pentasa 250mg tablet, 3 tablets of Z-206 placebo tablet per time (total 7 tablets). 3 times a day (t.i.d.) after each meal for 48 weeks.	Zeria Pharmaceutical Co.,LTD.		Not Recruiting	16years-old	64years-old	Male and Female	40	Phase 2,3	Japan
770	NCT00132899	December 2005	19 February 2015	COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)	A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Infliximab in Combination With Methotrexate for the Long-term Treatment of Crohn's Disease (CD)	Crohn's Disease	Drug: Methotrexate;Drug: Placebo	University of Western Ontario, Canada	Schering-Plough	Not recruiting	18 Years	N/A	Both	128	Phase 3	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
771	NCT00571337	December 2005	19 February 2015	Stop Infliximab in Patients With Crohn's Disease	Prospective Study of Predictive Factors of Sustained Remission of Crohn's Disease After Stopping Infliximab	Crohn Disease	Drug: Infliximab	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives		Not recruiting	18 Years	N/A	Both	126	Phase 3	Belgium;France
772	NCT00250198	November 3, 2005	16 December 2017	The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease	A Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease	Crohn's Disease	Drug: STA-5326	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	18 Years	75 Years	All	12	Phase 2	United States
773	NCT00234741	November 2005	19 February 2015	Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease	Crohn's Disease	Drug: STA-5326 mesylate	Synta Pharmaceuticals Corp.	National Institute of Allergy and Infectious Diseases (NIAID);National Institutes of Health (NIH)	Not recruiting	18 Years	75 Years	Both	12	Phase 2	United States
774	NCT00265772	November 2005	19 February 2015	Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis	Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis	Crohn's Disease;Pediatric	Drug: MODULEN IBD (R) (specific Enteral Nutrition);Drug: prednisolon	Hôpital Necker-Enfants Malades	Institut National de la Santé Et de la Recherche Médicale, France;Nestlé	Recruiting	6 Years	18 Years	Both	24	Phase 4	France
775	NCT00838149	November 2005	19 February 2015	Effect of Glutamine on Intestinal Permeability in Crohn's Disease	Effect of Glutamine Supplementation on the Structure and Function of the Mucosa of Small Intestine in Crohn's Disease: A Randomized Controlled Trial	Crohn's Disease	Dietary Supplement: Glutamine;Dietary Supplement: Whey protein	All India Institute of Medical Sciences, New Delhi		Not recruiting	15 Years	60 Years	Both	30	Phase 1	India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
776	NCT00225810	October 2005	19 February 2015	A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease	Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tbl. 500 mg in Children With Crohn´s Disease	Crohn's Disease	Drug: Crohn's Disease	Ferring Pharmaceuticals		Not recruiting	8 Years	18 Years	Both	50	Phase 4	Czech Republic
777	NCT02247258	October 2005	8 June 2015	Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.	Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.	Crohn Disease;Recurrence;Azathioprine;Prevention	Drug: Azathioprine;Drug: Azathioprine in case of endoscopic recurrence;Procedure: Ileocolonoscopy;Procedure: Small bowel follow trough	Universitaire Ziekenhuizen Leuven	International organization for the study of inflammatory bowel disease (IOIBD)	Not recruiting	16 Years	75 Years	Both	63	Phase 2	Belgium;Czech Republic;Greece
778	EUCTR2005-002472-15-SE	22/09/2005	19 March 2012	The effect on mucosal healing with Pentasa® Sachet 4 g in mild to moderate active small bowel Crohn's disease, evaluated with video capsule endoscopy after 6 and 12 weeks treatment. A pilot study. - N.A.	The effect on mucosal healing with Pentasa® Sachet 4 g in mild to moderate active small bowel Crohn's disease, evaluated with video capsule endoscopy after 6 and 12 weeks treatment. A pilot study. - N.A.	Mild to moderate active Crohn's disease MedDRA version: 7.1 Level: PT Classification code 10011401	Trade Name: Pentasa Sachet 1 g prolonged release granules Product Name: Pentasa Sachet 1 g Pharmaceutical Form: Prolonged-release granules INN or Proposed INN: mesalazine Other descriptive name: 5-Aminosalicylic acid Concentration unit: g gram(s) Concentration type: equal Concentration number: 1-	Ferring Laegemidler A/S		Not Recruiting			Female: yes Male: yes	10		Sweden
779	NCT00132184	September 2005	19 February 2015	Vitamin D Treatment for Crohn´s Disease	Remission Keeping and Remission Inducing Effect by Vitamin-D in Crohns Disease, and in Vitro Vitamin-D Mediated T-Cell Immunomodulation	Crohns Disease	Drug: Vitamin D	University of Aarhus		Not recruiting	18 Years	90 Years	Both	110	Phase 2/Phase 3	Denmark
780	NCT00252369	September 2005	19 February 2015	Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.	Instillation of Fibrin Glue After Induction of Local Conditions Using Infliximab, in the Treatment of Perianal Crohn's Disease.	Crohn's Disease	Drug: Infliximab;Procedure: Instillation of fibrin glue	Sheba Medical Center		Not recruiting	18 Years	90 Years	Both		N/A	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
781	NCT00130390	August 2005	19 February 2015	Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease	Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease in Adults	Crohn's Disease	Drug: Nitazoxanide;Other: Placebo	Romark Laboratories L.C.		Not recruiting	18 Years	N/A	Both	98	Phase 2	United States
782	NCT00138840	August 2005	19 February 2015	Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease	Crohn's Disease	Drug: STA-5326 mesylate	Synta Pharmaceuticals Corp.		Not recruiting	18 Years	75 Years	Both	282	Phase 2	United States;Canada
783	EUCTR2005-002048-25-SE	20/07/2005	19 March 2012	A pilot study to investigate the use of recombinant cholera toxin B subunit in the treatment of active Crohn’s disease.	A pilot study to investigate the use of recombinant cholera toxin B subunit in the treatment of active Crohn’s disease.	Inflammatory Bowel Disease (IBD) is the comprehensive term for disorders involving chronic inflammation in the gastrointestinal tract, often the small intestine and colon. It is believed to be a disorder mediated by T lymphocytes that arise in genetically susceptible persons as a result of a breakdown in the regulatory constraints on mucosal immune responses to enteric bacteria. Evidence suggests that Th1 T cells play an important pathogenetic role in Crohn´s disease. Level: PT Classification code 10011401	Product Name: rCTB-401 Pharmaceutical Form: Oral solution Other descriptive name: rCTB-401 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1-	SBL Vaccin AB		Not Recruiting			Female: yes Male: yes	25		Sweden
784	NCT00113503	July 2005	16 December 2017	Imuran Dosing in Crohn's Disease Study	A Multi-site Trial of Azathioprine Dosing in Crohn's Disease	Crohn's Disease	Drug: Azathioprine weight-based dose;Drug: Azathioprine individualised dose	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Prometheus Laboratories	Not recruiting	10 Years	70 Years	All	50	Phase 2	United States;Canada
785	NCT00167882	July 2005	19 February 2015	The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels		Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease	Drug: 5-aminosalicylate (Pentasa, Ferring)	VU University Medical Center		Not recruiting	18 Years	70 Years	Both	24	Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
786	NCT00546546	July 2005	4 May 2015	Early Immunosuppressants in Crohn's Disease	Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease	Crohn's Disease	Drug: early immunosuppressants (azathioprine, methotrexate)	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Société Nationale Française de Gastroentérologie;Société Nationale Française de Gastroentérologie	Not recruiting	18 Years	N/A	Both	120	Phase 4	France
787	EUCTR2005-001148-22-SK	27/06/2005	27 February 2017	A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease - Not applicable	A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease - Not applicable	Crohn's disease MedDRA version: 7.1 Level: Low Classification code 10011401	Trade Name: Certican Product Name: Certican Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Imuran Product Name: Imuran Pharmaceutical Form: Capsule* INN or Proposed INN: Azathioprine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	250	Phase 2	Slovakia
788	EUCTR2004-004387-72-DE	03/06/2005	19 March 2012	A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/A	A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/A	Crohn’s disease (CD) in patients with at least one perianal fistula. MedDRA version: 7.1 Level: LLT Classification code 10011401	Product Name: Visilizumab Product Code: HuM291 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Visilizumab Current Sponsor code: HuM291 Other descriptive name: Anti-CD3 Monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1-	PDL BioPharma, Inc.		Not Recruiting			Female: yes Male: yes	18	Phase 2a	Germany
789	EUCTR2004-004388-31-DE	03/06/2005	19 March 2012	A Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease - N/A	A Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease - N/A	Moderate-to-severe inflammatory, nonstricturing, nonpenetrating Crohn’s disease (CD). MedDRA version: 7.1 Level: LLT Classification code 10011401	Product Name: Visilizumab Product Code: HuM291 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Visilizumab Current Sponsor code: HuM291 Other descriptive name: Anti-CD3 Monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1-	PDL BioPharma, Inc		Not Recruiting			Female: yes Male: yes	18	Phase 2a	Germany
790	NCT00114465	June 2005	19 February 2015	VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease	Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease	Crohn's Disease	Drug: VSL#3;Other: Placebo	Orphan Australia		Not recruiting	18 Years	75 Years	Both	38	Phase 4	Australia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
791	EUCTR2004-002815-10-AT	04/05/2005	22 April 2013	Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease) SONIC - SONIC	Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease) SONIC - SONIC	moderate to severe Crohn’s Disease MedDRA version: 7.1 Classification code 10011401	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: infliximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Imuran Product Name: Imuran Pharmaceutical Form: Tablet INN or Proposed INN: azathioprine Other descriptive name: 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Centocor B.V.		Not Recruiting			Female: yes Male: yes	500		Spain;Denmark;Austria;Germany;United Kingdom;Sweden
792	NCT00126373	May 2005	19 February 2015	A Trial of Wellbutrin for Crohn's Disease	A Randomized Controlled Trial of Wellbutrin for Crohn's Disease	Crohn Disease	Drug: Wellbutrin (bupropion)	Altschuler, Eric, M.D.	GlaxoSmithKline	Not recruiting	18 Years	N/A	Both	1	Phase 2/Phase 3	United States
793	NCT00509639	May 2005	19 February 2015	Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease	Phase III Study to Evaluate the Effect of 10% Metronidazole Ointment, Applied Topically Three Times a Day in and Around the Anus and the Change in Perianal Crohn's Disease Activity	Crohn's Disease	Drug: 10% Metronidazole Ointment	S.L.A. Pharma AG		Not recruiting	18 Years	N/A	Both	74	Phase 3	United States;United Kingdom
794	NCT00829595	May 2005	19 February 2015	Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease	Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn Disease;Ulcerative Colitis	Biological: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)	Cedars-Sinai Medical Center		Not recruiting	18 Years	N/A	Both	69	N/A	United States
795	EUCTR2004-004854-19-SK	25/04/2005	20 February 2017	A randomized, double-blind, placebo-controlled, parallel group multicenter study to investigate efficacy and safety of ITF 2357 in the management of patients with active moderate to severe Crohn’s disease	A randomized, double-blind, placebo-controlled, parallel group multicenter study to investigate efficacy and safety of ITF 2357 in the management of patients with active moderate to severe Crohn’s disease	Crohn's disease	Product Name: ITF2357 Pharmaceutical Form: Capsule, hard Current Sponsor code: ITF2357 Other descriptive name: Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-100 Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Italfarmaco S.p.A.		Authorised			Female: yes Male: yes	50	Phase 2	Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
796	NCT00098111	April 2005	19 February 2015	Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease	A Double-Blinded, Randomized, Parallel Arm, Dose Ranging Study of IMURAN in Subjects With Active Crohn's Disease Requiring Treatment With Prednisone: A Crohn's Disease Optimal Range Dose of IMURAN Study (ACORDIS)	Crohn's Disease	Drug: azathioprine	Massachusetts General Hospital		Not recruiting	14 Years	N/A	Both	31	Phase 3	United States
797	NCT00109473	April 2005	16 December 2017	Trial of Growth Hormone Therapy in Pediatric Crohn's Disease	A Phase II Randomized Trial of Growth Hormone Therapy in Pediatric Crohn's Disease	Crohn's Disease	Drug: growth hormone;Drug: cortecosteroid	Children's Hospital Medical Center, Cincinnati	Genentech, Inc.	Not recruiting	5 Years	N/A	All	22	Phase 2	United States
798	NCT00271947	April 2005	19 October 2017	Crohn's Disease Stem Cell Transplantation	Crohn's Disease Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation (CDNST) Versus Standard Therapy	Crohn's Disease	Biological: Autologous Stem Cell Transplantation	Northwestern University		Not recruiting	18 Years	55 Years	All	1	Phase 2	United States
799	NCT00705471	April 2005	20 April 2015	Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)	Infliximab Use in Fistulizing Crohn's Disease: Impact on Health Care Resources	Crohn Disease	Biological: Infliximab	Merck Sharp & Dohme Corp.	Centocor, Inc.	Not recruiting	18 Years	N/A	Both	42	N/A
800	EUCTR2004-002693-37-DE	14/03/2005	19 March 2012	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - CD-2	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - CD-2	Patients with Moderately Active Crohn’s Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents MedDRA version: 7.1 Level: LLT Classification code 10011401	Trade Name: UVADEX Pharmaceutical Form: Solution for blood fraction modification INN or Proposed INN: methoxsalen CAS Number: 298-81-7 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 20-	Therakos		Not Recruiting			Female: yes Male: yes	25		Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
801	NCT00094458	March 2005	19 October 2017	Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na?ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC	Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE? (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy	Crohn Disease	Biological: infliximab infusion; AZA placebo caps;Other: infliximab (IFX) infusion; azathioprine (AZA) caps;Drug: infliximab (IFX) placebo infusion	Centocor Ortho Biotech Services, L.L.C.	Schering-Plough	Not recruiting	21 Years	99 Years	All	508	Phase 3	United States;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom
802	EUCTR2004-002934-20-BE	22/02/2005	15 July 2013	A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease who Have Lost Response or are Intolerant to Infliximab	A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease who Have Lost Response or are Intolerant to Infliximab	Crohn's Disease	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Injection* INN or Proposed INN: Adalimumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40/0.8- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Abbott GmbH & Co. KG		Not Recruiting			Female: yes Male: yes			Belgium
803	EUCTR2004-003839-31-DK	05/02/2005	19 March 2012	A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn's Disease Subjects Who Have Previously Participated in Natalizumab Crohn's Disease Study CD351 - CD354	A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn's Disease Subjects Who Have Previously Participated in Natalizumab Crohn's Disease Study CD351 - CD354	Crohn's Disease (CD)	Product Name: natalizumab Product Code: AN100226 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: natalizumab Current Sponsor code: AN100226 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Elan Pharma Ltd.		Not Recruiting			Female: yes Male: yes	1000	Phase 3	Denmark
804	NCT00267709	February 2005	19 February 2015	Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease	A Phase 2a, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients With Crohn's Disease	Crohn's Disease	Drug: Visilizumab	Facet Biotech	PDL BioPharma, Inc.	Not recruiting	18 Years	70 Years	Both	18	Phase 2	United States
805	NCT00267722	February 2005	19 February 2015	Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease	A Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's Disease	Crohn's Disease	Drug: Visilizumab	Facet Biotech	PDL BioPharma, Inc.	Not recruiting	18 Years	70 Years	Both	18	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
806	NCT00106314	January 2005	19 February 2015	An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease	A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease	Crohn's Disease	Drug: Dehydroepiandrosterone [DHEA]	Inflabloc Pharmaceuticals		Not recruiting	18 Years	N/A	Both	75	Phase 2	United States;Canada
807	NCT00688636	January 2005	19 October 2017	Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery	Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery	Crohn's Disease	Drug: infliximab;Drug: placebo	University of Pittsburgh	Centocor, Inc.	Not recruiting	18 Years	72 Years	All	24	Phase 4	United States
808	EUCTR2004-004083-77-CZ	13/12/2004	19 March 2012	A Randomised, International, Multicenter Study to assess the Efficacy and Safety of Mesalazine EC tablets 500 mg (4.5g/daily) and Salofalk® tablets 500 mg (4.5 g/daily) in the Treatment of Moderate Active Crohn disease	A Randomised, International, Multicenter Study to assess the Efficacy and Safety of Mesalazine EC tablets 500 mg (4.5g/daily) and Salofalk® tablets 500 mg (4.5 g/daily) in the Treatment of Moderate Active Crohn disease	Moderate active Crohn disease	Product Name: Mesalazine EC 500 mg Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: mesalazine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Product Name: Salofalk 500 mg Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: mesalazine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	Disphar International B.V.		Not Recruiting			Female: yes Male: yes	436		Czech Republic
809	EUCTR2004-002693-37-AT	10/12/2004	22 April 2013	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - N/A	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - N/A	Patients with Moderately Active Crohn’s Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents MedDRA version: 7.1 Level: LLT Classification code 10011401	Trade Name: UVADEX Pharmaceutical Form: Solution for blood fraction modification INN or Proposed INN: methoxsalen CAS Number: 298-81-7 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 20-	Therakos		Not Recruiting			Female: yes Male: yes	25		Austria;Germany
810	NCT00206661	December 2004	19 February 2015	Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease	Phase 1/2 Safety, Pharmacokinetic, and Pharmacodynamic Study of Sargramostim (Leukine®) in Pediatric Patients With Active Crohn's Disease, With One-year Surveillance and Retreatment Extension	Crohn Disease	Drug: Sargramostim (Leukine)	Genzyme, a Sanofi Company		Not recruiting	6 Years	16 Years	Both	22	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
811	NCT00221026	December 2004	31 October 2016	Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease	A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents	Crohn's Disease	Drug: Methoxsalen +ECP;Procedure: Extracorporeal Photopheresis	Mallinckrodt	ICON plc	Not recruiting	18 Years	N/A	Both	25	Phase 2	United States;Austria;Belgium;Germany
812	NCT00724958	December 2004	19 October 2017	Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)	Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension	Crohn's Disease	Biological: Infliximab	Merck Sharp & Dohme Corp.	Centocor, Inc.	Not recruiting	N/A	N/A	All	348	N/A	Austria
813	EUCTR2004-002163-24-HU	23/11/2004	28 August 2014	A Multi-Centre Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease.	A Multi-Centre Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease.	Crohn's Disease	Trade Name: Humira Product Name: Humira Pharmaceutical Form: Injection* INN or Proposed INN: Adalimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Abbott Laboratories		Not Recruiting			Female: yes Male: yes	960		Hungary;Belgium;Spain;Denmark;Germany;Italy;United Kingdom;Sweden
814	EUCTR2004-001213-34-CZ	02/11/2004	19 March 2012	Double-blind, double-dummy, randomized, multicentre study to compare the efficacy and safety of oral budesonide (9 mg) and oral mesalazine (4.5 g) in moderately active Crohn’s disease patients - Oral budesonide vs. oral mesalazine in active CD	Double-blind, double-dummy, randomized, multicentre study to compare the efficacy and safety of oral budesonide (9 mg) and oral mesalazine (4.5 g) in moderately active Crohn’s disease patients - Oral budesonide vs. oral mesalazine in active CD	moderately active Crohn’s disease (200 < CDAI < 400) MedDRA version: 7.0 Level: PT Classification code 10011401	Pharmaceutical Form: Tablet INN or Proposed INN: mesalazine CAS Number: 89-57-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Pharmaceutical Form: Capsule, hard INN or Proposed INN: budesonide CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Dr. Falk Pharma GmbH		Not Recruiting			Female: yes Male: yes	370		United Kingdom;Czech Republic
815	NCT00101946	October 2004	20 April 2015	Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease	A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: 683699	GlaxoSmithKline		Not recruiting	18 Years	65 Years	Both	17	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
816	NCT00105300	October 2004	19 February 2015	Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab	Crohn's Disease	Drug: Adalimumab	Abbott		Not recruiting	18 Years	75 Years	Both	300	Phase 3	United States;Belgium;Canada;France
817	NCT00599625	October 2004	19 February 2015	Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study	Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study	Crohn's Disease	Drug: Pravastatin	University of Virginia	American College of Gastroenterology	Recruiting	18 Years	65 Years	Both	40	N/A	United States
818	NCT00195715	September 2004	19 October 2017	Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease	A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease	Crohn's Disease	Biological: Adalimumab	Abbott		Not recruiting	18 Years	75 Years	All	777	Phase 3	United States;Australia;Belgium;Canada;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom
819	NCT00206674	September 2004	19 February 2015	Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease	Phase 3 Randomized, Double-Blind, Placebo Controlled Induction Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease	Crohn Disease	Drug: Sargramostim (Leukine);Drug: Placebo	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	Both	286	Phase 3	Argentina;Australia;Brazil;Canada;New Zealand;Russian Federation;Switzerland;Ukraine;United Kingdom
820	NCT00798473	September 2004	19 February 2015	Zoledronate for Osteopenia in Pediatric Crohn's	A Randomized Controlled Trial of Zoledronate in the Treatment of Osteopenia in Children and Adolescents With Crohn's Disease	Crohn's Disease;Osteopenia;Osteoporosis	Drug: zoledronic acid;Other: IV saline infusion	McGill University Health Center	Crohn's and Colitis Foundation	Not recruiting	6 Years	18 Years	Both	13	Phase 3	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
821	NCT00102921	August 2004	19 February 2015	Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn’s Disease	Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn’s Disease	Crohn Disease	Drug: CCX282-B	ChemoCentryx		Not recruiting	18 Years	65 Years	Both	70	Phase 2	United States
822	NCT00160524	July 2004	19 October 2017	A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]	A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032	Crohn's Disease	Biological: Certolizumab Pegol (CDP870)	UCB Pharma SA		Not recruiting	18 Years	N/A	All	596	Phase 3	United States;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Latvia;Lithuania;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Ukraine;Tunisia
823	NCT00206713	July 2004	19 February 2015	Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim	Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostim	Crohn Disease	Drug: Sargramostim (Leukine);Drug: Placebo	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	Both	264	Phase 3	United States
824	NCT00245947	April 2004	19 February 2015	Study Evaluating ERB-041 in Active Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease	Crohn's Disease	Drug: ERB-041	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	N/A	Both	22	Phase 1
825	NCT00265122	April 2004	19 October 2017	A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease	A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab 90 mg;Drug: Ustekinumab 4.5 mg/kg;Drug: Placebo SC;Drug: Placebo IV	Centocor, Inc.		Not recruiting	18 Years	N/A	All	131	Phase 2	United States;Belgium;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
826	NCT00308438	March 1, 2004	8 January 2018	Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008	An Open Label Extension Study of the Safety and Efficacy of ALX-0600 in Subjects With Crohn's Disease Who Completed the Pilot Study Protocol CL0600-008	Crohn's Disease	Drug: Teduglutide (ALX-0600)	Shire		Not recruiting	18 Years	N/A	All	67	Phase 2	United States;Canada
827	NCT00078611	March 2004	27 June 2016	A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease	A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn's Disease With Elevated C-Reactive Protein	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	N/A	Both	462	Phase 3	United States;Canada
828	NCT00088062	February 2004	19 February 2015	STA-5326 in Crohn's Disease Patients	A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450	Crohn's Disease	Drug: STA-5326	Synta Pharmaceuticals Corp.		Not recruiting	18 Years	65 Years	Both	48	Phase 1/Phase 2	United States
829	NCT00152425	February 2004	19 February 2015	Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).	A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870	Crohn's Disease	Drug: Certolizumab Pegol (CDP870)	UCB Pharma		Not recruiting	18 Years	N/A	Both	392	Phase 3
830	NCT00160706	February 2004	19 October 2017	A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease	A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease.	Crohn's Disease	Biological: Certolizumab Pegol (CDP870)	UCB Pharma SA		Not recruiting	18 Years	N/A	All	310	Phase 3	United States;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
831	NCT00224562	February 2004	19 February 2015	The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists	The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists	Rheumatoid Arthritis;Crohn's Disease;Ankylosing Spondylitis;Psoriasis	Drug: TNF-alpha antagonists	Assistance Publique - Hôpitaux de Paris		Recruiting	N/A	N/A	Both		N/A	France
832	NCT00114803	January 2004	19 February 2015	Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease	Use of Intranasally Administered Calcitonin in the Treatment of Osteopenia and Osteoporosis in Children, Adolescents and Young Adults With IBD: A Pilot Study	Ulcerative Colitis;Crohn's Disease	Drug: Calcitonin nasal spray (salmon)	Children's Hospital Boston	Crohn's and Colitis Foundation;National Institutes of Health (NIH)	Not recruiting	8 Years	22 Years	Both	66	N/A	United States
833	NCT00152490	December 2003	19 February 2015	A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)	A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease	Crohn's Disease	Drug: Certolizumab Pegol (CDP870)	UCB Pharma		Not recruiting	18 Years	N/A	Both	604	Phase 3
834	NCT00175292	December 2003	19 February 2015	A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.	A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.	Crohn's Disease;Inflammatory Bowel Disease	Drug: Probiotic - VSL#3	University of Alberta	Canadian Institutes of Health Research (CIHR)	Not recruiting	16 Years	N/A	Both	120	Phase 3	Canada
835	NCT00177866	December 2003	19 October 2017	Safety of Celecoxib in Patients With Crohn's Disease	The Safety of Celecoxib (Celebrex) in Patients With Crohn's Disease	Crohn's Disease	Drug: Celebrex;Drug: placebo	University of Pittsburgh	Shadyside Hospital Foundation;Pfizer	Not recruiting	18 Years	70 Years	All	28	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
836	NCT00796250	November 1, 2003	16 December 2017	Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)	Efficacy of Infliximab as Bridging Therapy in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine	Crohn's Disease	Biological: Infliximab;Drug: AZA;Drug: Placebo Prednisolone;Drug: Prednisolone;Biological: Placebo Infliximab	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	65 Years	All	9	Phase 3
837	NCT00072839	October 2003	23 November 2015	Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease	A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects With Moderately Active Crohn's Disease	Crohn's Disease	Drug: ALX-0600;Drug: placebo;Drug: teduglutide 0.05;Drug: teduglutide 0.2 mg;Drug: Teduglutide 0.05 dose;Drug: teduglutide 0.1 mg dose	Shire		Not recruiting	18 Years	N/A	Both	100	Phase 2	United States;Canada
838	NCT00077779	July 2003	19 February 2015	Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease	A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease	Crohn's Disease	Drug: Adalimumab	Abbott		Not recruiting	18 Years	75 Years	Both	854	Phase 3	United States
839	NCT00206596	July 2003	19 February 2015	Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease	Randomized, Stratified, Double-Blind, Placebo-Controlled Phase 2 Study of Steroid-Sparing Properties of Sargramostim (Leukine) Therapy in Patients With Cortico-Dependent Crohn's Disease	Crohn Disease	Drug: Sargramostim (Leukine);Drug: Placebo	Genzyme, a Sanofi Company		Not recruiting	18 Years	80 Years	Both	127	Phase 2	United States;Canada
840	NCT00705614	July 2003	16 December 2017	Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)	Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy	Crohn's Disease	Biological: Remicade	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	N/A	All	2662	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
841	NCT00741910	July 2003	19 February 2015	Extension Study of Semapimod 60 mg IV x 3 Days	Extension Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: Semapimod	Ferring Pharmaceuticals		Not recruiting	18 Years	N/A	Both	15	Phase 2	United States;Germany;Israel;Netherlands
842	NCT00056355	March 2003	19 February 2015	Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease	A Single Arm Study of Extracorporeal Photoimmune Therapy With Uvadex For Corticosteroid Sparing in Patients With Corticosteroid-Dependent Crohn's Disease Who May Also Be Refractory or Intolerant to Immunosuppressants and/or Anti-Tumor Necrosis Factor Agen	Crohn Disease	Drug: UVADEX and UVAR XTS Photopheresis System	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	N/A	N/A	Both	10	Phase 1	United States
843	NCT00206700	February 2003	19 February 2015	Open-label Trial of Leukine in Active Crohn's Disease	Open-label Trial of Leukine® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease	Crohn Disease	Drug: Sargramostim (Leukine)	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	Both	378	Phase 2	United States;Argentina;Australia;Brazil;Canada;New Zealand;Russian Federation;Switzerland;Ukraine;United Kingdom
844	NCT00207675	February 2003	19 February 2015	A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease	A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease.	Crohn Disease	Drug: infliximab	Centocor, Inc.	Centocor BV	Not recruiting	6 Years	17 Years	Both	112	Phase 3
845	NCT00613197	January 2003	19 February 2015	EPANOVA in Crohn's Disease, Study 1	A One Year, Multi-center, Randomised, Double-blind Placebo-controlled Parallel-groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/Day for Maintenance of Remission of Crohn's Disease.	Crohn's Disease	Drug: Epanova	Tillotts Pharma AG		Not recruiting	18 Years	70 Years	Both	384	Phase 3	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
846	NCT00740103	December 2002	19 February 2015	Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease	Long-term Study of Semapimod (CNI-1493) for Treatment of Moderate to Severe Crohn's Disease With Reference to Study CNI-1493-CD-04, 1 or 3 Days' Treatment vs. Placebo	Crohn's Disease	Drug: Semapimod	Ferring Pharmaceuticals		Not recruiting	18 Years	N/A	Both	119	Phase 2	United States;Belgium;Germany;Israel;Netherlands
847	NCT00818272	December 2002	19 October 2017	Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)	Remicade Safety Line (Crohn's Disease)	Crohn's Disease	Biological: Remicade (infliximab)	Merck Sharp & Dohme Corp.	Centocor, Inc.	Not recruiting	18 Years	N/A	All	148	N/A	Germany
848	NCT00739986	October 2002	19 February 2015	Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo	A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. Placebo	Crohn's Disease	Drug: Semapimod;Drug: Placebo	Ferring Pharmaceuticals		Not recruiting	18 Years	N/A	Both	152	Phase 2	United States;Belgium;Germany;Israel;Netherlands
849	NCT00976690	October 2002	19 February 2015	Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease	A Multicentre Randomized Open Study Comparing Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease	Crohn Disease	Drug: Azathioprine OR Mesalazine	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives		Not recruiting	18 Years	N/A	Both	83	Phase 3	France
850	NCT00074542	September 2002	19 February 2015	An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease	A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease	Crohn's Disease	Drug: Epanova™ (Omega-3 Free Fatty Acids)	Tillotts Pharma AG		Not recruiting	16 Years	N/A	Both	364	Phase 3	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
851	NCT00055497	August 2002	19 October 2017	Remission in Subjects With Crohn's Disease, 1 Year Phase	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease	Crohn's Disease	Biological: Double-blind (DB) adalimumab placebo;Biological: DB adalimumab 40 mg eow;Biological: DB adalimumab 40 mg ew;Biological: OL adalimumab 40 mg	Abbott		Not recruiting	18 Years	75 Years	All	276	Phase 3	United States
852	NCT01070303	August 2002	19 October 2017	Remission in Subjects With Crohn's Disease, Open Label Extension	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease, Open Label Extension	Crohn's Disease	Biological: Adalimumab 40 mg eow or ew	Abbott		Not recruiting	18 Years	75 Years	All	177	Phase 3	United States
853	NCT00042055	July 2002	19 February 2015	CP-461 for the Treatment of Crohn's Disease	A Phase II Pilot Study of CP-461 in the Treatment of Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: CP-461	Astellas Pharma Inc	Cell Pathways;OSI Pharmaceuticals	Not recruiting	18 Years	N/A	Both	30	Phase 2	United States
854	NCT00275418	July 2002	19 February 2015	Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease	Double-Blind Randomized Prospective Trial of Treatment With Natural Beta Carotene Vs. Placebo for Patients With Crohn's Disease in Remission	Crohn's Disease	Drug: beta carotene from Dunaliella algae	Bnai Zion Medical Center		Recruiting	17 Years	75 Years	Both	300	Phase 3	Israel
855	NCT00280956	July 2002	27 June 2016	Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease	A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	N/A	Both	2000	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
856	NCT00038766	June 2002	19 February 2015	CNI-1493 for Treatment of Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease	Crohn Disease	Drug: semapimod;Drug: placebo	Ferring Pharmaceuticals		Not recruiting	18 Years	N/A	Both	33	Phase 2	United States
857	NCT00152841	June 2002	19 February 2015	Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis	Effect of Iron and Antioxidant Vitamins on Disease Activity and Oxidative Stress in Inflammatory Bowel Disease (IBD)	Crohn's Disease;Ulcerative Colitis;Mild or Moderate Anaemia	Drug: Iron supplement 300-600 mg/day;Drug: Vitamin E 800IU	University Health Network, Toronto	Crohn's and Colitis Foundation	Not recruiting	18 Years	N/A	Both	30	Phase 2	Canada
858	NCT00048295	May 2002	19 February 2015	Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease	ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s Disease	Crohn's Disease	Drug: Alicaforsen	Isis Pharmaceuticals		Not recruiting	12 Years	N/A	Both	150	Phase 3	Belgium;Czech Republic;Germany;Italy;Poland;Spain
859	NCT00040521	April 2002	19 February 2015	Study Evaluating rhIL-11 in Active Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease	Crohn Disease;Inflammatory Bowel Disease	Drug: Recombinant Human Interleukin-11 (rhIL-11)	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	16 Years	N/A	Both		Phase 2	United States
860	NCT00055367	April 2002	27 June 2016	Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease	A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	12 Years	17 Years	Both	30	Phase 2	United States;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
861	NCT00055523	April 2002	19 February 2015	A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease	A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease	Crohn's Disease	Drug: Adalimumab (D2E7)	Abbott		Not recruiting	18 Years	75 Years	Both	300	Phase 2	United States
862	NCT00055536	April 2002	27 June 2016	Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease	A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	N/A	Both	60	Phase 2	United States
863	NCT00032786	March 2002	27 June 2016	Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease	A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	N/A	Both		Phase 3
864	NCT00072943	March 2002	19 February 2015	A Humanized Anti-Interferon-? Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease	A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-? Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease	Crohn's Disease;Colitis;Intestinal Disease;Gastrointestinal Disease;Digestive System Disease	Drug: anti-Interferon-gamma monoclonal antibody	Facet Biotech		Not recruiting	18 Years	70 Years	Both	175	Phase 2	United States;Canada
865	NCT00446433	March 2002	12 December 2016	A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease	Crohn's Disease	Drug: CC-5013	Celgene Corporation		Not recruiting	12 Years	75 Years	Both	90	Phase 2	United States;France;Israel;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
866	NCT00261976	February 2002	19 February 2015	A Long-term Safety Study of Infliximab (Remicade)	Long-term Safety Follow-up of REMICADE (RESULTS)	Arthritis, Rheumatoid;Crohn Disease;Psoriasis	Drug: Infliximab (Remicade)	Centocor, Inc.	Centocor BV	Not recruiting	N/A	N/A	Both	2971	Phase 4	United States;Argentina;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom
867	NCT00946946	February 2002	19 February 2015	Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine	Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study on the Efficacy and Safety of Azathioprine Versus Mesalazine for Prevention of Clinical Relapses in Crohn's Disease Patients With Postoperative Moderate or Severe Endoscopic Recurrence	Crohn's Disease	Drug: Azathioprine;Drug: Mesalazine;Drug: Azathioprine placebo;Drug: Mesalazine placebo	Dr. Falk Pharma GmbH		Not recruiting	18 Years	70 Years	Both	78	Phase 3	Austria;Germany
868	NCT00035503	January 2002	19 February 2015	Multicenter Trial For Patients With Acute Crohn's Disease		Crohn's Disease	Drug: etiprednol dicloacetate	Teva Branded Pharmaceutical Products, R&D Inc.		Not recruiting	18 Years	N/A	Both		Phase 2	United States;Canada
869	NCT00510978	January 2002	19 February 2015	Probiotics in GastroIntestinal Disorders	One Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative Colitis	Ulcerative Colitis;Crohn's Disease	Biological: Bifidobacterium infantis 35624;Biological: Lactobacillus salivarius UCC118;Biological: Placebo	University College Cork	European Commission	Not recruiting	N/A	75 Years	Both	360	Phase 2/Phase 3	Ireland
870	NCT00032799	December 2001	27 June 2016	Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease	A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	N/A	Both	905	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
871	NCT00304252	November 2001	19 February 2015	Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease	A Phase II, Multicenter, Randomised, Double-blind, Placebo Controlled, Dose Finding Study of Subcutaneously Administered Interferon Beta-1a for Maintenance of Remission in Patients With Crohn's Disease	Crohn's Disease	Drug: Interferon beta-1a	EMD Serono		Not recruiting	18 Years	N/A	Both	192	Phase 2	Germany;Italy;Sweden;Switzerland;United Kingdom
872	NCT00025805	October 23, 2001	16 December 2017	G-CSF to Treat Crohn's Disease	Granulocyte-Colony Stimulating Factor Treatment for Crohn's Disease: A Pilot Study Assessing Immune and Clinical Response	Crohn's Disease	Drug: G-CSF	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	18 Years	N/A	All	23	Phase 1	United States
873	NCT02209792	October 2001	19 February 2015	Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease	A Randomised, Double-blind, Placebo-controlled, Five* Parallel Groups, Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg) Administered Twice a Day Orally Over 8 Weeks in Patients With Moderate to Severe Crohn's Disease Followed by a 18 Weeks Treatment Extension in Patients With Clinical Remission or Clinical Response After 8 Weeks Treatment With the Respective Dose of BIRB 796 BS - Extension Phase. Subsequent to Amendment 4 (Dated 11 Jun 2002) a 60 mg b.i.d. Group Was Included.	Crohn Disease	Drug: Placebo;Drug: BIBR 796 BS, 5 mg;Drug: BIBR 796 BS, 20 mg	Boehringer Ingelheim		Not recruiting	18 Years	65 Years	Both	284	Phase 2
874	NCT00048113	September 2001	19 February 2015	Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease	ISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease	Crohn's Disease	Drug: Alicaforsen	Isis Pharmaceuticals		Not recruiting	12 Years	N/A	Both	150	Phase 3	United States;Canada
875	NCT00554710	May 2001	19 February 2015	Top Down Versus Step Up Strategies in Crohn's Disease	The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux	Crohn's Disease	Drug: infliximab+azathioprine;Drug: methylprednisolone or budesonide	Belgian IBD Research Group	Centocor BV;Schering-Plough	Not recruiting	16 Years	75 Years	Both	129	Phase 4	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
876	NCT00278577	April 2001	19 February 2015	Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease	Immune Ablation and Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease	CROHN'S DISEASE	Biological: Immune Ablation and Hematopoietic Stem Cell Support	Richard Burt, MD		Not recruiting	N/A	60 Years	Both	25	Phase 1	United States
877	NCT00007163	December 2000	19 February 2015	Monoclonal Antibody Treatment of Crohn's Disease	A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Levels of Subcutaneously Administered Human Monoclonal Antibody to Interleukin-12 (J695) in Patients With Active Crohn's Disease	Crohn's Disease	Drug: J695	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	N/A	N/A	Both	40	Phase 1	United States
878	NCT00207662	July 2000	19 February 2015	A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease	ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: infliximab or placebo	Centocor, Inc.		Not recruiting	18 Years	N/A	Both	580	Phase 3
879	NCT00940576	July 2000	19 October 2017	Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases	Dietetic Effects of Mare's Milk in Patients With Chronic Inflammatory Bowel Diseases (IBD) - a Double Blind Placebo Controlled Cross-over Study.	Ulcerative Colitis;Crohns Disease	Dietary Supplement: mare´s milk;Other: placebo drink	University of Jena	German Federal Ministry of Education and Research	Not recruiting	10 Years	50 Years	All	17	N/A	Germany
880	NCT00207766	June 2000	19 February 2015	A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease	ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease	Crohn Disease	Drug: infliximab or placebo	Centocor, Inc.		Not recruiting	18 Years	N/A	Both	306	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
881	NCT00269386	April 2000	19 February 2015	Clarithromycin in Active Crohn's Disease	Randomised Controlled Trial of Clarithromycin in Active Crohn's Disease	Crohn's Disease	Drug: Clarithromycin;Drug: Placebo	Royal Liverpool University Hospital	Abbott	Not recruiting	18 Years	N/A	Both	44	Phase 3	United Kingdom
882	NCT00655135	February 2000	19 February 2015	Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients	Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients With Mildly to Moderately Active Crohn's Disease	Crohn's Disease	Drug: LDP-02;Drug: Placebo	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	80 Years	Both	185	Phase 2
883	NCT00004941	July 1996	7 April 2015	Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease		Crohn's Disease	Drug: monoclonal antibody cA2	FDA Office of Orphan Products Development	Centocor, Inc.	Not recruiting	18 Years	65 Years	Both	94	Phase 3
884	NCT00269841	May 1996	19 February 2015	An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease	A Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease	Crohn Disease	Drug: Infliximab 10 mg/kg;Drug: Infliximab 5 mg/kg;Drug: Placebo	Centocor, Inc.		Not recruiting	18 Years	65 Years	Both	94	Phase 3
885	NCT00004423	December 1995	7 April 2015	Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease		Crohn's Disease	Drug: -aminosalicylic acid	University of Vermont		Not recruiting	18 Years	80 Years	Both	80	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
886	NCT00269854	June 1995	19 February 2015	An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease	A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease	Crohn Disease	Drug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Infliximab 20 mg/kg;Drug: Placebo	Centocor, Inc.		Not recruiting	18 Years	65 Years	Both	108	Phase 2/Phase 3
887	JPRN-JapicCTI-080566		23 April 2019	A Multicentre, Double-Blind, Randomised, Parallel-Group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease	A Multicentre, Double-Blind, Randomised, Parallel-Group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease	Crohn's Disease	Intervention name : Budesonide Dosage And administration of the intervention : Oral	AstraZeneca			18	65	BOTH		Phase 2
888	JPRN-JapicCTI-111460		23 April 2019	Phase II Study of Z-206 in Patients with Active Crohn's Disease	Phase II Study of Z-206 in Patients with Active Crohn's Disease	Active Crohn's disease	Intervention name : Z-206 INN of the intervention : Mesalazine Dosage And administration of the intervention : oral	Zeria Pharmaceutical Co., Ltd.	Kyowa Hakko Kirin Co., Ltd.		16	64	BOTH		Phase 2
889	JPRN-JapicCTI-121765		2 April 2019	A Multicentre, Double-blind, Randomised, Parallel-group, Phase3 Study to Assess Efficacy and Safety of D9421-C 9mg Versus Mesalazine 3g in Patients With Active Crohn's Disease (CD) in Japan	A Multicentre, Double-blind, Randomised, Parallel-group, Phase3 Study to Assess Efficacy and Safety of D9421-C 9mg Versus Mesalazine 3g in Patients With Active Crohn's Disease (CD) in Japan	Crohn's Disease	Intervention name : D9421-C Dosage And administration of the intervention : 9mg, Oral once daily Control intervention name : Mesalazine Dosage And administration of the control intervention : 1g, Oral three times a day	AstraZeneca			15		BOTH		Phase 3
890	JPRN-JapicCTI-183983		16 July 2019	Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease	A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of JnJ-64304500 in Subjects With Moderately to Severely Active Crohn's Disease	Crohn Disease	Intervention name : JNJ-64304500 Dosage And administration of the intervention : JNJ-64304500 Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22. JNJ-64304500 High Dose JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20. JNJ-64304500 Middle Dose JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20. JNJ-64304500 Low Dose JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Control intervention name : Placebo Dosage And administration of the control intervention : Part I : Placebo Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI <150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22. Control intervention name : Placebo Ustekinumab Dosage And administration of the control intervention : Part II : Placebo Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in CDAI or CDAI <150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ- 64304500 150 mg SC at Week 12 and then JNJ- 64304500 75 mg at Weeks 14, 16, and 20. Part II : Ustekinumab Participants will receive tiered doses of Ustekinumab 260 mg (weight <=55 kg), Ustekinumab 390 mg (weight >55 kg and <=85 kg), Ustekinumab 520 mg (weight >85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16.	Janssen Pharmaceutical K.K.		Recruiting	18		BOTH	40	Phase 2